1
00:00:06,840 --> 00:00:08,400
>> GOOD AFTERNOON,
EVERYONE.

2
00:00:08,400 --> 00:00:09,840
WE WILL NOW BEGIN OUR MEETING.

3
00:00:09,840 --> 00:00:20,440
THANK YOU TO EVERYONE ON THE YO.

4
00:00:23,040 --> 00:00:23,720
SO GOOD AFTERNOON.

5
00:00:23,720 --> 00:00:25,840
AS YOU KNOW, MY NAME IS MARY

6
00:00:25,840 --> 00:00:27,480
GLENSHAW, THE DESIGNATED FEDERAL

7
00:00:27,480 --> 00:00:29,000
OFFICIAL OF THE OFFICE OF AIDS

8
00:00:29,000 --> 00:00:30,320
RESEARCH ADVISORY COUNCIL.

9
00:00:30,320 --> 00:00:31,520
WELL KOL AND THANK YOU AGAIN FOR

10
00:00:31,520 --> 00:00:36,000
BEING HERE TODAY.

11
00:00:36,000 --> 00:00:37,960
OUR COUNCIL IS GOVERNED BY THE

12
00:00:37,960 --> 00:00:40,600
FEDERAL ADVISORY COMMITTEE ACT

13
00:00:40,600 --> 00:00:43,240
AS AMENDED WHICH SETS FORTH

14
00:00:43,240 --> 00:00:44,800
STANDARDS FOR THE FORMATION AND

15
00:00:44,800 --> 00:00:46,000
USE OF ADVISORY COMMITTEES.

16
00:00:46,000 --> 00:00:49,360
MY ROLE IS TO PREPARE MEETINGS,

17
00:00:49,360 --> 00:00:50,800
ORGANIZE, ATTEND AND APPROVE ALL

18
00:00:50,800 --> 00:00:52,000
COUNCIL AND SUBCOMMITTEE

19
00:00:52,000 --> 00:00:52,480
MEETINGS.

20
00:00:52,480 --> 00:00:54,240
I WILL ADJOURN ANY MEETING WHEN

21
00:00:54,240 --> 00:00:55,600
IT'S DETERMINED TO BE IN THE

22
00:00:55,600 --> 00:00:57,040
PUBLIC INTEREST, AND I'LL CHAIR

23
00:00:57,040 --> 00:00:59,880
MEETINGS WHEN DIRECTED BY THE

24
00:00:59,880 --> 00:01:05,320
OAR OR NIH DIRECTOR.

25
00:01:05,320 --> 00:01:06,440
MS. CORETTA BYRD, WHO YOU ALL

26
00:01:06,440 --> 00:01:08,640
ARE MEETING IN PERSON TODAY,

27
00:01:08,640 --> 00:01:09,800
WILL FULFILL THESE DUTIES IN THE

28
00:01:09,800 --> 00:01:11,160
EVENT THAT I'M ABSENT.

29
00:01:11,160 --> 00:01:13,560
SO SOME GUIDELINES FOR TODAY.

30
00:01:13,560 --> 00:01:15,560
FOLKS ON THE CALL AND IN PERSON,

31
00:01:15,560 --> 00:01:17,600
PLEASE STAY MUTED UNLESS YOU'RE

32
00:01:17,600 --> 00:01:17,920
SPEAKING.

33
00:01:17,920 --> 00:01:19,640
FOR PEOPLE ON ZOOM, PLEASE KEEP

34
00:01:19,640 --> 00:01:21,080
YOUR CAMERA ON FOR MOST OF THE

35
00:01:21,080 --> 00:01:21,320
MEETING.

36
00:01:21,320 --> 00:01:23,040
YOU CAN HIDE IF YOU NEED TO

37
00:01:23,040 --> 00:01:24,600
LEAVE MOMENTARILY.

38
00:01:24,600 --> 00:01:26,320
AND THEN PLEASE TURN IT BACK ON

39
00:01:26,320 --> 00:01:28,520
WHEN YOU RETURN.

40
00:01:28,520 --> 00:01:30,680
TO PARTICIPATE IN DISCUSSIONS,

41
00:01:30,680 --> 00:01:34,120
WE WILL FACILITATE TWO SORT OF

42
00:01:34,120 --> 00:01:35,320
ROUNDS OF DISCUSSION.

43
00:01:35,320 --> 00:01:36,520
DR. TURNBULL WILL FACILITATE THE

44
00:01:36,520 --> 00:01:38,520
ZOOM DISCUSSIONS AND I WILL

45
00:01:38,520 --> 00:01:39,800
FACILITATE THE IN-PERSON

46
00:01:39,800 --> 00:01:41,920
DISCUSSIONS AND WE'LL HAND OFF

47
00:01:41,920 --> 00:01:43,080
TO AVOID SPEAKING OVER EACH

48
00:01:43,080 --> 00:01:46,280
OTHER.

49
00:01:46,280 --> 00:01:47,960
FOLKS ON THE ZOOM CALL, IF YOU

50
00:01:47,960 --> 00:01:51,800
COULD PLEASE SEND MESSAGES

51
00:01:51,800 --> 00:01:52,640
THROUGH ZOOM CHAT FOR THE

52
00:01:52,640 --> 00:01:53,680
MEETING HOSTS ONLY, THAT WOULD

53
00:01:53,680 --> 00:01:55,040
BE APPRECIATED.

54
00:01:55,040 --> 00:01:56,600
IF YOU HAVE ANY CONCERNS, PLEASE

55
00:01:56,600 --> 00:02:00,720
SEND ME AN EMAIL.

56
00:02:00,720 --> 00:02:02,040
PLEASE REMEMBER THAT THIS IS

57
00:02:02,040 --> 00:02:03,320
BEING VIDEOCAST LIVE AND IF

58
00:02:03,320 --> 00:02:04,560
YOU'D LIKE TO SEE THE CLOSED

59
00:02:04,560 --> 00:02:06,280
CAPTION FOR THE MEETING, PLEASE

60
00:02:06,280 --> 00:02:08,520
CLICK ON THE CC ICON ON THE

61
00:02:08,520 --> 00:02:11,320
BOTTOM RIGHT-HAND CORNER OF THE

62
00:02:11,320 --> 00:02:15,040
VIDEOCAST SCREEN.

63
00:02:15,040 --> 00:02:17,440
FOR OUR VOTING MEMBERS I'D LIKE

64
00:02:17,440 --> 00:02:19,760
TO REMIND YOU OF OUR POLICIES

65
00:02:19,760 --> 00:02:20,800
REGARDING CONFLICT OF INTEREST.

66
00:02:20,800 --> 00:02:22,800
COUNCCOUNCILMEMBERS MAY NOT

67
00:02:22,800 --> 00:02:23,800
PARTICIPATE IN THE REVIEW OR

68
00:02:23,800 --> 00:02:26,000
DISCUSSION OF A SPECIFIC PROGRAM

69
00:02:26,000 --> 00:02:27,320
OR PROJECT FOR WHICH THEY HAVE A

70
00:02:27,320 --> 00:02:29,840
REAL OR APPARENT CONFLICT OF

71
00:02:29,840 --> 00:02:30,160
INTEREST.

72
00:02:30,160 --> 00:02:32,320
IF A PROGRAM OR PROJECT IS

73
00:02:32,320 --> 00:02:33,200
DISCUSSED THAT PRESENTS A

74
00:02:33,200 --> 00:02:35,200
CONFLICT FOR YOU, PLEASE EXCUSE

75
00:02:35,200 --> 00:02:36,160
YOURSELF FROM THE MEETING.

76
00:02:36,160 --> 00:02:38,320
TO DO THIS ON ZOOM, PLEASE

77
00:02:38,320 --> 00:02:40,400
SIGNAL US AND WE WILL MOVE YOU

78
00:02:40,400 --> 00:02:41,520
TO A PRIVATE ROOM.

79
00:02:41,520 --> 00:02:42,880
IF THIS OCCURS IN PERSON, PLEASE

80
00:02:42,880 --> 00:02:44,280
STEP OUT OF THE ROOM.

81
00:02:44,280 --> 00:02:48,960
AND PLEASE RETURN WHEN THE

82
00:02:48,960 --> 00:02:49,840
CONFLICT -- THE CONVERSATION

83
00:02:49,840 --> 00:02:52,360
ABOUT THE CONFLICT IS OVER.

84
00:02:52,360 --> 00:02:54,120
AFTER THE MEETING, KINDLY SIGN

85
00:02:54,120 --> 00:02:55,360
THE CONFLICT OF INTEREST FORM

86
00:02:55,360 --> 00:02:57,200
THAT WILL BE EMAILED TO YOU OR

87
00:02:57,200 --> 00:02:58,720
WILL BE HANDED TO YOU HERE IN

88
00:02:58,720 --> 00:03:00,360
PERSON.

89
00:03:00,360 --> 00:03:02,200
AND I THINK THAT TAKES CARE OF

90
00:03:02,200 --> 00:03:04,040
ALL THE HOUSEKEEPING ISSUES.

91
00:03:04,040 --> 00:03:06,600
ARE THERE ANY CONFLICTS OF

92
00:03:06,600 --> 00:03:07,680
INTEREST ANTICIPATED TODAY FOR

93
00:03:07,680 --> 00:03:11,840
ANY OF YOU?

94
00:03:11,840 --> 00:03:14,120
OKAY, GREAT.

95
00:03:14,120 --> 00:03:15,240
SO THIS MEETING IS OPEN TO THE

96
00:03:15,240 --> 00:03:15,920
GENERAL PUBLIC.

97
00:03:15,920 --> 00:03:18,720
WE ACCEPT PUBLIC COMMENTS, AND

98
00:03:18,720 --> 00:03:22,360
WE ARE NOW LIVE AND BEING

99
00:03:22,360 --> 00:03:22,680
RECORDED.

100
00:03:22,680 --> 00:03:23,760
I'LL TURN THE MEETING OVER TO

101
00:03:23,760 --> 00:03:27,040
OUR CHAIR, DR. IVY TURNBULL.

102
00:03:27,040 --> 00:03:27,800
DR. TURNBULL HAS BEEN A MEMBER

103
00:03:27,800 --> 00:03:30,400
OF THE OARAC SINCE 2020, AND

104
00:03:30,400 --> 00:03:31,960
THIS IS HER FIRST MEETING AS

105
00:03:31,960 --> 00:03:34,600
CHAIR.

106
00:03:34,600 --> 00:03:35,560
DR. TURNBULL, IF YOU COULD

107
00:03:35,560 --> 00:03:36,440
KINDLY NOW BRING THE MEETING TO

108
00:03:36,440 --> 00:03:36,640
ORDER.

109
00:03:36,640 --> 00:03:39,280
THANK YOU.

110
00:03:39,280 --> 00:03:42,160
>> THANK YOU, CAPTAIN
GLENSHAW,

111
00:03:42,160 --> 00:03:44,080
AND GOOD AFTERNOON, EVERYONE.

112
00:03:44,080 --> 00:03:45,280
THE 63RD MEETING OF THE OFFICE

113
00:03:45,280 --> 00:03:47,280
OF AIDS RESEARCH ADVISORY

114
00:03:47,280 --> 00:03:51,120
COUNCIL IS NOW IN SESSION.

115
00:03:51,120 --> 00:03:54,200
WELCOME, COUNCILMEMBERS, INVITED

116
00:03:54,200 --> 00:03:56,560
SPEAKERS, NIH COLLEAGUES, AND

117
00:03:56,560 --> 00:03:57,560
GUESTS.

118
00:03:57,560 --> 00:03:58,880
COLLEAGUES, WE WILL NOW CONDUCT

119
00:03:58,880 --> 00:04:00,160
ROLL CALL.

120
00:04:00,160 --> 00:04:02,480
WHEN I CALL YOUR NAME, PLEASE

121
00:04:02,480 --> 00:04:05,120
STATE YOUR POSITION AND

122
00:04:05,120 --> 00:04:08,080
INSTITUTIONAL AFFILIATION.

123
00:04:08,080 --> 00:04:09,840
STARTING WITH OARAC VOTING

124
00:04:09,840 --> 00:04:10,840
MEMBERS.

125
00:04:10,840 --> 00:04:18,680
DR. KATHLEEN COLLINS.

126
00:04:18,680 --> 00:04:20,440
>> SORRY, TOOK ME A MINUTE
TO

127
00:04:20,440 --> 00:04:21,120
UNMUTE.

128
00:04:21,120 --> 00:04:22,960
MY NAME IS KATHY COLLINS.

129
00:04:22,960 --> 00:04:24,480
I AM PROFESSOR OF INTERNAL

130
00:04:24,480 --> 00:04:26,120
MEDICINE AT THE UNIVERSITY OF

131
00:04:26,120 --> 00:04:27,760
MICHIGAN, AND I RUN A RESEARCH

132
00:04:27,760 --> 00:04:30,280
LAB THAT STUDIES HIV

133
00:04:30,280 --> 00:04:30,840
PERSISTENCE.

134
00:04:30,840 --> 00:04:33,560
I ALSO AM THE DIRECTOR OF THE

135
00:04:33,560 --> 00:04:36,840
MICP AND ASSOCIATE DEAN OF

136
00:04:36,840 --> 00:04:37,600
PHYSICIAN SCIENTIST EDUCATION

137
00:04:37,600 --> 00:04:39,480
AND TRAINING.

138
00:04:39,480 --> 00:04:41,880
>> DR. OMAR GALARRAGA.

139
00:04:41,880 --> 00:04:43,960
>> GOOD MORNING.

140
00:04:43,960 --> 00:04:45,600
I'M ASSOCIATE PROFESSOR AT THE

141
00:04:45,600 --> 00:04:46,480
BROWN UNIVERSITY SCHOOL OF

142
00:04:46,480 --> 00:04:46,840
PUBLIC HEALTH.

143
00:04:46,840 --> 00:04:50,080
I'M ALSO THE DIRECTOR OF THE HSR

144
00:04:50,080 --> 00:04:51,640
PH.D. PROGRAM AND MY RESEARCH IS

145
00:04:51,640 --> 00:04:53,080
IN ECONOMIC ASPECTS OF HIV

146
00:04:53,080 --> 00:04:53,920
PREVENTION AND TREATMENT WITH

147
00:04:53,920 --> 00:04:56,120
PROJECTS IN MEXICO, SOUTH

148
00:04:56,120 --> 00:04:57,520
AFRICA, KENYA, AND THE U.S.

149
00:04:57,520 --> 00:04:58,120
HAPPY TO BE HERE.

150
00:04:58,120 --> 00:05:00,840
THANK YOU.

151
00:05:00,840 --> 00:05:06,760
>> DR. LUIS MO NTANER.

152
00:05:06,760 --> 00:05:13,040
>> PROFESSOR AT THE WISTAR

153
00:05:13,040 --> 00:05:14,840
INSTITUTE.

154
00:05:14,840 --> 00:05:19,240
INTERNATIONAL CLINICAL TRIALS.

155
00:05:19,240 --> 00:05:27,960
>> DR. MOJGAN NAGHAVI.

156
00:05:27,960 --> 00:05:30,920
I GO BY MOJ.

157
00:05:30,920 --> 00:05:32,640
I'M AT NORTHWESTERN UNIVERSITY

158
00:05:32,640 --> 00:05:34,760
DEPARTMENT OF

159
00:05:34,760 --> 00:05:35,240
MICROBIOLOGY-IMMUNOLOGY.

160
00:05:35,240 --> 00:05:39,200
MY RESEARCH FOCUSES ON HIV HOST

161
00:05:39,200 --> 00:05:42,600
IINTRACTION WITH A FOCUS ON HIV

162
00:05:42,600 --> 00:05:45,800
TRAFFICS WITHIN INFECTED CELLS.

163
00:05:45,800 --> 00:05:50,280
>> DR. ANNE NEILAN.

164
00:05:50,280 --> 00:05:51,640
>> GOOD AFTERNOON.

165
00:05:51,640 --> 00:05:53,360
MY NAME IS ANNE NEILAN.

166
00:05:53,360 --> 00:05:55,680
I AM AN INFECTIOUS DISEASES

167
00:05:55,680 --> 00:05:56,840
PHYSICIAN AT MASS GENERAL

168
00:05:56,840 --> 00:05:58,280
HOSPITAL AND AN ASSISTANT

169
00:05:58,280 --> 00:06:01,120
PROFESSOR OF PEDIATRICS AND OF

170
00:06:01,120 --> 00:06:02,200
MEDICINE AT HARVARD MEDICAL

171
00:06:02,200 --> 00:06:03,520
SCHOOL, AND MY CLINICAL AND

172
00:06:03,520 --> 00:06:04,960
RESEARCH INTERESTS FOCUS ON ADD

173
00:06:04,960 --> 00:06:09,800
LE SEPTADOLESCENTS USING

174
00:06:09,800 --> 00:06:11,320
COST-EFFECTIVENESS ANALYSIS AND

175
00:06:11,320 --> 00:06:12,280
SIMULATION MODELING.

176
00:06:12,280 --> 00:06:13,360
THANK YOU.

177
00:06:13,360 --> 00:06:17,640
>> DR. JOHN SLEASMAN.

178
00:06:17,640 --> 00:06:20,320
>> HI, PROFESSOR AND CHIEF
OF

179
00:06:20,320 --> 00:06:21,960
THE DIVISION OF ALLERGY AND

180
00:06:21,960 --> 00:06:25,320
IMMUNOLOGY AT DUKE UNIVERSITY.

181
00:06:25,320 --> 00:06:27,960
MY RESEARCH IS FOCUSED IN HIV

182
00:06:27,960 --> 00:06:29,280
PATHOGENESIS IN CHILDREN AND

183
00:06:29,280 --> 00:06:32,240
ADOLESCENTS.

184
00:06:32,240 --> 00:06:36,480
>> OARAC EX-OFFICIOS.

185
00:06:36,480 --> 00:06:39,640
COLONEL JULIE AKE.

186
00:06:39,640 --> 00:06:41,520
>> I'M JULIE AKE,
INFECTIOUS

187
00:06:41,520 --> 00:06:43,360
DISEASES PHYSICIAN, AND I DIRECT

188
00:06:43,360 --> 00:06:45,880
THE U.S. MILITARY HIV RESEARCH

189
00:06:45,880 --> 00:06:47,320
PROGRAM, WHICH IS AT THE WALTER

190
00:06:47,320 --> 00:06:50,960
REED ARMY INSTITUTE OF RESEARCH.

191
00:06:50,960 --> 00:06:55,640
>> DR. ROBERT EISINGER.

192
00:06:55,640 --> 00:06:57,600
>> HE'LL BE JOINING LATER.

193
00:06:57,600 --> 00:06:57,840
THANKS.

194
00:06:57,840 --> 00:07:00,680
>> OKAY.

195
00:07:00,680 --> 00:07:04,000
DR. VICTORIA DAVEY.

196
00:07:04,000 --> 00:07:10,520
>> HI, I'M VICKY DAVEY
WITH THE

197
00:07:10,520 --> 00:07:11,720
U.S. DEPARTMENT OF VETERANS

198
00:07:11,720 --> 00:07:13,040
AFFAIRS, INFECTIOUS DISEASES

199
00:07:13,040 --> 00:07:13,360
EPIDEMIOLOGY.

200
00:07:13,360 --> 00:07:14,960
THANK YOU.

201
00:07:14,960 --> 00:07:17,560
>> DR. CARL DIEFFENBACH.

202
00:07:17,560 --> 00:07:18,760
>> HI, EVERYBODY.

203
00:07:18,760 --> 00:07:20,560
I'M CARL DIEFFENBACH, DIRECTOR

204
00:07:20,560 --> 00:07:23,640
OF THE DIVISION OF AIDS IN

205
00:07:23,640 --> 00:07:25,640
NIAID.

206
00:07:25,640 --> 00:07:27,960
>> DR. ROHAN HAZRA.

207
00:07:27,960 --> 00:07:28,880
>> GOOD AFTERNOON.

208
00:07:28,880 --> 00:07:30,000
I'M ROHAN HAZRA.

209
00:07:30,000 --> 00:07:31,720
I'M A PEDIATRIC INFECTIOUS

210
00:07:31,720 --> 00:07:32,440
DISEASE PHYSICIAN BY TRAINING

211
00:07:32,440 --> 00:07:33,840
AND THE DIRECTOR OF THE DIVISION

212
00:07:33,840 --> 00:07:36,120
OF EXTRAMURAL RESEARCH AT NICHD,

213
00:07:36,120 --> 00:07:39,000
THE CHILD HEALTH INSTITUTE, HERE

214
00:07:39,000 --> 00:07:40,760
AT NIH.

215
00:07:40,760 --> 00:07:51,440
>> REAR ADMIRAL JONATHAN
MI MER.

216
00:07:53,720 --> 00:07:55,960
>> HE CAN'T JOIN US TODAY.

217
00:07:55,960 --> 00:08:03,120
>> DR. FRANCIS ALI-OSMAN.

218
00:08:03,120 --> 00:08:05,560
>> I WORK ON BRAIN TUMOR
THERAPY

219
00:08:05,560 --> 00:08:07,080
AND MECHANISMS OF RESISTANCE.

220
00:08:07,080 --> 00:08:08,440
I'M REPRESENTING THE NATIONAL

221
00:08:08,440 --> 00:08:11,160
CANCER ADVISORY BOARD.

222
00:08:11,160 --> 00:08:14,760
>> DR. MONICA GANDHI.

223
00:08:14,760 --> 00:08:17,920
>> HI, MY NAME IS DR.
MONICA

224
00:08:17,920 --> 00:08:18,240
GANDHI.

225
00:08:18,240 --> 00:08:19,760
I AM PROFESSOR OF MEDICINE AND

226
00:08:19,760 --> 00:08:21,960
THE DIRECTOR OF THE UCSF CENTER

227
00:08:21,960 --> 00:08:25,480
FOR AIDS RESEARCH AT UCSF, AND I

228
00:08:25,480 --> 00:08:34,240
AM HERE AS EX-OFFICIO FROM ARAC.

229
00:08:34,240 --> 00:08:34,640
THANK YOU.

230
00:08:34,640 --> 00:08:35,640
>> DR. MELANIE OTT.

231
00:08:35,640 --> 00:08:36,840
>> GOOD MORNING,
EVERYBODY.

232
00:08:36,840 --> 00:08:38,600
MY NAME IS MELANIE OTT.

233
00:08:38,600 --> 00:08:40,120
I'M DIRECTING THE GLADSTONE

234
00:08:40,120 --> 00:08:41,040
INSTITUTE OF VIROLOGY.

235
00:08:41,040 --> 00:08:42,960
I'M ALSO PROFESSOR OF MEDICINE

236
00:08:42,960 --> 00:08:44,160
AT UCSF.

237
00:08:44,160 --> 00:08:46,360
MY RESEARCH IS FOCUSED ON HIV

238
00:08:46,360 --> 00:08:48,560
CURE AND I'M REPRESENTING NIDA.

239
00:08:48,560 --> 00:08:51,960
THANK YOU.

240
00:08:51,960 --> 00:08:54,360
>> OARAC LEADERSHIP AND

241
00:08:54,360 --> 00:08:56,440
SPEAKERS.

242
00:08:56,440 --> 00:08:56,920
DR. BILL KAPOGIANNIS.

243
00:08:56,920 --> 00:08:59,040
>> GOOD MORNING, EVERYONE,
AND

244
00:08:59,040 --> 00:08:59,720
WELCOME.

245
00:08:59,720 --> 00:09:00,560
BILL KAPOGIANNIS.

246
00:09:00,560 --> 00:09:02,200
I'M AN ADULT AND PEDIATRIC

247
00:09:02,200 --> 00:09:03,760
INFECTIOUS DISEASE PHYSICIAN BY

248
00:09:03,760 --> 00:09:06,200
TRAINING, AND NOW CURRENTLY THE

249
00:09:06,200 --> 00:09:07,640
ACTING DIRECTOR OF THE NIH

250
00:09:07,640 --> 00:09:10,680
OFFICE OF AIDS RESEARCH.

251
00:09:10,680 --> 00:09:20,320
>> REAR ADMIRAL TIMOTHY
HOLTZ.

252
00:09:20,320 --> 00:09:23,040
>> MY NAME IS TIMOTHY
HOLTZ,

253
00:09:23,040 --> 00:09:27,080
INTERNIST AND INFECTIOUS DISEASE

254
00:09:27,080 --> 00:09:28,840
EPIDEMIOLOGIST AND DEPUTY

255
00:09:28,840 --> 00:09:30,000
DIRECTOR OF OAR.

256
00:09:30,000 --> 00:09:32,040
>> CAPTAIN MARY GLENSHAW.

257
00:09:32,040 --> 00:09:33,640
>> GOOD MORNING, EVERYONE.

258
00:09:33,640 --> 00:09:34,640
MARY GLENSHAW.

259
00:09:34,640 --> 00:09:36,680
I'M AN EPIDEMIOLOGIST BY

260
00:09:36,680 --> 00:09:38,360
TRAINING AND SENIOR SCIENCE

261
00:09:38,360 --> 00:09:39,320
ADVISOR AT THE OAR.

262
00:09:39,320 --> 00:09:41,240
THANKS.

263
00:09:41,240 --> 00:09:49,080
>> MISS RAHEL ABEBE.

264
00:09:49,080 --> 00:09:52,360
>> RAHEL, YOU'RE ON MUTE.

265
00:09:52,360 --> 00:09:53,840
>> GOOD AFTERNOON,
EVERYONE.

266
00:09:53,840 --> 00:09:56,200
MY NAME IS RAHEL ABEBE.

267
00:09:56,200 --> 00:09:57,920
I'M A PUBLIC HEALTH ANALYST IN

268
00:09:57,920 --> 00:09:58,120
OAR.

269
00:09:58,120 --> 00:10:01,760
THANK YOU.

270
00:10:01,760 --> 00:10:07,240
>> DR. GEETANJALI BONSAL.

271
00:10:07,240 --> 00:10:10,280
>> GOOD AFTERNOON,
EVERYONE.

272
00:10:10,280 --> 00:10:12,640
SENIOR SCIENCE ADVISOR AND

273
00:10:12,640 --> 00:10:14,440
HEALTH SCIENCE ADMINISTRATOR

274
00:10:14,440 --> 00:10:16,320
HERE AT OFFICE OF AIDS

275
00:10:16,320 --> 00:10:16,640
RESEARCHMENT

276
00:10:16,640 --> 00:10:19,800
>> DR. ELIZABETH BARR.

277
00:10:19,800 --> 00:10:22,320
>> HI, I'M ELIZABETH BARR.

278
00:10:22,320 --> 00:10:25,400
I'M A SOCIAL SCIENCE -- SOCIAL

279
00:10:25,400 --> 00:10:27,480
SCIENTIST AT THE OFFICE OF

280
00:10:27,480 --> 00:10:29,560
RESEARCH ON WOMEN'S HEALTH.

281
00:10:29,560 --> 00:10:31,880
MY BACKGROUND IS IN

282
00:10:31,880 --> 00:10:33,840
COMMUNITY-LED HIV TREATMENT

283
00:10:33,840 --> 00:10:34,760
RESEARCH

284
00:10:34,760 --> 00:10:37,000
>> MISS CORETTA BYRD.

285
00:10:37,000 --> 00:10:38,880
>> GOOD MORNING AND GOOD

286
00:10:38,880 --> 00:10:39,480
AFTERNOON.

287
00:10:39,480 --> 00:10:40,960
MY NAME IS CORETTA BYRD.

288
00:10:40,960 --> 00:10:45,000
I'M A HEALTH SCIENTIST POLICY

289
00:10:45,000 --> 00:10:45,840
ANALYST AT THE OFFICE OF AIDS

290
00:10:45,840 --> 00:10:46,120
RESEARCH.

291
00:10:46,120 --> 00:10:47,760
THANK YOU.

292
00:10:47,760 --> 00:10:51,840
>> DR. JANINE CLAYTON.

293
00:10:51,840 --> 00:10:54,280
>> GOOD AFTERNOON,
EVERYONE.

294
00:10:54,280 --> 00:10:55,920
I'M JANINE CLAYTON, THE NIH

295
00:10:55,920 --> 00:10:57,240
ASSOCIATE DIRECTOR FOR RESEARCH

296
00:10:57,240 --> 00:10:58,960
ON WOMEN'S HEALTH AND IN THAT

297
00:10:58,960 --> 00:11:00,240
CAPACITY, I AM ALSO THE DIRECTOR

298
00:11:00,240 --> 00:11:01,920
OF THE OFFICE OF RESEARCH ON

299
00:11:01,920 --> 00:11:02,320
WOMEN'S HEALTH.

300
00:11:02,320 --> 00:11:03,920
THANK YOU.

301
00:11:03,920 --> 00:11:08,200
>> MR. ROBERT CRAIG.

302
00:11:08,200 --> 00:11:09,800
>> GOOD AFTERNOON.

303
00:11:09,800 --> 00:11:12,360
MY NAME IS ROBERT CRAIG, I OOM A

304
00:11:12,360 --> 00:11:13,080
HEALTH SCIENTIST IN THE OFFICE

305
00:11:13,080 --> 00:11:16,000
OF AIDS RESEARCH AND LEAD THE

306
00:11:16,000 --> 00:11:18,920
ANALYTICS TEAM FOR OAR.

307
00:11:18,920 --> 00:11:24,240
>> DR. SEBLE KASSAYE.

308
00:11:24,240 --> 00:11:26,600
>> INFECTIOUS DISEASE
PHYSICIAN

309
00:11:26,600 --> 00:11:28,000
AT GEORGETOWN UNIVERSITY,

310
00:11:28,000 --> 00:11:28,920
EPIDEMIOLOGIST ALSO BY TRAINING

311
00:11:28,920 --> 00:11:30,640
AND I WORK WITH COHORTS LOOKING

312
00:11:30,640 --> 00:11:32,280
AT LONG TERM OUTCOMES AMONG

313
00:11:32,280 --> 00:11:35,120
PEOPLE WITH HIV.

314
00:11:35,120 --> 00:11:37,760
>> DR. LESLIE MARSHALL.

315
00:11:37,760 --> 00:11:39,520
>> GOOD AFTERNOON.

316
00:11:39,520 --> 00:11:41,920
I'M LESLIE MARSHALL, AND I'M

317
00:11:41,920 --> 00:11:43,400
SENIOR SCIENCE ADVISOR ON THE

318
00:11:43,400 --> 00:11:45,840
SCIENCE TEAM AT THE NIH OAR, AND

319
00:11:45,840 --> 00:11:47,480
I'M A MOLECULAR VIROLOGIST BY

320
00:11:47,480 --> 00:11:49,440
TRAINING.

321
00:11:49,440 --> 00:11:55,480
>> DR. DIANNE ROUSH.

322
00:11:55,480 --> 00:11:58,240
>> I'M DIANNE ROUSH,
DIRECTOR OF

323
00:11:58,240 --> 00:11:59,920
THE DIVISION OF AIDS RESEARCH AT

324
00:11:59,920 --> 00:12:00,360
NIMH.

325
00:12:00,360 --> 00:12:02,440
I AM HERE FOR MARGUERITA

326
00:12:02,440 --> 00:12:03,760
LIGHTFOOT, OUR NIMH

327
00:12:03,760 --> 00:12:04,680
REPRESENTATIVE ON OUR COUNCIL

328
00:12:04,680 --> 00:12:05,920
WHO COULDN'T MAKE IT, SO I'M

329
00:12:05,920 --> 00:12:06,840
GOING TO PRESENT FOR HER.

330
00:12:06,840 --> 00:12:08,960
THANK YOU.

331
00:12:08,960 --> 00:12:11,880
>> LASTLY, OUR INVITED
GUESTS,

332
00:12:11,880 --> 00:12:13,080
SOME OF WHOM MAY JOIN THE

333
00:12:13,080 --> 00:12:14,520
MEETING LATER.

334
00:12:14,520 --> 00:12:16,680
>> ACTUALLY DR. TURNBULL?

335
00:12:16,680 --> 00:12:16,920
>> YES.

336
00:12:16,920 --> 00:12:18,760
>> I BELIEVE ALL OF OUR
GUESTS

337
00:12:18,760 --> 00:12:20,400
WILL BE JOINING LATER.

338
00:12:20,400 --> 00:12:21,280
>> OH, OKAY.

339
00:12:21,280 --> 00:12:22,160
ALL RIGHT.

340
00:12:22,160 --> 00:12:25,520
THANK YOU, DR. GLENSHAW, FOR THE

341
00:12:25,520 --> 00:12:26,200
CLARIFICATION.

342
00:12:26,200 --> 00:12:36,040
WE HAVE DR. HENRY MASUR, AND DR.

343
00:12:36,040 --> 00:12:39,040
IS THERE ANYONE I DID NOT

344
00:12:39,040 --> 00:12:46,360
ANNOUNCE?

345
00:12:46,360 --> 00:12:47,320
OKAY.

346
00:12:47,320 --> 00:12:48,920
THANK YOU THEN, EVERYONE.

347
00:12:48,920 --> 00:12:52,160
AS A REMINDER, PER OUR CHARTER

348
00:12:52,160 --> 00:12:54,240
AND LEGISLATION, THE OARAC

349
00:12:54,240 --> 00:12:56,760
ADVISES THE OAR DIRECTOR ON

350
00:12:56,760 --> 00:12:58,520
BROAD MATTERS RELATING TO HIV

351
00:12:58,520 --> 00:13:01,480
RESEARCH POLICIES, PRIORITIES

352
00:13:01,480 --> 00:13:03,880
AND EXTRA TEE JEJ PLANNING.

353
00:13:03,880 --> 00:13:06,040
INCLUDING THE REVIEW OF NIH

354
00:13:06,040 --> 00:13:08,280
HIV/AIDS PROGRAMS.

355
00:13:08,280 --> 00:13:10,040
I WILL NOW PROVIDE A BRIEF

356
00:13:10,040 --> 00:13:11,680
OVERVIEW OF TODAY'S AGENDA,

357
00:13:11,680 --> 00:13:14,160
WHICH WILL INCLUDE A REPORT FROM

358
00:13:14,160 --> 00:13:19,240
THE OAR DIRECTOR, A PRESENTATION

359
00:13:19,240 --> 00:13:20,960
FROM THE DIRECTOR OF THE NIH

360
00:13:20,960 --> 00:13:24,360
OFFICE OF RESEARCH ON WOMEN'S

361
00:13:24,360 --> 00:13:30,400
HEALTH, AN UP TATE UPDATE ON THV

362
00:13:30,400 --> 00:13:31,800
AND WOMEN'S SIGNATURE PROGRAM, A

363
00:13:31,800 --> 00:13:33,680
PRESENTATION FROM ONE OF THE

364
00:13:33,680 --> 00:13:38,080
PDIs OF THE NATIONAL MACS WHIS

365
00:13:38,080 --> 00:13:40,600
COMBINED COHORT STUDY AND THE

366
00:13:40,600 --> 00:13:43,200
STAR COHORT, AN UPDATE ON THE

367
00:13:43,200 --> 00:13:45,600
NIH HIV AND AGING AND EARLY

368
00:13:45,600 --> 00:13:48,560
CAREER INVESTIGATOR SIGNATURE

369
00:13:48,560 --> 00:13:51,080
PROGRAMS, A PRESENTATION ON THE

370
00:13:51,080 --> 00:13:54,920
NEW NIH OAR DATA HUB, UPDATES

371
00:13:54,920 --> 00:13:58,200
FROM NIH ADVISORY COUNCILS, AND

372
00:13:58,200 --> 00:14:01,680
FINALLY, UPDATES FROM THE OARAC

373
00:14:01,680 --> 00:14:03,320
HIV CLINICAL GUIDELINES WORKING

374
00:14:03,320 --> 00:14:05,840
GROUPS.

375
00:14:05,840 --> 00:14:07,480
THE AGENDA ALSO INCLUDES TIME

376
00:14:07,480 --> 00:14:11,840
FOR REGISTERED COMMENTS.

377
00:14:11,840 --> 00:14:17,120
ANYONE LISTENING TODAY WH WHO

378
00:14:17,120 --> 00:14:18,440
WISHES TO MAKE A PUBLIC COMMENT

379
00:14:18,440 --> 00:14:26,000
SHOULD EMAIL CAPTAIN GLENSHAW AT

380
00:14:26,000 --> 00:14:27,200
OARACINFO@NIH.GOV.

381
00:14:27,200 --> 00:14:30,480
WITH YOUR NAME, AFFILIATION, AND

382
00:14:30,480 --> 00:14:32,760
QUESTION OR COMMENTS.

383
00:14:32,760 --> 00:14:36,160
PLEASE VISIT THE NIH OAR WEBSITE

384
00:14:36,160 --> 00:14:37,800
OR THE FEDERAL REGISTER NOTICE

385
00:14:37,800 --> 00:14:40,760
FOR MORE DETAILS.

386
00:14:40,760 --> 00:14:45,880
NOW, I WILL INTRODUCE DR. BILL

387
00:14:45,880 --> 00:14:47,000
KAPOGIANNIS.

388
00:14:47,000 --> 00:14:51,480
BILL JOINED OAR AND IS SERVING

389
00:14:51,480 --> 00:14:53,600
AS THE ACTING NIH ASSOCIATE

390
00:14:53,600 --> 00:14:55,440
DIRECTOR IN AIDS RESEARCH AND

391
00:14:55,440 --> 00:14:58,160
ACTING DIRECTOR OF OAR, WHILE A

392
00:14:58,160 --> 00:14:59,920
NATIONAL SEARCH FOR A NEW

393
00:14:59,920 --> 00:15:02,880
DIRECTOR IS CONDUCTED.

394
00:15:02,880 --> 00:15:06,480
IN THIS ROLE, HE LEADS OAR IN

395
00:15:06,480 --> 00:15:09,120
COORDINATING THE NIH HIV AGENDA

396
00:15:09,120 --> 00:15:11,920
TO END HIV PANDEMIC AND IMPROVE

397
00:15:11,920 --> 00:15:15,680
HEALTH OF PEOPLE WITH HIV.

398
00:15:15,680 --> 00:15:21,040
PRIOR TO JOINING OAR, DR

399
00:15:21,040 --> 00:15:24,000
DR. KAPOGIANNIS SERVED AT THE

400
00:15:24,000 --> 00:15:24,920
EUNICE KENNEDY SHRIVER NATIONAL

401
00:15:24,920 --> 00:15:26,240
INSTITUTE OF CHILD HEALTH AND

402
00:15:26,240 --> 00:15:28,480
HUMAN DEVELOPMENT.

403
00:15:28,480 --> 00:15:31,120
WHERE HE LED SEVERAL DOMESTIC

404
00:15:31,120 --> 00:15:32,200
AND INTERNATIONAL RESEARCH

405
00:15:32,200 --> 00:15:35,160
NETWORKS AND CONSORTIA, FOCUSED

406
00:15:35,160 --> 00:15:37,920
ON INFECTIOUS DISEASE AND

407
00:15:37,920 --> 00:15:41,040
COMPLICATIONS SUCH AS HIV AND

408
00:15:41,040 --> 00:15:43,600
COVID-19 AFFECTING CHILDREN,

409
00:15:43,600 --> 00:15:46,400
ADOLESCENTS, AND YOUNG ADULTS.

410
00:15:46,400 --> 00:15:48,480
HE IS ALSO THE EXECUTIVE

411
00:15:48,480 --> 00:15:50,280
SECRETARY AND EDITOR OF THE

412
00:15:50,280 --> 00:15:50,880
GUIDELINES FOR THE PREVENTION

413
00:15:50,880 --> 00:15:54,160
AND TREATMENT OF OPPORTUNISTIC

414
00:15:54,160 --> 00:15:55,840
INFECTIONS IN CHILDREN WITH AND

415
00:15:55,840 --> 00:15:58,760
EXPOSED TO HIV.

416
00:15:58,760 --> 00:16:01,120
BILL IS A BOARD CERTIFIED

417
00:16:01,120 --> 00:16:02,840
INFECTIOUS DISEASE SPECIALIST IN

418
00:16:02,840 --> 00:16:05,120
PEDIATRICS AND INTERNAL

419
00:16:05,120 --> 00:16:05,480
MEDICINE.

420
00:16:05,480 --> 00:16:09,080
HE EARNED HIS M.D. FROM THE

421
00:16:09,080 --> 00:16:11,160
UNIVERSITY OF ILLINOIS AT

422
00:16:11,160 --> 00:16:11,800
CHICAGO COLLEGE OF MEDICINE,

423
00:16:11,800 --> 00:16:14,600
WHERE HE ALSO COMPLETED

424
00:16:14,600 --> 00:16:15,960
RESIDENCY IN INTERNAL MEDICINE

425
00:16:15,960 --> 00:16:18,040
AT PEDIATRICS.

426
00:16:18,040 --> 00:16:20,360
HE COMPLETED A COMBINED

427
00:16:20,360 --> 00:16:23,280
FELLOWSHIP IN INFECTIOUS DISEASE

428
00:16:23,280 --> 00:16:25,680
AND PEDIATRICS AT EMORY

429
00:16:25,680 --> 00:16:27,440
UNIVERSITY SCHOOL OF MEDICINE IN

430
00:16:27,440 --> 00:16:29,640
ATLANTA, GEORGIA.

431
00:16:29,640 --> 00:16:30,880
DR. KAPOGIANNIS, I WILL TURN IT

432
00:16:30,880 --> 00:16:39,920
OVER TO YOU.

433
00:16:39,920 --> 00:16:41,760
>> THANK YOU, IVY, FOR
THOSE

434
00:16:41,760 --> 00:16:45,200
KIND WORDS, AND ONCE AGAIN, GOOD

435
00:16:45,200 --> 00:16:48,000
MORNING AND GOOD AFTERNOON AND

436
00:16:48,000 --> 00:16:48,640
WELCOME, EVERYBODY.

437
00:16:48,640 --> 00:16:50,280
IT IS A GREAT PLEASURE TO

438
00:16:50,280 --> 00:16:51,840
WELCOME YOU HERE, BOTH VIRTUALLY

439
00:16:51,840 --> 00:16:54,440
AND IN PERSON.

440
00:16:54,440 --> 00:16:58,200
AND JUST WANT TO GO OVER A

441
00:16:58,200 --> 00:17:00,600
LITTLE BIT OF THE STRUCTURE OF

442
00:17:00,600 --> 00:17:02,800
MY BRIEF TALK TODAY.

443
00:17:02,800 --> 00:17:04,200
I'M GOING TO GIVE A BRIEF

444
00:17:04,200 --> 00:17:07,120
INTRODUCTION TO ME AND SOME

445
00:17:07,120 --> 00:17:09,120
POINTS ON A VISION, BOTH FOR THE

446
00:17:09,120 --> 00:17:12,920
OFFICE AND THE COUNCIL, AND

447
00:17:12,920 --> 00:17:16,120
AGAIN, REALLY HIGHLIGHT ALL OF

448
00:17:16,120 --> 00:17:19,360
OUR MEMBERSHIP UPDATES, GO A

449
00:17:19,360 --> 00:17:25,000
LITTLE BIT INTO THE FY 2025 NIH

450
00:17:25,000 --> 00:17:26,400
HIV/AIDS PROFESSIONAL JUDGMENT

451
00:17:26,400 --> 00:17:28,600
BUDGET, AND THEN HIGHLIGHT SOME

452
00:17:28,600 --> 00:17:30,640
KEY OAR ACTIVITIES SINCE THE

453
00:17:30,640 --> 00:17:32,840
MARCH OARAC MEETING.

454
00:17:32,840 --> 00:17:36,560
TOUCH ON THE STRATEGIC PLANNING

455
00:17:36,560 --> 00:17:40,320
DEVELOPMENT AND ALSO END WITH A

456
00:17:40,320 --> 00:17:41,640
REALLY IMPORTANT TOPIC, WHICH IS

457
00:17:41,640 --> 00:17:45,520
THE WOMEN AND HIV SESSION.

458
00:17:45,520 --> 00:17:48,600
SO REALLY, I WANT TO TAKE A

459
00:17:48,600 --> 00:17:50,680
MOMENT HERE TO REALLY

460
00:17:50,680 --> 00:17:55,040
ACKNOWLEDGE THAT THERE IS A REAL

461
00:17:55,040 --> 00:17:56,240
TRANSITION THAT HAS TAKEN PLACE,

462
00:17:56,240 --> 00:17:59,200
AND I REALLY, REALLY OWE A DEBT

463
00:17:59,200 --> 00:18:01,720
OF GRATITUDE, WE OWE A DEBT OF

464
00:18:01,720 --> 00:18:04,040
GRATITUDE TO DR. MAUREEN

465
00:18:04,040 --> 00:18:08,880
GOODENOW, WHO ON MARCH 26TH, HAS

466
00:18:08,880 --> 00:18:12,680
TRANSITIONED TO ME, IN THIS

467
00:18:12,680 --> 00:18:14,440
ROLE, AND SHE TRANSITIONED TO

468
00:18:14,440 --> 00:18:16,000
HER NEW ROLE AS SENIOR ADVISOR

469
00:18:16,000 --> 00:18:18,360
TO THE NIH OFFICE OF THE

470
00:18:18,360 --> 00:18:19,040
DIRECTOR.

471
00:18:19,040 --> 00:18:25,040
MAUREEN HAS LED OAR SINCE 2016.

472
00:18:25,040 --> 00:18:25,920
NOTABLY SHE WAS THE FIRST WOMAN

473
00:18:25,920 --> 00:18:28,800
TO DIRECT THE OFFICE.

474
00:18:28,800 --> 00:18:30,000
HER ACCOMPLISHMENTS ARE MANY AND

475
00:18:30,000 --> 00:18:31,400
I'LL JUST NAME A FEW HERE.

476
00:18:31,400 --> 00:18:35,360
SHE COORDINATED A $250 MILLION

477
00:18:35,360 --> 00:18:37,240
INCREASE IN NIH HIV RESEARCH

478
00:18:37,240 --> 00:18:39,640
BUDGET OVER THE LAST FIVE YEARS,

479
00:18:39,640 --> 00:18:41,360
IMPLEMENTED THE FIRST FIVE-YEAR

480
00:18:41,360 --> 00:18:44,560
NIH STRATEGIC PLAN FOR HIV AND

481
00:18:44,560 --> 00:18:46,440
HIV-RELATED RESEARCH, AND WORKED

482
00:18:46,440 --> 00:18:47,640
AT THE WHITE HOUSE OFFICE OF

483
00:18:47,640 --> 00:18:49,600
NATIONAL AIDS POLICY TO ENSURE

484
00:18:49,600 --> 00:18:51,200
STRONG RESEARCH REPRESENTATION

485
00:18:51,200 --> 00:18:55,160
IN THE REVISED 2022-25 NATIONAL

486
00:18:55,160 --> 00:18:58,760
HIV/AIDS STRATEGY, OR NHAS.

487
00:18:58,760 --> 00:19:00,080
I'M SURE YOU'LL JOIN ME IN

488
00:19:00,080 --> 00:19:02,520
THANKING MAUREEN FOR ADVANCING

489
00:19:02,520 --> 00:19:04,680
HIV RESEARCH DURING HER OAR

490
00:19:04,680 --> 00:19:05,240
TENURE.

491
00:19:05,240 --> 00:19:06,960
SO WITH THIS TRANSITION OF

492
00:19:06,960 --> 00:19:08,840
LEADERSHIP, IT IS AN HONOR FOR

493
00:19:08,840 --> 00:19:11,880
ME, AND I'M HUMBLED, TO SERVE AS

494
00:19:11,880 --> 00:19:13,840
THE ACTING NIH ASSOCIATE

495
00:19:13,840 --> 00:19:15,280
DIRECTOR OF AIDS RESEARCH AND

496
00:19:15,280 --> 00:19:19,440
ACTING DIRECTOR OF OAR'S -- THE

497
00:19:19,440 --> 00:19:21,200
OFFICE, WHILE A NATIONWIDE

498
00:19:21,200 --> 00:19:24,480
SEARCH FOR A NEW DIRECTOR IS

499
00:19:24,480 --> 00:19:25,320
CONDUCTED.

500
00:19:25,320 --> 00:19:27,520
THE LAST 18 YEARS OF MY CAREER

501
00:19:27,520 --> 00:19:29,960
HAVE BEEN COMMITTED TO HIV

502
00:19:29,960 --> 00:19:31,360
RESEARCH IN DIFFERENT

503
00:19:31,360 --> 00:19:34,160
CAPACITIES, AS IVY MENTIONED, AT

504
00:19:34,160 --> 00:19:35,000
THE EUNICE KENNEDY SHRIVER, MY

505
00:19:35,000 --> 00:19:36,520
HOME, THE NATIONAL INSTITUTE OF

506
00:19:36,520 --> 00:19:40,360
CHILD HEALTH AND HUMAN DEVEL

507
00:19:40,360 --> 00:19:42,400
DEVELOPMENT, MOSTLY AS

508
00:19:42,400 --> 00:19:43,640
DR. TURNBULL ALLUDED TO, I'VE

509
00:19:43,640 --> 00:19:45,000
FOCUSED A LOT ON ADOLESCENTS AND

510
00:19:45,000 --> 00:19:46,920
YOUNG ADULTS WITH HIV THROUGH MY

511
00:19:46,920 --> 00:19:50,560
WORK WITH THE ADOLESCENT TRIALS

512
00:19:50,560 --> 00:19:52,760
NETWORK DOMESTICALLY, AND THEN

513
00:19:52,760 --> 00:19:54,960
THROUGH THE PATCH CONSORTIUM IN

514
00:19:54,960 --> 00:19:56,920
LMICs AND SUB-SAHARAN AFRICA

515
00:19:56,920 --> 00:19:57,600
AND BRAZIL.

516
00:19:57,600 --> 00:20:01,520
SO CLINICALLY, I'VE PRACTICED

517
00:20:01,520 --> 00:20:04,040
SEEING ADD LE SENTSZ AND YOUNG

518
00:20:04,040 --> 00:20:06,680
ADULTS WITH HIV AT JOHNS HOPKINS

519
00:20:06,680 --> 00:20:07,880
IN BALTIMORE THROUGH MY

520
00:20:07,880 --> 00:20:09,840
VOLUNTEER WORK.

521
00:20:09,840 --> 00:20:11,640
AND OF COURSE AS MENTIONED, ALSO

522
00:20:11,640 --> 00:20:15,320
MANY OF YOU KNOW ME THROUGH THE

523
00:20:15,320 --> 00:20:16,640
PEDS OPPORTUNISTIC INFECTION

524
00:20:16,640 --> 00:20:17,520
GUIDELINES AS THE EXECUTIVE

525
00:20:17,520 --> 00:20:19,360
SECRETARY.

526
00:20:19,360 --> 00:20:21,760
SO AS ACTING DIRECTOR, I AM

527
00:20:21,760 --> 00:20:23,720
COMMITTED TO CONTINUE WORKING TO

528
00:20:23,720 --> 00:20:25,680
DEVELOP THE NECESSARY TOOLS AND

529
00:20:25,680 --> 00:20:27,760
INTERVENTIONS TO END HIV IN THE

530
00:20:27,760 --> 00:20:29,520
U.S. AND GLOBALLY.

531
00:20:29,520 --> 00:20:31,840
IN KEEPING WITH MY CLINICAL AND

532
00:20:31,840 --> 00:20:35,760
NIH ROOTS, I'M ALSO COMMITTED TO

533
00:20:35,760 --> 00:20:36,960
REDOUBLING OUR EFFORTS TO

534
00:20:36,960 --> 00:20:38,960
ADDRESS HEALTH DISPARITIES AND

535
00:20:38,960 --> 00:20:41,120
INEQUITIES IN MARGINALIZED AND

536
00:20:41,120 --> 00:20:43,200
MINORITIZED COMMUNITIES

537
00:20:43,200 --> 00:20:44,120
DISPROPORTIONATELY IMPACTED BY

538
00:20:44,120 --> 00:20:45,520
HIV ACROSS THE U.S.

539
00:20:45,520 --> 00:20:48,480
I'M GRATEFUL TO THE OAR'S

540
00:20:48,480 --> 00:20:50,440
ADVISORY COUNCIL FOR THEIR

541
00:20:50,440 --> 00:20:51,640
CONTRIBUTIONS AND VISION, AND I

542
00:20:51,640 --> 00:20:53,200
LOOK FORWARD TO OUR CONTINUED

543
00:20:53,200 --> 00:20:57,320
COLLABORATION.

544
00:20:57,320 --> 00:20:58,640
NOW I'M GOING TO PIVOT A LITTLE

545
00:20:58,640 --> 00:20:59,880
BIT TO TELL US ABOUT OUR

546
00:20:59,880 --> 00:21:00,520
MEMBERSHIP UPDATES.

547
00:21:00,520 --> 00:21:02,280
AS NOTED EARLIER IN TODAY'S

548
00:21:02,280 --> 00:21:05,360
MEETING, WE WELCOME DR. IVY

549
00:21:05,360 --> 00:21:07,400
TURNBULL AS THE INCOMING OARAC

550
00:21:07,400 --> 00:21:08,280
CHAIR.

551
00:21:08,280 --> 00:21:09,720
DR. TURNBULL SERVES AS THE

552
00:21:09,720 --> 00:21:11,000
DEPUTY EXECUTIVE DIRECTOR OF THE

553
00:21:11,000 --> 00:21:12,200
AIDS ALLIANCE FOR WOMEN,

554
00:21:12,200 --> 00:21:14,640
INFANTS, CHILDREN, YOUTH AND

555
00:21:14,640 --> 00:21:16,600
FAMILIES, AND THE FOUNDING

556
00:21:16,600 --> 00:21:17,400
MEMBER AND CHAIR OF THE BOARD OF

557
00:21:17,400 --> 00:21:19,240
DIRECTORS OF THE NATIONAL BLACK

558
00:21:19,240 --> 00:21:20,400
WOMEN'S HIV/AIDS NETWORK.

559
00:21:20,400 --> 00:21:22,840
THE PRE-EMINENT POLICY AND

560
00:21:22,840 --> 00:21:24,040
ADVOCACY ORGANIZATION FOR BLACK

561
00:21:24,040 --> 00:21:26,840
WOMEN AND GIRLS LIVING WITH AND

562
00:21:26,840 --> 00:21:29,640
IMPACTED BY HIV AND OTHER HEALTH

563
00:21:29,640 --> 00:21:30,280
DISPARITIES.

564
00:21:30,280 --> 00:21:32,480
IVY, WE ARE VERY GRATEFUL FOR

565
00:21:32,480 --> 00:21:34,560
YOU AGREEING TO SERVE AS THE

566
00:21:34,560 --> 00:21:35,200
OARAC CHAIR.

567
00:21:35,200 --> 00:21:39,360
WE ALSO WELCOME THE FOLLOWING

568
00:21:39,360 --> 00:21:42,000
MEMBERS TO -- THE FOLLOWING

569
00:21:42,000 --> 00:21:43,080
OARAC VOTING MEMBERS.

570
00:21:43,080 --> 00:21:45,080
I'LL START OFF WITH DR. OMAR

571
00:21:45,080 --> 00:21:46,360
GALARRAGA, WHO SERVES AS THE

572
00:21:46,360 --> 00:21:48,680
DIRECTOR OF THE HEALTH SERVICES

573
00:21:48,680 --> 00:21:49,960
RESEARCH DOCTORAL PROGRAM AT

574
00:21:49,960 --> 00:21:52,720
BROWN UNIVERSITY, WHERE HE'S AN

575
00:21:52,720 --> 00:21:53,680
ASSOCIATE PROFESSOR OF HEALTH

576
00:21:53,680 --> 00:21:54,960
SERVICES POLICY AND PRACTICE AT

577
00:21:54,960 --> 00:21:56,080
THE SCHOOL OF PUBLIC HEALTH.

578
00:21:56,080 --> 00:21:57,840
HE BRINGS GLOBAL AND DOMESTIC

579
00:21:57,840 --> 00:21:59,960
HEALTH ECONOMICS EXPERTISE TO

580
00:21:59,960 --> 00:22:00,520
OARAC.

581
00:22:00,520 --> 00:22:02,240
HIS RESEARCH INCLUDES BEHAVIORAL

582
00:22:02,240 --> 00:22:05,440
AND OTHER HEALTH INTERVENTIONS

583
00:22:05,440 --> 00:22:07,160
AND HEALTH SYSTEMS AND HEALTH

584
00:22:07,160 --> 00:22:08,480
ECONOMICS EVALUATIONS.

585
00:22:08,480 --> 00:22:12,120
ALSO WELCOME DR. LUIS MONTANER,

586
00:22:12,120 --> 00:22:19,120
VI. INCLUDING HIV, CANCER, COVI,

587
00:22:19,120 --> 00:22:20,960
AND OTHER EMERGING VIRAL

588
00:22:20,960 --> 00:22:22,200
INFECTIONS, AND EXPLORES NEW

589
00:22:22,200 --> 00:22:23,920
STRATEGIES TO BOOST THE

590
00:22:23,920 --> 00:22:28,640
NATURALLY MEUN FUNATURALLY MEUNO

591
00:22:28,640 --> 00:22:33,800
COMBAT THESE CONDITIONS.

592
00:22:33,800 --> 00:22:35,440
DR. MOJGAN NAGHAVI AT THE

593
00:22:35,440 --> 00:22:37,280
FEINBERG SCHOOL OF MEDICINE AT

594
00:22:37,280 --> 00:22:38,240
NORTHWESTERN UNIVERSITY, BACK IN

595
00:22:38,240 --> 00:22:40,120
MY HOMETOWN, CHICAGO.

596
00:22:40,120 --> 00:22:42,840
HER RESEARCH LAB FOCUSES ON HIV

597
00:22:42,840 --> 00:22:45,240
BIOLOGY DURING EARLY INFECTION

598
00:22:45,240 --> 00:22:45,800
AND NEURODEGENERATION.

599
00:22:45,800 --> 00:22:47,880
AND LAST BUT NOT LEAST IS MY

600
00:22:47,880 --> 00:22:51,600
COLLEAGUE AND FRIEND GR ANNE

601
00:22:51,600 --> 00:22:55,200
NEILAN, PEDIATRIC I.D. PHYSICIAN

602
00:22:55,200 --> 00:22:59,200
WHO SERVES AS THE -- SERVES AS

603
00:22:59,200 --> 00:23:00,160
ASSISTANT PROFESSOR OF MEDICINE

604
00:23:00,160 --> 00:23:01,640
AND PEDIATRICS AT HARVARD

605
00:23:01,640 --> 00:23:02,040
MEDICAL SCHOOL.

606
00:23:02,040 --> 00:23:03,760
IN ADDITION TO CLINICAL CARE OF

607
00:23:03,760 --> 00:23:05,440
ADOLESCENTS AND YOUNG ADULTS,

608
00:23:05,440 --> 00:23:07,920
HER RESEARCH INCLUDES MODELING

609
00:23:07,920 --> 00:23:10,680
THE HIV CASCADE TO ASSESS

610
00:23:10,680 --> 00:23:12,000
CLINICAL IMPACT, COST AND

611
00:23:12,000 --> 00:23:12,640
COST-EFFECTIVENESS.

612
00:23:12,640 --> 00:23:14,600
AND THANK YOU, ANNE, FOR

613
00:23:14,600 --> 00:23:16,240
AGREEING TO SERVE ADDITIONALLY

614
00:23:16,240 --> 00:23:18,000
AS THE OARAC REPRESENTATIVE TO

615
00:23:18,000 --> 00:23:20,920
THE NIAID AIDS RESEARCH ADVISORY

616
00:23:20,920 --> 00:23:25,000
COMMITTEE OR THE ARAC.

617
00:23:25,000 --> 00:23:30,680
SO NOW I'D RIEK TO START WITH AN

618
00:23:30,680 --> 00:23:32,160
OVERVIEW OF A KEY OARAC ACTIVITY

619
00:23:32,160 --> 00:23:33,120
SINCE THE LAST MEETING.

620
00:23:33,120 --> 00:23:34,200
I'D LIKE TO CALL ATTENTION TO

621
00:23:34,200 --> 00:23:36,480
THE COMPLETION OF THE 2025

622
00:23:36,480 --> 00:23:37,600
HIV/AIDS PROFESSIONAL JUDGMENT

623
00:23:37,600 --> 00:23:41,520
BUDGET OR THE P.J., AS WE

624
00:23:41,520 --> 00:23:42,520
AFFECTIONATELY CALL IT, WHICH IS

625
00:23:42,520 --> 00:23:44,840
AVAILABLE ON OAR'S WEBSITE.

626
00:23:44,840 --> 00:23:46,320
THIS DOCUMENT HIGHLIGHTS

627
00:23:46,320 --> 00:23:47,960
ACCOMPLISHMENTS ON HIV/AIDS

628
00:23:47,960 --> 00:23:48,880
RESEARCH DURING THE PREVIOUS

629
00:23:48,880 --> 00:23:50,920
YEAR AND ESTIMATES THE AMOUNT OF

630
00:23:50,920 --> 00:23:52,480
ADDITIONAL FUNDS THAT ARE NEEDED

631
00:23:52,480 --> 00:23:53,680
TO ADVANCE PROGRAMS IN PRIORITY

632
00:23:53,680 --> 00:23:55,560
AREAS OF SCIENCE AS OUTLINED IN

633
00:23:55,560 --> 00:23:59,480
THE FY 2021-25 NIH STRATEGIC

634
00:23:59,480 --> 00:24:03,080
PLAN FOR NIH AND HIV-RELATED

635
00:24:03,080 --> 00:24:03,360
RESEARCH.

636
00:24:03,360 --> 00:24:05,400
IN THE LAST CALENDAR YEAR, OAR

637
00:24:05,400 --> 00:24:06,320
HAS ACCELERATED THE DEVELOPMENT

638
00:24:06,320 --> 00:24:10,840
OF THE FY 2024 AND 2025 PJs TO

639
00:24:10,840 --> 00:24:11,920
ALIGN BETTER WITH THE

640
00:24:11,920 --> 00:24:12,960
GOVERNMENT -- THE U.S.

641
00:24:12,960 --> 00:24:16,320
GOVERNMENT BUDGET PROCESS.

642
00:24:16,320 --> 00:24:20,360
THE FY 2025 P.J. BUDGET

643
00:24:20,360 --> 00:24:21,440
HIGHLIGHTS KEY INVESTMENT

644
00:24:21,440 --> 00:24:24,320
OPPORTUNITIES ACROSS FOUR AREAS.

645
00:24:24,320 --> 00:24:25,600
THOSE ARE, BASIC RESEARCH TO

646
00:24:25,600 --> 00:24:27,120
PROMOTE DISCOVERY AND ADVANCE

647
00:24:27,120 --> 00:24:29,120
HIV SCIENCE, THE DEVELOPMENT AND

648
00:24:29,120 --> 00:24:30,120
ASSESSMENT OF MO VEL

649
00:24:30,120 --> 00:24:31,360
INTERVENTIONS INCLUDING CLINICAL

650
00:24:31,360 --> 00:24:35,280
TRIALS ACROSS THE LIFESPAN,

651
00:24:35,280 --> 00:24:36,440
TRANSLATION, IMPLEMENTATION AND

652
00:24:36,440 --> 00:24:38,280
DISSEMINATION OF HIV RESEARCH

653
00:24:38,280 --> 00:24:39,400
DISCOVERIES TO OPTIMIZE PUBLIC

654
00:24:39,400 --> 00:24:41,040
HEALTH IMPACT, AND AN

655
00:24:41,040 --> 00:24:41,920
INFRASTRUCTURE AND WORKFORCE

656
00:24:41,920 --> 00:24:43,160
DEVELOPMENT TO ENHANCE RESEARCH

657
00:24:43,160 --> 00:24:45,640
CAPACITY AND INCREASE DIVERSITY.

658
00:24:45,640 --> 00:24:49,920
THIS P.J. REQUESTS A

659
00:24:49,920 --> 00:24:51,880
$659 MILLION INCREASE FOR A

660
00:24:51,880 --> 00:24:55,520
TOTAL PROPOSED BUDGET OF

661
00:24:55,520 --> 00:24:58,320
$3.953 BILLION FOR FY 2025, AN

662
00:24:58,320 --> 00:25:01,080
INCREASE OF 20% OVER THE FY 2023

663
00:25:01,080 --> 00:25:05,240
ENACTED BUDGET.

664
00:25:05,240 --> 00:25:08,280
SO NOW TO PIVOT, I'D LIKE TO

665
00:25:08,280 --> 00:25:09,200
BRIEFLY HIGHLIGHT THREE

666
00:25:09,200 --> 00:25:10,920
SIGNIFICANT OAR ENGAGEMENTS

667
00:25:10,920 --> 00:25:12,000
SINCE MARCH.

668
00:25:12,000 --> 00:25:13,320
EARLY LAST MONTH I REPRESENTED

669
00:25:13,320 --> 00:25:15,520
NIH IN AN IN-PERSON BRIEFING AT

670
00:25:15,520 --> 00:25:17,240
THE U.S. CAPITOL VISITORS CENTER

671
00:25:17,240 --> 00:25:19,560
THAT YOU CAN SEE PICTURES THERE.

672
00:25:19,560 --> 00:25:20,760
THE BRIEFING WAS ORGANIZED BY

673
00:25:20,760 --> 00:25:22,480
THE RESEARCH WORKING GROUP OF

674
00:25:22,480 --> 00:25:24,920
THE FEDERAL AIDS POLICY

675
00:25:24,920 --> 00:25:26,800
PARTNERSHIP, OR FAPP.

676
00:25:26,800 --> 00:25:29,520
IN THAT BRIEFING IN PRERECORDED

677
00:25:29,520 --> 00:25:30,720
REMARKS, REPRESENTATIVE BARBARA

678
00:25:30,720 --> 00:25:33,120
LEE SPOKE HIGHLY OF THE NIH HIV

679
00:25:33,120 --> 00:25:34,800
RESEARCH SUPPORTING LONG TERM

680
00:25:34,800 --> 00:25:36,080
UNITED STATES COMPETITIVENESS ON

681
00:25:36,080 --> 00:25:38,240
A GLOBAL SCALE.

682
00:25:38,240 --> 00:25:41,440
OTHER INVITED SPEAKERS INCLUDED

683
00:25:41,440 --> 00:25:43,880
MR. HAROLD PHILLIPS, DIRECTOR OF

684
00:25:43,880 --> 00:25:45,040
THE OFFICE OF NATIONAL AIDS

685
00:25:45,040 --> 00:25:45,800
POLICY, AS WELL AS

686
00:25:45,800 --> 00:25:49,440
REPRESENTATIVES FROM THE HIV

687
00:25:49,440 --> 00:25:52,080
VACCINE TRIALS NETWORK AND VC

688
00:25:52,080 --> 00:25:54,400
CENTER FOR AIDS RESEARCH AND THE

689
00:25:54,400 --> 00:25:55,680
MILITARY HIV RESEARCH PROGRAM.

690
00:25:55,680 --> 00:25:58,480
SO NOW I WANT TO PIVOT A LITTLE

691
00:25:58,480 --> 00:26:01,320
BIT ON MORE ACTIVITIES HERE AND

692
00:26:01,320 --> 00:26:03,200
THIS IS TO ACKNOWLEDGE AND

693
00:26:03,200 --> 00:26:08,880
REMEUND MREMIND ME THAT THE OARY

694
00:26:08,880 --> 00:26:10,200
DIRECTOR REAR ADMIRAL TIMOTHY

695
00:26:10,200 --> 00:26:12,400
HOLTZ REPRESENTED THE NIH AT A

696
00:26:12,400 --> 00:26:13,920
VIRTUAL BRIEFING FOR SENATE AND

697
00:26:13,920 --> 00:26:18,040
APPROPRIATIONS STAFF AT HHS AS

698
00:26:18,040 --> 00:26:20,240
ASPR AS THEY'RE KNOWN ON ENDING

699
00:26:20,240 --> 00:26:25,240
THE HIV EPIDEMIC OR EHE SPENDING

700
00:26:25,240 --> 00:26:26,400
PLAN FOR 2023.

701
00:26:26,400 --> 00:26:27,480
THERE WERE ALSO PRESENTATIONS

702
00:26:27,480 --> 00:26:28,600
FROM THE OFFICE OF THE

703
00:26:28,600 --> 00:26:30,880
ASSISTANCE SECRETARY FOR HEALTH,

704
00:26:30,880 --> 00:26:32,800
CDC, HRSA AND THE INDIAN HEALTH

705
00:26:32,800 --> 00:26:33,320
SERVICE.

706
00:26:33,320 --> 00:26:34,760
THE SLIDE HERE THAT YOU SEE

707
00:26:34,760 --> 00:26:37,720
SHOWS A BRE BREAKDOWN OF THE

708
00:26:37,720 --> 00:26:43,760
$26 MILLION ALLOCATED TO NIH FOR

709
00:26:43,760 --> 00:26:45,680
EHE ACTIVITIES IN FY 2023.

710
00:26:45,680 --> 00:26:48,080
WE PLAN TO SPEND $5.6 MILLION OF

711
00:26:48,080 --> 00:26:49,760
THOSE DOLLARS TO SUPPORT THE

712
00:26:49,760 --> 00:26:53,160
FINAL YEAR OF FY 2022 EHE

713
00:26:53,160 --> 00:26:55,440
PROJECT, FOCUSING ON HIV-RELATED

714
00:26:55,440 --> 00:26:56,520
HEALTH EQUITY RESEARCH.

715
00:26:56,520 --> 00:26:58,640
THE REMAINING $20.4 MILLION OF

716
00:26:58,640 --> 00:27:00,600
THOSE WILL SUPPORT NEW TWO-YEAR

717
00:27:00,600 --> 00:27:01,880
IMPLEMENTATION RESEARCH PROJECTS

718
00:27:01,880 --> 00:27:03,240
AWARDED THROUGH THE CENTERS FOR

719
00:27:03,240 --> 00:27:06,400
AIDS RESEARCH, AND AIDS RESEARCH

720
00:27:06,400 --> 00:27:11,520
CENTERS IN THE FOLLOWING AREAS.

721
00:27:11,520 --> 00:27:13,120
THE FOCUS AREAS ARE SEEN IN THAT

722
00:27:13,120 --> 00:27:16,880
SECOND COLUMN, WHICH INCLUDE

723
00:27:16,880 --> 00:27:18,760
SYNDEMIC APPROACHES, LEVERAGING

724
00:27:18,760 --> 00:27:21,240
PHARMACIES, TO DECENTRALIZE CARE

725
00:27:21,240 --> 00:27:24,280
AND PREVENTION, LINKAGE TO CARE

726
00:27:24,280 --> 00:27:26,760
AND INCARCERATION, AND ALSO HIV

727
00:27:26,760 --> 00:27:28,040
CLUSTER DETECTION AND RESPONSE.

728
00:27:28,040 --> 00:27:29,920
THESE ACTIVITIES CONTINUE TO

729
00:27:29,920 --> 00:27:31,680
EMPHASIZE PARTNERING RESEARCHERS

730
00:27:31,680 --> 00:27:33,080
FROM HISTORICALLY BLACK COLLEGES

731
00:27:33,080 --> 00:27:34,280
AND UNIVERSITIES AND MINORITY

732
00:27:34,280 --> 00:27:34,960
SERVING INSTITUTIONS.

733
00:27:34,960 --> 00:27:39,440
NOW THE NEXT SLIDE.

734
00:27:39,440 --> 00:27:40,840
DR. HOLTZ ALSO PARTICIPATED AT

735
00:27:40,840 --> 00:27:42,160
THE 76TH FULL COUNCIL MEETING OF

736
00:27:42,160 --> 00:27:43,280
THE PRESIDENTIAL ADVISORY

737
00:27:43,280 --> 00:27:45,920
COUNCIL ON HIV/AIDS, ALSO KNOWN

738
00:27:45,920 --> 00:27:49,080
AS PACHA IN MARCH AND PROVIDED

739
00:27:49,080 --> 00:27:50,800
REMARKS ON FEDERAL UPDATES ON

740
00:27:50,800 --> 00:27:52,240
EHE.

741
00:27:52,240 --> 00:27:53,960
ADDITIONALLY OUR OAR SENIOR

742
00:27:53,960 --> 00:27:56,960
SCIENCE ADVISOR, CAPTAIN

743
00:27:56,960 --> 00:27:59,120
DR. MARY GLENSHAW, ATTENDED SITE

744
00:27:59,120 --> 00:28:01,320
VISITS WITH HHS ASSISTANT

745
00:28:01,320 --> 00:28:05,240
SECRETARY DR. RACHEL LEVINE AND

746
00:28:05,240 --> 00:28:07,480
PACHA LEADERSHIP, INCLUDING TWO

747
00:28:07,480 --> 00:28:13,120
COMMUNITY CLINKING WITH NIH CLIH

748
00:28:13,120 --> 00:28:18,080
FUNDING.

749
00:28:18,080 --> 00:28:21,160
TOLL DATE, NIH EHE FUNDING HAS

750
00:28:21,160 --> 00:28:25,320
BEEN AWARDED OVER 200 -- IT'S

751
00:28:25,320 --> 00:28:27,240
ACTUALLY 201 HIGHLY MERITORIOUS

752
00:28:27,240 --> 00:28:29,440
EHE PROJECTS, INCLUDING 66

753
00:28:29,440 --> 00:28:31,560
PROJECTS FROM FY 22 WITH A FOCUS

754
00:28:31,560 --> 00:28:35,040
ON STRATEGIC PARTNERSHIPS ACROSS

755
00:28:35,040 --> 00:28:36,720
JURISDICTIONS WITH HIGH HIV

756
00:28:36,720 --> 00:28:37,800
BURDEN IN THE U.S.

757
00:28:37,800 --> 00:28:39,640
THE FY 2023 AWARDS ARE EXPECTED

758
00:28:39,640 --> 00:28:44,360
THIS SUMMER.

759
00:28:44,360 --> 00:28:46,760
NOW MOVING TO THE NIH HIV

760
00:28:46,760 --> 00:28:47,640
STRATEGIC PLANNING.

761
00:28:47,640 --> 00:28:52,120
SHIFTING GEARS HERE, THIS IS --

762
00:28:52,120 --> 00:28:53,120
STRATEGIC PLANNING IS AN

763
00:28:53,120 --> 00:28:54,440
IMPORTANT ELEMENT OF OUR

764
00:28:54,440 --> 00:28:56,400
LEGISLATIVE MANDATE.

765
00:28:56,400 --> 00:28:58,560
WE'RE CURRENTLY -- COVERING

766
00:28:58,560 --> 00:29:01,760
FISCAL YEARS 2021 THROUGH 2025.

767
00:29:01,760 --> 00:29:04,200
AS A REMINDER, FISCAL YEAR 2025

768
00:29:04,200 --> 00:29:08,240
ENDS IN SEPTEMBER OF 2025, AND

769
00:29:08,240 --> 00:29:10,240
THUS, WE WILL SOON START WORKING

770
00:29:10,240 --> 00:29:11,280
ON THE NEXT ITERATION OF THE

771
00:29:11,280 --> 00:29:13,160
STRATEGIC PLAN.

772
00:29:13,160 --> 00:29:14,600
THE PLAN CONTAINS STRATEGIC

773
00:29:14,600 --> 00:29:15,840
GOALS AND SCIENTIFIC PRIORITIES

774
00:29:15,840 --> 00:29:19,080
THAT WERE DEVELOPED WITH INPUT

775
00:29:19,080 --> 00:29:20,080
FROM MULTIPLE SOURCES.

776
00:29:20,080 --> 00:29:21,840
THOSE INCLUDE PORTFOLIO

777
00:29:21,840 --> 00:29:23,240
ANALYSIS, REQUESTS FOR

778
00:29:23,240 --> 00:29:24,120
INFORMATION, LISTENING SESSIONS

779
00:29:24,120 --> 00:29:25,720
THAT INCLUDED COMMUNITY AND

780
00:29:25,720 --> 00:29:27,720
PARTNER ENGAGEMENT, AND INTERNAL

781
00:29:27,720 --> 00:29:29,480
AND EXTERNAL ADVISORY GROUPS

782
00:29:29,480 --> 00:29:31,760
SUCH AS THE NIH AIDS EXECUTIVE

783
00:29:31,760 --> 00:29:34,400
COMMITTEE, AND THE OARAC.

784
00:29:34,400 --> 00:29:35,720
DEVELOPING THE NEXT STRATEGIC

785
00:29:35,720 --> 00:29:37,600
PLAN PROVIDES AN OPPORTUNITY TO

786
00:29:37,600 --> 00:29:39,320
REVIEW HIV RESEARCH PRIORITIES

787
00:29:39,320 --> 00:29:42,080
ACROSS THE NIH TO ENSURE THAT

788
00:29:42,080 --> 00:29:43,480
RESOURCES ARE OPTIMALLY ALIGNED

789
00:29:43,480 --> 00:29:45,800
TO THE NEEDS OF THE RESEARCH

790
00:29:45,800 --> 00:29:47,320
AGENDA AND COMMUNITY.

791
00:29:47,320 --> 00:29:50,480
SO AS YOU CAN SEE, WHICH IS

792
00:29:50,480 --> 00:29:51,520
DEPICTED ON THE SCHEMATIC THERE

793
00:29:51,520 --> 00:29:53,880
IN THE LOWER LEVEL BUBBLE ON THE

794
00:29:53,880 --> 00:29:56,600
STRATEGIC PLAN DIAGRAM.

795
00:29:56,600 --> 00:29:59,040
THE NIH HIV RESEARCH STRATEGY IN

796
00:29:59,040 --> 00:30:01,240
TURN INFORMS THE DEVELOPMENT AND

797
00:30:01,240 --> 00:30:03,520
IMPLEMENTATION OF OUR

798
00:30:03,520 --> 00:30:04,560
LEGISLATIVELY MANDATED DOCUMENTS

799
00:30:04,560 --> 00:30:07,160
SUCH AS THE CONGRESSIONAL BUDGET

800
00:30:07,160 --> 00:30:08,200
JUSTIFICATION OR THE C.J., WHICH

801
00:30:08,200 --> 00:30:10,760
IS THE UPPER BUBBLE AT THE TOP,

802
00:30:10,760 --> 00:30:14,040
AND THEN THE PROFESSIONAL

803
00:30:14,040 --> 00:30:16,560
JUSTIFICATION BUDGET, THE P.J.,

804
00:30:16,560 --> 00:30:17,440
THE LOWER RIGHT BUBBLE.

805
00:30:17,440 --> 00:30:19,440
SO OARAC INPUT WILL BE ESSENTIAL

806
00:30:19,440 --> 00:30:21,040
IN THE DEVELOPMENT OF OUR NEXT

807
00:30:21,040 --> 00:30:21,920
PLAN.

808
00:30:21,920 --> 00:30:22,880
WE ANTICIPATE ESTABLISHING

809
00:30:22,880 --> 00:30:25,720
WORKING GROUPS LATER THIS YEAR

810
00:30:25,720 --> 00:30:26,600
AND WILL HAVE MUCH MORE

811
00:30:26,600 --> 00:30:28,040
DISCUSSION ON THIS TOPIC AT

812
00:30:28,040 --> 00:30:29,240
FUTURE OARAC MEETINGS AND LOOK

813
00:30:29,240 --> 00:30:34,160
FORWARD TO ENGAGING WITH YOU.

814
00:30:34,160 --> 00:30:36,360
NOW MOVING TO OUR SIGNATURE

815
00:30:36,360 --> 00:30:37,680
PROGRAMS, THESE WERE FORMED TO

816
00:30:37,680 --> 00:30:39,240
COORDINATE NIH-WIDE ACTIVITIES

817
00:30:39,240 --> 00:30:40,560
IN MULTIDISCIPLINARY AND

818
00:30:40,560 --> 00:30:42,200
CROSS-CUTTING AREAS.

819
00:30:42,200 --> 00:30:44,600
THESE FOUR PROGRAMS THAT YOU SEE

820
00:30:44,600 --> 00:30:48,000
HERE HIGHLIGHTED ARE HIV AND

821
00:30:48,000 --> 00:30:49,640
AGING, HIV AND WOMEN, TECHNOLOGY

822
00:30:49,640 --> 00:30:52,040
FOR HIV RESEARCH, AND EARLY

823
00:30:52,040 --> 00:30:54,120
CAREER INVESTIGATORS.

824
00:30:54,120 --> 00:30:56,440
THEY PLAY A SIGNIFICANT ROLE IN

825
00:30:56,440 --> 00:30:57,480
GUIDING CURRENT AND FUTURE

826
00:30:57,480 --> 00:30:58,920
ACTIVITIES OF OAR AND NIH.

827
00:30:58,920 --> 00:31:00,480
WE WILL HEAR MORE DETAILED

828
00:31:00,480 --> 00:31:03,200
REPORTS ON THE HIV AND AGING AND

829
00:31:03,200 --> 00:31:05,160
ECI SIGNATURE PROGRAMS LATER

830
00:31:05,160 --> 00:31:06,040
TODAY.

831
00:31:06,040 --> 00:31:07,240
TODAY'S AGENDA BEGIN WITH A

832
00:31:07,240 --> 00:31:09,440
FOCUS ON HIV AND WOMEN, AND I'D

833
00:31:09,440 --> 00:31:11,520
LIKE TO BRIEFLY PROVIDE SOME

834
00:31:11,520 --> 00:31:15,240
THOUGHTS ABOUT HIV AND WOMEN AND

835
00:31:15,240 --> 00:31:16,360
OUR SIGNATURE PROGRAM BEFORE WE

836
00:31:16,360 --> 00:31:20,600
HEAR FROM OUR SPEAKERS.

837
00:31:20,600 --> 00:31:24,640
SO NIH'S -- NIH OAR'S HIV AND

838
00:31:24,640 --> 00:31:26,000
WOMEN SIGNATURE PROGRAM IS A

839
00:31:26,000 --> 00:31:28,560
PARTNERSHIP WITH THE DPCPSI'S

840
00:31:28,560 --> 00:31:29,920
OFFICE OF RESEARCH ON WOMEN'S

841
00:31:29,920 --> 00:31:30,240
HEALTH.

842
00:31:30,240 --> 00:31:31,520
IT HAS TWO MAIN OBJECTIVES.

843
00:31:31,520 --> 00:31:33,640
ONE IS TO PROMOTE THE NIH VISION

844
00:31:33,640 --> 00:31:35,360
FOR WOMEN'S HEALTH WHERE ALL

845
00:31:35,360 --> 00:31:37,800
WOMEN RECEIVE EVIDENCE-BASED

846
00:31:37,800 --> 00:31:39,520
TAILORED HIV PREVENTION, CARE

847
00:31:39,520 --> 00:31:40,160
AND TREATMENT.

848
00:31:40,160 --> 00:31:41,840
THE OTHER IS TO SUPPORT WOMEN IN

849
00:31:41,840 --> 00:31:43,040
SCIENCE CAREERS SO THEY CAN

850
00:31:43,040 --> 00:31:47,640
ACHIEVE THEIR FULL POTENTIAL.

851
00:31:47,640 --> 00:31:51,480
TO SET THE STAGE, WHY THE FOCUS

852
00:31:51,480 --> 00:31:53,360
AND WHY IS THIS A PROBLEM WE

853
00:31:53,360 --> 00:31:58,240
SHOULD BE LOOKING MORE INTO?

854
00:31:58,240 --> 00:31:59,680
OUR SPEAKERS TODAY WILL GO INTO

855
00:31:59,680 --> 00:32:01,240
MORE DETAILS BUT I WANTED TO

856
00:32:01,240 --> 00:32:02,080
JUST ARTICULATE HERE WITH THIS

857
00:32:02,080 --> 00:32:04,600
SLIDE SOME OF THE EPIDEMIOLOGY.

858
00:32:04,600 --> 00:32:08,680
IN 2021, GLOBALLY, 54% OF ALL

859
00:32:08,680 --> 00:32:11,520
PEOPLE WITH HIV WERE WOMEN AND

860
00:32:11,520 --> 00:32:12,840
GIRLS, TRANSLATING TO ABOUT

861
00:32:12,840 --> 00:32:13,360
20 MILLION.

862
00:32:13,360 --> 00:32:14,840
AND ALMOST 50% OF ALL NEW

863
00:32:14,840 --> 00:32:17,200
INFECTIONS WERE IN WOMEN.

864
00:32:17,200 --> 00:32:19,480
AN ESTIMATED 20% OF TRANSGENDER

865
00:32:19,480 --> 00:32:22,600
WOMEN LIVING WITH HIV IN 2021

866
00:32:22,600 --> 00:32:25,600
AND THEN NOTABLY TRANS WOMEN

867
00:32:25,600 --> 00:32:27,600
WERE 14 TIMES MORE LIKELY TO

868
00:32:27,600 --> 00:32:29,240
ACQUIRE HIV COMPARED TO

869
00:32:29,240 --> 00:32:29,880
CISGENDER WOMEN.

870
00:32:29,880 --> 00:32:33,000
IN TERMS OF NIH RESOURCES OVER

871
00:32:33,000 --> 00:32:34,840
THE PAST FIVE YEARS,

872
00:32:34,840 --> 00:32:37,000
APPROXIMATELY 15 TO 19% OF HIV

873
00:32:37,000 --> 00:32:38,760
FUNDING HAS BEEN CODED AS

874
00:32:38,760 --> 00:32:40,960
RELATED TO WOMEN'S HEALTH.

875
00:32:40,960 --> 00:32:43,360
WE ARE CURRENTLY ANALYZING THIS

876
00:32:43,360 --> 00:32:45,200
PORTFOLIO TO BEST CAPTURE THIS

877
00:32:45,200 --> 00:32:46,640
INVESTMENT AND UNDERSTAND IT,

878
00:32:46,640 --> 00:32:48,720
AND REALLY ONE CAN ARGUE THERE'S

879
00:32:48,720 --> 00:32:53,640
ROOM FOR GROWTH HERE.

880
00:32:53,640 --> 00:32:56,600
SO TO IDENTIFY GAPS AND

881
00:32:56,600 --> 00:32:57,240
PRIORITIES AT THE INTERSECTION

882
00:32:57,240 --> 00:33:00,760
OF WOMEN'S HEALTH AND HIV, WE

883
00:33:00,760 --> 00:33:02,720
RECENTLY SUSTAIN ESTABLISHED THE

884
00:33:02,720 --> 00:33:03,840
HIV AND WOMEN'S WORKING GROUP.

885
00:33:03,840 --> 00:33:06,880
THE WORKING GROUP LAUNCHED A NEW

886
00:33:06,880 --> 00:33:09,880
WEBPAGE ON THE O.A.R. WEBSITE.

887
00:33:09,880 --> 00:33:11,280
YOU CAN SEE THE CODE ON THE

888
00:33:11,280 --> 00:33:13,560
SLIDE AND REACH IF YOU'D LIKE,

889
00:33:13,560 --> 00:33:15,520
TO KEEP THE PUBLIC AWARE AND

890
00:33:15,520 --> 00:33:17,040
INFORMED OF UPCOMING ACTIVITIES,

891
00:33:17,040 --> 00:33:18,720
AND THESE ACTIVITIES INCLUDE A

892
00:33:18,720 --> 00:33:20,080
WORKSHOP ON THE CURRENT AND

893
00:33:20,080 --> 00:33:22,360
FUTURE DIRECTIONS OF HIV AND

894
00:33:22,360 --> 00:33:23,560
WOMEN'S RESEARCH IN CONJUNCTION

895
00:33:23,560 --> 00:33:27,920
WITH THE U.S. CHA CONFERENCE IN

896
00:33:27,920 --> 00:33:31,000
SEPTEMBER, AND AN NIH HIV AND

897
00:33:31,000 --> 00:33:33,040
WOMEN VIRTUAL WORKSHOP IN

898
00:33:33,040 --> 00:33:34,000
MARCH 2024, AND YOU'LL HEAR MORE

899
00:33:34,000 --> 00:33:35,240
ABOUT THESE EVENTS LATER ON IN

900
00:33:35,240 --> 00:33:38,520
THE PROGRAM.

901
00:33:38,520 --> 00:33:39,960
SO NOW JUST TO LOOK AT THE DAY

902
00:33:39,960 --> 00:33:41,600
AHEAD AND OUR AGENDA, THE REST

903
00:33:41,600 --> 00:33:43,120
OF THE AGENDA INCLUDES A FOCUS

904
00:33:43,120 --> 00:33:46,640
ON HIV AND WOMEN WITH

905
00:33:46,640 --> 00:33:49,600
PERSPECTIVES FROM ORWH DIRECTOR

906
00:33:49,600 --> 00:33:51,040
DR. JANINE CLAYTON, ADDITIONAL

907
00:33:51,040 --> 00:33:52,480
DETAILS THEN WILL BE PROVIDED ON

908
00:33:52,480 --> 00:33:55,200
THE HIV AND WOMEN SIGNATURE

909
00:33:55,200 --> 00:33:57,040
PROGRAM FROM DRS. ELIZABETH BARR

910
00:33:57,040 --> 00:34:00,760
OF ORWH AND LESLIE MARSHALL OF

911
00:34:00,760 --> 00:34:01,320
OAR.

912
00:34:01,320 --> 00:34:05,400
AND THEN FINALLY, RECENT

913
00:34:05,400 --> 00:34:10,080
FINDINGS FROM THE WHIS COHORT

914
00:34:10,080 --> 00:34:12,880
WILL BE PRESENTED BY DR. SEBLE

915
00:34:12,880 --> 00:34:13,800
KASSAYE, THANK YOU FOR JOINING

916
00:34:13,800 --> 00:34:15,000
US FROM GEORGETOWN UNIVERSITY IN

917
00:34:15,000 --> 00:34:15,760
PERSON HERE.

918
00:34:15,760 --> 00:34:17,120
THEN WE'LL HEAR UPDATES FROM OUR

919
00:34:17,120 --> 00:34:18,640
EARLY CAREER INVESTIGATORS AND

920
00:34:18,640 --> 00:34:20,280
HIV AND AGING SIGNATURE

921
00:34:20,280 --> 00:34:22,760
PROGRAMS, FOLLOWED BY A

922
00:34:22,760 --> 00:34:25,520
PRESENTATION ON THE NIH O.A.R.

923
00:34:25,520 --> 00:34:26,720
DATA HUB, A NEW RESOURCE

924
00:34:26,720 --> 00:34:27,920
AVAILABLE ON THE O.A.R. WEBSITE

925
00:34:27,920 --> 00:34:30,360
THAT PROVIDES INFORMATION ON THE

926
00:34:30,360 --> 00:34:32,160
NIH HIV/AIDS RESEARCH PORTFOLIO.

927
00:34:32,160 --> 00:34:35,240
AND LASTLY, WE'LL HEAR FROM OUR

928
00:34:35,240 --> 00:34:36,680
ADVISORY COUNCIL REPRESENTATIVES

929
00:34:36,680 --> 00:34:38,200
AND FROM THE CLINICAL GUIDELINES

930
00:34:38,200 --> 00:34:41,520
WORKING GROUPS OF OARAC.

931
00:34:41,520 --> 00:34:43,280
SO THE NEXT OARAC MEETING IS

932
00:34:43,280 --> 00:34:45,840
GOING TO BE ON THURSDAY, OCTOBE.

933
00:34:45,840 --> 00:34:49,080
WE REALLY APPRECIATE AND THANK

934
00:34:49,080 --> 00:34:50,640
YOU FOR CONTINUING TO MAKE THESE

935
00:34:50,640 --> 00:34:52,720
MEETINGS A PRIORITY AND LOOK

936
00:34:52,720 --> 00:34:54,520
FORWARD TO SEEING YOU THEN AT

937
00:34:54,520 --> 00:34:55,800
THE NEXT MEETING.

938
00:34:55,800 --> 00:34:57,000
JUST WANTED TO TAKE A BRIEF

939
00:34:57,000 --> 00:34:59,760
MOMENT TO HIGHLIGHT THE NATIONAL

940
00:34:59,760 --> 00:35:03,680
HIV TESTING DAY BEFORE CLOSING.

941
00:35:03,680 --> 00:35:05,400
THIS NEXT WEEK ON JUNE 27TH.

942
00:35:05,400 --> 00:35:06,960
THIS YEAR'S THEME:  TAKE THE

943
00:35:06,960 --> 00:35:09,920
TEST AND TAKE THE NEXT STEP,

944
00:35:09,920 --> 00:35:10,800
EMPHASIZES THE POINT THAT WHEN A

945
00:35:10,800 --> 00:35:12,080
PERSON KNOWS THEIR STATUS, THEY

946
00:35:12,080 --> 00:35:14,720
CAN CHOOSE HOW TO STAY HEALTHY.

947
00:35:14,720 --> 00:35:16,120
O.A.R. IS IN THE EARLY STAGES OF

948
00:35:16,120 --> 00:35:18,560
PLANNING A VIRTUAL WORKSHOP WITH

949
00:35:18,560 --> 00:35:20,400
THE NIH AIDS EXECUTIVE

950
00:35:20,400 --> 00:35:22,400
COMMITTEE, AND THE WORKSHOP IS

951
00:35:22,400 --> 00:35:24,040
ENTITLED COMMUNITY VOICES,

952
00:35:24,040 --> 00:35:26,440
FORGING THE PATH FORWARD FOR HIV

953
00:35:26,440 --> 00:35:27,520
SELF-TESTING AND PERSONALIZED

954
00:35:27,520 --> 00:35:28,720
VIRAL LOAD MONITORING.

955
00:35:28,720 --> 00:35:31,480
THIS WILL BE HELD NOVEMBER 1ST

956
00:35:31,480 --> 00:35:32,760
AND 2ND.

957
00:35:32,760 --> 00:35:33,680
ADDITIONAL DETAILS WILL BE

958
00:35:33,680 --> 00:35:35,240
PROVIDED AT OUR NEXT OARAC

959
00:35:35,240 --> 00:35:35,880
MEETING.

960
00:35:35,880 --> 00:35:38,600
SO WITH THAT, I'M GOING TO SAY

961
00:35:38,600 --> 00:35:39,920
AS A REMINDER, THERE ARE MANY

962
00:35:39,920 --> 00:35:41,240
WAYS TO STAY CONNECTED WITH

963
00:35:41,240 --> 00:35:42,360
O.A.R. AND ALL OF OUR

964
00:35:42,360 --> 00:35:44,440
ACTIVITIES, AND I THANK YOU,

965
00:35:44,440 --> 00:35:48,720
MADAM CHAIR, IVY, BACK TO YOU.

966
00:35:48,720 --> 00:35:50,840
>> THANK YOU, BILL, FOR
SUCH A

967
00:35:50,840 --> 00:35:52,560
GREAT UPDATE.

968
00:35:52,560 --> 00:35:54,240
WE'RE GOING TO HOLD QUESTIONS

969
00:35:54,240 --> 00:35:57,240
UNTIL THE OPEN DISCUSSION PER 

970
00:35:57,240 --> 00:35:59,080
PERIOD.

971
00:35:59,080 --> 00:36:01,200
WE WILL NOW HEAR FROM DR. JANINE

972
00:36:01,200 --> 00:36:02,720
CLAYTON, ASSOCIATE DIRECTOR FOR

973
00:36:02,720 --> 00:36:03,920
RESEARCH ON WOMEN'S HEALTH AND

974
00:36:03,920 --> 00:36:05,040
DIRECTOR OF THE OFFICE OF

975
00:36:05,040 --> 00:36:06,560
RESEARCH ON WOMEN'S HEALTH AT

976
00:36:06,560 --> 00:36:10,040
NIH.

977
00:36:10,040 --> 00:36:10,880
DR. CLAYTON IS A KEY ARCHITECT

978
00:36:10,880 --> 00:36:14,120
OF THE NIH POLICY REQUIRING

979
00:36:14,120 --> 00:36:17,800
SCIENTISTS TO CONSIDER SET AS A

980
00:36:17,800 --> 00:36:19,000
LOGICAL VARIABLE ACROSS THE

981
00:36:19,000 --> 00:36:21,840
RESEARCH SPECTRUM.

982
00:36:21,840 --> 00:36:22,760
DR. CLAYTON, PLEASE BEGIN WHEN

983
00:36:22,760 --> 00:36:26,640
YOU'RE READY.

984
00:36:26,640 --> 00:36:28,000
>> THANK YOU SO MUCH,

985
00:36:28,000 --> 00:36:28,520
DR. TURNBULL.

986
00:36:28,520 --> 00:36:29,720
IT'S MY PLEASURE TO BE HERE

987
00:36:29,720 --> 00:36:31,640
TODAY AND TO TALK A LITTLE BIT

988
00:36:31,640 --> 00:36:33,240
ABOUT THE NIH OFFICE OF RESEARCH

989
00:36:33,240 --> 00:36:34,320
ON WOMEN'S HEALTH AND HOW MUCH

990
00:36:34,320 --> 00:36:35,720
OUR PRIORITIES INTERSECT WITH

991
00:36:35,720 --> 00:36:38,280
THE OFFICE OF AIDS RESEARCH.

992
00:36:38,280 --> 00:36:40,120
WE HAVE SEVERAL SHARED GOALS.

993
00:36:40,120 --> 00:36:42,440
AT THE OUTSET, INCLUSION OF

994
00:36:42,440 --> 00:36:45,080
WOMEN IN EVERYTHING WE DO,

995
00:36:45,080 --> 00:36:46,920
PARTNERSHIPS ACROSS NIH, ACROSS

996
00:36:46,920 --> 00:36:48,440
STAKEHOLDERS, ACROSS SECTORS,

997
00:36:48,440 --> 00:36:52,280
AND ADDRESSING AREAS THAT ARE

998
00:36:52,280 --> 00:36:53,400
GAPS IN OUR FUNDING.

999
00:36:53,400 --> 00:36:54,560
I WANT TO TELL YOU A LITTLE BIT

1000
00:36:54,560 --> 00:36:56,680
ABOUT THE MISSION AND VISION OF

1001
00:36:56,680 --> 00:36:57,240
ORWH.

1002
00:36:57,240 --> 00:37:01,080
WE WERE FOUNDED OUT OF ADVOCACY,

1003
00:37:01,080 --> 00:37:02,240
WOMEN AND MEN IN CONGRESS

1004
00:37:02,240 --> 00:37:03,400
ESSENTIALLY DEMANDED THAT NIH

1005
00:37:03,400 --> 00:37:05,160
CREATE AN OFFICE OF RESEARCH ON

1006
00:37:05,160 --> 00:37:06,920
WOMEN'S HEALTH TO ADDRESS THE

1007
00:37:06,920 --> 00:37:08,400
FACT THAT WOMEN WERE NOT BEING

1008
00:37:08,400 --> 00:37:10,080
ROUTINELY INCLUDED IN NIH

1009
00:37:10,080 --> 00:37:10,920
SUPPORTED CLINICAL RESEARCH AND

1010
00:37:10,920 --> 00:37:12,800
THE FINDINGS WERE BEING APPLIED

1011
00:37:12,800 --> 00:37:14,520
TO WOMEN.

1012
00:37:14,520 --> 00:37:16,320
SO OUR MISSION IS TO EXPAND

1013
00:37:16,320 --> 00:37:17,400
WOMEN'S HEALTH RESEARCH TO MAKE

1014
00:37:17,400 --> 00:37:19,920
SURE THAT WOMEN IN

1015
00:37:19,920 --> 00:37:21,000
UNDERREPRESENTED RACIAL AND

1016
00:37:21,000 --> 00:37:21,760
ETHNIC MINORITY GROUPS ARE

1017
00:37:21,760 --> 00:37:23,120
INCLUDED IN NIH SUPPORTED

1018
00:37:23,120 --> 00:37:25,240
CLINICAL RESEARCH AND ADVANCE

1019
00:37:25,240 --> 00:37:26,800
WOMEN IN STEM CAREERS.

1020
00:37:26,800 --> 00:37:28,720
WE IMAGINE A WORLD WHERE ALL

1021
00:37:28,720 --> 00:37:30,040
WOMEN RECEIVE EVIDENCE-BASED

1022
00:37:30,040 --> 00:37:31,760
TREATMENT AND CARE.

1023
00:37:31,760 --> 00:37:33,120
IMAGINE A WORLD WHERE SEX AND

1024
00:37:33,120 --> 00:37:34,640
GENDER FACTORS ARE INTEGRATED

1025
00:37:34,640 --> 00:37:36,720
ACROSS THE HEALTH RESEARCH

1026
00:37:36,720 --> 00:37:38,480
CONTINUUM, AND A WORLD WHERE ALL

1027
00:37:38,480 --> 00:37:40,280
WOMEN IN SCIENCE REACH THEIR

1028
00:37:40,280 --> 00:37:43,640
FULL POTENTIAL.

1029
00:37:43,640 --> 00:37:46,360
THIS IS THE WAY WE THINK ABOUT

1030
00:37:46,360 --> 00:37:47,480
EXECUTING AND IMPLEMENTING THAT

1031
00:37:47,480 --> 00:37:47,720
VISION.

1032
00:37:47,720 --> 00:37:49,920
WE SEEK TO INCORPORATE SEX AND

1033
00:37:49,920 --> 00:37:51,320
GENDER CONSIDERATIONS ACROSS THE

1034
00:37:51,320 --> 00:37:53,600
ENTIRE RESEARCH CONTINUUM,

1035
00:37:53,600 --> 00:37:54,800
RANGING FROM BASIC AND

1036
00:37:54,800 --> 00:37:56,600
LABORATORY STUDIES THROUGH

1037
00:37:56,600 --> 00:37:59,400
TRANSLATION TO CLINICAL AND

1038
00:37:59,400 --> 00:37:59,880
APPLIED.

1039
00:37:59,880 --> 00:38:02,160
WE ALSO WANT TO ADDRESS SEX AS A

1040
00:38:02,160 --> 00:38:03,720
BIOLOGICAL VARIABLE ACROSS TYPES

1041
00:38:03,720 --> 00:38:05,800
OF RESEARCH FROM THE

1042
00:38:05,800 --> 00:38:08,200
PRE-CLINICAL INTO THE CLINICAL

1043
00:38:08,200 --> 00:38:09,520
SPACE, INTENTIONALLY INTEGRATING

1044
00:38:09,520 --> 00:38:10,640
CONSIDERATIONS OF SEX AND

1045
00:38:10,640 --> 00:38:12,280
GENDER, MAKING SURE THAT WE

1046
00:38:12,280 --> 00:38:14,800
INCLUDE SEX AND GENDER IN OUR

1047
00:38:14,800 --> 00:38:17,000
RESULTS REPORTING FROM RESEARCH

1048
00:38:17,000 --> 00:38:19,320
SO THOSE FINDINGS CAN INFORM

1049
00:38:19,320 --> 00:38:21,320
FUTURE STUDIES.

1050
00:38:21,320 --> 00:38:22,720
WE BELIEVE THAT INCORPORATING

1051
00:38:22,720 --> 00:38:23,720
SEX AND GENDER ACROSS THIS

1052
00:38:23,720 --> 00:38:26,400
RESEARCH CONTINUUM ADVANCES

1053
00:38:26,400 --> 00:38:29,080
RIGOR, BY DEFINITION, DISCOVERY,

1054
00:38:29,080 --> 00:38:33,120
INNOVATION, AND EQUITY.

1055
00:38:33,120 --> 00:38:34,360
ORWH AND O.A.R. HAVE A HISTORY

1056
00:38:34,360 --> 00:38:35,080
OF WORKING TOGETHER.

1057
00:38:35,080 --> 00:38:36,760
IT WAS MY PLEASURE TO WORK

1058
00:38:36,760 --> 00:38:38,560
CLOSELY WITH THE FORMER DIRECTOR

1059
00:38:38,560 --> 00:38:40,440
OF O.A.R., DR. MAUREEN GOODENOW,

1060
00:38:40,440 --> 00:38:42,360
IN COMMEMORATING 40 YEARS OF

1061
00:38:42,360 --> 00:38:45,520
ACCOMPLISHMENTS AND ADVANCES IN

1062
00:38:45,520 --> 00:38:48,040
WOMEN IN HIV/AIDS RESEARCH HERE

1063
00:38:48,040 --> 00:38:50,040
AT NIH FAIRLY RECENTLY, AND WE

1064
00:38:50,040 --> 00:38:51,320
HAVE A NEW PARTNERSHIP AS YOU

1065
00:38:51,320 --> 00:38:52,440
HEARD AND WE'RE LOOKING FORWARD

1066
00:38:52,440 --> 00:38:56,040
TO GROWING THIS AS WE MOVE

1067
00:38:56,040 --> 00:38:56,360
FORWARD.

1068
00:38:56,360 --> 00:38:58,680
WE KNOW, FOR EXAMPLE, THAT WOMEN

1069
00:38:58,680 --> 00:39:00,680
FACE MEEK CONSIDERATIONS NR HIV

1070
00:39:00,680 --> 00:39:01,240
RESEARCH.

1071
00:39:01,240 --> 00:39:02,880
PREGNANCY IN PEOPLE WITH HIV IS

1072
00:39:02,880 --> 00:39:04,640
LINKED TO 2 TO 10 TIMES

1073
00:39:04,640 --> 00:39:07,520
INCREASED RISK OF DEATH, AND

1074
00:39:07,520 --> 00:39:08,280
MULTI-MORBIDITY IS MORE COMMON

1075
00:39:08,280 --> 00:39:10,840
IN WOMEN WITH HIV, INCLUDING

1076
00:39:10,840 --> 00:39:13,120
INCREASED PREVALENCE OF NON-AIDS

1077
00:39:13,120 --> 00:39:13,640
COMORBIDITIES.

1078
00:39:13,640 --> 00:39:15,440
SOMETIMES OF DISEASE OFTEN

1079
00:39:15,440 --> 00:39:20,000
DIFFER FROM MEN, AND WE NEED TO

1080
00:39:20,000 --> 00:39:22,320
PAY ATTENTION TO THE ROLE OF

1081
00:39:22,320 --> 00:39:23,320
EXOGENOUS HORMONE THERAPY,

1082
00:39:23,320 --> 00:39:24,120
ESPECIALLY IN POPULATIONS OF

1083
00:39:24,120 --> 00:39:24,680
WOMEN.

1084
00:39:24,680 --> 00:39:26,160
THERE ARE ALSO BEHAVIORAL AND

1085
00:39:26,160 --> 00:39:27,480
SOCIAL SCIENCE CONCERNS.

1086
00:39:27,480 --> 00:39:28,800
WE KNOW THAT INTERSECTIONAL

1087
00:39:28,800 --> 00:39:30,440
STIGMA CAN IMPACT PREVENTION,

1088
00:39:30,440 --> 00:39:34,840
TREATMENT AND OUTCOMES, AND THAT

1089
00:39:34,840 --> 00:39:36,160
INTERPERSONAL AND GENDER BASED

1090
00:39:36,160 --> 00:39:37,440
VIOLENCE INCREASE THE RISK OF

1091
00:39:37,440 --> 00:39:38,560
HIV ACQUISITION.

1092
00:39:38,560 --> 00:39:39,880
WE WERE RECENTLY PLEASED TO HEAR

1093
00:39:39,880 --> 00:39:42,280
THE U.S. GOVERNMENT'S FIRST EVER

1094
00:39:42,280 --> 00:39:43,080
GOVERNMENT-WIDE NATIONAL ACTION

1095
00:39:43,080 --> 00:39:46,480
PLAN ON GENDER-BASED VIOLENCE.

1096
00:39:46,480 --> 00:39:48,120
THERE'S ALSO UNIQUE MENTAL

1097
00:39:48,120 --> 00:39:49,120
HEALTH BURDEN FOR WOMEN WITH

1098
00:39:49,120 --> 00:39:50,760
HIV, AND WE NEED TO INCORPORATE

1099
00:39:50,760 --> 00:39:52,200
CONSIDERATIONS OF

1100
00:39:52,200 --> 00:39:54,800
GENDER-AFFIRMING CARE AS WELL.

1101
00:39:54,800 --> 00:39:57,680
AT ORWH, WE TAKE A LIFE COURSE

1102
00:39:57,680 --> 00:39:59,440
PERSPECTIVE, MEANING WE THINK

1103
00:39:59,440 --> 00:40:00,520
ABOUT THE ENTIRE LIFE COURSE OF

1104
00:40:00,520 --> 00:40:02,600
A WOMAN AND THE FACT THAT YOU

1105
00:40:02,600 --> 00:40:03,960
MUST CONSIDER EVERYTHING THAT

1106
00:40:03,960 --> 00:40:05,360
CAME BEFORE WHEN YOU CONSIDER

1107
00:40:05,360 --> 00:40:07,920
THE HEALTH OF WOMEN, WHETHER

1108
00:40:07,920 --> 00:40:10,840
THAT'S A STRESS TESS OF

1109
00:40:10,840 --> 00:40:13,600
PREGNANCY, OR THE ONSET OF

1110
00:40:13,600 --> 00:40:17,320
PERIMENOPAUSE OR MENOPAUSE, OR

1111
00:40:17,320 --> 00:40:21,360
THE POST-MENOPAUSAL TRANSITION.

1112
00:40:21,360 --> 00:40:23,680
REPRODUCTIVE AGING AND MENOPAUSE

1113
00:40:23,680 --> 00:40:25,760
WAS SO IMPORTANT THAT WE DEVOTED

1114
00:40:25,760 --> 00:40:30,040
THIS YE YEAR'S VIVIAN PINN

1115
00:40:30,040 --> 00:40:31,040
SYMPOSIUM TO MENOPAUSE.

1116
00:40:31,040 --> 00:40:31,960
WE NOTE THAT THE AGE OF

1117
00:40:31,960 --> 00:40:33,680
MENOPAUSE IS ACTUALLY SLIGHTLY

1118
00:40:33,680 --> 00:40:35,320
LOWER FOR WOMEN WITH HIV.

1119
00:40:35,320 --> 00:40:38,280
AT THE VIVIAN PINN SYMPOSIUM,

1120
00:40:38,280 --> 00:40:40,160
DR. SARAH LUBY TALKED ABOUT

1121
00:40:40,160 --> 00:40:42,600
WOMEN WITH HIV IN THE CONTEXT OF

1122
00:40:42,600 --> 00:40:42,840
MENOPAUSE.

1123
00:40:42,840 --> 00:40:44,000
SHE SHARED THAT THEY'RE MORE

1124
00:40:44,000 --> 00:40:45,560
LIKELY TO EXPERIENCE DEPRESSIVE

1125
00:40:45,560 --> 00:40:47,960
SYMPTOMS AS WELL AS ANXIETY.

1126
00:40:47,960 --> 00:40:49,800
ALSO, WOMEN WITH HIV HAVE MORE

1127
00:40:49,800 --> 00:40:51,360
FREQUENT AND SEVERE HOT FLASHES

1128
00:40:51,360 --> 00:40:53,080
AND WE KNOW THAT THIS CAN IMPACT

1129
00:40:53,080 --> 00:40:55,320
QUALITY OF LIFE.

1130
00:40:55,320 --> 00:40:58,400
WOMEN WITH HIV ALSO CAN HAVE

1131
00:40:58,400 --> 00:41:00,040
DIFFICULTY DISTINGUISHING

1132
00:41:00,040 --> 00:41:00,680
MENOPAUSAL SYMPTOMS FROM

1133
00:41:00,680 --> 00:41:02,920
SYMPTOMS OF HIV, AND THESE ARE

1134
00:41:02,920 --> 00:41:06,720
JUST SOME OF THE AREAS THAT ARE

1135
00:41:06,720 --> 00:41:09,920
OF CONCERN RELATED TO

1136
00:41:09,920 --> 00:41:10,760
REPRODUCTIVE AGING AND ITS

1137
00:41:10,760 --> 00:41:11,280
INTERSECTION WITH HIV.

1138
00:41:11,280 --> 00:41:12,880
WE KNOW THE SEVERITY OF

1139
00:41:12,880 --> 00:41:13,840
UROGENITAL SYMPTOMS, FOR

1140
00:41:13,840 --> 00:41:16,680
EXAMPLE, NEEDS MORE ATTENTION AS

1141
00:41:16,680 --> 00:41:18,480
WELL AS EVALUATING MENOPAUSAL

1142
00:41:18,480 --> 00:41:19,400
HORMONE THERAPY USE IN WOMEN

1143
00:41:19,400 --> 00:41:22,120
WITH HIV.

1144
00:41:22,120 --> 00:41:24,640
SO HOW DOES ORWH SUPPORT HIV

1145
00:41:24,640 --> 00:41:25,160
RESEARCH?

1146
00:41:25,160 --> 00:41:26,280
WE WANT TO ALWAYS ADDRESS THE

1147
00:41:26,280 --> 00:41:29,680
MOST AFFECTED POPULATIONS,

1148
00:41:29,680 --> 00:41:30,800
INITIATE RESEARCH THAT

1149
00:41:30,800 --> 00:41:32,320
INCORPORATES SEX AS A BIOLOGICAL

1150
00:41:32,320 --> 00:41:34,760
VARIABLE OR SABV FROM THE STUDY

1151
00:41:34,760 --> 00:41:36,320
DESIGN AND SUPPORT RESEARCH THAT

1152
00:41:36,320 --> 00:41:37,320
STUDIES THE INTERSECTION OF SEX

1153
00:41:37,320 --> 00:41:39,560
AND GENDER FACTORS.

1154
00:41:39,560 --> 00:41:40,840
AND ONE OF THE WAYS THAT WE DO

1155
00:41:40,840 --> 00:41:43,000
THIS IS THROUGH OUR

1156
00:41:43,000 --> 00:41:43,600
U3 INTERDISCIPLINARY RESEARCH

1157
00:41:43,600 --> 00:41:45,960
PROGRAM THAT WAS CREATED BY ORWH

1158
00:41:45,960 --> 00:41:47,960
TO DRAW ATTENTION TO THE LACK OF

1159
00:41:47,960 --> 00:41:49,840
RESEARCH ON PERSISTENT

1160
00:41:49,840 --> 00:41:50,960
DISPARITIES IN WOMEN'S HEALTH

1161
00:41:50,960 --> 00:41:52,520
AND HEALTHCARE, AND TO SUPPORT

1162
00:41:52,520 --> 00:41:53,800
RESEARCH AND EVIDENCE-BASED

1163
00:41:53,800 --> 00:41:57,000
PROGRAMS TO ADDRESS THESE GAPS.

1164
00:41:57,000 --> 00:41:59,640
SO U3 STANDS FOR UNDERSTUDIED,

1165
00:41:59,640 --> 00:42:00,640
UNDERREPRESENTED AND

1166
00:42:00,640 --> 00:42:01,720
UNDERREPORTED POPULATIONS, SO WE

1167
00:42:01,720 --> 00:42:04,280
SEEK TO BRING THOSE POPULATIONS

1168
00:42:04,280 --> 00:42:06,360
IN FOCUS, ATTENDING TO THOSE

1169
00:42:06,360 --> 00:42:08,440
THAT HAVE BEEN EXCLUDED

1170
00:42:08,440 --> 00:42:09,560
HISTORICALLY OR ARE OFTEN

1171
00:42:09,560 --> 00:42:09,880
OVERLOOKED.

1172
00:42:09,880 --> 00:42:12,360
THIS CAN INCORPORATE RURAL

1173
00:42:12,360 --> 00:42:13,800
POPULATIONS, WOMEN FROM

1174
00:42:13,800 --> 00:42:15,880
MARGINALIZED RACIAL AND ETHNIC

1175
00:42:15,880 --> 00:42:18,880
GROUPS, AND OTHER DEMOGRAPHICS.

1176
00:42:18,880 --> 00:42:20,640
AND HERE IS A MAP OF THE CURRENT

1177
00:42:20,640 --> 00:42:26,240
AND PREVIOUSLY SUPPORTED ORWH UR

1178
00:42:26,240 --> 00:42:27,640
WEBSITE, AND YOU CAN SEE THAT

1179
00:42:27,640 --> 00:42:29,320
THEY DO SCATTER THE COUNTRY AND

1180
00:42:29,320 --> 00:42:33,080
YOU CAN SORT THIS BY THE

1181
00:42:33,080 --> 00:42:34,080
U3 POPULATION.

1182
00:42:34,080 --> 00:42:35,160
I'M JUST GOING TO HIGHLIGHT A

1183
00:42:35,160 --> 00:42:36,360
FEW FOR YOU HERE.

1184
00:42:36,360 --> 00:42:40,000
AT THE UNIVERSITY OF TEXAS, THE

1185
00:42:40,000 --> 00:42:41,680
TARGET POPULATION IS RURAL,

1186
00:42:41,680 --> 00:42:42,840
AFRICAN AMERICAN AND BLACK WOMEN

1187
00:42:42,840 --> 00:42:44,720
AT HIGH RISK FOR HIV.

1188
00:42:44,720 --> 00:42:49,000
THIS STUDY IS LOOKING AT

1189
00:42:49,000 --> 00:42:50,240
INCREASING HIV/STI HOME TESTING,

1190
00:42:50,240 --> 00:42:52,200
LICKAGES TO CARE, AND LINKAGES

1191
00:42:52,200 --> 00:42:55,160
TO PREP VIA A DIGITAL

1192
00:42:55,160 --> 00:42:56,280
INTERVENTION IN A PARTICULAR

1193
00:42:56,280 --> 00:42:58,800
GEOGRAPHIC HOT SPOT.

1194
00:42:58,800 --> 00:43:00,800
THE SECOND IS IN BALTIMORE AT

1195
00:43:00,800 --> 00:43:01,800
JOHNS HOPKINS LOOKING AT RACIAL

1196
00:43:01,800 --> 00:43:03,840
AND ETHNIC MINORITY FEMALE

1197
00:43:03,840 --> 00:43:05,160
ADOLESCENTS AND YOUNG ADULTS,

1198
00:43:05,160 --> 00:43:07,280
LOOKING AT THE VAGINAL

1199
00:43:07,280 --> 00:43:08,840
MICROBIOME, INFLAMMATION AND STI

1200
00:43:08,840 --> 00:43:10,480
AND HIV RISK.

1201
00:43:10,480 --> 00:43:14,280
THE THIRD EXAMPLE IS AROUND ANAL

1202
00:43:14,280 --> 00:43:20,240
CANCER RISK IN HIV-POSITIVE,

1203
00:43:20,240 --> 00:43:21,000
LOW-SOCIOECONOMIC STATUS AFRICAN

1204
00:43:21,000 --> 00:43:23,960
AMERICAN OR BLACK AND

1205
00:43:23,960 --> 00:43:25,760
HISPANIC/LATINO WOMEN.

1206
00:43:25,760 --> 00:43:27,160
THESE ARE JUST THREE EXAMPLES OF

1207
00:43:27,160 --> 00:43:29,680
SOME OF THE U3 PROGRAMS THAT WE

1208
00:43:29,680 --> 00:43:33,800
ARE SUPPORTING NOW THROUGH THE

1209
00:43:33,800 --> 00:43:35,040
U3 EFFORT IN COLLABORATION WITH

1210
00:43:35,040 --> 00:43:35,960
MULTIPLE INSTITUTES AND CENTERS

1211
00:43:35,960 --> 00:43:38,040
AND OFFICES.

1212
00:43:38,040 --> 00:43:40,160
CHRONIC DISEASE IS ALSO AN

1213
00:43:40,160 --> 00:43:41,800
IMPORTANT ISSUE FOR WOMEN ACROSS

1214
00:43:41,800 --> 00:43:43,760
THE LIFESPAN, INCLUDING WOMEN

1215
00:43:43,760 --> 00:43:46,000
WITH HIV, AND WE RECENTLY, IN

1216
00:43:46,000 --> 00:43:47,160
PARTNERSHIP WITH SEVERAL

1217
00:43:47,160 --> 00:43:49,600
INSTITUTES, CENTERS AND OFFICES,

1218
00:43:49,600 --> 00:43:54,520
INCLUDING O.A.R., ISSUED AN

1219
00:43:54,520 --> 00:43:56,760
UNDERSTANDING CHRONIC CONDITIONS

1220
00:43:56,760 --> 00:43:58,520
UNDERSTUDIED AMONG WOMEN FUNDING

1221
00:43:58,520 --> 00:44:03,000
OPPORTUNITY IN AN R01 AND R21.

1222
00:44:03,000 --> 00:44:04,360
DISEASES THAT ARE MORE COMMON IN

1223
00:44:04,360 --> 00:44:06,200
WOMEN, HAVE HIGHER MORBIDITY IN

1224
00:44:06,200 --> 00:44:08,720
WOMEN AND JUST A FEW OF THEM ARE

1225
00:44:08,720 --> 00:44:11,160
DEPICTED HERE ON THE SLIDE.

1226
00:44:11,160 --> 00:44:13,080
AND THE NEXT DUE DATE IS

1227
00:44:13,080 --> 00:44:15,040
JUNE 20TH NEXT YEAR.

1228
00:44:15,040 --> 00:44:16,680
OUR SPECIALIZED CENTERS OF

1229
00:44:16,680 --> 00:44:18,280
RESEARCH EXCELLENCE, OR SCORE

1230
00:44:18,280 --> 00:44:20,280
PROGRAM, IS A U54, WHICH

1231
00:44:20,280 --> 00:44:21,480
REPRESENTS A COOPERATIVE

1232
00:44:21,480 --> 00:44:22,800
AGREEMENT THAT EXPANDED FROM THE

1233
00:44:22,800 --> 00:44:24,880
P50 THAT WE FUNDED IN THE PAST.

1234
00:44:24,880 --> 00:44:28,400
THIS IS NIH'S ONLY

1235
00:44:28,400 --> 00:44:29,520
DISEASE-AGNOSTIC SEX DIFFERENCES

1236
00:44:29,520 --> 00:44:32,360
CENTER LEVEL PROGRAM AND IT

1237
00:44:32,360 --> 00:44:33,880
ADDRESSES SEX DIFFERENCES IN THE

1238
00:44:33,880 --> 00:44:36,200
CONTEXT OF DISEASES THAT ARE

1239
00:44:36,200 --> 00:44:37,200
IMPORTANT TO INFORM AND IMPROVE

1240
00:44:37,200 --> 00:44:38,080
THE HEALTH OF WOMEN.

1241
00:44:38,080 --> 00:44:40,280
WE IN THE SCORE PROGRAM, THERE

1242
00:44:40,280 --> 00:44:42,680
ARE THREE HIGHLY INTEGRATED

1243
00:44:42,680 --> 00:44:44,040
SYNERGISTIC RESEARCH PROJECTS.

1244
00:44:44,040 --> 00:44:45,120
THERE'S AN ADMINISTRATIVE CORE,

1245
00:44:45,120 --> 00:44:46,440
A CAREER ENHANCEMENT CORE AS

1246
00:44:46,440 --> 00:44:47,760
WELL.

1247
00:44:47,760 --> 00:44:50,840
AND WE HELP TO EXPAND EFFORTS

1248
00:44:50,840 --> 00:44:55,280
LIKE SABV THROUGH THE SCORE, AS

1249
00:44:55,280 --> 00:44:58,440
WELL AS EFFECT EXAMPLES, AND

1250
00:44:58,440 --> 00:45:00,320
I'LL GIVE A FEW FOR YOU HERE.

1251
00:45:00,320 --> 00:45:01,680
SOME OF THE SCORE SCIENTIST

1252
00:45:01,680 --> 00:45:03,600
MODEL WAYS TO OBTAIN THE FULL

1253
00:45:03,600 --> 00:45:06,240
BENEFIT OF SEX AWARE STUDIES,

1254
00:45:06,240 --> 00:45:08,120
EITHER THROUGH SEX STRATIFIED

1255
00:45:08,120 --> 00:45:09,360
RANDOMIZATION OR POWERED

1256
00:45:09,360 --> 00:45:11,640
ANALYSIS FOR SEX-DEPENDENT

1257
00:45:11,640 --> 00:45:15,240
EFFECTS, OR DEMONSTRATING

1258
00:45:15,240 --> 00:45:15,800
SEX-DISAGGREGATED RESULTS

1259
00:45:15,800 --> 00:45:16,720
REPORTING AS JUST A FEW

1260
00:45:16,720 --> 00:45:19,440
EXAMPLES.

1261
00:45:19,440 --> 00:45:20,560
WE ENCOURAGE COLLABORATION

1262
00:45:20,560 --> 00:45:21,720
ACROSS THE SCORE PROGRAMS AND WE

1263
00:45:21,720 --> 00:45:24,200
ALSO HOPE TO LEVERAGE THE SCORE

1264
00:45:24,200 --> 00:45:26,680
SUCCESSES IN DISSEMINATING

1265
00:45:26,680 --> 00:45:29,440
WIDESPREAD ADOPTION OF

1266
00:45:29,440 --> 00:45:30,920
APPLICATION OF SEX AS A

1267
00:45:30,920 --> 00:45:31,960
BIOLOGICAL VARIABLE ACROSS

1268
00:45:31,960 --> 00:45:34,280
VARIOUS DISEASES, STUDY AND

1269
00:45:34,280 --> 00:45:35,040
DISCIPLINES.

1270
00:45:35,040 --> 00:45:37,280
HERE ARE A COUPLE OF THE SCORE

1271
00:45:37,280 --> 00:45:39,360
INVESTIGATORS WHO ARE ADDRESSING

1272
00:45:39,360 --> 00:45:44,320
RESEARCH RELEVANT TO HIV/AIDS.

1273
00:45:44,320 --> 00:45:47,040
HERE A NEUROHYPOTHALAMIC

1274
00:45:47,040 --> 00:45:48,200
PITUITARY ADRENAL AXIS STUDY

1275
00:45:48,200 --> 00:45:49,880
THAT IS LOOKING AT THE

1276
00:45:49,880 --> 00:45:52,440
UNDERSTANDING BETWEEN BIOLOGICAL

1277
00:45:52,440 --> 00:45:54,400
AGING AND THE PROGNOSIS OF WOMEN

1278
00:45:54,400 --> 00:45:57,360
WITH HIV, SO WE'VE GOT THAT

1279
00:45:57,360 --> 00:45:58,240
REPRODUCTIVE AGING GOING ON AT

1280
00:45:58,240 --> 00:46:00,680
THE SAME TIME, AND IT'S SEEKING

1281
00:46:00,680 --> 00:46:03,200
TO CHARACTERIZE THE LINK BETWEEN

1282
00:46:03,200 --> 00:46:05,280
IMMUNOSENESCENCE AND ENDOCRINE

1283
00:46:05,280 --> 00:46:06,560
SENESCENCE.

1284
00:46:06,560 --> 00:46:07,400
THE SECOND IN THIS SCORE IS

1285
00:46:07,400 --> 00:46:10,240
LOOKING AT HIV AND

1286
00:46:10,240 --> 00:46:12,080
ANTIRETROVIRAL THERAPY, AND

1287
00:46:12,080 --> 00:46:14,600
ESTROGEN DEFICIENCY-INDUCED

1288
00:46:14,600 --> 00:46:16,040
INFLAMMATORY EVENTS, AND

1289
00:46:16,040 --> 00:46:17,720
DETERMINE WHETHER THEY COLLIDE

1290
00:46:17,720 --> 00:46:19,720
IN AN ADDITIVE OR SYNERGISTIC

1291
00:46:19,720 --> 00:46:20,800
MANNER RELATED TO INFLAMMATION

1292
00:46:20,800 --> 00:46:22,680
IN THE CONTEXT OF BONE LOSS,

1293
00:46:22,680 --> 00:46:25,280
WHICH WE KNOW IS INCREASED IN

1294
00:46:25,280 --> 00:46:27,040
HIV, AND IN TERMS OF

1295
00:46:27,040 --> 00:46:27,960
CARDIOVASCULAR RISK IN WOMEN

1296
00:46:27,960 --> 00:46:29,920
WITH HIV, ANALYZING THE IMPACT

1297
00:46:29,920 --> 00:46:33,080
OF HIV-RELATED CHANGES ON THE

1298
00:46:33,080 --> 00:46:34,440
REGENERATIVE CAPACITY,

1299
00:46:34,440 --> 00:46:36,720
ENDOTHELIAL FUNCTION AND

1300
00:46:36,720 --> 00:46:38,600
ARTERIAL STIFFNESS ON PREVALENT

1301
00:46:38,600 --> 00:46:40,400
CORONARY AND CAROTID ARTERIAL

1302
00:46:40,400 --> 00:46:40,720
DISEASE.

1303
00:46:40,720 --> 00:46:42,640
SO JUST AN EXAMPLE OF THREE

1304
00:46:42,640 --> 00:46:43,800
INTEGRATED PROGRAMS IN OUR SCORE

1305
00:46:43,800 --> 00:46:44,360
PROGRAM.

1306
00:46:44,360 --> 00:46:46,360
WE ALSO INITIATED, SEVERAL YEARS

1307
00:46:46,360 --> 00:46:48,760
AGO, NIH'S FIRST EVER

1308
00:46:48,760 --> 00:46:49,560
R01 FOCUSED ON THE INTERSECTION

1309
00:46:49,560 --> 00:46:51,680
OF SEX AND GENDER INFLUENCES ON

1310
00:46:51,680 --> 00:46:55,280
HEALTH AND DISEASE WITH OUR ICO

1311
00:46:55,280 --> 00:46:56,680
PARTNERS, AND HAVE SUPPORTED TO

1312
00:46:56,680 --> 00:47:01,800
DATE 17 AWARDS WITH 11ICO 11 ICO

1313
00:47:01,800 --> 00:47:02,320
PARTNERS.

1314
00:47:02,320 --> 00:47:04,280
THIS ADDRESSES THE FIRST GOAL OF

1315
00:47:04,280 --> 00:47:05,320
THE NIH WIDE STRATEGIC PLAN.

1316
00:47:05,320 --> 00:47:06,480
I CALL THAT THE ULTIMATE GOAL OF

1317
00:47:06,480 --> 00:47:08,280
THE PLAN.

1318
00:47:08,280 --> 00:47:10,560
THE NEXT RECEIPT DATE IS IN

1319
00:47:10,560 --> 00:47:11,280
NOVEMBER AND HERE ARE SOME

1320
00:47:11,280 --> 00:47:12,920
EXAMPLES OF FUNDED INVESTIGATORS

1321
00:47:12,920 --> 00:47:17,120
UNDER OUR SEX AND GENDER R01.

1322
00:47:17,120 --> 00:47:19,240
ALBERTO BOSQUE IS LOOKING AT

1323
00:47:19,240 --> 00:47:22,000
HORMONAL CONTROL OF HIV LATENCY,

1324
00:47:22,000 --> 00:47:23,600
EILEEN SKULLY IS LOOKING AT THE

1325
00:47:23,600 --> 00:47:25,840
SEX AND GENDER OF THE

1326
00:47:25,840 --> 00:47:27,400
IMMUNOPATHOGENESIS OF HIV AND

1327
00:47:27,400 --> 00:47:31,920
MICHELLE YBARRA IS LOOKING AT

1328
00:47:31,920 --> 00:47:32,920
HARNESSING A PROGRAM FOR

1329
00:47:32,920 --> 00:47:33,360
TRANSGENDER GIRLS.

1330
00:47:33,360 --> 00:47:34,720
WE'RE ALSO ADDRESSING THE NEED

1331
00:47:34,720 --> 00:47:36,560
TO SUPPORT CAREERS IN HIV

1332
00:47:36,560 --> 00:47:38,680
RESEARCH.

1333
00:47:38,680 --> 00:47:42,320
AND HAVE CREATED AN R25 FOCUSED

1334
00:47:42,320 --> 00:47:43,720
ON GALVANIZING HEALTH EQUITY

1335
00:47:43,720 --> 00:47:45,160
THROUGH NOVEL AND DIVERSE

1336
00:47:45,160 --> 00:47:46,560
EDUCATIONAL RESOURCES TO HELP

1337
00:47:46,560 --> 00:47:48,480
MEET THE NEED FOR

1338
00:47:48,480 --> 00:47:50,200
GENDER-SPECIFIC TRAINING IN

1339
00:47:50,200 --> 00:47:51,760
SCIENCE, MEDICINE AND ALLIED

1340
00:47:51,760 --> 00:47:54,160
HEALTH PROFESSIONS.

1341
00:47:54,160 --> 00:47:55,400
NEXT AIDS APPLICATION DUE DATE

1342
00:47:55,400 --> 00:47:56,800
IS SEPTEMBER, AND THIS IS GOING

1343
00:47:56,800 --> 00:47:58,800
TO SUPPORT THE DEVELOPMENT OF

1344
00:47:58,800 --> 00:48:00,920
GENDER-FOCUSED CURRICULA AND

1345
00:48:00,920 --> 00:48:02,520
INCLUDING FOR THE EXTRAMURAL

1346
00:48:02,520 --> 00:48:04,040
COMMUNITY AND THE PUBLIC.

1347
00:48:04,040 --> 00:48:05,080
THROUGH A VARIETY OF OUR

1348
00:48:05,080 --> 00:48:06,760
PROGRAMS, WE TRY TO ENSURE THAT

1349
00:48:06,760 --> 00:48:10,480
WOMEN ARE SUPPORTED AND WOMEN'S

1350
00:48:10,480 --> 00:48:13,920
HEALTH RESEARCHERS, OUR BIRCWH

1351
00:48:13,920 --> 00:48:15,800
PROGRAM, WE'VE SUPPORTED OVER

1352
00:48:15,800 --> 00:48:16,760
700 SCHOLARS AND WE'RE

1353
00:48:16,760 --> 00:48:19,480
COLLABORATING WITH NINE HBCUs

1354
00:48:19,480 --> 00:48:20,760
TO SUPPORT WOMEN'S HEALTH

1355
00:48:20,760 --> 00:48:21,960
RESEARCHERS.

1356
00:48:21,960 --> 00:48:23,560
OUR TEAM SCIENCE LEADERSHIP

1357
00:48:23,560 --> 00:48:25,720
SCHOLAR PROGRAM IS OUR NEWEST

1358
00:48:25,720 --> 00:48:27,280
PROGRAM, SEEKING TO SUPPORT TEAM

1359
00:48:27,280 --> 00:48:30,560
SCIENCE LEADERSHIP IN A

1360
00:48:30,560 --> 00:48:31,120
CROSS-SECTIONAL -- SECTORAL,

1361
00:48:31,120 --> 00:48:33,320
EXCUSE ME, FASHION.

1362
00:48:33,320 --> 00:48:34,840
AND OUR CAREER CONTINUITY

1363
00:48:34,840 --> 00:48:36,280
AWARDS, WE CREATED THOSE WITH

1364
00:48:36,280 --> 00:48:38,400
THE NIH WORKING GROUP ON WOMEN

1365
00:48:38,400 --> 00:48:43,880
IN BIOMEDICAL CAREERS ON MAF OFF

1366
00:48:43,880 --> 00:48:46,960
OF NIH TO ALLOW K AND FIRST TIME

1367
00:48:46,960 --> 00:48:53,640
RPG AWARDEES TO -- DURING

1368
00:48:53,640 --> 00:48:56,600
CRITICAL LIFE EVENTS, AND

1369
00:48:56,600 --> 00:48:57,960
RETENTION ACTUALLY RE-ENTRY

1370
00:48:57,960 --> 00:49:00,280
PROGRAMS HERE, SUPPORT

1371
00:49:00,280 --> 00:49:01,560
INVESTIGATORS WHO'VE EXPERIENCED

1372
00:49:01,560 --> 00:49:04,360
THE NEED TO LEAVE RESEARCH AND

1373
00:49:04,360 --> 00:49:06,320
RE-ENTER, OR A DISCRIMINATORY OR

1374
00:49:06,320 --> 00:49:07,400
UNSAFE ENVIRONMENT, INCLUDING

1375
00:49:07,400 --> 00:49:08,480
SEXUAL HARASSMENT.

1376
00:49:08,480 --> 00:49:11,680
SO THOSE ARE SOME OF THE PROG 

1377
00:49:11,680 --> 00:49:12,600
PROGRAMS, AND OUR SIGNATURE

1378
00:49:12,600 --> 00:49:15,840
PROGRAM FOR CAREERS IS OUR

1379
00:49:15,840 --> 00:49:16,320
BIRCWH PROGRAM.

1380
00:49:16,320 --> 00:49:18,680
I DO WANT TO HIGHLIGHT ALSO FOR

1381
00:49:18,680 --> 00:49:20,400
YOU THAT I HAVE THE PRIVILEGE OF

1382
00:49:20,400 --> 00:49:22,360
CO-CHAIRING THE NIH WORKING

1383
00:49:22,360 --> 00:49:24,760
GROUP ON WOMEN IN BIOMEDICAL

1384
00:49:24,760 --> 00:49:26,080
CAREERS WITH THE NIH DIRECTOR,

1385
00:49:26,080 --> 00:49:27,520
AND THROUGH THAT EFFORT, WE HAVE

1386
00:49:27,520 --> 00:49:29,120
FUNDED RESEARCH ON INTERVENTIONS

1387
00:49:29,120 --> 00:49:30,400
THAT ARE DESIGNED TO SUPPORT

1388
00:49:30,400 --> 00:49:32,720
WOMEN IN STEM, THE LANDMARK

1389
00:49:32,720 --> 00:49:35,960
BEING THE CAUSAL FACTORS AND

1390
00:49:35,960 --> 00:49:37,800
INTERVENTIONS RFA, THROUGH WHICH

1391
00:49:37,800 --> 00:49:38,800
14 GRANTS WERE SUPPORTED THAT

1392
00:49:38,800 --> 00:49:40,760
HAVE GENERATED OVER 100 PAPERS

1393
00:49:40,760 --> 00:49:43,080
THAT HAVE DEMONSTRATED WHICH

1394
00:49:43,080 --> 00:49:44,840
INTERVENTIONS WORK AND HOW TO

1395
00:49:44,840 --> 00:49:46,680
EXECUTE AND IMPLEMENT THOSE.

1396
00:49:46,680 --> 00:49:47,880
ONE OTHER ACTIVITY OF THE

1397
00:49:47,880 --> 00:49:49,240
WORKING GROUP IS THE WOMEN OF

1398
00:49:49,240 --> 00:49:52,680
COLOR RESEARCH NETWORK, WHICH IS

1399
00:49:52,680 --> 00:49:53,720
A LINKEDIN COMMUNITY AND HAS

1400
00:49:53,720 --> 00:49:57,000
FOUR REGIONAL CHAPTERS, AND IS

1401
00:49:57,000 --> 00:49:58,080
AVAILABLE TO SUPPORT WOMEN OF

1402
00:49:58,080 --> 00:49:59,520
COLOR IN RESEARCH AND ALL WHO

1403
00:49:59,520 --> 00:50:00,840
SUPPORT WOMEN OF COLOR IN

1404
00:50:00,840 --> 00:50:02,720
RESEARCH, AND WE HAVE ALMOST

1405
00:50:02,720 --> 00:50:08,400
2500 MEMBERS IN THAT COMMUNITY.

1406
00:50:08,400 --> 00:50:09,520
INTERSECTIONALITY IS SOMETHING

1407
00:50:09,520 --> 00:50:12,040
VERY IMPORTANT TO TEAM ORWH AND

1408
00:50:12,040 --> 00:50:13,280
WE'RE ALWAYS LOOKING FOR THE

1409
00:50:13,280 --> 00:50:14,800
CONTEXT OF HOW INTERSECTIONALITY

1410
00:50:14,800 --> 00:50:16,160
AFFECTS THE HEALTH OF WOMEN.

1411
00:50:16,160 --> 00:50:18,200
WE CREATED A DIVERSE VOICES

1412
00:50:18,200 --> 00:50:20,040
WEBINAR SERIES CALLED

1413
00:50:20,040 --> 00:50:20,760
INTERSECTIONALITY AND THE HEALTH

1414
00:50:20,760 --> 00:50:22,240
OF WOMEN, AND THE UPCOMING

1415
00:50:22,240 --> 00:50:23,680
SESSIONS ARE BOTH HIGHLY

1416
00:50:23,680 --> 00:50:27,280
RELEVANT TO HIV RESEARCH.

1417
00:50:27,280 --> 00:50:28,160
FOCUSING ON INTERSECTIONAL

1418
00:50:28,160 --> 00:50:29,280
APPROACHES TO SUBSTANCE USE AND

1419
00:50:29,280 --> 00:50:34,440
MISUSE.

1420
00:50:34,440 --> 00:50:36,560
DR. JAIMIE MEYER WILL BE FOE

1421
00:50:36,560 --> 00:50:37,920
KUTION ON HER CLINICAL RESEARCH

1422
00:50:37,920 --> 00:50:39,880
ON HIV PREVENTION AND TREATMENT

1423
00:50:39,880 --> 00:50:41,480
FOR WOMEN ADDRESSING SOCIAL AND

1424
00:50:41,480 --> 00:50:42,200
STRUCTURAL DETERMINANTS OF

1425
00:50:42,200 --> 00:50:46,080
HEALTH, AND DR. STEPHANIE

1426
00:50:46,080 --> 00:50:46,880
MEYERS-PANTELE WILL BE LOOKING

1427
00:50:46,880 --> 00:50:48,400
AT QUANTITATIVE AND QUANTITATIVE

1428
00:50:48,400 --> 00:50:49,800
AS WELL AS MIXED METHOD STUDIES

1429
00:50:49,800 --> 00:50:51,840
TO LOOK AT THE EFFECTIVE

1430
00:50:51,840 --> 00:50:52,760
INTERSECTIONAL STIGMA ON THE

1431
00:50:52,760 --> 00:50:55,080
HEALTH AND WELL-BEING OF

1432
00:50:55,080 --> 00:50:56,600
POPULATIONS DISPROPORTIONATELY

1433
00:50:56,600 --> 00:50:58,880
AFFECTED BY HIV, WOMEN WHO USE

1434
00:50:58,880 --> 00:51:00,720
DRUGS AND SEXUAL GENDER MINORITY

1435
00:51:00,720 --> 00:51:01,480
POPULATIONS AS WELL.

1436
00:51:01,480 --> 00:51:03,760
SO PLEASE JOIN US ON JULY 27TH.

1437
00:51:03,760 --> 00:51:07,040
AND YOU CAN JOIN IN ANY OF THE

1438
00:51:07,040 --> 00:51:09,000
ORWH EVENTS BY SIGNING UP ON OUR

1439
00:51:09,000 --> 00:51:11,560
WEBSITE TO RECEIVE OUR QUARTERLY

1440
00:51:11,560 --> 00:51:13,760
PUBLICATIONS OR GET EXPOSED TO

1441
00:51:13,760 --> 00:51:14,840
OUR E-LEARNING PROGRAMS.

1442
00:51:14,840 --> 00:51:16,320
SO WITH THAT, I WILL STOP

1443
00:51:16,320 --> 00:51:18,280
SHARING AND TURN IT BACK OVER TO

1444
00:51:18,280 --> 00:51:22,040
DR. TURNBULL.

1445
00:51:22,040 --> 00:51:25,080
>> THANK YOU, JANINE, FOR
THIS

1446
00:51:25,080 --> 00:51:26,360
COMPREHENSIVE OVERVIEW OF

1447
00:51:26,360 --> 00:51:29,080
WOMEN'S HEALTH AND HIV.

1448
00:51:29,080 --> 00:51:31,480
THE NEXT PRESENTATION IS AN

1449
00:51:31,480 --> 00:51:36,560
UPDATE ON THE HIV NIH WOMEN'S

1450
00:51:36,560 --> 00:51:38,760
SIGNATURE PROGRAM.

1451
00:51:38,760 --> 00:51:41,400
WE WILL HEAR FROM DOCTORS

1452
00:51:41,400 --> 00:51:45,240
ELIZABETH BARR AND LESLIE

1453
00:51:45,240 --> 00:51:46,000
MARSHALL.

1454
00:51:46,000 --> 00:51:46,960
DR. BARR IS A PROGRAM OFFICER

1455
00:51:46,960 --> 00:51:48,360
FOR THE NIH OFFICE OF RESEARCH

1456
00:51:48,360 --> 00:51:50,320
ON WOMEN'S HEALTH.

1457
00:51:50,320 --> 00:51:52,320
AND DR. MARSHALL IS A SENIOR

1458
00:51:52,320 --> 00:51:54,360
SCIENCE ADD VAI SORE IN THE NIH

1459
00:51:54,360 --> 00:51:56,040
OFFICE OF AIDS RESEARCH.

1460
00:51:56,040 --> 00:51:58,880
AND LEADS THE CLINICAL RESEARCH

1461
00:51:58,880 --> 00:52:02,480
WORK STREAM.

1462
00:52:02,480 --> 00:52:03,640
DR. BARR AND DR. MARSHALL, OVER

1463
00:52:03,640 --> 00:52:06,600
TO YOU.

1464
00:52:06,600 --> 00:52:08,320
>> THANK YOU, DR. TURN
BELL.

1465
00:52:08,320 --> 00:52:11,800
MY NAME IS LESLIE MY SHALL, I'M

1466
00:52:11,800 --> 00:52:13,320
A SENIOR SCIENCE ADVISOR AT THE

1467
00:52:13,320 --> 00:52:14,880
NIH OAR.

1468
00:52:14,880 --> 00:52:15,920
ALTHOUGH I'M DISAPPOINTED I

1469
00:52:15,920 --> 00:52:16,880
COULDN'T JOIN YOU IN PERSON

1470
00:52:16,880 --> 00:52:18,080
TODAY, I'M EXCITED TO BE HERE

1471
00:52:18,080 --> 00:52:19,720
WITH MY COLLEAGUE, DR. ELIZABETH

1472
00:52:19,720 --> 00:52:22,280
BARR, TO INTRODUCE THE O.A.R.

1473
00:52:22,280 --> 00:52:23,480
ORWH JOINT SIGNATURE PROGRAM

1474
00:52:23,480 --> 00:52:26,760
SUPPORTING RESEARCH FOR HIV AND

1475
00:52:26,760 --> 00:52:33,840
WOMEN AT THE NIH.

1476
00:52:33,840 --> 00:52:39,000
DURING TODAY'S TALK, WE WILL BE

1477
00:52:39,000 --> 00:52:40,520
REVIEWING PROGRAM RATIONALE,

1478
00:52:40,520 --> 00:52:41,640
OBJECTIVES, CURRENT ACTIVITIES,

1479
00:52:41,640 --> 00:52:43,840
AND ASPIRATIONAL PLANS FOR 2024

1480
00:52:43,840 --> 00:52:51,880
AND BEYOND.

1481
00:52:51,880 --> 00:52:54,600
AS DR. CLAYTON DESCRIBED, O.A.R.

1482
00:52:54,600 --> 00:52:56,640
AND ORWH HAVE BEEN ACTIVELY

1483
00:52:56,640 --> 00:53:00,720
ENGAGED IN SUPPORT OF RESEARCH

1484
00:53:00,720 --> 00:53:04,320
FOR WOMEN WITH AND IMPACTED BY

1485
00:53:04,320 --> 00:53:05,560
HIV.

1486
00:53:05,560 --> 00:53:06,840
IS AND WILL CONTINUE TO BE

1487
00:53:06,840 --> 00:53:08,280
CRITICAL TO ADVANCING RESEARCH

1488
00:53:08,280 --> 00:53:10,000
AT THE INTERSECTION OF HIV AND

1489
00:53:10,000 --> 00:53:11,880
WOMEN'S HEALTH.

1490
00:53:11,880 --> 00:53:13,320
OFTEN, THERE IS A LIMITED

1491
00:53:13,320 --> 00:53:15,640
AWARENESS OF NIH'S WOMEN'S

1492
00:53:15,640 --> 00:53:18,280
HEALTH PROGRAMS WITHIN THE HIV

1493
00:53:18,280 --> 00:53:20,720
RESEARCH COMMUNITY, INCLUDING

1494
00:53:20,720 --> 00:53:23,560
THE SEX AS A BIOLOGICAL VARIABLE

1495
00:53:23,560 --> 00:53:25,320
INCLUSION POLICIES, AS WELL AS

1496
00:53:25,320 --> 00:53:26,840
CONGRESSIONALLY MANDATED EFFORTS

1497
00:53:26,840 --> 00:53:29,880
ON MATERNAL MORBIDITY AND

1498
00:53:29,880 --> 00:53:34,440
MORTALITY, AND WOMEN'S HEALTH --

1499
00:53:34,440 --> 00:53:36,400
WOMEN'S MULTI-MORBIDITY BURDEN.

1500
00:53:36,400 --> 00:53:38,000
FROM THESE GAPS, THE OFFICE

1501
00:53:38,000 --> 00:53:39,120
IDENTIFIED OPPORTUNITIES FOR

1502
00:53:39,120 --> 00:53:40,760
IMPROVED PROGRAMMATIC

1503
00:53:40,760 --> 00:53:41,840
COORDINATION AND INFORMATION

1504
00:53:41,840 --> 00:53:44,200
DISSEMINATION ACROSS THE NIH.

1505
00:53:44,200 --> 00:53:46,080
MECHANISMS BEING UTILIZED

1506
00:53:46,080 --> 00:53:49,000
INCLUDE CROSS-PROMOTION THROUGH

1507
00:53:49,000 --> 00:53:51,200
SOCIAL MEDIA, EMAIL BLASTS, AND

1508
00:53:51,200 --> 00:53:52,480
THE OFFICE'S WEBSITES.

1509
00:53:52,480 --> 00:53:54,200
AS WELL AS O.D. SUPPORT FOR

1510
00:53:54,200 --> 00:53:55,080
FUNDING OPPORTUNITIES.

1511
00:53:55,080 --> 00:53:56,760
IMPORTANTLY, WE ALSO RECOGNIZE

1512
00:53:56,760 --> 00:53:58,640
THE NEED FOR CREATING A

1513
00:53:58,640 --> 00:54:00,560
DEDICATED SPACE FOR HIV AND

1514
00:54:00,560 --> 00:54:01,560
WOMEN'S HEALTH PROGRAMMATIC

1515
00:54:01,560 --> 00:54:07,240
STAFF TO SYNERGIZE.

1516
00:54:07,240 --> 00:54:11,040
IN THAT SPIRIT, O.A.R. AND ORWH

1517
00:54:11,040 --> 00:54:13,560
HAVE FORMED A PARTNERSHIP

1518
00:54:13,560 --> 00:54:15,520
THROUGH THE NIH HIV AND WOMEN

1519
00:54:15,520 --> 00:54:16,160
SIGNATURE PROGRAM.

1520
00:54:16,160 --> 00:54:17,800
THE CORNERSTONE IS AN

1521
00:54:17,800 --> 00:54:19,880
INTERSECTIONAL EQUITY-INFORMED

1522
00:54:19,880 --> 00:54:22,600
DATA-DRIVEN APPROACH TO RESEARCH

1523
00:54:22,600 --> 00:54:23,680
ON HIV AND WOMEN.

1524
00:54:23,680 --> 00:54:26,160
THE OBJECTIVES OF THIS JOINT

1525
00:54:26,160 --> 00:54:27,360
PROGRAM ARE TO PROMOTE THE NIH

1526
00:54:27,360 --> 00:54:30,560
VISION FOR WOMEN'S HEALTH, WHERE

1527
00:54:30,560 --> 00:54:32,240
ALL WOMEN, INCLUDING TRANSGENDER

1528
00:54:32,240 --> 00:54:34,200
WOMEN, GENDER DIVERSE PEOPLE,

1529
00:54:34,200 --> 00:54:35,760
AND INDIVIDUALS ASSIGNED FEMALE

1530
00:54:35,760 --> 00:54:39,840
AT BIRTH RECEIVE EVIDENCE-BASED,

1531
00:54:39,840 --> 00:54:41,800
GENDER-AFFIRMING, TAILORED HIV

1532
00:54:41,800 --> 00:54:43,880
PREVENTION, CARE, AND TREATMENT.

1533
00:54:43,880 --> 00:54:45,840
AND IT ALSO SUPPORTS WOMEN IN

1534
00:54:45,840 --> 00:54:47,240
SCIENCE CAREERS TO REACH THEIR

1535
00:54:47,240 --> 00:54:50,440
FULL POTENTIAL.

1536
00:54:50,440 --> 00:54:51,800
STRATEGIES TO ACHIEVE THESE

1537
00:54:51,800 --> 00:54:53,760
OBJECTIVES INCLUDE INCREASING

1538
00:54:53,760 --> 00:54:56,680
INFORMATION DISSEMINATION AND

1539
00:54:56,680 --> 00:54:57,600
NIH-WIDE COLLABORATION THROUGH

1540
00:54:57,600 --> 00:54:59,520
ESTABLISHMENT OF AN NIH HIV AND

1541
00:54:59,520 --> 00:55:01,920
WOMEN WORKING GROUP, AN HIV AND

1542
00:55:01,920 --> 00:55:03,880
WOMEN WEBPAGE AND A

1543
00:55:03,880 --> 00:55:04,600
COMPREHENSIVE EXTERNAL

1544
00:55:04,600 --> 00:55:06,240
ENGAGEMENT CALENDAR, INCLUDING

1545
00:55:06,240 --> 00:55:07,640
LISTENING SESSIONS, WORKSHOPS,

1546
00:55:07,640 --> 00:55:13,000
AND SYMPOSIA.

1547
00:55:13,000 --> 00:55:15,000
THE JOINT SIGNATURE PROGRAM

1548
00:55:15,000 --> 00:55:17,560
LAUNCHED IN FEBRUARY OF 2023 AT

1549
00:55:17,560 --> 00:55:19,280
THE INTERNATIONAL WORKSHOP ON

1550
00:55:19,280 --> 00:55:23,040
HIV AND WOMEN DURING THE O.A.R.

1551
00:55:23,040 --> 00:55:25,720
ORWH CO-SPONSORED SYMPOSIUM, HIV

1552
00:55:25,720 --> 00:55:26,920
AND WOMEN, CONSIDERATIONS FROM

1553
00:55:26,920 --> 00:55:29,880
ACROSS THE LIFESPAN.

1554
00:55:29,880 --> 00:55:32,120
THIS SYMPOSIUM FEATURED

1555
00:55:32,120 --> 00:55:33,200
PRESENTATIONS FROM EARLY CAREER

1556
00:55:33,200 --> 00:55:34,320
INVESTIGATORS AND REFLECTIONS

1557
00:55:34,320 --> 00:55:36,240
FROM ESTABLISHED INVESTIGATORS

1558
00:55:36,240 --> 00:55:37,560
ON PRIORITY TOPICS INCLUDING

1559
00:55:37,560 --> 00:55:40,600
AGING AND WOMEN'S

1560
00:55:40,600 --> 00:55:41,360
MULTI-MORBIDITY BURDEN, SOCIAL

1561
00:55:41,360 --> 00:55:42,520
AND STRUCTURAL CONSIDERATIONS

1562
00:55:42,520 --> 00:55:43,840
FOR WOMEN, AND ADOLESCENT GIRLS

1563
00:55:43,840 --> 00:55:46,040
AND YOUNG WOMEN.

1564
00:55:46,040 --> 00:55:47,600
THIS SYMPOSIUM ALSO PROVIDED AN

1565
00:55:47,600 --> 00:55:48,960
OPPORTUNITY TO HEAR FROM

1566
00:55:48,960 --> 00:55:51,240
COMMUNITY MEMBERS ON ISSUES

1567
00:55:51,240 --> 00:55:52,680
RELATED TO HIV AND WOMEN'S

1568
00:55:52,680 --> 00:55:53,320
HEALTH THAT ARE IMPORTANT TO

1569
00:55:53,320 --> 00:55:54,080
THEM.

1570
00:55:54,080 --> 00:55:55,880
YOU CAN READ MORE ABOUT THIS

1571
00:55:55,880 --> 00:55:57,320
EVENT, INCLUDING THE EXECUTIVE

1572
00:55:57,320 --> 00:55:59,080
SUMMARY, USING THE QR CODE SHOWN

1573
00:55:59,080 --> 00:56:03,280
HERE.

1574
00:56:03,280 --> 00:56:05,160
WE'D NOW LIKE TO REVIEW SOME

1575
00:56:05,160 --> 00:56:07,920
ONGOING ACTIVITIES.

1576
00:56:07,920 --> 00:56:10,040
IN APRIL 2022, THE SIGNATURE

1577
00:56:10,040 --> 00:56:12,560
PROGRAM LAUNCHED THE HIV AND

1578
00:56:12,560 --> 00:56:13,480
WOMEN WEBPAGE WHICH CAN BE

1579
00:56:13,480 --> 00:56:15,560
ACCESSED USING THE QR CODE SHOWN

1580
00:56:15,560 --> 00:56:17,280
HERE.

1581
00:56:17,280 --> 00:56:18,800
THE WEBPAGE AIMS TO SERVE AS AN

1582
00:56:18,800 --> 00:56:21,720
EASY TO NAVIGATE ONE-STOP SHOP

1583
00:56:21,720 --> 00:56:22,960
TO ACCESS RELEVANT INFORMATION

1584
00:56:22,960 --> 00:56:24,840
AND CURATED CONTENT FROM ACROSS

1585
00:56:24,840 --> 00:56:28,160
THE NIH AND FEDERAL GOVERNMENT.

1586
00:56:28,160 --> 00:56:29,320
THE WEBPAGE INCLUDES GENERAL

1587
00:56:29,320 --> 00:56:31,920
RESOURCES SUCH AS LINKS TO THE

1588
00:56:31,920 --> 00:56:33,560
NIH HIV AND WOMEN'S HEALTH

1589
00:56:33,560 --> 00:56:35,880
STRATEGIC PLANS, AND SEX AS A

1590
00:56:35,880 --> 00:56:36,840
BIOLOGICAL VARIABLE AND

1591
00:56:36,840 --> 00:56:38,760
INCLUSION POLICIES.

1592
00:56:38,760 --> 00:56:41,120
CLINICAL RESOURCES SUCH AS LINKS

1593
00:56:41,120 --> 00:56:44,920
TO RELEVANT CLINICAL GUIDELINES

1594
00:56:44,920 --> 00:56:50,560
AND NIH INFO, LINKS TO EXTERNAL

1595
00:56:50,560 --> 00:56:52,000
RESOURCES AND FUNDING TEUPTS

1596
00:56:52,000 --> 00:56:53,200
RELATED TO HIV AND WOMEN.

1597
00:56:53,200 --> 00:56:54,600
THE PAGE IS UPDATED REGULARLY

1598
00:56:54,600 --> 00:56:56,360
AND A COMPREHENSIVE SET OF LINKS

1599
00:56:56,360 --> 00:56:58,000
TO RELATED CONTENT FROM ACROSS

1600
00:56:58,000 --> 00:57:00,840
THE NIH INSTITUTES, OFFICES AND

1601
00:57:00,840 --> 00:57:03,280
CENTERS IS CURRENTLY UNDERWAY.

1602
00:57:03,280 --> 00:57:11,440
DR. BARR, OVER TO YOU.

1603
00:57:11,440 --> 00:57:14,400
>> BOTH OAR AND ORWH ARE

1604
00:57:14,400 --> 00:57:15,320
COORDINATING OFFICES LOCATED

1605
00:57:15,320 --> 00:57:17,560
WITHIN THE NIH OFFICE OF THE

1606
00:57:17,560 --> 00:57:18,160
DIRECTOR.

1607
00:57:18,160 --> 00:57:20,520
AS SUCH, OUR MISSIONS ENTAIL

1608
00:57:20,520 --> 00:57:21,960
COORDINATION OF RESEARCH THAT IS

1609
00:57:21,960 --> 00:57:25,080
RELEVANT TO OUR OFFICE MISSIONS

1610
00:57:25,080 --> 00:57:26,480
ACROSS THE 27 INSTITUTES AND

1611
00:57:26,480 --> 00:57:28,680
CENTERS OF NIH.

1612
00:57:28,680 --> 00:57:31,040
FOR BOTH OFFICES, THE NIH

1613
00:57:31,040 --> 00:57:33,840
REVITALIZATION ACT OF 1993

1614
00:57:33,840 --> 00:57:35,720
ESTABLISHED NIH-WIDE

1615
00:57:35,720 --> 00:57:39,240
COORDINATING COMMITTEES, THE NIH

1616
00:57:39,240 --> 00:57:41,840
HIV/AIDS EXECUTIVE COMMITTEE, OR

1617
00:57:41,840 --> 00:57:43,680
NAEC, AND THE COORDINATING

1618
00:57:43,680 --> 00:57:44,680
COMMITTEE FOR RESEARCH ON

1619
00:57:44,680 --> 00:57:47,080
WOMEN'S HEALTH, CCRWH.

1620
00:57:47,080 --> 00:57:50,560
LAST YEAR, THE OAR AND ORWH

1621
00:57:50,560 --> 00:57:52,160
DIRECTORS ESTABLISHED A JOINT

1622
00:57:52,160 --> 00:57:53,760
WORKING GROUP OF THE

1623
00:57:53,760 --> 00:57:55,640
COORDINATING COMMITTEES TO

1624
00:57:55,640 --> 00:57:59,960
PROMOTE SIN RG IN EFFORTS SYNERS

1625
00:57:59,960 --> 00:58:01,600
RELATING TO WOMEN AND NIH.

1626
00:58:01,600 --> 00:58:05,640
THE NAEC-CCRWH WORKING GROUP ON

1627
00:58:05,640 --> 00:58:07,600
WOMEN AND HIV IS CHARGED TO

1628
00:58:07,600 --> 00:58:08,360
PROMOTE HEALTH AND WELL-BEING

1629
00:58:08,360 --> 00:58:10,840
FOR ALL WOMEN WITH OR AFFECTED

1630
00:58:10,840 --> 00:58:12,680
BY HIV AND TO SUPPORT CAREER

1631
00:58:12,680 --> 00:58:15,560
DEVELOPMENT FOR WOMEN IN HIV

1632
00:58:15,560 --> 00:58:18,520
RESEARCHMENT THE OVERARCHING

1633
00:58:18,520 --> 00:58:19,880
GOAL OF THE JOINT WORKING GROUP

1634
00:58:19,880 --> 00:58:22,720
IS TO MAXIMIZE COLLABORATION

1635
00:58:22,720 --> 00:58:25,800
ACROSS NIH TO PROMOTE MEANINGFUL

1636
00:58:25,800 --> 00:58:27,120
RESEARCH FOCUSED ON HIV AND

1637
00:58:27,120 --> 00:58:27,840
WOMEN.

1638
00:58:27,840 --> 00:58:29,600
TO ACCOMPLISH THIS GOAL, WE MEET

1639
00:58:29,600 --> 00:58:31,400
MONTHLY AND RECEIVE REGULAR

1640
00:58:31,400 --> 00:58:33,640
UPDATES ON ONGOING DEVELOPING

1641
00:58:33,640 --> 00:58:35,600
AND ASPIRATIONAL ACTIVITIES

1642
00:58:35,600 --> 00:58:39,120
RELATED TO WOMEN AND HIV.

1643
00:58:39,120 --> 00:58:40,520
STANDING TOPICS FOR OUR WORKING

1644
00:58:40,520 --> 00:58:41,720
GROUP MEETINGS ARE SHOWN ON THIS

1645
00:58:41,720 --> 00:58:45,480
SLIDE.

1646
00:58:45,480 --> 00:58:47,880
I'M HAPPY TO SHARE A BRIEF HIGH

1647
00:58:47,880 --> 00:58:49,480
LEVEL OVERVIEW OF THE JOINT

1648
00:58:49,480 --> 00:58:50,800
WORKING GROUP'S ONGOING

1649
00:58:50,800 --> 00:58:52,200
ACTIVITIES.

1650
00:58:52,200 --> 00:58:53,880
WE'VE BEEN WORKING WITH THE NIH

1651
00:58:53,880 --> 00:58:55,840
LIBRARY TO COMPLETE A LITERATURE

1652
00:58:55,840 --> 00:58:57,360
REVIEW TO ASSESS THE STATE OF

1653
00:58:57,360 --> 00:58:59,960
THE SCIENCE IN KEY AREAS AT THE

1654
00:58:59,960 --> 00:59:03,480
INTERSECTION OF WOMEN AND HIV.

1655
00:59:03,480 --> 00:59:05,320
INITIAL AREAS OF FOCUS ARE

1656
00:59:05,320 --> 00:59:06,720
SOCIAL AND STRUCTURAL VARIABLES

1657
00:59:06,720 --> 00:59:08,880
THAT IMPACT HIV PREVENTION,

1658
00:59:08,880 --> 00:59:11,280
TREATMENT, AND OUTCOMES.

1659
00:59:11,280 --> 00:59:13,280
AGING AND A LIFE COURSE

1660
00:59:13,280 --> 00:59:15,440
PERSPECTIVE.

1661
00:59:15,440 --> 00:59:16,560
MULTI-MORBIDITY, CO-MORBIDITY

1662
00:59:16,560 --> 00:59:20,120
AND POLYPHARMACY, CURE-RELATED

1663
00:59:20,120 --> 00:59:21,960
RESEARCH, DEMOGRAPHIC DIVERSITY,

1664
00:59:21,960 --> 00:59:24,600
AND TRAUMA-INFORMED

1665
00:59:24,600 --> 00:59:26,320
GENDER-AFFIRMING HIV CARE

1666
00:59:26,320 --> 00:59:28,200
RESEARCH AND TREATMENT.

1667
00:59:28,200 --> 00:59:31,040
IN PARALLEL, WE ARE COMPLETING A

1668
00:59:31,040 --> 00:59:33,320
PORTFOLIO ANALYSIS OF NIH

1669
00:59:33,320 --> 00:59:34,840
FUNDING AT THE INTERSECTION OF

1670
00:59:34,840 --> 00:59:36,920
HIV AND WOMEN TO CHARACTERIZE

1671
00:59:36,920 --> 00:59:39,320
THE FUNDING LANDSCAPE.

1672
00:59:39,320 --> 00:59:40,760
WE'LL BE LEADING A WORKSHOP AT

1673
00:59:40,760 --> 00:59:44,000
THIS YEAR'S U.S. CHA THAT WILL

1674
00:59:44,000 --> 00:59:45,960
REVIEW NIH EFFORTS RELATED TO

1675
00:59:45,960 --> 00:59:49,320
WOMEN AND HIV, DESCRIBE CURRENT

1676
00:59:49,320 --> 00:59:51,480
NIH PRIORITIES IN WOMEN IN HIV,

1677
00:59:51,480 --> 00:59:56,080
AND CORRECTICA CRITICALLY, INVIP

1678
00:59:56,080 --> 00:59:57,280
ATTENDEES TO PROVIDE INPUT ON

1679
00:59:57,280 --> 00:59:58,440
THESE PROVIDE ORTS AS WELL AS

1680
00:59:58,440 --> 01:00:00,120
FUTURE EFFORTS.

1681
01:00:00,120 --> 01:00:01,280
FINALLY, WE INVITE TO YOU SAVE

1682
01:00:01,280 --> 01:00:03,000
THE DATES FOR A VIRTUAL

1683
01:00:03,000 --> 01:00:04,640
SCIENTIFIC WORKSHOP WE WILL HOST

1684
01:00:04,640 --> 01:00:05,320
IN CONJUNCTION WITH NATIONAL

1685
01:00:05,320 --> 01:00:06,760
WOMEN AND GIRLS HIV AWARENESS

1686
01:00:06,760 --> 01:00:10,760
DAY IN MARCH 2024.

1687
01:00:10,760 --> 01:00:11,840
THIS VIRTUAL WORKSHOP WILL

1688
01:00:11,840 --> 01:00:13,360
REVIEW THE STATE OF THE SCIENCE

1689
01:00:13,360 --> 01:00:19,800
ON NIH AND WOMEN, INFORM AN NIH

1690
01:00:19,800 --> 01:00:21,440
HIV AND WOMEN RESEARCH AGENDA

1691
01:00:21,440 --> 01:00:23,680
AND PRIORITIES FOR PROGRAMMATIC

1692
01:00:23,680 --> 01:00:23,920
EFFORTS.

1693
01:00:23,920 --> 01:00:24,920
AS WE CLOSE OUT THIS

1694
01:00:24,920 --> 01:00:26,120
PRESENTATION, I WOULD LIKE TO

1695
01:00:26,120 --> 01:00:27,480
HIGHLIGHT OUR ASPIRATIONAL

1696
01:00:27,480 --> 01:00:29,600
PLANNING FOR THE NEXT FISCAL

1697
01:00:29,600 --> 01:00:33,120
YEAR AND BEYOND.

1698
01:00:33,120 --> 01:00:34,200
THE ONGOING ACTIVITIES THAT

1699
01:00:34,200 --> 01:00:35,600
DR. MARSHALL AND I HAVE JUST

1700
01:00:35,600 --> 01:00:36,360
DESCRIBED, WHICH ARE SHOWN

1701
01:00:36,360 --> 01:00:41,080
ACROSS THE TOP OF THIS SLIDE,

1702
01:00:41,080 --> 01:00:42,160
WILL INFORM OUR EFFORTS IN THE

1703
01:00:42,160 --> 01:00:42,520
COMING YEARS.

1704
01:00:42,520 --> 01:00:43,640
WE WILL USE THE DATA AND

1705
01:00:43,640 --> 01:00:44,720
FINDINGS OF THE PORTFOLIO

1706
01:00:44,720 --> 01:00:46,760
ANALYSIS AND LITERATURE REVIEW,

1707
01:00:46,760 --> 01:00:49,680
AS WELL AS THE INPUT AND

1708
01:00:49,680 --> 01:00:52,840
EXPERTISE OF THE NAEC-CCRWH

1709
01:00:52,840 --> 01:00:53,920
WORKING GROUP MEMBERS, TO SHAPE

1710
01:00:53,920 --> 01:00:57,080
OUR FUTURE ENGAGEMENTS AND

1711
01:00:57,080 --> 01:01:00,120
ACTIVITIES.

1712
01:01:00,120 --> 01:01:02,360
ACROSS THE BOTTOM OF THIS SLIDE

1713
01:01:02,360 --> 01:01:03,640
ARE THREE ASPIRATIONS FOR

1714
01:01:03,640 --> 01:01:07,520
UPCOMING YEARS, INCLUDING

1715
01:01:07,520 --> 01:01:08,680
IDENTIFYING FUNDING GAPS,

1716
01:01:08,680 --> 01:01:09,520
STRATEGIES AND OPPORTUNITIES,

1717
01:01:09,520 --> 01:01:12,080
HOSTING WORKSHOPS ON HIV AND

1718
01:01:12,080 --> 01:01:16,160
WOMEN, AND ENSURING THIS IS

1719
01:01:16,160 --> 01:01:18,160
INCORPORATED ACROSS OUR OFFICE'S

1720
01:01:18,160 --> 01:01:19,160
STRATEGIC PLANNING.

1721
01:01:19,160 --> 01:01:20,640
WE INVITE YOU TO STAY CONNECTED

1722
01:01:20,640 --> 01:01:22,640
AND INFORMED USING ANY OF THE

1723
01:01:22,640 --> 01:01:24,200
METHODS SHOWN ON THIS SLIDE AND

1724
01:01:24,200 --> 01:01:34,080
I THANK YOU FOR YOUR ATTENTION.

1725
01:01:34,080 --> 01:01:44,520
BACK TO YOU, DR. TURNBULL.

1726
01:01:45,120 --> 01:01:46,840
>> DR. TURNBULL, WE'RE NOT

1727
01:01:46,840 --> 01:01:49,240
HEARING YOU.

1728
01:01:49,240 --> 01:01:50,480
ONLINE.

1729
01:01:50,480 --> 01:01:51,360
>> I'M SORRY.

1730
01:01:51,360 --> 01:01:53,320
I DIDN'T UNMUTE MY LINE.

1731
01:01:53,320 --> 01:01:55,120
CAN YOU HEAR ME NOW?

1732
01:01:55,120 --> 01:01:56,000
>> YES.

1733
01:01:56,000 --> 01:01:58,760
>> OKAY, GREAT.

1734
01:01:58,760 --> 01:02:01,200
SO THANK YOU ONCE AGAIN, LESLIE

1735
01:02:01,200 --> 01:02:02,440
AND ELIZABETH, FOR YOUR

1736
01:02:02,440 --> 01:02:03,360
PRESENTATION.

1737
01:02:03,360 --> 01:02:06,560
WE WILL NOW HEAR FROM OUR GUEST

1738
01:02:06,560 --> 01:02:17,040
SPEAKER, DR. SEBLE KASSAYE.

1739
01:02:17,640 --> 01:02:19,800
SHE IS PRINCIPAL INVESTIGATOR OF

1740
01:02:19,800 --> 01:02:22,160
THE COMBINED COHORT STUDY AND

1741
01:02:22,160 --> 01:02:23,280
STAR COHORT.

1742
01:02:23,280 --> 01:02:26,200
OVER TO YOU, DR. KASSAYE.

1743
01:02:26,200 --> 01:02:28,600
>> THANK YOU, DR.
TURNBULL, GOOD

1744
01:02:28,600 --> 01:02:29,120
AFTERNOON, EVERYONE.

1745
01:02:29,120 --> 01:02:30,520
THANK YOU TO THE OFFICE OF AIDS

1746
01:02:30,520 --> 01:02:31,600
RESEARCH FOR THE OPPORTUNITY TO

1747
01:02:31,600 --> 01:02:33,440
PRESENT TODAY.

1748
01:02:33,440 --> 01:02:35,760
AND FOR THE FOCUS ON HIV AMONG

1749
01:02:35,760 --> 01:02:36,440
WOMEN.

1750
01:02:36,440 --> 01:02:37,760
I'D LIKE TO ACKNOWLEDGE THE

1751
01:02:37,760 --> 01:02:38,920
FIRST GENERATION OF

1752
01:02:38,920 --> 01:02:40,120
INVESTIGATORS IN THIS AREA WHO

1753
01:02:40,120 --> 01:02:41,320
HAVE LAID THE FOUNDATION FOR

1754
01:02:41,320 --> 01:02:42,840
MUCH OF THE DATA I WILL BE

1755
01:02:42,840 --> 01:02:53,160
PRESENTING TODAY.

1756
01:02:59,400 --> 01:03:00,680
SO GLOBALLY AS WE'VE JUST HEARD

1757
01:03:00,680 --> 01:03:02,080
OVER HALF OF THE PERSONS

1758
01:03:02,080 --> 01:03:05,240
AFFECTED WITH HIV ARE WOMEN, AND

1759
01:03:05,240 --> 01:03:07,640
IN THE U.S. AND IN THE D.C. 

1760
01:03:07,640 --> 01:03:09,960
REGIONS IN PARTICULAR, THE

1761
01:03:09,960 --> 01:03:12,480
EPIDEMIC IS HIGHLY MINORITIZED

1762
01:03:12,480 --> 01:03:14,320
WITH WOMEN OF COLOR BEING

1763
01:03:14,320 --> 01:03:21,800
HEAVILY AFFECTED BY HIV.

1764
01:03:21,800 --> 01:03:25,080
AND IN THIS, WE ALSO KNOW WE

1765
01:03:25,080 --> 01:03:26,600
HAVE REALLY MADE GREAT STRIDES

1766
01:03:26,600 --> 01:03:27,720
IN HAVING EFFECTIVE THERAPIES

1767
01:03:27,720 --> 01:03:29,960
THAT REALLY HAVE TURNED THE

1768
01:03:29,960 --> 01:03:33,120
OVERALL EPIDEMIC WITH

1769
01:03:33,120 --> 01:03:34,200
SIGNIFICANT IMPROVEMENTS IN

1770
01:03:34,200 --> 01:03:35,240
MORTALITY SINCE THE EARLY DAYS

1771
01:03:35,240 --> 01:03:37,400
OF THE EPIDEMIC, SUCH THAT A

1772
01:03:37,400 --> 01:03:39,640
YOUNG PERSON WHO'S NOW AFFECTED

1773
01:03:39,640 --> 01:03:44,680
WITH HIV SHOULD EX-SECRE EXPECTE

1774
01:03:44,680 --> 01:03:46,000
ALMOST THE SAME LIFESPAN AS

1775
01:03:46,000 --> 01:03:49,280
SOMEONE WHO IS UNINFECTED.

1776
01:03:49,280 --> 01:03:52,560
SIMILARLY, THESE EFFORTS HAVE

1777
01:03:52,560 --> 01:03:53,640
ALSO TRANSLATED INTO

1778
01:03:53,640 --> 01:03:55,920
IMPROVEMENTS IN TRANSMISSION,

1779
01:03:55,920 --> 01:04:02,800
AND HENCE IN THIS BACKDROP, THE

1780
01:04:02,800 --> 01:04:04,000
NIH CARE CONTINUUM REALLY

1781
01:04:04,000 --> 01:04:06,560
PROVIDES A CONSTRUCT FOR US TO

1782
01:04:06,560 --> 01:04:07,760
QUANTIFY OUR PROGRESS TOWARDS

1783
01:04:07,760 --> 01:04:09,000
PROVIDING CARE AND TREATMENT

1784
01:04:09,000 --> 01:04:12,360
SERVICES TO PERSONS WITH HIV.

1785
01:04:12,360 --> 01:04:13,640
SURVEILLANCE DATA DEMONSTRATE

1786
01:04:13,640 --> 01:04:15,400
EXCELLENT PROGRESS IN DIAGNOSIS

1787
01:04:15,400 --> 01:04:18,080
OF INDIVIDUALS WITH HIV LOCALLY,

1788
01:04:18,080 --> 01:04:19,640
NATIONALLY AND IN THE GLOBAL

1789
01:04:19,640 --> 01:04:20,160
ARENA.

1790
01:04:20,160 --> 01:04:21,600
HOWEVER, THERE ARE UNMET NEEDS

1791
01:04:21,600 --> 01:04:23,880
WHEN IT COMES TO LINKAGE TO CARE

1792
01:04:23,880 --> 01:04:29,920
AND VIRAL SUPPRESSION.

1793
01:04:29,920 --> 01:04:32,200
DELIVERY OF EFFECTIVE

1794
01:04:32,200 --> 01:04:34,400
ANTIRETROVIRALS IS KEY TO

1795
01:04:34,400 --> 01:04:36,440
PREVENTING HIV TRANSMISSION, AND

1796
01:04:36,440 --> 01:04:38,080
EFFORTS TO ELIMINATE PEDIATRIC

1797
01:04:38,080 --> 01:04:39,960
HIV IS A NOTABLE AREA OF GREAT

1798
01:04:39,960 --> 01:04:40,960
SUCCESS, INCLUDING FOR WOMEN.

1799
01:04:40,960 --> 01:04:43,120
THESE ARE DATA FROM A STUDY THAT

1800
01:04:43,120 --> 01:04:46,720
I DESIGNED WHILE WORKING AT THE

1801
01:04:46,720 --> 01:04:47,600
ELIZABETH GLAI SER PEDIATRIC

1802
01:04:47,600 --> 01:04:48,640
AIDS FOUNDATION.

1803
01:04:48,640 --> 01:04:50,760
THIS OBSERVATIONAL COHORT WAS

1804
01:04:50,760 --> 01:04:52,280
CONDUCTED TO DETERMINE PROGRAM

1805
01:04:52,280 --> 01:04:53,160
EFFECTIVENESS FOLLOWING THE

1806
01:04:53,160 --> 01:04:54,360
IMPLEMENTATION OF UNIVERSAL

1807
01:04:54,360 --> 01:04:59,400
TREATMENT FOR ALL PREGNANT WOMEN

1808
01:04:59,400 --> 01:05:01,720
WHERE HIV PREVALENCE FOR WOMEN

1809
01:05:01,720 --> 01:05:04,280
AT THE TIME WAS OVER 25%.

1810
01:05:04,280 --> 01:05:07,800
WE ENROLLED 650 WOMEN WITH HIV

1811
01:05:07,800 --> 01:05:11,600
AND 941 WOMEN WITHOUT HIV FROM

1812
01:05:11,600 --> 01:05:12,600
JUNE 2014 THROUGH 2016.

1813
01:05:12,600 --> 01:05:15,080
AND COMPLETED 24 MONTH FOLLOW-UP

1814
01:05:15,080 --> 01:05:18,440
BY SEPTEMBER 2018.

1815
01:05:18,440 --> 01:05:19,800
WE IDENTIFIED SEVERAL IMPORTANT

1816
01:05:19,800 --> 01:05:21,000
FINDINGS IN THIS STUDY.

1817
01:05:21,000 --> 01:05:22,840
THE MOTHER TO CHILD TRANSMISSION

1818
01:05:22,840 --> 01:05:26,440
RATE AT 24 MONTHS WAS 2.8%.

1819
01:05:26,440 --> 01:05:27,960
DESPITE THIS VERY POSITIVE

1820
01:05:27,960 --> 01:05:29,920
FINDING, WE DID IDENTIFY THAT

1821
01:05:29,920 --> 01:05:31,960
MORE NIH EXPOSED INFANTS DIED

1822
01:05:31,960 --> 01:05:33,960
DURING THE FOLLOW-UP PERIOD,

1823
01:05:33,960 --> 01:05:42,720
RESULTING IN 91-POINT  8%

1824
01:05:42,720 --> 01:05:47,400
COMPARED TO 96.3% IN UNEXPOSED

1825
01:05:47,400 --> 01:05:50,000
INFANTS.

1826
01:05:50,000 --> 01:05:54,240
THE STUDY DOES ESTABLISH THAT

1827
01:05:54,240 --> 01:05:55,480
THE PROGRAM WAS PERFORMING ON

1828
01:05:55,480 --> 01:05:57,240
PAR WITH THAT THE OTHER HIGH

1829
01:05:57,240 --> 01:05:59,240
PERFORMING COUNTRIES IN

1830
01:05:59,240 --> 01:06:02,480
SUB-SAHARAN AFRICA.

1831
01:06:02,480 --> 01:06:04,120
FROM HERE ON, I WILL FOCUS ON

1832
01:06:04,120 --> 01:06:07,120
DATA COLLECTED HERE IN THE U.S.

1833
01:06:07,120 --> 01:06:08,200
OBSERVATIONAL COHORTS HAVE BEEN

1834
01:06:08,200 --> 01:06:09,920
IMPORTANT TO ELUCIDATE THE

1835
01:06:09,920 --> 01:06:13,120
EFFECT OF HIV AMONG WOMEN.

1836
01:06:13,120 --> 01:06:14,360
THE WOMEN'S INTERAGENCY HIV

1837
01:06:14,360 --> 01:06:17,040
STUDY IS A NATIONAL MULTI-SITE

1838
01:06:17,040 --> 01:06:17,800
OBSERVATIONAL INTERVAL COHORT

1839
01:06:17,800 --> 01:06:21,000
THAT STARTED ENROLLMENT IN 1994.

1840
01:06:21,000 --> 01:06:25,640
THIS WAS COMBINED IN 2019, WITH

1841
01:06:25,640 --> 01:06:26,800
THE MULTICENTER AIDS COHORT

1842
01:06:26,800 --> 01:06:31,480
STUDY THAT PREDATED THE WIHS BY

1843
01:06:31,480 --> 01:06:33,080
ABOUT A DECADE.

1844
01:06:33,080 --> 01:06:35,480
THE WIHS COHORT HAS CONTRIBUTE

1845
01:06:35,480 --> 01:06:36,920
TODAY IMPORTANT FINDINGS RELATED

1846
01:06:36,920 --> 01:06:38,240
TO HIV AMONG WOMEN.

1847
01:06:38,240 --> 01:06:39,760
SOME OF WHICH HAVE ALREADY BEEN

1848
01:06:39,760 --> 01:06:41,040
MENTIONED IN EARLIER

1849
01:06:41,040 --> 01:06:43,240
PRESENTATIONS.

1850
01:06:43,240 --> 01:06:46,040
THE D.C.  WIHS WAS ONE OF THE

1851
01:06:46,040 --> 01:06:48,480
ORIGINAL STUDY SITES SET OF BUT

1852
01:06:48,480 --> 01:06:50,640
MY PREDECESSOR DR. MARY YOUNG AS

1853
01:06:50,640 --> 01:06:53,480
A MULTISITE COLLABORATION WITH A

1854
01:06:53,480 --> 01:06:55,440
RECRUITMENT STRATEGY DESIGNED TO

1855
01:06:55,440 --> 01:06:56,480
ENSURE ADEQUATE REPRESENTATION

1856
01:06:56,480 --> 01:07:00,040
OF THE AFFECTED POPULATION.

1857
01:07:00,040 --> 01:07:01,400
WE UNDERTOOK A STUDY TO

1858
01:07:01,400 --> 01:07:02,920
DETERMINE VIRAL SUPPRESSION

1859
01:07:02,920 --> 01:07:04,680
OUTCOMES AMONG WOMEN.

1860
01:07:04,680 --> 01:07:06,320
OUR INITIAL D.C.  FOCUSED

1861
01:07:06,320 --> 01:07:08,720
ANALYSIS USE DATA THROUGH 2012.

1862
01:07:08,720 --> 01:07:11,320
AS YOU CAN SEE, WHEN WE LOOKED

1863
01:07:11,320 --> 01:07:12,880
CROSS-SECTIONALLY, WE IDENTIFIED

1864
01:07:12,880 --> 01:07:13,880
INCREASING VIRAL SUPPRESSION

1865
01:07:13,880 --> 01:07:17,040
OVER TIME WITH THE MOST RECENT

1866
01:07:17,040 --> 01:07:17,800
TIME POINT DEMONSTRATING ABOUT

1867
01:07:17,800 --> 01:07:19,200
60% OF WOMEN WITH VIRAL

1868
01:07:19,200 --> 01:07:19,840
SUPPRESSION.

1869
01:07:19,840 --> 01:07:22,560
AND THIS WAS QUITE GOOD ACTUALLY

1870
01:07:22,560 --> 01:07:24,120
BASED ON SURVEILLANCE DATA THAT

1871
01:07:24,120 --> 01:07:26,040
WERE BEING REPORTED AT THE TIME.

1872
01:07:26,040 --> 01:07:29,360
HOWEVER, WHEN WE LOOKED

1873
01:07:29,360 --> 01:07:32,200
LONGITUDALLY USED A GROUP BASED

1874
01:07:32,200 --> 01:07:33,960
PROBABILITY MODELING APPROACH WE

1875
01:07:33,960 --> 01:07:36,120
IDENTIFIED THERE WERE THREE

1876
01:07:36,120 --> 01:07:38,760
DISTINCT PATTERNS OF VIREMIA.

1877
01:07:38,760 --> 01:07:40,080
APPROXIMATELY 28% FELL INTO A

1878
01:07:40,080 --> 01:07:43,800
GROUP OF LOW PROP PROBABILITY OF

1879
01:07:43,800 --> 01:07:46,520
VIREMIA SO THEY WERE DOING VERY

1880
01:07:46,520 --> 01:07:47,720
WELL.

1881
01:07:47,720 --> 01:07:49,120
36.3% WERE IN A GROUP WITH

1882
01:07:49,120 --> 01:07:50,680
INTERMEDIATE PROBABILITY OF

1883
01:07:50,680 --> 01:07:53,120
VIREMIA, AND A THIRD GROUP, 36%,

1884
01:07:53,120 --> 01:07:56,200
HAD A HIGH PROBABILITY OF VIE

1885
01:07:56,200 --> 01:07:59,160
VIREMIA, INCLUDING IN THE RECENT

1886
01:07:59,160 --> 01:08:00,400
YEARS.

1887
01:08:00,400 --> 01:08:08,120
12 YEA EVEN WHEN ADJUSTED FOR

1888
01:08:08,120 --> 01:08:10,080
CD4 COUNT, ART USE, ADHERENCE,

1889
01:08:10,080 --> 01:08:12,120
AND HOUSING, THE FACTORS WE

1890
01:08:12,120 --> 01:08:13,880
IDENTIFIED AS ASSOCIATED WITH

1891
01:08:13,880 --> 01:08:14,680
BELONGING IN THE HIGH

1892
01:08:14,680 --> 01:08:16,960
PROBABILITY OF VIREMIA GROUP

1893
01:08:16,960 --> 01:08:18,040
WERE AFRICAN AMERICAN RACE,

1894
01:08:18,040 --> 01:08:20,720
YOUNGER AGE, LOWER EDUCATION,

1895
01:08:20,720 --> 01:08:23,080
MODERATE OR HIGHER ALCOHOL USE,

1896
01:08:23,080 --> 01:08:25,800
AND THE PRESENCE OF DEPRESSIVE

1897
01:08:25,800 --> 01:08:30,600
SYMPTOMS.

1898
01:08:30,600 --> 01:08:32,040
WE EXPANDED THIS ANALYSIS TO

1899
01:08:32,040 --> 01:08:34,560
LOOK COHORT-WIDE TO DETERMINE

1900
01:08:34,560 --> 01:08:36,960
WHETHER THE PHENOMENON WE

1901
01:08:36,960 --> 01:08:37,960
DESCRIBED WERE UNIQUE.

1902
01:08:37,960 --> 01:08:40,240
WE SIMILARLY IDENTIFIED THREE

1903
01:08:40,240 --> 01:08:42,080
DISTINCT GROUPS USING THE

1904
01:08:42,080 --> 01:08:43,040
GROUP-BASED TRAJECTORY APPROACH

1905
01:08:43,040 --> 01:08:44,600
WITH THE CONVERGENCE IN

1906
01:08:44,600 --> 01:08:46,400
PROBABILITY OF VIREMIA AMONG THE

1907
01:08:46,400 --> 01:08:48,640
LOW AND INTERMEDIATE PROBABILITY

1908
01:08:48,640 --> 01:08:50,360
OF VIREMIA GROUPS BY 2009.

1909
01:08:50,360 --> 01:08:52,120
WE SEE THAT THE SLOPE OF THE

1910
01:08:52,120 --> 01:08:55,160
DECLINE IN THE PROBABILITY OF

1911
01:08:55,160 --> 01:08:55,840
VIREMIA WAS LONGER AMONG

1912
01:08:55,840 --> 01:08:56,600
INDIVIDUALS IN THE HIGH

1913
01:08:56,600 --> 01:08:59,440
PROBABILITY OF VIREMIA GROUP.

1914
01:08:59,440 --> 01:09:01,840
WE THEN FOCUSED ON THE TIME

1915
01:09:01,840 --> 01:09:03,400
BETWEEN 2015 TO '17,

1916
01:09:03,400 --> 01:09:04,720
ANTICIPATING THAT THE MOVE TO

1917
01:09:04,720 --> 01:09:06,600
UNIVERSAL TREATMENT BASED ON

1918
01:09:06,600 --> 01:09:07,560
RECOMMENDATIONS AND GUIDELINES

1919
01:09:07,560 --> 01:09:09,720
STARTING IN 2012, MAY HAVE TAKEN

1920
01:09:09,720 --> 01:09:12,920
TIME TO IMPLEMENT.

1921
01:09:12,920 --> 01:09:15,320
WHEN WE LOOKED

1922
01:09:15,320 --> 01:09:16,760
CROSS-SECTIONALLY, APPROXIMATELY

1923
01:09:16,760 --> 01:09:19,480
83% OF WOMEN ACHIEVED VIRAL IS

1924
01:09:19,480 --> 01:09:21,240
SUPPRESSION IN 2017 BUT WHEN WE

1925
01:09:21,240 --> 01:09:22,280
LOOKED OVER THE PERIOD OF THREE

1926
01:09:22,280 --> 01:09:25,160
YEARS, ONLY 71% DEMONSTRATED

1927
01:09:25,160 --> 01:09:25,720
DURABLE VIRAL SUPPRESSION.

1928
01:09:25,720 --> 01:09:27,240
AS YOU CAN SEE IN THE RIGHT

1929
01:09:27,240 --> 01:09:30,040
UPPER FIGURE, 41% OF WOMEN IN

1930
01:09:30,040 --> 01:09:32,160
THE HIGH PROBABILITY OF VIREMIA

1931
01:09:32,160 --> 01:09:34,000
GROUP REMAINED VIREMIC IN THE

1932
01:09:34,000 --> 01:09:35,440
MOST RECENT TIME PERIOD,

1933
01:09:35,440 --> 01:09:36,560
SUGGESTING THAT THERE IS

1934
01:09:36,560 --> 01:09:37,600
SOMETHING UNIQUE ABOUT THIS

1935
01:09:37,600 --> 01:09:40,480
GROUP THAT WE NEED TO UNDERSTAND

1936
01:09:40,480 --> 01:09:43,840
IF OUR GOAL IS TO ACHIEVE

1937
01:09:43,840 --> 01:09:45,400
UNIVERSAL DURABLE VIRAL

1938
01:09:45,400 --> 01:09:47,600
SUPPRESSION.

1939
01:09:47,600 --> 01:09:48,880
IN ADDITION TO THE FACTORS WE

1940
01:09:48,880 --> 01:09:50,000
PREVIOUSLY IDENTIFIED ASSOCIATED

1941
01:09:50,000 --> 01:09:53,080
WITH HIGH PROBABILITY OF VIREMIA

1942
01:09:53,080 --> 01:09:56,120
AMONG THE PARTICIPANTS, UNSTABLE

1943
01:09:56,120 --> 01:09:57,120
HOUSING, DEPRESSIVE SYMPTOMS,

1944
01:09:57,120 --> 01:09:59,160
DRUG USE, AND MODERATE OR

1945
01:09:59,160 --> 01:10:00,080
GREATER ALCOHOL USE WAS

1946
01:10:00,080 --> 01:10:01,800
ASSOCIATED WITH VIREMIA.

1947
01:10:01,800 --> 01:10:03,600
WE PLAN TO REPEAT THESE ANALYSES

1948
01:10:03,600 --> 01:10:09,480
NOW INCLUDING MEN  TO LOOK FOR X

1949
01:10:09,480 --> 01:10:11,560
DIFFERENCES AND ALSO TO LOOK AT

1950
01:10:11,560 --> 01:10:12,320
GEOGRAPHIC VARIATIONS WITH THE

1951
01:10:12,320 --> 01:10:13,520
MORE RECENT ADDITION OF SOUTHERN

1952
01:10:13,520 --> 01:10:14,720
U.S. SITES THAT WERE NOT A PART

1953
01:10:14,720 --> 01:10:18,520
OF OUR EARLIER ANALYSES.

1954
01:10:18,520 --> 01:10:20,400
THE FINDINGS FROM THE

1955
01:10:20,400 --> 01:10:21,480
GROUP-BASED TRAJECTORY ANALYSIS

1956
01:10:21,480 --> 01:10:23,880
HELPED US BETTER CHARACTERIZE

1957
01:10:23,880 --> 01:10:25,080
THE LIKELIHOOD OF VIRAL

1958
01:10:25,080 --> 01:10:25,880
SUPPRESSION AND WAS THE BASIS

1959
01:10:25,880 --> 01:10:28,800
FOR THE NEXT SET OF STUDIES THAT

1960
01:10:28,800 --> 01:10:29,320
WE UNDERTOOK.

1961
01:10:29,320 --> 01:10:31,440
IN A PROJECT WE CALLED BOTTLING

1962
01:10:31,440 --> 01:10:33,120
SUCCESS, FUNDING THROUGH

1963
01:10:33,120 --> 01:10:35,040
SUPPLEMENTAL FUNDS FOR NIMHD, WE

1964
01:10:35,040 --> 01:10:37,000
SOUGHT TO IDENTIFY THE SOCIAL,

1965
01:10:37,000 --> 01:10:38,000
BEHAVIORAL, STRUCTURAL AND

1966
01:10:38,000 --> 01:10:39,520
CLINICAL BASIS FOR VIRAL

1967
01:10:39,520 --> 01:10:41,560
SUPPRESSION USING THE SOCIAL

1968
01:10:41,560 --> 01:10:43,440
COGNITIVE THEORETICAL FRAMEWORK.

1969
01:10:43,440 --> 01:10:45,320
OUR GOAL WAS TO IDENTIFY

1970
01:10:45,320 --> 01:10:46,840
MODIFIABLE ELEMENTS THAT WOULD

1971
01:10:46,840 --> 01:10:48,680
IMPROVE LONG TERM VIRAL

1972
01:10:48,680 --> 01:10:50,360
SUPPRESSION.

1973
01:10:50,360 --> 01:10:51,880
THE UNDERLYING PREMISE OF THE

1974
01:10:51,880 --> 01:10:53,080
FRAMEWORK IS THAT INTERACTIONS

1975
01:10:53,080 --> 01:10:54,840
BETWEEN INDIVIDUAL AND

1976
01:10:54,840 --> 01:10:56,360
INTERPERSONAL FACTORS LEAD TO

1977
01:10:56,360 --> 01:10:58,560
MANIFESTED BEHAVIORS, THUS

1978
01:10:58,560 --> 01:11:00,400
INFLUENCING BIOLOGIC OUTCOMES.

1979
01:11:00,400 --> 01:11:02,360
KEY TO THIS FRAMEWORK IS A

1980
01:11:02,360 --> 01:11:04,120
CONCEPT OF SELF-EFFICACY THAT IS

1981
01:11:04,120 --> 01:11:05,960
SHAPED BY SOCIAL STRUCTURES AND

1982
01:11:05,960 --> 01:11:08,360
ENVIRONMENTAL EXPOSURES.

1983
01:11:08,360 --> 01:11:09,800
COGNITION AND BEHAVIOR CAN BE

1984
01:11:09,800 --> 01:11:11,120
INFLUENCED AND SHAPED, LEADING

1985
01:11:11,120 --> 01:11:12,640
TO IMPROVEMENTS IN

1986
01:11:12,640 --> 01:11:13,360
SELF-EFFICACY.

1987
01:11:13,360 --> 01:11:15,960
AND THEREBY THE DESIRED

1988
01:11:15,960 --> 01:11:17,360
BEHAVIORS ON HEALTH OUTCOMES.

1989
01:11:17,360 --> 01:11:19,240
SO WE SOUGHT TO QUANTIFY AND

1990
01:11:19,240 --> 01:11:21,320
DETERMINE WHETHER TREATMENT

1991
01:11:21,320 --> 01:11:22,120
SELF-EFFICACY IS ASSOCIATED WITH

1992
01:11:22,120 --> 01:11:22,800
VIRAL SUPPRESSION.

1993
01:11:22,800 --> 01:11:24,200
WE ALSO INCLUDED MEASURES OF

1994
01:11:24,200 --> 01:11:26,040
PERSONAL SOCIAL INVENTORY,

1995
01:11:26,040 --> 01:11:28,000
PERCEIVED STRESS, AND

1996
01:11:28,000 --> 01:11:28,720
PROVIDER-PATIENT INTERACTIONS

1997
01:11:28,720 --> 01:11:30,080
THAT MAY INFLUENCE

1998
01:11:30,080 --> 01:11:34,240
HEALTH-SEEKING BEHAVIORS.

1999
01:11:34,240 --> 01:11:36,960
IN THIS MANUSCRIPT LED BY

2000
01:11:36,960 --> 01:11:38,480
DR. BLARE SPENCE, AN INFECTIOUS

2001
01:11:38,480 --> 01:11:39,720
DISEASES PHYSICIAN AND EARLY

2002
01:11:39,720 --> 01:11:41,120
STAGE INVESTIGATOR IN MY GROUP,

2003
01:11:41,120 --> 01:11:44,480
WE ANALYZED DATA FROM THE DC

2004
01:11:44,480 --> 01:11:45,760
WIHS WOMEN WITH HIV, JUST OVER

2005
01:11:45,760 --> 01:11:47,960
TWO THIRDS OF WHOM HAD DURABLE

2006
01:11:47,960 --> 01:11:49,480
VIRAL SUPPRESSION BETWEEN 2015

2007
01:11:49,480 --> 01:11:50,080
AND 2018.

2008
01:11:50,080 --> 01:11:51,240
IN THIS ANALYSIS WE FOUND THAT

2009
01:11:51,240 --> 01:11:53,240
HIGHER TREATMENT SELF-EFFICACY

2010
01:11:53,240 --> 01:11:55,320
WAS ASSOCIATED WITH VIRAL

2011
01:11:55,320 --> 01:11:58,280
SUPPRESSION, WHILE USE OF

2012
01:11:58,280 --> 01:12:00,240
ILLICIT DRUGS WAS ASSOCIATED

2013
01:12:00,240 --> 01:12:00,560
WITH VIREMIA.

2014
01:12:00,560 --> 01:12:05,720
WE DID NOT FIND A -- WHICH MAY

2015
01:12:05,720 --> 01:12:07,040
BE DRIVEN BY THE HIGH PREVALENCE

2016
01:12:07,040 --> 01:12:09,240
OF HIV IN OUR REGION AND

2017
01:12:09,240 --> 01:12:13,080
POTENTIALLY SHIFTING SOCIETAL

2018
01:12:13,080 --> 01:12:16,320
ISSUES -- CONCEPTS AROUND STIGMA

2019
01:12:16,320 --> 01:12:20,880
IN OUR REGION.

2020
01:12:20,880 --> 01:12:22,280
DR. KATE MICHELLE WHO JOINED MY

2021
01:12:22,280 --> 01:12:23,920
GROUP AS A POSTDOCTORAL FELLOW

2022
01:12:23,920 --> 01:12:25,440
AND WHO IS NOW IN THE D.C. 

2023
01:12:25,440 --> 01:12:27,760
HEALTH DEPARTMENT FOCUSED ON

2024
01:12:27,760 --> 01:12:29,160
MATERNAL HEALTH MADE GREAT

2025
01:12:29,160 --> 01:12:31,240
HEADWAY IN ANALYZING DATA WE

2026
01:12:31,240 --> 01:12:32,080
COLLECTED RELATED TO TRUST.

2027
01:12:32,080 --> 01:12:34,080
WHEN WE LOOKED AT PROVIDER TRUST

2028
01:12:34,080 --> 01:12:35,840
IN VIRAL OUTCOMES, HIGH PROVIDER

2029
01:12:35,840 --> 01:12:37,240
TRUST WAS ASSOCIATED WITH

2030
01:12:37,240 --> 01:12:40,160
GREATER ART ADHERENCE AND LOWER

2031
01:12:40,160 --> 01:12:43,320
HEALTHCARE SERVICE DISTRUST.

2032
01:12:43,320 --> 01:12:45,200
SOMEWHAT DISTURBING WAS OUR

2033
01:12:45,200 --> 01:12:46,640
FINDING AMONG WOMEN WHO HAD

2034
01:12:46,640 --> 01:12:47,720
COMPLETED THE TRUST

2035
01:12:47,720 --> 01:12:48,800
QUESTIONNAIRES IN 2006 AND THEN

2036
01:12:48,800 --> 01:12:51,120
AGAIN IN 2017-18.

2037
01:12:51,120 --> 01:12:52,640
28% OF THESE WOMEN REPORTED A

2038
01:12:52,640 --> 01:12:54,720
DECREASE IN TRUST IN THE

2039
01:12:54,720 --> 01:12:56,480
INTERVENING DECADE, WHILE

2040
01:12:56,480 --> 01:12:57,680
ANOTHER 25% REPORTED AN INCREASE

2041
01:12:57,680 --> 01:12:59,880
IN TRUST.

2042
01:12:59,880 --> 01:13:01,520
THIS IS AN IMPORTANT FINDING IN

2043
01:13:01,520 --> 01:13:03,400
OUR CONTINUED UNDERSTANDING OF

2044
01:13:03,400 --> 01:13:05,600
HOW WOMEN RELATE TO THE

2045
01:13:05,600 --> 01:13:07,240
HEALTHCARE SYSTEM IS PIVOTAL, AS

2046
01:13:07,240 --> 01:13:09,720
WE STRIVE TO ACHIEVE AND

2047
01:13:09,720 --> 01:13:13,680
MAINTAIN DURABLE VIRAL

2048
01:13:13,680 --> 01:13:15,400
SUPPRESSION OUTCOMES.

2049
01:13:15,400 --> 01:13:16,840
THIS COMPONENT OF THE STUDY I

2050
01:13:16,840 --> 01:13:17,920
FIND PARTICULARLY INTERESTING.

2051
01:13:17,920 --> 01:13:20,680
IT WAS A COLLABORATION THAT WE

2052
01:13:20,680 --> 01:13:21,880
HAD WITH OUR COLLEAGUES AT THE

2053
01:13:21,880 --> 01:13:22,880
D.C.  HEALTH DEPARTMENT, WHERE

2054
01:13:22,880 --> 01:13:25,360
WE SENT A WEB-BASED SURVEY TO

2055
01:13:25,360 --> 01:13:27,480
ALL D.C. -LICENSED PHYSICIANS

2056
01:13:27,480 --> 01:13:28,680
AND MID LEVEL PROVIDERS TO

2057
01:13:28,680 --> 01:13:30,640
ASSESS HIV KNOWLEDGE AND

2058
01:13:30,640 --> 01:13:32,600
ATTITUDES, INCLUDING A VALIDATED

2059
01:13:32,600 --> 01:13:34,600
HIV STIGMA QUESTIONNAIRE.

2060
01:13:34,600 --> 01:13:37,320
OVER A ONE-MONTH PERIOD, WE

2061
01:13:37,320 --> 01:13:38,320
ENROLLED 436 PROVIDER WITH A

2062
01:13:38,320 --> 01:13:41,400
MEAN AGE OF 46 YEARS, 70% OF

2063
01:13:41,400 --> 01:13:44,240
WHOM ARE FEMALE, 62% WHITE, 19%

2064
01:13:44,240 --> 01:13:46,920
ASIAN, AND 12% BLACK.

2065
01:13:46,920 --> 01:13:49,120
44% WERE BASED IN AN ACADEMIC

2066
01:13:49,120 --> 01:13:52,200
MEDICAL CENTER, WHILE 45% WERE

2067
01:13:52,200 --> 01:13:54,520
IN NON-PROCEDURAL SPECIALTIES.

2068
01:13:54,520 --> 01:13:55,480
ALTHOUGH THE CITY REQUIRED

2069
01:13:55,480 --> 01:13:57,120
CONTINUING MEDICAL EDUCATION

2070
01:13:57,120 --> 01:13:59,760
RELATED TO HIV FOR THE PRECEDING

2071
01:13:59,760 --> 01:14:00,840
FIVE YEARS BEFORE THE STUDY

2072
01:14:00,840 --> 01:14:03,760
PERIOD, WE IDENTIFIED GAPS IN

2073
01:14:03,760 --> 01:14:05,560
COMFORT WITH TALKING ABOUT HIV

2074
01:14:05,560 --> 01:14:07,520
RISK, ASSESSING DRUG USE, AND

2075
01:14:07,520 --> 01:14:09,600
DISCUSSING SEXUAL PRACTICES.

2076
01:14:09,600 --> 01:14:11,440
NOTABLY, WE FOUND THAT LOWER HIV

2077
01:14:11,440 --> 01:14:13,200
STIGMA WAS ASSOCIATED WITH

2078
01:14:13,200 --> 01:14:15,720
GREATER HIV KNOWLEDGE AND

2079
01:14:15,720 --> 01:14:17,040
COMFORT WITH COUNSELING.

2080
01:14:17,040 --> 01:14:18,760
THE FINDINGS FROM THESE SERIES

2081
01:14:18,760 --> 01:14:20,200
OF SURVEYS PROVIDE DATA

2082
01:14:20,200 --> 01:14:21,520
SUPPORTING THE NEED TO DEVELOP

2083
01:14:21,520 --> 01:14:23,880
INTERVENTIONS TO INCREASE

2084
01:14:23,880 --> 01:14:24,400
TREATMENT SELF-EFFICACY,

2085
01:14:24,400 --> 01:14:25,800
IMPROPER AND SUPPORT PATIENT AND

2086
01:14:25,800 --> 01:14:27,320
PROVIDER INTERACTIONS AND

2087
01:14:27,320 --> 01:14:27,960
EFFECTIVELY ADDRESS DRUG AND

2088
01:14:27,960 --> 01:14:29,200
ALCOHOL USE.

2089
01:14:29,200 --> 01:14:31,280
STUDIES TO DETERMINE WHICH AND

2090
01:14:31,280 --> 01:14:33,480
WHAT COMBINATION OF THESE

2091
01:14:33,480 --> 01:14:34,760
INTERVENTIONS WOULD IMPROVE

2092
01:14:34,760 --> 01:14:37,160
VIRAL OUTCOMES ARE NEEDED.

2093
01:14:37,160 --> 01:14:38,600
I'LL SWITCH GEARS TO DISCUSS

2094
01:14:38,600 --> 01:14:39,600
VERY BRIEFLY A COUPLE OF STUDIES

2095
01:14:39,600 --> 01:14:42,560
THAT WE HAVE DONE RELATED TO

2096
01:14:42,560 --> 01:14:43,200
COMORBIDITIES IN THE SETTING OF

2097
01:14:43,200 --> 01:14:43,640
HIV.

2098
01:14:43,640 --> 01:14:46,280
WE KNOW FROM CLINIC-BASED AND

2099
01:14:46,280 --> 01:14:47,400
OBSERVATIONAL COHORTS INCLUDING

2100
01:14:47,400 --> 01:14:50,080
THE WIHS THAT NON-AIDS

2101
01:14:50,080 --> 01:14:51,440
COMORBIDITIES EMERGE EARLIER

2102
01:14:51,440 --> 01:14:53,080
AMONG PERSONS WITH HIV.

2103
01:14:53,080 --> 01:14:55,480
DR. MATT LEVY, EPIDEMIOLOGIST

2104
01:14:55,480 --> 01:14:56,320
WHO TRAINED AT GEORGE

2105
01:14:56,320 --> 01:14:58,320
WASHINGTON, USED DATA FROM THE

2106
01:14:58,320 --> 01:14:59,840
LONGITUDINAL CAROTID ULTRASOUND

2107
01:14:59,840 --> 01:15:02,320
IMAGING THAT WAS CONDUCTED AMONG

2108
01:15:02,320 --> 01:15:04,000
700 WIHS PARTICIPANTS WITH A

2109
01:15:04,000 --> 01:15:07,920
MEDIAN AGE OF 47 OVER AN

2110
01:15:07,920 --> 01:15:09,000
APPROXIMATELY SEVEN-YEAR TIME

2111
01:15:09,000 --> 01:15:09,280
SPAN.

2112
01:15:09,280 --> 01:15:12,200
HIS GOAL WAS TO DETERMINE THE

2113
01:15:12,200 --> 01:15:12,760
ASSOCIATION BETWEEN MENTAL

2114
01:15:12,760 --> 01:15:14,560
HEALTH CHARACTERISTICS AND

2115
01:15:14,560 --> 01:15:16,680
SUBCLINICAL ATHEROSCLEROSIS,

2116
01:15:16,680 --> 01:15:22,440
MAKIMAKE EXCELLENT USE OF --

2117
01:15:22,440 --> 01:15:23,400
INCLUDING NIMH.

2118
01:15:23,400 --> 01:15:24,960
THE PARENT STUDY CONDUCTED

2119
01:15:24,960 --> 01:15:26,800
THROUGH R01 FUNDING TO

2120
01:15:26,800 --> 01:15:28,280
DR. ROBERT KAPLAN IN THE BRONX

2121
01:15:28,280 --> 01:15:32,160
IDENTIFIED HIGHER SUBCLINI

2122
01:15:32,160 --> 01:15:32,720
SUBCLINICAL@THROW SCLEROSIS

2123
01:15:32,720 --> 01:15:35,680
AMONG WOMEN WITH HIV TO

2124
01:15:35,680 --> 01:15:37,880
COMPARABLE WOMEN WITHOUT HIV,

2125
01:15:37,880 --> 01:15:41,880
14% VE VERSUS THE%.

2126
01:15:41,880 --> 01:15:43,560
DR. LEVY IDENTIFIED HIGH

2127
01:15:43,560 --> 01:15:44,320
PSYCHOSOCIAL RISK PRIMARILY

2128
01:15:44,320 --> 01:15:45,760
DRIVEN BY DEPRESSIVE SYMPTOMS

2129
01:15:45,760 --> 01:15:48,760
WAS ASSOCIATED WITH PREVALENT

2130
01:15:48,760 --> 01:15:49,000
PLAQUE.

2131
01:15:49,000 --> 01:15:52,560
USING THE LONG TEUJAL DATA,

2132
01:15:52,560 --> 01:15:55,160
DR. LEVY IDENTIFIED@THROW

2133
01:15:55,160 --> 01:15:57,800
SCLEROSIS WAS HIGHER AMONG WOMEN

2134
01:15:57,800 --> 01:15:59,760
WITH SIGNIFICANT DEPRESSIVE

2135
01:15:59,760 --> 01:16:03,480
SYMPTOMS, 17%, COMPARED TO 7 TO

2136
01:16:03,480 --> 01:16:05,000
10% OF THOSE WITH NO OR

2137
01:16:05,000 --> 01:16:07,520
SOMETIMES DEPRESSIVE SYMPTOMS.

2138
01:16:07,520 --> 01:16:10,360
COLLEAGUES ARE NOW CONDUCTING

2139
01:16:10,360 --> 01:16:12,680
MULTI-OMIC STUDIES SUPPORTED BY

2140
01:16:12,680 --> 01:16:17,280
SUPPLEMENTAL FUNDING SUPPO

2141
01:16:17,280 --> 01:16:19,240
SUPPORTED -- PREMATURE@THROW

2142
01:16:19,240 --> 01:16:21,200
SCLEROSIS IN THIS COHORT.

2143
01:16:21,200 --> 01:16:22,320
CERVICAL CANCER WAS IDENTIFIED

2144
01:16:22,320 --> 01:16:26,280
EARLY ON AS AN AIDS-ASSOCIATED

2145
01:16:26,280 --> 01:16:28,040
DISEASE.

2146
01:16:28,040 --> 01:16:29,240
THE WIHS PLATFORM HAS BEEN USED

2147
01:16:29,240 --> 01:16:31,960
TO STUDY CERVICAL DYSPLASIA AND

2148
01:16:31,960 --> 01:16:34,360
INFORM CURRENT DAY PRACTICE

2149
01:16:34,360 --> 01:16:36,520
GUIDELINES.

2150
01:16:36,520 --> 01:16:39,320
WITH SUPPORT FROM NCI AS THE

2151
01:16:39,320 --> 01:16:41,360
CO-FUNDING INSTITUTE.

2152
01:16:41,360 --> 01:16:42,640
CERVICAL CANCER REMAINS AN

2153
01:16:42,640 --> 01:16:46,160
IMPORTANT CAUSE OF CANCER DEATHS

2154
01:16:46,160 --> 01:16:47,480
NATIONALLY AND GLOBALLY.

2155
01:16:47,480 --> 01:16:48,920
MY COLLEAGUE AT GEORGETOWN NOTED

2156
01:16:48,920 --> 01:16:50,760
A NUMBER OF WOMEN WITH MODERATE

2157
01:16:50,760 --> 01:16:51,880
CERVICAL DYSPLASIA LIMITED TO

2158
01:16:51,880 --> 01:16:54,280
THE UPPER TWO THIRDS OF THE

2159
01:16:54,280 --> 01:16:55,040
MUCOSAL SURFACE HAD RESOLUTION

2160
01:16:55,040 --> 01:16:56,400
OF THEIR LESIONS WITHOUT

2161
01:16:56,400 --> 01:16:57,440
INTERVENTION.

2162
01:16:57,440 --> 01:16:59,440
SHE WONDERED WHETHER THE

2163
01:16:59,440 --> 01:17:02,040
STANDARD PRACTICE PROCEDURES TO

2164
01:17:02,040 --> 01:17:03,680
REMOVE THE PRECANCEROUS CELLS

2165
01:17:03,680 --> 01:17:06,240
THAT COULD LEAD TO CERVICAL

2166
01:17:06,240 --> 01:17:06,880
INCOMPETENCE, THEREBY INCREASING

2167
01:17:06,880 --> 01:17:08,320
RISK FOR PREGNANCY

2168
01:17:08,320 --> 01:17:11,240
COMPLICATIONS, WERE INDEED

2169
01:17:11,240 --> 01:17:13,760
WARRANTED IN AN ERA OF MORE

2170
01:17:13,760 --> 01:17:14,640
EFFECTIVE ANTIRETROVIRALS.

2171
01:17:14,640 --> 01:17:17,080
WE FOUND AND IDENTIFIED A SUBSET

2172
01:17:17,080 --> 01:17:18,960
OF WOMEN -- INTERESTING FINDINGS

2173
01:17:18,960 --> 01:17:21,360
INCLUDE HIGH RATES OF DISEASE

2174
01:17:21,360 --> 01:17:23,120
REGRESSION AMONG 62% OF THESE

2175
01:17:23,120 --> 01:17:24,080
WOMEN.

2176
01:17:24,080 --> 01:17:26,160
ONLY 13% HAD DISEASE

2177
01:17:26,160 --> 01:17:28,000
PROGRESSION, OVER A DECADE OF

2178
01:17:28,000 --> 01:17:30,880
FOLLOW-UP, WITH NONE DEVELOPING

2179
01:17:30,880 --> 01:17:31,640
CANCER.

2180
01:17:31,640 --> 01:17:32,840
WOMEN'S IMMUNE STATUS AS

2181
01:17:32,840 --> 01:17:34,480
MEASURED BY CD4 WAS ASSOCIATED

2182
01:17:34,480 --> 01:17:36,360
WITH DISEASE PROGRESSION WITH

2183
01:17:36,360 --> 01:17:37,800
LOWER CD4 ASSOCIATED WITH HIGHER

2184
01:17:37,800 --> 01:17:41,280
ODDS OF PROGRESSION TO -- 3.

2185
01:17:41,280 --> 01:17:43,480
WE ARE NOW STUDYING THE ROLE OF

2186
01:17:43,480 --> 01:17:46,000
HPV IN THE MICROBIOME ON THE

2187
01:17:46,000 --> 01:17:47,320
OBSERVED DISEASE PATTERNS, AND

2188
01:17:47,320 --> 01:17:49,600
IMPROVEMENTS IN OUR BIOMARKERS

2189
01:17:49,600 --> 01:17:51,160
TO ASSESS RISK FOR CERVICAL

2190
01:17:51,160 --> 01:17:52,480
CANCER AND REFINE MANAGEMENT

2191
01:17:52,480 --> 01:17:54,320
STRATEGIES WITH THE ROLLOUT OF

2192
01:17:54,320 --> 01:17:55,840
HPV VACCINATION REMAINS PAIR

2193
01:17:55,840 --> 01:17:57,080
MOUNT AND SOMETHING THAT WE HOPE

2194
01:17:57,080 --> 01:17:59,480
TO STUDY IN THE STAR COHORT THAT

2195
01:17:59,480 --> 01:18:02,920
IS SUPPORTED BY NICHD.

2196
01:18:02,920 --> 01:18:04,560
I'LL BRIEFLY TALK ABOUT SOME OF

2197
01:18:04,560 --> 01:18:07,760
OUR PREP STUDIES.

2198
01:18:07,760 --> 01:18:10,000
ALMOST HALF A MILLION OF THE

2199
01:18:10,000 --> 01:18:10,800
1.2 MILLION PERSONS WHO ARE

2200
01:18:10,800 --> 01:18:12,400
THOUGHT TO BENEFIT FROM PREP IN

2201
01:18:12,400 --> 01:18:16,680
THE U.S. ARE WOMEN.

2202
01:18:16,680 --> 01:18:17,440
HOWEVER, PREP UPTAKE AND THE

2203
01:18:17,440 --> 01:18:18,440
ROLLOUT OF PREP FOR WOMEN HAS

2204
01:18:18,440 --> 01:18:20,080
BEEN QUITE POOR, WITH ONLY 10%

2205
01:18:20,080 --> 01:18:22,120
OF WOMEN WHO WOULD BENEFIT FROM

2206
01:18:22,120 --> 01:18:24,920
THE MEDICATION HAVING RECEIVED

2207
01:18:24,920 --> 01:18:27,320
PREP.

2208
01:18:27,320 --> 01:18:29,280
WE ANALYZED DATA FROM THE WIHS

2209
01:18:29,280 --> 01:18:31,800
TO DETERMINE PREP ELIGIBILITY

2210
01:18:31,800 --> 01:18:35,000
AND UPTAKE AMONG 716 WOMEN.

2211
01:18:35,000 --> 01:18:36,400
BETWEEN 2014 TO '19, WE FOUND

2212
01:18:36,400 --> 01:18:37,960
ANYWHERE FROM 10 TO 15% OF WOMEN

2213
01:18:37,960 --> 01:18:41,240
WERE ELIGIBLE FOR PREP BASED ON

2214
01:18:41,240 --> 01:18:42,800
CDC ELIGIBILITY CRITERIA AT EACH

2215
01:18:42,800 --> 01:18:43,080
TIME POINT.

2216
01:18:43,080 --> 01:18:45,280
WHEN WE LOOKED LONGITUDINALLY,

2217
01:18:45,280 --> 01:18:46,480
36% OF WOMEN WOULD HAVE BEEN

2218
01:18:46,480 --> 01:18:47,800
ELIGIBLE FOR PREP.

2219
01:18:47,800 --> 01:18:49,480
THE FIGURE ON THE RIGHT IS A

2220
01:18:49,480 --> 01:18:52,080
HEAT MAP THAT WE DEVELOPED.

2221
01:18:52,080 --> 01:18:55,400
EACH ROW REPRESENTS A WOMAN, AND

2222
01:18:55,400 --> 01:18:57,160
THE PREP ELIGIBILITY AND

2223
01:18:57,160 --> 01:18:58,360
TREATMENT IS SHOWN IN THE

2224
01:18:58,360 --> 01:18:59,560
DIFFERENT COLORS OVER A

2225
01:18:59,560 --> 01:19:00,920
FIVE-YEAR SPAN IN THE COLUMNS.

2226
01:19:00,920 --> 01:19:02,760
THE 64% OF WOMEN WHO ARE NOT

2227
01:19:02,760 --> 01:19:04,200
ELIGIBLE FOR PREP AND DID NOT

2228
01:19:04,200 --> 01:19:07,000
RECEIVE PREP ARE SHOWN IN BLUE.

2229
01:19:07,000 --> 01:19:10,480
TIME POINTS IN RED REPRESENT

2230
01:19:10,480 --> 01:19:12,920
TIMES WHEN WOMEN DID MEET

2231
01:19:12,920 --> 01:19:17,840
ELIGIBILITY TRY TIER YA CRITERIE

2232
01:19:17,840 --> 01:19:19,240
NOT PRESCRIBED PREP.

2233
01:19:19,240 --> 01:19:21,080
THE FEW SPECS OF GREEN SHOW

2234
01:19:21,080 --> 01:19:22,640
LIMITED UPTAKE AMONG THOSE WHO

2235
01:19:22,640 --> 01:19:24,200
MET ELIGIBILITY CRITERIA.

2236
01:19:24,200 --> 01:19:25,080
ONLY 3% OF THE WOMEN REPORTED

2237
01:19:25,080 --> 01:19:27,320
EVER USING PREP AND AS YOU CAN

2238
01:19:27,320 --> 01:19:28,880
SEE, PREP USE WAS NOT

2239
01:19:28,880 --> 01:19:31,960
PERSISTENT.

2240
01:19:31,960 --> 01:19:34,080
CIRCLING BACK TO OUR PROVIDER

2241
01:19:34,080 --> 01:19:34,600
SURVEYS.

2242
01:19:34,600 --> 01:19:35,800
WE TRIED TO UNDERSTAND THE

2243
01:19:35,800 --> 01:19:37,240
POTENTIAL ROLE OF PRIMARY CARE

2244
01:19:37,240 --> 01:19:38,240
PROVIDERS IN THE PREP ROLLOUT

2245
01:19:38,240 --> 01:19:39,800
FOR WOMEN.

2246
01:19:39,800 --> 01:19:41,520
ONLY HALF OF THOSE WHO COMPLETED

2247
01:19:41,520 --> 01:19:45,760
THE SURVEYS RESPONDED THAT THEY

2248
01:19:45,760 --> 01:19:50,480
ROUTINELY ASKED ABOUT SEX

2249
01:19:50,480 --> 01:19:51,400
PRACTICES.

2250
01:19:51,400 --> 01:19:53,760
ONLY A QUARTER REGULARLY ASK

2251
01:19:53,760 --> 01:19:55,000
ABOUT DRUG USE AND WE WERE SAD

2252
01:19:55,000 --> 01:19:59,480
TO SEE THAT TWRO  40% SAID THEYD

2253
01:19:59,480 --> 01:20:00,920
NOT ASK ABOUT DRUGS OR SEX, EVEN

2254
01:20:00,920 --> 01:20:04,120
IF GIVEN MORE TIME.

2255
01:20:04,120 --> 01:20:07,520
I HOPE I HAVE SHARED WITH YOU,

2256
01:20:07,520 --> 01:20:09,160
IN CLOSING, THAT THE

2257
01:20:09,160 --> 01:20:10,760
OBSERVATIONAL COHORTS THAT ARE

2258
01:20:10,760 --> 01:20:11,800
FUNDED THROUGH NIH AND THE

2259
01:20:11,800 --> 01:20:13,080
OFFICE OF AIDS RESEARCH AND

2260
01:20:13,080 --> 01:20:16,440
OTHER U.S. FUNDERS REALLY

2261
01:20:16,440 --> 01:20:17,720
PROVIDE GREAT OPPORTUNITY FOR US

2262
01:20:17,720 --> 01:20:20,840
TO GET INSIGHTS INTO THE

2263
01:20:20,840 --> 01:20:22,720
BIOLOGY, AS WELL AS

2264
01:20:22,720 --> 01:20:23,240
IMPLEMENTATION CHALLENGES

2265
01:20:23,240 --> 01:20:25,840
RELATED TO HIV AND WOMEN, AS

2266
01:20:25,840 --> 01:20:27,480
WELL AS SERVING AS AN IMPORTANT

2267
01:20:27,480 --> 01:20:29,960
PLATFORM FOR EDUCATING THE NEXT

2268
01:20:29,960 --> 01:20:31,920
GENERATION OF INVESTIGATORS.

2269
01:20:31,920 --> 01:20:34,360
THANK YOU.

2270
01:20:34,360 --> 01:20:35,000
DR. TURNBULL, TURNING BACK TO

2271
01:20:35,000 --> 01:20:40,120
YOU.

2272
01:20:40,120 --> 01:20:40,960
>> THANK YOU VERY MUCH.

2273
01:20:40,960 --> 01:20:42,280
AND THANK YOU TO ALL OF OUR

2274
01:20:42,280 --> 01:20:43,920
PRESENTERS.

2275
01:20:43,920 --> 01:20:46,800
WE WILL NOW HAVE TIME FOR OPEN

2276
01:20:46,800 --> 01:20:48,120
DISCUSSION.

2277
01:20:48,120 --> 01:20:49,320
THIS IS THE TIME TO ASK

2278
01:20:49,320 --> 01:20:50,480
QUESTIONS ABOUT THE

2279
01:20:50,480 --> 01:20:54,120
PRESENTATIONS WE'VE JUST HEARD.

2280
01:20:54,120 --> 01:20:58,320
DR. GLENSHAW AND I WILL MODERATE

2281
01:20:58,320 --> 01:20:59,320
THIS DISCUSSION SECTION STARTING

2282
01:20:59,320 --> 01:21:01,600
WITH MEMBERS ON THE ZOOM CALL.

2283
01:21:01,600 --> 01:21:06,000
ANY MEMBER WHO WISHES TO

2284
01:21:06,000 --> 01:21:06,880
PARTICIPATE ON THE ZOOM CALL,

2285
01:21:06,880 --> 01:21:08,520
PLEASE USE THE ZOOM RAISE YOUR

2286
01:21:08,520 --> 01:21:13,440
HAND FUNCTION.

2287
01:21:13,440 --> 01:21:14,440
DR. GLENSHAW, YOU'LL BE LOOKING

2288
01:21:14,440 --> 01:21:15,400
OUT FOR THE INDIVIDUALS OR THE

2289
01:21:15,400 --> 01:21:16,080
QUESTIONS THAT WE HAVE IN THE

2290
01:21:16,080 --> 01:21:21,840
ROOM.

2291
01:21:21,840 --> 01:21:22,080
OKAY.

2292
01:21:22,080 --> 01:21:26,600
ANY QUESTIONS?

2293
01:21:26,600 --> 01:21:27,400
DR. GANDHI.

2294
01:21:27,400 --> 01:21:30,280
>> THOSE WERE GREAT

2295
01:21:30,280 --> 01:21:32,880
PRESENTATIONS, AND I THINK THE

2296
01:21:32,880 --> 01:21:38,160
COMMITMENT THAT THE NIH HAS HAD,

2297
01:21:38,160 --> 01:21:40,000
SPECIFICALLY IN HIV RESEARCH TO

2298
01:21:40,000 --> 01:21:43,960
DEFINING SEX DIFFERENCES ARE

2299
01:21:43,960 --> 01:21:44,520
REALLY PROFOUND.

2300
01:21:44,520 --> 01:21:46,960
THE WIHS STUDY IS ACTUALLY THE

2301
01:21:46,960 --> 01:21:53,040
LARGEST SPECIFIC STUDY FOR WOMEN

2302
01:21:53,040 --> 01:21:54,920
AND HAS DEFINED MANY IMPORTANT

2303
01:21:54,920 --> 01:21:55,200
OBJECTIVES.

2304
01:21:55,200 --> 01:21:58,000
SO I GUESS MY QUESTION IS THAT

2305
01:21:58,000 --> 01:22:00,440
THE WIHS STUDY IS OBSERVATIONAL,

2306
01:22:00,440 --> 01:22:01,480
AND IS VERY CAREFUL ABOUT NOT

2307
01:22:01,480 --> 01:22:03,680
BEING ABLE TO PERFORM

2308
01:22:03,680 --> 01:22:05,680
INTERVENTIONAL RESEARCH.

2309
01:22:05,680 --> 01:22:08,400
HOWEVER, YOU KNOW, WE ARE SEEING

2310
01:22:08,400 --> 01:22:12,680
THAT, FOR EXAMPLE, WHAT SEBLE

2311
01:22:12,680 --> 01:22:14,000
JUST PRESENTED ABOUT THE REALLY

2312
01:22:14,000 --> 01:22:16,080
LOW RATES -- THAT YES, PREP RISK

2313
01:22:16,080 --> 01:22:17,480
GOES UP AND DOWN, RISK GOES UP

2314
01:22:17,480 --> 01:22:18,720
AND DOWN, BUT WE ALL KNOW THAT

2315
01:22:18,720 --> 01:22:20,240
THE OVERALL RATES OF UPTAKE OF

2316
01:22:20,240 --> 01:22:23,160
PREP AMONG WOMEN IN THE U.S. IS

2317
01:22:23,160 --> 01:22:24,760
VERY WOEFULLY INADEQUATE AND NOW

2318
01:22:24,760 --> 01:22:33,240
WE HAVE THIS TOOL THAT 9%

2319
01:22:33,240 --> 01:22:35,360
MORE -- AND SO HOW DO WE -- AND

2320
01:22:35,360 --> 01:22:38,880
THIS IS A QUESTION I GUESS FOR

2321
01:22:38,880 --> 01:22:40,480
THE PROGRAM, IS HOW DO WE TAKE

2322
01:22:40,480 --> 01:22:43,040
THE WIHS PLATFORM AND ADD ON

2323
01:22:43,040 --> 01:22:43,840
INTERVENTIONS?

2324
01:22:43,840 --> 01:22:44,560
AND I KNOW THAT THAT HASN'T BEEN

2325
01:22:44,560 --> 01:22:46,320
A PART OF THE WIHS PLATFORM, BUT

2326
01:22:46,320 --> 01:22:50,480
HOW DO WE TAKE THIS INCREDIBLE

2327
01:22:50,480 --> 01:22:52,240
PLATFORM WHERE PARTICIPANTS ARE

2328
01:22:52,240 --> 01:22:53,560
RECRUITED AND RETAINED AT REALLY

2329
01:22:53,560 --> 01:22:56,600
HIGH LEVELS, AND HAVE

2330
01:22:56,600 --> 01:22:59,480
INTERVENTIONS AT LEAST, YOU

2331
01:22:59,480 --> 01:23:02,120
KNOW, STEM OFF OF WIHS.

2332
01:23:02,120 --> 01:23:04,400
HAS ANYONE USED THIS PLATFORM

2333
01:23:04,400 --> 01:23:05,400
FOR INTERVENTION, OR THOUGHT

2334
01:23:05,400 --> 01:23:07,760
ABOUT THAT, OR HOW TO COMBINE

2335
01:23:07,760 --> 01:23:12,600
THOSE?

2336
01:23:12,600 --> 01:23:14,000
>> THANK YOU, DR. GANDHI.

2337
01:23:14,000 --> 01:23:15,400
SO I WILL COMMENT THAT THERE

2338
01:23:15,400 --> 01:23:19,080
HAVE BEEN INTERVENTIONS DONE

2339
01:23:19,080 --> 01:23:21,200
LOCALLY TO LOOK AT ALCOHOL

2340
01:23:21,200 --> 01:23:22,720
CESSATION, AND THERE ARE ALSO

2341
01:23:22,720 --> 01:23:24,480
EFFORTS ONGOING TO TRY TO LOOK

2342
01:23:24,480 --> 01:23:27,560
AT TO RECRUIT FROM THE WIHS TO

2343
01:23:27,560 --> 01:23:29,400
STUDY THINGS SUCH AS

2344
01:23:29,400 --> 01:23:31,920
INTERVENTIONS TO STUDY METABOLIC

2345
01:23:31,920 --> 01:23:33,400
SYNDROME THROUGH VARIOUS

2346
01:23:33,400 --> 01:23:34,360
INTERVENTIONS, AND THEN USING

2347
01:23:34,360 --> 01:23:39,480
THE PLATFORM, TO USE SAMPLES AND

2348
01:23:39,480 --> 01:23:41,120
DATA THAT WILL NOT ADDITIONALLY

2349
01:23:41,120 --> 01:23:41,920
NEED TO BE COLLECTED.

2350
01:23:41,920 --> 01:23:43,880
SO I DO THINK IT'S POSSIBLE TO

2351
01:23:43,880 --> 01:23:46,200
LEVERAGE THE COHORT FOR SUCH

2352
01:23:46,200 --> 01:23:48,080
INTERVENTIONS, AND REALLY WHAT I

2353
01:23:48,080 --> 01:23:50,360
DO THINK IS QUITE DISTINCT,

2354
01:23:50,360 --> 01:23:52,200
THOUGH, IS BY THIS NOT BEING A

2355
01:23:52,200 --> 01:23:53,560
CLINICAL TRIAL, IT DOES ALLOW US

2356
01:23:53,560 --> 01:23:55,640
TO REALLY KEEP AN EYE ON WHAT

2357
01:23:55,640 --> 01:23:58,040
THE POPULATION EFFECTS OF OUR

2358
01:23:58,040 --> 01:24:01,560
VARIOUS PROGRAMS CLINICALLY ARE

2359
01:24:01,560 --> 01:24:02,640
WHEN WE TRANSLATE IT INTO

2360
01:24:02,640 --> 01:24:02,960
PRACTICE.

2361
01:24:02,960 --> 01:24:05,040
SO I DO THINK THERE'S CONTINUED

2362
01:24:05,040 --> 01:24:07,040
NEED FOR HAVING SUCH A

2363
01:24:07,040 --> 01:24:10,000
POPULATION-BASED COHORT TO

2364
01:24:10,000 --> 01:24:11,520
ASSESS THE IMPACT THAT WOOR

2365
01:24:11,520 --> 01:24:14,240
HAVING WITH PROG WE'RE

2366
01:24:14,240 --> 01:24:14,840
HAVING WITH PROGRAMS.

2367
01:24:14,840 --> 01:24:16,120
SO I DO THINK IT CAN BE

2368
01:24:16,120 --> 01:24:17,640
LEVERAGED FOR INTERVENTION BUT I

2369
01:24:17,640 --> 01:24:19,320
DO THINK THERE'S DISTINCT VALUE

2370
01:24:19,320 --> 01:24:21,480
TO HAVING IT REMAIN

2371
01:24:21,480 --> 01:24:22,040
OBSERVATIONAL AS WELL.

2372
01:24:22,040 --> 01:24:24,040
>> I WOULD AGREE WITH YOU
AND I

2373
01:24:24,040 --> 01:24:25,200
WOULD JUST URGE MORE LEVERAGING

2374
01:24:25,200 --> 01:24:26,760
OF THE PLATFORM FOR

2375
01:24:26,760 --> 01:24:28,640
INTERVENTIONS, ESPECIALLY WITH

2376
01:24:28,640 --> 01:24:35,440
OPENING OF THESE OTHER INSIGHTS.

2377
01:24:35,440 --> 01:24:38,080
>> DR. ALI OSMAN.

2378
01:24:38,080 --> 01:24:39,800
>> THANK YOU VERY MUCH.

2379
01:24:39,800 --> 01:24:42,800
AND THANKS TO THE THREE SPEAKERS

2380
01:24:42,800 --> 01:24:44,720
FOR VERY INSIGHTFUL

2381
01:24:44,720 --> 01:24:45,280
PRESENTATION.

2382
01:24:45,280 --> 01:24:51,000
MY QUESTION IS, I THINK IT'S

2383
01:24:51,000 --> 01:24:52,960
RELEVANT, ESPECIALLY DR. GANDHI

2384
01:24:52,960 --> 01:24:54,280
MENTIONING INTERVENTIONS, WHICH

2385
01:24:54,280 --> 01:24:56,880
I WOULD CONSIDER INCLUDES ALSO

2386
01:24:56,880 --> 01:24:59,320
THERAPEUTIC INTERVENTIONS.

2387
01:24:59,320 --> 01:25:00,560
AS I'M SURE YOU KNOW, CURRENTLY

2388
01:25:00,560 --> 01:25:02,280
THERE'S A SIGNIFICANT SHORTAGE

2389
01:25:02,280 --> 01:25:05,920
OF KEY ANTI-CANCER AGENTS,

2390
01:25:05,920 --> 01:25:07,600
INCLUDING MANY CHEMOTHERAPEUTICS

2391
01:25:07,600 --> 01:25:08,960
THAT ARE STABLES IN PROTOCOLS

2392
01:25:08,960 --> 01:25:10,360
FOR VARIOUS CANCERS.

2393
01:25:10,360 --> 01:25:15,760
YOU KNOW, CISPLATIN, AND SO ON.

2394
01:25:15,760 --> 01:25:17,320
THIS IS HAVING AN IMPACT ON THE

2395
01:25:17,320 --> 01:25:19,400
PRACTICE OF ONCOLOGY, CERTAINLY

2396
01:25:19,400 --> 01:25:23,000
ON CLINICAL TRIALS.

2397
01:25:23,000 --> 01:25:25,000
I DIDN'T HEAR ANY REFERENCE TO

2398
01:25:25,000 --> 01:25:26,520
THAT, BUT -- WHICH MAY BE GOOD

2399
01:25:26,520 --> 01:25:27,880
NEWS THAT YOU'RE NOT DEALING

2400
01:25:27,880 --> 01:25:30,880
WITH THIS PROBLEM, BUT ARE YOU

2401
01:25:30,880 --> 01:25:35,200
DEALING WITH IT OR IS THERE A

2402
01:25:35,200 --> 01:25:38,120
PROSPECT -- SHORTAGE IN DRUGS

2403
01:25:38,120 --> 01:25:41,360
MIGHT LIMIT SOME OF THE PROGRAMS

2404
01:25:41,360 --> 01:25:43,360
THAT YOU HAVE, PARTICULARLY

2405
01:25:43,360 --> 01:25:48,160
INTERVENTIONAL PROGRAMS?

2406
01:25:48,160 --> 01:25:50,480
AND I'M JUST CURIOUS WHETHER

2407
01:25:50,480 --> 01:25:51,640
THAT'S SOMETHING THAT YOU HAVE.

2408
01:25:51,640 --> 01:25:53,320
I'M REPRESENTING THE NATIONAL

2409
01:25:53,320 --> 01:25:55,240
CANCER ADVISORY BOARD, SO AT THE

2410
01:25:55,240 --> 01:25:57,880
NCI, THAT'S A MAJOR ISSUE THAT'S

2411
01:25:57,880 --> 01:25:58,800
BEING GRAPPLED WITH RIGHT NOW.

2412
01:25:58,800 --> 01:26:01,640
IS THIS SOMETHING THAT COULD

2413
01:26:01,640 --> 01:26:03,920
IMPACT SOME OF THE PROGRAMS THAT

2414
01:26:03,920 --> 01:26:08,880
YOU HAVE?

2415
01:26:08,880 --> 01:26:11,120
>> SO WE DO HAVE EXCELLENT

2416
01:26:11,120 --> 01:26:12,800
ACCESS TO ANTIRETROVIRAL

2417
01:26:12,800 --> 01:26:13,200
THERAPIES.

2418
01:26:13,200 --> 01:26:14,000
THEY ARE AVAILABLE.

2419
01:26:14,000 --> 01:26:15,360
HOWEVER, ACCESS WHEN IT COMES TO

2420
01:26:15,360 --> 01:26:17,200
REQUIRING PRIOR APPROVALS,

2421
01:26:17,200 --> 01:26:18,520
ESPECIALLY FOR THE MORE

2422
01:26:18,520 --> 01:26:20,680
EXPENSIVE INJECTABLE PRODUCTS

2423
01:26:20,680 --> 01:26:22,440
THAT MAY IMPROVE OUR ADHERENCE,

2424
01:26:22,440 --> 01:26:24,640
CAN BE CHALLENGING.

2425
01:26:24,640 --> 01:26:26,840
AND THE REIMBURSEMENT ALSO FOR

2426
01:26:26,840 --> 01:26:28,480
SOME OF THESE SERVICES,

2427
01:26:28,480 --> 01:26:29,840
ESPECIALLY WHEN IT COMES TO

2428
01:26:29,840 --> 01:26:31,040
PREVENTION, IS PARTICULARLY

2429
01:26:31,040 --> 01:26:31,640
CHALLENGING.

2430
01:26:31,640 --> 01:26:32,880
SO THESE ARE STRUCTURAL PROBLEMS

2431
01:26:32,880 --> 01:26:35,320
THAT WE DO HAVE TO DEAL WITH,

2432
01:26:35,320 --> 01:26:37,080
AND ARE NOT MEASURED WITHIN THE

2433
01:26:37,080 --> 01:26:38,560
WIHS, BUT CERTAINLY THESE SHOULD

2434
01:26:38,560 --> 01:26:41,640
BE MEASURED AND BE STUDIED.

2435
01:26:41,640 --> 01:26:46,840
>> SO IT'S NOT IMPACTING
THE

2436
01:26:46,840 --> 01:26:47,760
HIV-ASSOCIATED CANCERS BECAUSE

2437
01:26:47,760 --> 01:26:51,360
YOU HAVE, YOU KNOW, SITUATIONS

2438
01:26:51,360 --> 01:26:52,680
WHERE SOME AGENTS ARE NEEDED TO

2439
01:26:52,680 --> 01:26:54,640
TREAT PATIENTS WHO MAY HAVE

2440
01:26:54,640 --> 01:26:54,960
CANCERS.

2441
01:26:54,960 --> 01:26:57,000
YOU DON'T SEE THAT PROBLEM?

2442
01:26:57,000 --> 01:27:00,640
>> I DO SEE THE NEED TO

2443
01:27:00,640 --> 01:27:02,440
SPECIFICALLY REQUEST PRIOR

2444
01:27:02,440 --> 01:27:06,040
APPROVAL FROM AN INSURANCE

2445
01:27:06,040 --> 01:27:07,240
COMPANY'S -- THAT CAN LEAD TO

2446
01:27:07,240 --> 01:27:08,480
SOME DELAYS.

2447
01:27:08,480 --> 01:27:09,800
ULTIMATELY, USUALLY WE ARE ABLE

2448
01:27:09,800 --> 01:27:13,720
TO ACCESS CARE.

2449
01:27:13,720 --> 01:27:15,280
FOR PEOPLE WHO NEED TO MAKE

2450
01:27:15,280 --> 01:27:15,520
SWITCHES.

2451
01:27:15,520 --> 01:27:17,080
>> THAT'S GREAT NEWS.

2452
01:27:17,080 --> 01:27:20,160
THANKS.

2453
01:27:20,160 --> 01:27:23,840
>> DR. GANDHI, DR. DIANNE
ROUSH

2454
01:27:23,840 --> 01:27:25,720
FROM NIMH IS SHARING THAT THERE

2455
01:27:25,720 --> 01:27:28,120
ARE ACTUALLY NUMEROUS RFAs

2456
01:27:28,120 --> 01:27:31,520
THAT LEVERAGE THE MAX WIHS

2457
01:27:31,520 --> 01:27:35,600
CLINICAL COHORT FOR INTERVENTION

2458
01:27:35,600 --> 01:27:36,200
ACTIVITIES, WE'D BE HAPPY TO

2459
01:27:36,200 --> 01:27:36,880
SHARE THOSE.

2460
01:27:36,880 --> 01:27:40,560
>> THANK YOU.

2461
01:27:40,560 --> 01:27:45,080
>> ANY QUESTIONS FROM THE
ROOM?

2462
01:27:45,080 --> 01:27:45,440
DR. MONTANER?

2463
01:27:45,440 --> 01:27:47,240
>> IT'S NOT SO MUCH A
QUESTION

2464
01:27:47,240 --> 01:27:49,440
BUT PERHAPS SERVING AS ADVISORY,

2465
01:27:49,440 --> 01:27:51,200
GIVING YOU AT LEAST INSIGHTS.

2466
01:27:51,200 --> 01:27:53,760
YOU KNOW, IN MENTORING OVER 26

2467
01:27:53,760 --> 01:27:55,480
YEARS AND GETTING ENGAGED WITH

2468
01:27:55,480 --> 01:27:57,000
DIFFERENT CLINICAL EFFORTS, I

2469
01:27:57,000 --> 01:27:59,640
MEAN, THE TOPIC OF WOMEN AND HIV

2470
01:27:59,640 --> 01:28:01,520
HAVE BEEN WITH US EVER SINCE.

2471
01:28:01,520 --> 01:28:04,240
SO I REALLY WANT TO CONGRATULATE

2472
01:28:04,240 --> 01:28:07,160
THE OFFICE ON ITS INITIATIVE AND

2473
01:28:07,160 --> 01:28:08,560
ALL OF THE EFFORTS UNDERWAY.

2474
01:28:08,560 --> 01:28:11,840
I THINK THAT THEY'RE ON THE

2475
01:28:11,840 --> 01:28:12,600
RIGHT TRACK.

2476
01:28:12,600 --> 01:28:14,560
SO I WOULD JUST OFFER FOUR

2477
01:28:14,560 --> 01:28:17,000
SUGGESTIONS, MAYBE SOME QUICK

2478
01:28:17,000 --> 01:28:19,320
SUGGESTIONS FOR THE PROGRAM TO

2479
01:28:19,320 --> 01:28:19,920
CONSIDER.

2480
01:28:19,920 --> 01:28:21,400
THE FIRST ONE IS THERE'S ALWAYS

2481
01:28:21,400 --> 01:28:24,880
A RECURRENT GAP BETWEEN THE

2482
01:28:24,880 --> 01:28:26,560
EXECUTION OF THE RESEARCH WHEN

2483
01:28:26,560 --> 01:28:28,960
THE GRANT IS AWARDED AND THE

2484
01:28:28,960 --> 01:28:29,720
RECRUITMENT RESOURCES AVAILABLE

2485
01:28:29,720 --> 01:28:30,880
TO GET WOMEN INTO RESEARCH.

2486
01:28:30,880 --> 01:28:32,720
SO I THINK THAT YOU COULD ALTER

2487
01:28:32,720 --> 01:28:36,120
THE HUMAN SUBJECT SECTION BY

2488
01:28:36,120 --> 01:28:37,120
SPECIFICALLY REQUESTING TEXT ON

2489
01:28:37,120 --> 01:28:38,440
RESOURCES THAT ARE BEING PLANNED

2490
01:28:38,440 --> 01:28:43,640
FOR THE RETRUETTMENT OF WOMEN. .

2491
01:28:43,640 --> 01:28:45,240
AND ON THE BUDGET JUSTIFICATION,

2492
01:28:45,240 --> 01:28:47,160
ALSO REQUEST AS YOU DO FOR DATA

2493
01:28:47,160 --> 01:28:48,080
MANAGEMENT, A SPECIFIC COMMENT

2494
01:28:48,080 --> 01:28:50,240
ON USE OF RESOURCES FOR

2495
01:28:50,240 --> 01:28:51,560
RECRUITMENT OF DIVERSE

2496
01:28:51,560 --> 01:28:52,880
POPULATIONS, BECAUSE THERE'S A

2497
01:28:52,880 --> 01:28:55,640
GAP AT THE END THAT OFTEN

2498
01:28:55,640 --> 01:28:56,920
INVESTIGATORS SAY WE DON'T HAVE

2499
01:28:56,920 --> 01:28:58,680
THE MONEY TO COVER CHILD CARE,

2500
01:28:58,680 --> 01:29:02,760
WE DON'T HAVE THE MONEY TO HAVE

2501
01:29:02,760 --> 01:29:04,800
PEOPLE COME IN AT 7:00 A.M. OR

2502
01:29:04,800 --> 01:29:05,920
MEET WOMEN AT 7:00 P.M.

2503
01:29:05,920 --> 01:29:07,400
SO I THINK WE CAN DO SIMPLE

2504
01:29:07,400 --> 01:29:08,440
THINGS TO THE GRANT PROCESS TO

2505
01:29:08,440 --> 01:29:09,640
GET PEOPLE TO THINK ABOUT THAT

2506
01:29:09,640 --> 01:29:10,760
AHEAD OF TIME.

2507
01:29:10,760 --> 01:29:13,440
I THINK WITH REGARDS TO GETTING,

2508
01:29:13,440 --> 01:29:16,160
YOU KNOW, WOMEN INTO THE

2509
01:29:16,160 --> 01:29:17,680
WORKFORCE, I THINK THE RESEARCH

2510
01:29:17,680 --> 01:29:19,120
MINORITY NETWORK AND OTHER SUCH

2511
01:29:19,120 --> 01:29:20,440
NETWORKS THAT ARE BASED

2512
01:29:20,440 --> 01:29:25,480
PRIMARILY IN NON-R01-HEAVY

2513
01:29:25,480 --> 01:29:27,320
CENTERS, HAVE A LOT OF

2514
01:29:27,320 --> 01:29:28,320
INDIVIDUALS THAT EITHER HAVE

2515
01:29:28,320 --> 01:29:33,040
STARTED IN TEACHING AS ASSISTANT

2516
01:29:33,040 --> 01:29:33,800
PROFESSORS AND EVENTUALLY WANT

2517
01:29:33,800 --> 01:29:35,600
TO GET INTO RESEARCH, AND OUR

2518
01:29:35,600 --> 01:29:38,120
SYSTEM NOW WITH STUDY SECTIONS

2519
01:29:38,120 --> 01:29:39,960
PENALIZES WOMEN THAT DON'T FIT

2520
01:29:39,960 --> 01:29:43,080
THE NORM OF WHEN AN ASSISTANT

2521
01:29:43,080 --> 01:29:45,240
PROFESSOR WITH THREE YEARS AND

2522
01:29:45,240 --> 01:29:49,120
R01 BY 4 YEARS AND TWO R01s

2523
01:29:49,120 --> 01:29:51,840
FOR ASSISTANT PROFESSOR TENURE

2524
01:29:51,840 --> 01:29:53,160
AND NOW WE CAN REWARD YOU FOR

2525
01:29:53,160 --> 01:29:53,840
THAT.

2526
01:29:53,840 --> 01:29:57,000
THAT PATTERN DOESN'T HAPPEN IN

2527
01:29:57,000 --> 01:29:57,880
NON-R01 INSTITUTIONS.

2528
01:29:57,880 --> 01:29:59,520
AND OUR SYSTEM DOESN'T REALLY

2529
01:29:59,520 --> 01:30:00,520
ACKNOWLEDGE THAT.

2530
01:30:00,520 --> 01:30:02,840
IN OTHER WORDS, WE DON'T REALLY

2531
01:30:02,840 --> 01:30:05,360
TELL REVIEWERS, YOU NEED TO TAKE

2532
01:30:05,360 --> 01:30:07,680
THE TRAJECTORY OF THE ENGAGEMENT

2533
01:30:07,680 --> 01:30:09,360
AS IT STANDS NOW FOR YOUR

2534
01:30:09,360 --> 01:30:11,160
CANDIDATE AND NOT THE ENGAGEMENT

2535
01:30:11,160 --> 01:30:13,080
OVER THE LAST 15 YEARS.

2536
01:30:13,080 --> 01:30:16,920
SO WE EITHER NEED TO INTRODUCE

2537
01:30:16,920 --> 01:30:20,440
REVIEWER CRITERIA RE-EDUCATION

2538
01:30:20,440 --> 01:30:22,720
OR MAYBE USE THE RCMI -- YOU

2539
01:30:22,720 --> 01:30:24,480
KNOW, WE PUT A LOT OF MONEY INTO

2540
01:30:24,480 --> 01:30:26,240
PILOT PROJECTS AND THEY ALL GO

2541
01:30:26,240 --> 01:30:28,080
TO NEW INVESTIGATORS, NEW

2542
01:30:28,080 --> 01:30:29,240
PH.D.s, BUT THERE'S A LOT OF

2543
01:30:29,240 --> 01:30:30,600
POTENTIAL ON CANDIDATES THAT

2544
01:30:30,600 --> 01:30:32,080
HAVE NOT TAKEN THE TRADITIONAL

2545
01:30:32,080 --> 01:30:34,400
ROUTE AND WANT TO COME BACK, BUT

2546
01:30:34,400 --> 01:30:36,000
WHEN THEY DO THE PILOT AND THEY

2547
01:30:36,000 --> 01:30:38,240
GO TO STUDY SECTION, THEY GET

2548
01:30:38,240 --> 01:30:41,080
PENALIZED FOR THE GAP IN THEIR

2549
01:30:41,080 --> 01:30:41,560
CAREER.

2550
01:30:41,560 --> 01:30:42,960
SO ALTHOUGH YOU TRY TO STIMULATE

2551
01:30:42,960 --> 01:30:44,960
THEM, WE HAVE STUDY SECTIONS

2552
01:30:44,960 --> 01:30:48,600
THAT DON'T REALLY WANT TO

2553
01:30:48,600 --> 01:30:49,440
ACKNOWLEDGE THAT CAREER.

2554
01:30:49,440 --> 01:30:50,800
SO WE EITHER NEED TO CHANGE THE

2555
01:30:50,800 --> 01:30:52,640
RULES FOR THE STUDY SECTION OR

2556
01:30:52,640 --> 01:30:54,280
MAKE IT VERY INTENTIONAL THAT WE

2557
01:30:54,280 --> 01:30:56,480
HAVE A REINTEGRATION PROGRAM FOR

2558
01:30:56,480 --> 01:30:58,880
WOMEN AND IT'S NOT A PILOT

2559
01:30:58,880 --> 01:31:01,280
PROJECT IN THE SENSE OF A PH.D.,

2560
01:31:01,280 --> 01:31:04,400
NEW PH.D. YOUNG INVESTIGATOR.

2561
01:31:04,400 --> 01:31:07,320
I THINK THE R21 IS ANOTHER

2562
01:31:07,320 --> 01:31:08,600
INSTRUMENT THAT IS

2563
01:31:08,600 --> 01:31:10,480
UNDERUTILIZED.

2564
01:31:10,480 --> 01:31:12,400
CURRENTLY IT LANDS IN STUDY

2565
01:31:12,400 --> 01:31:13,680
SECTIONS AND IT GETS BASICALLY

2566
01:31:13,680 --> 01:31:14,960
REVIEWED LIKE AN R01.

2567
01:31:14,960 --> 01:31:16,920
I'VE BEEN IN STUDY SECTIONS FOR

2568
01:31:16,920 --> 01:31:19,400
20 YEARS AND I'VE NEVER SEEN AN

2569
01:31:19,400 --> 01:31:20,360
R21 WITHOUT PRELIMINARY DATA.

2570
01:31:20,360 --> 01:31:22,200
TO THE POINT WE TELL OUR YOUNG

2571
01:31:22,200 --> 01:31:24,120
INVESTIGATORS, DON'T EVEN BOTHER

2572
01:31:24,120 --> 01:31:25,680
TO WRITE AN R21, YOU'RE GOING TO

2573
01:31:25,680 --> 01:31:29,400
GET THE SAME RUBRIC AS AN R01.

2574
01:31:29,400 --> 01:31:30,720
SO IF YOU'RE GOING TO PUT IN ALL

2575
01:31:30,720 --> 01:31:32,920
THE WORK, JUST GO FOR THE

2576
01:31:32,920 --> 01:31:34,120
R01 AND TRY TO HIT THAT BECAUSE

2577
01:31:34,120 --> 01:31:35,120
THE CRITERIA FOR WHICH THE

2578
01:31:35,120 --> 01:31:36,480
REVIEW HAPPENS DOESN'T GIVE YOU

2579
01:31:36,480 --> 01:31:39,400
MUCH ALLOWANCE FOR AN R21.

2580
01:31:39,400 --> 01:31:40,920
BUT IT'S REALLY A STIMULUS

2581
01:31:40,920 --> 01:31:44,400
GRANT, AND WHEN WE THEN LOOK AT

2582
01:31:44,400 --> 01:31:47,560
WOMEN IN NON-R01 CENTERS, IT

2583
01:31:47,560 --> 01:31:48,720
WOULD BE GREAT TO HAVE A

2584
01:31:48,720 --> 01:31:50,680
STIMULUS GRANT, CALL IT AN R22,

2585
01:31:50,680 --> 01:31:51,960
CALL IT SOMETHING ELSE IF YOU

2586
01:31:51,960 --> 01:31:55,240
WANT, BUT A TWO-YEAR, 275, THAT

2587
01:31:55,240 --> 01:31:56,600
STIMULATES THE TOPIC, BECAUSE I

2588
01:31:56,600 --> 01:31:57,720
THINK THERE'S A LOT OF

2589
01:31:57,720 --> 01:31:58,960
INVESTIGATORS THAT HAVE

2590
01:31:58,960 --> 01:32:02,040
POTENTIAL TO COME IN TO WOMEN'S

2591
01:32:02,040 --> 01:32:04,640
RESEARCH FOR PREMENOPAUSE,

2592
01:32:04,640 --> 01:32:06,680
MENOPAUSE OR THAT NEED ENOUGH

2593
01:32:06,680 --> 01:32:07,480
RESOURCES TO STIMULATE THE

2594
01:32:07,480 --> 01:32:10,200
RESEARCH TO START, BUT RIGHT NOW

2595
01:32:10,200 --> 01:32:15,280
THE TOOLS ARE AN R03 BUT VERY

2596
01:32:15,280 --> 01:32:16,120
FEW HAVE THAT.

2597
01:32:16,120 --> 01:32:22,200
AN R01 WH -- OR PILOT PROJECTS E

2598
01:32:22,200 --> 01:32:24,240
USUALLY 60 OR 4 40,000 AND THEYE

2599
01:32:24,240 --> 01:32:25,680
NOT ENOUGH TO BREAK INTO A NEW

2600
01:32:25,680 --> 01:32:26,280
TOPIC.

2601
01:32:26,280 --> 01:32:27,600
SO I WOULD ENCOURAGE YOU TO

2602
01:32:27,600 --> 01:32:32,400
RENAME THE R21 INTO -- OR -- IN

2603
01:32:32,400 --> 01:32:34,000
STIMULUS GRANT AND MAYBE TRY TO

2604
01:32:34,000 --> 01:32:35,000
INCENTIVIZE THE RESEARCH AS

2605
01:32:35,000 --> 01:32:37,400
OPPOSED TO PUT THE RUBRIC OF

2606
01:32:37,400 --> 01:32:39,880
INNOVATION AND THE EXPECTATION

2607
01:32:39,880 --> 01:32:42,320
FROM THE REVIEWERS THAT THIS IS

2608
01:32:42,320 --> 01:32:43,440
A MINI R01.

2609
01:32:43,440 --> 01:32:45,960
AND LASTLY, I WOULD SAY WE HAVE

2610
01:32:45,960 --> 01:32:47,520
A GREAT RESOURCE IN THE FEDERAL

2611
01:32:47,520 --> 01:32:50,040
QUALIFIED HEALTH SYSTEM.

2612
01:32:50,040 --> 01:32:51,480
THIS IS A NETWORK NATIONALLY

2613
01:32:51,480 --> 01:32:52,800
THAT SERVES A LOT OF THE

2614
01:32:52,800 --> 01:32:54,240
POPULATIONS WE WANT TO REACH,

2615
01:32:54,240 --> 01:32:56,120
LIKE PREP IS A GOOD EXAMPLE.

2616
01:32:56,120 --> 01:32:58,840
YOU KNOW, THEY GIVE GOLD AWARDS

2617
01:32:58,840 --> 01:33:00,040
AND SILVER AWARDS WHENEVER THEY

2618
01:33:00,040 --> 01:33:02,240
CAN ACTUALLY GET ENOUGH

2619
01:33:02,240 --> 01:33:04,400
INDIVIDUALS TO GET WHATEVER

2620
01:33:04,400 --> 01:33:05,960
INTERVENTION THE FEDERAL

2621
01:33:05,960 --> 01:33:07,440
QUALIFIED HEALTH SYSTEMS WANTS

2622
01:33:07,440 --> 01:33:08,960
TO PROMOTE, AND ALL THE OF THEM

2623
01:33:08,960 --> 01:33:10,680
NEED TO MEET THESE BENCHMARKS.

2624
01:33:10,680 --> 01:33:12,920
AND IT'S REALLY A MISSED

2625
01:33:12,920 --> 01:33:14,680
OPPORTUNITY THAT NIH HASN'T

2626
01:33:14,680 --> 01:33:16,760
PARTNERED WITH THIS NETWORK TO

2627
01:33:16,760 --> 01:33:18,440
TRY TO INCENTIVIZE THE ACCESS TO

2628
01:33:18,440 --> 01:33:20,360
PREP, AND TO ENCOURAGE

2629
01:33:20,360 --> 01:33:22,560
INVESTIGATORS TO COME UP WITH

2630
01:33:22,560 --> 01:33:24,880
SOME DEGREE OF COLLABORATIVE

2631
01:33:24,880 --> 01:33:26,000
RESEARCH EFFORTS WITH THIS

2632
01:33:26,000 --> 01:33:26,600
NETWORK.

2633
01:33:26,600 --> 01:33:29,360
SO I WOULD ENCOURAGE THAT THAT

2634
01:33:29,360 --> 01:33:33,800
PERHAPS COULD BE EXPLORED.

2635
01:33:33,800 --> 01:33:36,000
>> THANK YOU SO MUCH,

2636
01:33:36,000 --> 01:33:36,520
DR. MONTANER.

2637
01:33:36,520 --> 01:33:38,400
ANY FURTHER COMMENTS?

2638
01:33:38,400 --> 01:33:38,720
DR. SLEASMAN.

2639
01:33:38,720 --> 01:33:44,000
>> I'D LIKE TO FOLLOW UP
ON WHAT

2640
01:33:44,000 --> 01:33:45,880
LUIS AND ALSO GO BACK TO WHAT

2641
01:33:45,880 --> 01:33:46,280
DR. GANDHI SAID.

2642
01:33:46,280 --> 01:33:47,920
I THINK IT'S TIME THAT THE

2643
01:33:47,920 --> 01:33:49,720
WOMEN'S INITIATIVE STOP BEING A

2644
01:33:49,720 --> 01:33:50,840
CAMEO OR PILOT PROJECT AND

2645
01:33:50,840 --> 01:33:52,320
REALLY START TO GET INTO THE

2646
01:33:52,320 --> 01:33:52,640
MAINSTREAM.

2647
01:33:52,640 --> 01:33:54,800
I THINK THE POINTS LUIS MADE IS

2648
01:33:54,800 --> 01:33:56,120
SOMETHING WE SEE IN THE

2649
01:33:56,120 --> 01:33:58,080
PEDIATRIC AREA IN TERMS OF

2650
01:33:58,080 --> 01:34:00,040
RECRUITMENT AND RETENTION, SOME

2651
01:34:00,040 --> 01:34:03,040
OF THE LIMITATIONS, PARTICULARLY

2652
01:34:03,040 --> 01:34:05,000
WOMEN WITH CHILDREN AND SINGLE

2653
01:34:05,000 --> 01:34:06,120
MOMS, WE NEED TO PROVIDE MUCH

2654
01:34:06,120 --> 01:34:07,440
MORE IN TERMS OF INCENTIVE.

2655
01:34:07,440 --> 01:34:09,200
I THINK THIS NEEDS TO BE A VERY

2656
01:34:09,200 --> 01:34:12,240
HIGH PRIORITY FOR FUNDING FOR

2657
01:34:12,240 --> 01:34:14,480
O.A.R. AS WE START TO RE-LOOK AT

2658
01:34:14,480 --> 01:34:17,800
THE P.J. BUDGET AND THE C.J.

2659
01:34:17,800 --> 01:34:18,840
BUDGETS AND START TO REALLY LOOK

2660
01:34:18,840 --> 01:34:20,120
AT THESE THINGS, HOW ARE WE

2661
01:34:20,120 --> 01:34:21,680
GOING TO CARVE OUT FUNDING FOR

2662
01:34:21,680 --> 01:34:24,280
THIS INITIATIVE, AND THERE MAY

2663
01:34:24,280 --> 01:34:26,800
BE THINGS THAT HAVE TO BE

2664
01:34:26,800 --> 01:34:29,520
EITHER, YOU KNOW, DECREASED AND

2665
01:34:29,520 --> 01:34:30,360
REPRIORITIZED, BECAUSE THIS IS

2666
01:34:30,360 --> 01:34:31,920
SOMETHING WE'VE BEEN TALKING

2667
01:34:31,920 --> 01:34:34,240
ABOUT SINCE I HAD HAIR, THAT,

2668
01:34:34,240 --> 01:34:38,960
YOU KNOW, WOMEN CAN'T -- WE

2669
01:34:38,960 --> 01:34:41,680
TALKED ABOUT THIS -- DURING THIS

2670
01:34:41,680 --> 01:34:43,680
PHASE OF 076, WE WERE TALKING

2671
01:34:43,680 --> 01:34:45,800
ABOUT ENROLLING WOMEN IN THE

2672
01:34:45,800 --> 01:34:47,280
1990s, AND HERE WE ARE, WE'RE

2673
01:34:47,280 --> 01:34:48,560
HAVING THE SAME CONVERSATION.

2674
01:34:48,560 --> 01:34:50,440
I THINK THIS IS A VERY PIVOTAL

2675
01:34:50,440 --> 01:34:51,520
STAGE AND A GOOD TIME TO START

2676
01:34:51,520 --> 01:34:55,280
TO REALLY PUT SOME TRUE

2677
01:34:55,280 --> 01:34:56,400
RECOMMENDATIONS INTO HOW THE

2678
01:34:56,400 --> 01:34:58,800
RULES ARE PUT OUT FOR

2679
01:34:58,800 --> 01:35:05,960
INVESTIGATORS AND FOR PROGRAM.

2680
01:35:05,960 --> 01:35:08,360
>> THANK YOU.

2681
01:35:08,360 --> 01:35:09,200
DR. TURNBULL, I THINK WE'RE GOOD

2682
01:35:09,200 --> 01:35:13,400
IN THE ROOM.

2683
01:35:13,400 --> 01:35:13,800
SO --

2684
01:35:13,800 --> 01:35:15,520
>> CAN I MAKE ONE
ADDITIONAL

2685
01:35:15,520 --> 01:35:15,800
COMMENT?

2686
01:35:15,800 --> 01:35:18,000
I'M SO SORRY.

2687
01:35:18,000 --> 01:35:19,440
JUST REALLY QUICK, I ACTUALLY

2688
01:35:19,440 --> 01:35:21,960
THOUGHT THAT WAS AN INCREDIBLY

2689
01:35:21,960 --> 01:35:24,000
ASTUTE POINT ABOUT --

2690
01:35:24,000 --> 01:35:26,400
DR. MONTANER, ABOUT THE R03 AND

2691
01:35:26,400 --> 01:35:27,080
R21 MECHANISMS, BECAUSE REMEMBER

2692
01:35:27,080 --> 01:35:29,680
THE NEXT INVESTIGATOR INITIATIVE

2693
01:35:29,680 --> 01:35:32,920
THAT GOT DESIGNED WHEN THERE

2694
01:35:32,920 --> 01:35:33,920
WAS -- REMEMBER WHEN THERE WAS A

2695
01:35:33,920 --> 01:35:34,720
POINT SYSTEM THAT WAS GOING TO

2696
01:35:34,720 --> 01:35:38,280
BE ESTABLISHED, AND THEN

2697
01:35:38,280 --> 01:35:38,880
EXPERIENCED INVESTIGATORS SORT

2698
01:35:38,880 --> 01:35:41,360
OF PROTESTED AND THEN THE NEXT

2699
01:35:41,360 --> 01:35:42,480
INVESTIGATOR INITIATIVE WAS

2700
01:35:42,480 --> 01:35:44,320
LAUNCHED.

2701
01:35:44,320 --> 01:35:47,320
IN THAT, THERE WAS REALLY A PUSH

2702
01:35:47,320 --> 01:35:49,120
TOWARDS NEW INVESTIGATORS, EARLY

2703
01:35:49,120 --> 01:35:52,240
STAGE INVESTIGATORS PUTTING IN

2704
01:35:52,240 --> 01:35:54,040
R03s, R21s, BECAUSE THEY

2705
01:35:54,040 --> 01:35:55,600
WOULDN'T TAKE AWAY YOUR ESI

2706
01:35:55,600 --> 01:35:56,920
STATUS, AND THEY WERE SUPPOSEDLY

2707
01:35:56,920 --> 01:35:59,160
LOW HANGING FRUIT AND, INDEED,

2708
01:35:59,160 --> 01:36:03,400
THE NIAID PAYLINES FOR THOSE

2709
01:36:03,400 --> 01:36:05,480
GRANTS ARE AROUND 29.

2710
01:36:05,480 --> 01:36:06,960
SO MUCH BETTER THAN THE PAYLINE

2711
01:36:06,960 --> 01:36:08,840
FOR AN R01.

2712
01:36:08,840 --> 01:36:11,040
BUT I LOVE THE COMMENT ABOUT

2713
01:36:11,040 --> 01:36:13,760
THAT IN THE STUDY SECTION, WE

2714
01:36:13,760 --> 01:36:16,000
HAVE TO, YOU KNOW, ENSURE THAT

2715
01:36:16,000 --> 01:36:17,560
THEY'RE SCORED AND NOT EXPECTED

2716
01:36:17,560 --> 01:36:21,360
TO BE R01s BECAUSE EVEN IF YOU

2717
01:36:21,360 --> 01:36:24,840
GET A WORSE SCORE IN THE 29

2718
01:36:24,840 --> 01:36:26,560
YOU'RE GOING TO GET IT, YOU

2719
01:36:26,560 --> 01:36:28,440
SHOULDN'T BE JUDGED ON THE SAME

2720
01:36:28,440 --> 01:36:31,080
CRITERIA, ESPECIALLY WHEN IT'S A

2721
01:36:31,080 --> 01:36:32,880
$275,000 GRANT OVER TWO YEARS.

2722
01:36:32,880 --> 01:36:34,080
SO I LOVE THAT, I'VE ALWAYS

2723
01:36:34,080 --> 01:36:38,040
PUSHED OUR EARLY ASIs TO DO

2724
01:36:38,040 --> 01:36:40,440
R21s AND A03s AND I LOVE

2725
01:36:40,440 --> 01:36:42,040
THAT COMMENT ABOUT THE EARLY

2726
01:36:42,040 --> 01:36:42,400
REVIEW PROCESS.

2727
01:36:42,400 --> 01:36:44,880
THANK YOU.

2728
01:36:44,880 --> 01:36:47,720
>> ARE THERE ANY OTHER

2729
01:36:47,720 --> 01:36:50,000
ADDITIONAL COMMENTS IN THE ROOM,

2730
01:36:50,000 --> 01:36:50,200
MARY?

2731
01:36:50,200 --> 01:36:51,440
I DON'T SEE ANY ON THE ZOOM.

2732
01:36:51,440 --> 01:36:53,000
>> NO, MA'AM.

2733
01:36:53,000 --> 01:36:53,440
>> OKAY.

2734
01:36:53,440 --> 01:36:55,960
THANK YOU.

2735
01:36:55,960 --> 01:36:57,640
COLLEAGUES, THANK YOU FOR THIS

2736
01:36:57,640 --> 01:36:58,320
FRUITFUL CONVERSATION.

2737
01:36:58,320 --> 01:37:00,480
WE WILL NOW TAKE A 15-MINUTE

2738
01:37:00,480 --> 01:37:02,160
BREAK, AND WE'LL RESTART

2739
01:37:02,160 --> 01:37:13,320
PROMPTLY AT 1:50 P.M. EASTERN 1.

2740
01:37:13,320 --> 01:37:14,120
PLEASE DO NOT LOG OUT OF THE

2741
01:37:14,120 --> 01:37:19,760
ZOOM MEETING BUT FEEL FREE TO --

2742
01:37:19,760 --> 01:37:22,040
WE'LL SEE YOU BACK AT 2:05.

2743
01:37:22,040 --> 01:37:24,600
WELCOME BACK, EVERYONE, FROM THE

2744
01:37:24,600 --> 01:37:24,800
BREAK.

2745
01:37:24,800 --> 01:37:26,760
WE WILL RESUME THE MEETING

2746
01:37:26,760 --> 01:37:29,880
HEARING UPDATES ABOUT THE NIH

2747
01:37:29,880 --> 01:37:32,800
O.A.R. SIGNATURE PROGRAMS, HIV

2748
01:37:32,800 --> 01:37:35,120
AND AGING, AND EARLY CAREER

2749
01:37:35,120 --> 01:37:36,440
INVESTIGATORS.

2750
01:37:36,440 --> 01:37:43,480
FIRST UP IS HIV AND AGING.

2751
01:37:43,480 --> 01:37:45,520
DR. GEETANJALI BANSAL IS A

2752
01:37:45,520 --> 01:37:48,480
SENIOR SCIENCE ADVISOR AT THE

2753
01:37:48,480 --> 01:37:52,080
O.A.R., AND LEADS THE O.A.R. HIV

2754
01:37:52,080 --> 01:37:56,120
AND AGING SIGNATURE PROGRAM.

2755
01:37:56,120 --> 01:38:02,960
AFTER DR. BANSAL, WE WILL HAVE

2756
01:38:02,960 --> 01:38:03,760
MISS RAHEL ABEBE, WHO WILL GIVE

2757
01:38:03,760 --> 01:38:07,800
US UPDATES ON THE EARLY CAREER

2758
01:38:07,800 --> 01:38:09,520
INVESTIGATORS.

2759
01:38:09,520 --> 01:38:12,080
MS. ABEBE JOINED THE O.A.R. IN

2760
01:38:12,080 --> 01:38:14,960
2016, AND CURRENTLY WORKS AS A

2761
01:38:14,960 --> 01:38:18,120
PUBLIC HEALTH ANALYST.

2762
01:38:18,120 --> 01:38:18,880
DR. BANSAL, OVER TO YOU TO

2763
01:38:18,880 --> 01:38:26,160
START.

2764
01:38:26,160 --> 01:38:29,440
>> THANK YOU, DR.
TURNBULL.

2765
01:38:29,440 --> 01:38:33,200
GOOD AFTERNOON, EVERYONE.

2766
01:38:33,200 --> 01:38:33,840
I'M GEETANJALI BANSAL.

2767
01:38:33,840 --> 01:38:36,600
I'M A SENIOR SCIENCE ADVISOR IN

2768
01:38:36,600 --> 01:38:38,280
HEALTH SCIENTIST ADMINISTRATOR

2769
01:38:38,280 --> 01:38:39,720
IN NIH OFFICE OF AIDS RESEARCH

2770
01:38:39,720 --> 01:38:41,400
AND MANAGE THE HIV AND AGING

2771
01:38:41,400 --> 01:38:48,920
SIGNATURE PROGRAM.

2772
01:38:48,920 --> 01:38:50,680
AS DR. KAPOGIANNIS MENTIONED IN

2773
01:38:50,680 --> 01:38:54,520
HIS PRESENTATION, O.A.R. HAS

2774
01:38:54,520 --> 01:38:56,240
FOUR SIGNATURE PROGRAMS.

2775
01:38:56,240 --> 01:38:58,320
AND I'M HERE TO PROVIDE YOU AN

2776
01:38:58,320 --> 01:39:00,760
UPDATE FOR THE SIGNATURE PROGRAM

2777
01:39:00,760 --> 01:39:05,920
ON HIV AND AGING.

2778
01:39:05,920 --> 01:39:07,920
SO I WILL START WITH A

2779
01:39:07,920 --> 01:39:09,200
BACKGROUND ABOUT HOW THE

2780
01:39:09,200 --> 01:39:11,160
SIGNATURE PROGRAM CAME ABOUT TO

2781
01:39:11,160 --> 01:39:12,880
BE, AND AN UPDATE ON THE CURRENT

2782
01:39:12,880 --> 01:39:15,920
AND FUTURE ACTIVITIES, AS WELL

2783
01:39:15,920 --> 01:39:17,600
AS A TIMELINE FOR ALL THE

2784
01:39:17,600 --> 01:39:24,320
EVENTS.

2785
01:39:24,320 --> 01:39:27,240
SO AS DR. I KASSAYE MENTIONED AD

2786
01:39:27,240 --> 01:39:30,000
AS WE ALL KNOW, THE SUCCESS OF

2787
01:39:30,000 --> 01:39:30,760
ANTIRETROVIRAL THERAPIES, PEOPLE

2788
01:39:30,760 --> 01:39:32,560
WITH HIV ARE LIVING LONGER, AND

2789
01:39:32,560 --> 01:39:35,560
NOW CAN HAVE A NEARLY NORMAL

2790
01:39:35,560 --> 01:39:36,960
LIFESPAN WITH APPROPRIATE

2791
01:39:36,960 --> 01:39:37,280
TREATMENT.

2792
01:39:37,280 --> 01:39:38,640
MORE THAN HALF OF THE PEOPLE

2793
01:39:38,640 --> 01:39:40,960
LIVING WITH HIV IN THE UNITED

2794
01:39:40,960 --> 01:39:43,680
STATES ARE 50 YEARS AND OLDER.

2795
01:39:43,680 --> 01:39:46,480
THE NUMBER PROJECTED TO GO UP TO

2796
01:39:46,480 --> 01:39:49,560
75% BY 2030.

2797
01:39:49,560 --> 01:39:51,200
GLOBALLY, ONE ESTIMATE FROM U.N.

2798
01:39:51,200 --> 01:39:52,480
AIDS IS THAT NUMBER OF PEOPLE

2799
01:39:52,480 --> 01:39:54,880
WITH HIV IN THIS AGE GROUP

2800
01:39:54,880 --> 01:39:57,320
INCREASED TO OVER 8 MILLION IN

2801
01:39:57,320 --> 01:39:58,840
2020, AND EXPECTED TO INCREASE

2802
01:39:58,840 --> 01:40:00,520
STEADILY.

2803
01:40:00,520 --> 01:40:02,920
OLDER ADULTS WITH HIV FACE

2804
01:40:02,920 --> 01:40:05,240
SIMILAR ISSUES AS THEIR PEERS

2805
01:40:05,240 --> 01:40:05,920
WITHOUT HIV.

2806
01:40:05,920 --> 01:40:07,280
THEY ALSO FACE SOME UNIQUE

2807
01:40:07,280 --> 01:40:08,920
CHALLENGES.

2808
01:40:08,920 --> 01:40:12,200
OLDER PEOPLE WITH HIV FACE

2809
01:40:12,200 --> 01:40:13,800
ACCELERATED AGING FOR CERTAIN

2810
01:40:13,800 --> 01:40:14,880
COMORBIDITIES SUCH AS

2811
01:40:14,880 --> 01:40:17,200
NEUROCOGNITIVE IMPAIRMENT,

2812
01:40:17,200 --> 01:40:20,040
FRAILTY, MULTI-MORBIDITY AND

2813
01:40:20,040 --> 01:40:21,440
SUBSTANCE USE AND POLYPHARMACY,

2814
01:40:21,440 --> 01:40:22,800
AS YOU SEE HERE.

2815
01:40:22,800 --> 01:40:24,080
MULTIPLE INTERSECTIONAL STIGMAS

2816
01:40:24,080 --> 01:40:26,680
AND OTHER MENTAL COMORBIDITIES.

2817
01:40:26,680 --> 01:40:28,600
SO AGING WITH HIV IS MORE

2818
01:40:28,600 --> 01:40:30,520
COMPLEX WITH MORE COMPLEX CARE

2819
01:40:30,520 --> 01:40:32,280
AND SUPPORT NEEDS.

2820
01:40:32,280 --> 01:40:34,120
RECOGNIZING THE UNIQUE

2821
01:40:34,120 --> 01:40:36,160
CHALLENGES OLDER PEOPLE WITH HIV

2822
01:40:36,160 --> 01:40:39,160
FACE, HIV AND AGING IS A HIGH

2823
01:40:39,160 --> 01:40:40,880
PRIORITY TOPIC FOR

2824
01:40:40,880 --> 01:40:47,600
ADMINISTRATION, HHS AND NIH.

2825
01:40:47,600 --> 01:40:49,800
BASED ON INPUT FROM VARIOUS

2826
01:40:49,800 --> 01:40:51,240
PERSPECTIVES AND COMMUNITY

2827
01:40:51,240 --> 01:40:53,240
VOICES, NIH O.A.R. LAUNCHED THE

2828
01:40:53,240 --> 01:40:54,880
SIGNATURE PROGRAM ON HIV AND

2829
01:40:54,880 --> 01:40:57,200
AGING LAST YEAR, BUILDING ON THE

2830
01:40:57,200 --> 01:40:59,040
CURRENT NIH EFFORTS.

2831
01:40:59,040 --> 01:41:01,520
THIS PROGRAM AIMS TO CATALYZE

2832
01:41:01,520 --> 01:41:02,640
COLLABORATIONS TO ADDRESS

2833
01:41:02,640 --> 01:41:04,360
RESEARCH GAPS AND OPPORTUNITIES

2834
01:41:04,360 --> 01:41:06,760
AT THE INTERSECTION OF HIV AND

2835
01:41:06,760 --> 01:41:09,320
AGING WITH FOCUS ON BIOMEDICAL

2836
01:41:09,320 --> 01:41:11,760
AS WELL AS BEHAVIORAL AND SOCIAL

2837
01:41:11,760 --> 01:41:13,080
NEEDS AND ASPECTS OF THE

2838
01:41:13,080 --> 01:41:22,400
RESEARCH.

2839
01:41:22,400 --> 01:41:24,320
SO THIS SLIDE JUST GIVES AN

2840
01:41:24,320 --> 01:41:25,880
OVERVIEW OF ALL THE CURRENT AND

2841
01:41:25,880 --> 01:41:30,400
FUTURE ACTIVITIES, STARTING WITH

2842
01:41:30,400 --> 01:41:34,480
THE MULTI-ICO WORKING GROUP.

2843
01:41:34,480 --> 01:41:37,520
EARLIER THIS YEAR, NIH O.A.R.

2844
01:41:37,520 --> 01:41:39,520
LAUNCHED A MULTI-IC HIV AND

2845
01:41:39,520 --> 01:41:42,120
AGING WORKING GROUP THAT IS

2846
01:41:42,120 --> 01:41:44,960
CO-LED BY NIA AND NIH O.A.R.

2847
01:41:44,960 --> 01:41:46,720
THIS IS AN INTERNAL GROUP

2848
01:41:46,720 --> 01:41:50,240
COMPRISING MAINLY OF NIH PROGRAM

2849
01:41:50,240 --> 01:41:50,760
STAFF.

2850
01:41:50,760 --> 01:41:52,600
SINCE ITS LAUNCH, THE NUMBER OF

2851
01:41:52,600 --> 01:41:54,240
ICOs IN THIS GROUP HAS ALMOST

2852
01:41:54,240 --> 01:41:57,200
DOUBLED WITH CURRENTLY 12, PLUS

2853
01:41:57,200 --> 01:42:00,440
O.A.R., SO REPRESENTING THE

2854
01:42:00,440 --> 01:42:01,560
MULTI-I.C., MULTIFACETED HIV AND

2855
01:42:01,560 --> 01:42:03,080
AGING PORTFOLIO.

2856
01:42:03,080 --> 01:42:08,640
THE GOAL OF THE WORKING GROUP IS

2857
01:42:08,640 --> 01:42:10,600
TO FACILITATE INTEGRATIVE

2858
01:42:10,600 --> 01:42:11,560
COLLABORATIONS FOR

2859
01:42:11,560 --> 01:42:13,920
INTERDISCIPLINARY RESEARCH AND

2860
01:42:13,920 --> 01:42:14,720
TRAINING AT THE INTERSECTION OF

2861
01:42:14,720 --> 01:42:16,800
HIV AND AGING, AND TO IDENTIFY

2862
01:42:16,800 --> 01:42:18,320
RESEARCH GAPS AND OPPORTUNITIES

2863
01:42:18,320 --> 01:42:19,640
TO ADDRESS THE NEEDS OF PEOPLE

2864
01:42:19,640 --> 01:42:21,240
AGING WITH HIV.

2865
01:42:21,240 --> 01:42:23,560
AS A FIRST STEP, THE WORK GROUP

2866
01:42:23,560 --> 01:42:25,960
IS COLLATING INFORMATION ON HIV

2867
01:42:25,960 --> 01:42:27,560
AND AGING RELATED RESEARCH

2868
01:42:27,560 --> 01:42:28,840
RESOURCES AND ACTIVITIES.

2869
01:42:28,840 --> 01:42:31,560
FOR EXAMPLE, COHORTS, NETWORKS,

2870
01:42:31,560 --> 01:42:32,480
REPOSITORIES, RESEARCH PROGRAMS,

2871
01:42:32,480 --> 01:42:34,960
ET CETERA, TO LEVERAGE EXISTING

2872
01:42:34,960 --> 01:42:36,360
RESOURCES AND TO IDENTIFY

2873
01:42:36,360 --> 01:42:38,120
OPPORTUNITIES FOR NEW

2874
01:42:38,120 --> 01:42:39,400
COLLABORATIONS AND DEVELOP

2875
01:42:39,400 --> 01:42:40,840
INFORMATIONAL DOCUMENTS FOR THE

2876
01:42:40,840 --> 01:42:47,400
COMMUNITY AND COLLABORATIONS.

2877
01:42:47,400 --> 01:42:49,000
THE WORKING GROUP ALSO HAS

2878
01:42:49,000 --> 01:42:49,880
DISCUSSED IMPORTANT RESEARCH

2879
01:42:49,880 --> 01:42:53,720
QUESTIONS SUCH AS HOW DOES

2880
01:42:53,720 --> 01:42:56,440
AGING -- IS DIFFERENT FROM AGING

2881
01:42:56,440 --> 01:42:59,680
WITHOUT -- IN PEOPLE WITH HIV

2882
01:42:59,680 --> 01:43:01,200
VERSUS WITHOUT HIV, AND IN THE

2883
01:43:01,200 --> 01:43:05,200
SAME IN THE COU CONTEXT OF DIFFT

2884
01:43:05,200 --> 01:43:11,520
COMOCOMORBIDITIES, MACS WIHS TOE

2885
01:43:11,520 --> 01:43:13,160
A FEW TO POTENTIALLY ANSWER SUCH

2886
01:43:13,160 --> 01:43:13,600
QUESTIONS.

2887
01:43:13,600 --> 01:43:16,920
RECENTLY THE WORKING GROUP AND

2888
01:43:16,920 --> 01:43:21,320
NIH O.A.R. CO-HOSTED DR. AMY

2889
01:43:21,320 --> 01:43:28,520
JUSTIJUST WHO SHARED 25 YEARS HY

2890
01:43:28,520 --> 01:43:30,240
OF THE COHORT WHICH IS A LARGE

2891
01:43:30,240 --> 01:43:32,600
COHORT OF OVER 60,000 PEOPLE

2892
01:43:32,600 --> 01:43:33,760
WITH NIH.

2893
01:43:33,760 --> 01:43:35,720
THIS WAS AN INTERNAL NIH

2894
01:43:35,720 --> 01:43:37,800
ACTIVITY AND EXPLORED ANSWERS TO

2895
01:43:37,800 --> 01:43:39,720
SEVERAL QUESTIONS THAT THE

2896
01:43:39,720 --> 01:43:41,600
WORKING GROUP HAS BEEN

2897
01:43:41,600 --> 01:43:43,240
DISCUSSING AND OPPORTUNITIES AND

2898
01:43:43,240 --> 01:43:44,120
AREAS THAT WE CAN FURTHER

2899
01:43:44,120 --> 01:43:48,360
DISCUSS.

2900
01:43:48,360 --> 01:43:50,280
THE WORKING GROUP WILL ALSO BE

2901
01:43:50,280 --> 01:43:53,600
HOLDING A WORKSHOP AND A LINKAGE

2902
01:43:53,600 --> 01:43:55,120
SESSION THAT WILL TAKE PLACE IN

2903
01:43:55,120 --> 01:43:56,680
CONNECTION WITH THE U.S.

2904
01:43:56,680 --> 01:44:01,960
CONFERENCE ON HIV AND AIDS OR

2905
01:44:01,960 --> 01:44:05,240
US CHA IN SEPTEMBER.

2906
01:44:05,240 --> 01:44:07,200
THIS YEAR THE PLANNING GROUP FOR

2907
01:44:07,200 --> 01:44:10,360
THESE ACTIVITIES INCLUDES AND IS

2908
01:44:10,360 --> 01:44:12,000
BEING INFORMED BY COMMUNITY, AS

2909
01:44:12,000 --> 01:44:14,520
WELL AS NIH SIBLING AGENCIES,

2910
01:44:14,520 --> 01:44:16,880
CDC AND HRSA.

2911
01:44:16,880 --> 01:44:19,640
IT HAS TWO COMPONENTS.

2912
01:44:19,640 --> 01:44:20,880
THE FIRST IS A RESEARCH WORKSHOP

2913
01:44:20,880 --> 01:44:23,080
WHICH WILL BE ALL VIRTUAL, AND

2914
01:44:23,080 --> 01:44:24,560
THE SECOND PART IS THE LINKAGE

2915
01:44:24,560 --> 01:44:26,560
SESSION, WHICH IS ENVISIONED AS

2916
01:44:26,560 --> 01:44:29,520
A PANEL DISCUSSION ON CURRENT

2917
01:44:29,520 --> 01:44:31,160
LANDSCAPE AND OPPORTUNITIES FOR

2918
01:44:31,160 --> 01:44:32,800
HIV AND AGING EFFORTS.

2919
01:44:32,800 --> 01:44:35,160
AND THIS DISCUSSION IS AGAIN

2920
01:44:35,160 --> 01:44:41,560
PLANNED TO INVOLVE U.S. AGENCIES

2921
01:44:41,560 --> 01:44:42,840
AND RESEARCH COMMUNITIES, THIS

2922
01:44:42,840 --> 01:44:49,960
SESSION BEING HYBRID.

2923
01:44:49,960 --> 01:44:51,160
SO THIS WORKSHOP AND THE SESSION

2924
01:44:51,160 --> 01:44:52,280
ARE BEING DEVELOPED AROUND THE

2925
01:44:52,280 --> 01:44:55,680
FOUR PILLARS THAT YOU SEE ON THE

2926
01:44:55,680 --> 01:44:57,720
SCREEN, THE FOUR Is, AS WE

2927
01:44:57,720 --> 01:44:58,680
CALL THAT.

2928
01:44:58,680 --> 01:45:00,560
CONSIDERING THE

2929
01:45:00,560 --> 01:45:02,560
INTERSECTIONALITY OF STIGMAS OF

2930
01:45:02,560 --> 01:45:05,560
HIV INFECTION, AGING AND RELATED

2931
01:45:05,560 --> 01:45:08,560
COMORBIDITIES IN BIOLOGICAL AND

2932
01:45:08,560 --> 01:45:11,520
SOCIAL AND BEHAVIORAL CONTEXT.

2933
01:45:11,520 --> 01:45:12,480
INTERDISCIPLINE AREA RESEARCH IS

2934
01:45:12,480 --> 01:45:13,600
NEEDED.

2935
01:45:13,600 --> 01:45:15,440
THERE IS URGENT NEED FOR

2936
01:45:15,440 --> 01:45:17,040
INTEGRATED MODELS OF CARE AND

2937
01:45:17,040 --> 01:45:18,480
IMPLEMENTATION RESEARCH, AND

2938
01:45:18,480 --> 01:45:21,560
DIFFERENT U.S. AGENCIES HAVING

2939
01:45:21,560 --> 01:45:22,240
DIFFERENT ROLES, INTERAGENCY

2940
01:45:22,240 --> 01:45:23,720
EFFORTS PLAY A CRUCIAL ROLE IN

2941
01:45:23,720 --> 01:45:25,360
ADDRESSING THE NEEDS OF OLDER

2942
01:45:25,360 --> 01:45:28,360
ADULTS WITH HIV.

2943
01:45:28,360 --> 01:45:33,720
HENCE THE FOUR Is,

2944
01:45:33,720 --> 01:45:35,040
INTERDISCIPLINARY RESEARCH,

2945
01:45:35,040 --> 01:45:36,200
INTEGRATED MODELS OF CARE,

2946
01:45:36,200 --> 01:45:37,800
IMPLEMENTATION RESEARCH AND

2947
01:45:37,800 --> 01:45:39,560
INTERAGENCY EFFORTS LEADING

2948
01:45:39,560 --> 01:45:41,400
THESE TWO EVENTS.

2949
01:45:41,400 --> 01:45:43,600
SO THIS SLIDE JUST SHOWS THE

2950
01:45:43,600 --> 01:45:44,800
TIMELINE OF EVENTS.

2951
01:45:44,800 --> 01:45:46,840
WE STARTED WITH AN ANALYSIS OF

2952
01:45:46,840 --> 01:45:49,880
THE NIH-WIDE HIV AND AGING

2953
01:45:49,880 --> 01:45:53,440
PORTFOLIO, WHICH IS DONE BY NIH

2954
01:45:53,440 --> 01:45:54,640
O.A.R. ANALYTICS AND SCIENCE

2955
01:45:54,640 --> 01:45:56,880
TEAMS, AND WE SHARED WITH YOU AT

2956
01:45:56,880 --> 01:46:00,520
THE LAST OARAC IN MARCH DURING

2957
01:46:00,520 --> 01:46:03,640
THE HIV AND AGING SESSION LED BY

2958
01:46:03,640 --> 01:46:06,080
NIA DIRECTOR DR. HODES.

2959
01:46:06,080 --> 01:46:08,800
THAT PLUS THE HIV AND AGING

2960
01:46:08,800 --> 01:46:11,600
WORKING GROUP CO-LED BY NIH AND

2961
01:46:11,600 --> 01:46:13,040
O.A.R. AND PLANNING GROUP IN

2962
01:46:13,040 --> 01:46:15,320
PARTNERSHIP WITH OTHER ICs AND

2963
01:46:15,320 --> 01:46:16,600
COLLABORATORS ARE ACTIVELY

2964
01:46:16,600 --> 01:46:17,800
INFORMING THESE ACTIVITIES UNDER

2965
01:46:17,800 --> 01:46:21,880
THE LEADERSHIP OF DR. HOLTZ,

2966
01:46:21,880 --> 01:46:23,840
DEPUTY DIRECTOR, PREVIOUSLY

2967
01:46:23,840 --> 01:46:25,480
DR. GOODENOW, AND NOW ACTING

2968
01:46:25,480 --> 01:46:27,880
DIRECTOR DR. KAPOGIANNIS.

2969
01:46:27,880 --> 01:46:34,440
ANOTHER ACTIVITY IS THE MULTIPLE

2970
01:46:34,440 --> 01:46:37,280
I.C.NOSI PUBLISHED IN APRIL, LED

2971
01:46:37,280 --> 01:46:38,800
BY NIA IN PARTNERSHIP WITH

2972
01:46:38,800 --> 01:46:44,360
O.A.R. AND OTHER ICs.

2973
01:46:44,360 --> 01:46:49,280
DRTHE SEMINAR WE HAD EARLIER THS

2974
01:46:49,280 --> 01:46:50,440
MONTH, SO WE ARE HERE IN THE

2975
01:46:50,440 --> 01:46:52,080
LAST QUARTER OF THIS FISCAL

2976
01:46:52,080 --> 01:46:52,760
YEAR.

2977
01:46:52,760 --> 01:46:53,960
THE WEBPAGE FOR SIGNATURE

2978
01:46:53,960 --> 01:46:55,720
PROGRAM IS CURRENTLY UNDER

2979
01:46:55,720 --> 01:46:57,640
DEVELOPMENT, AND THE UPCOMING

2980
01:46:57,640 --> 01:46:58,280
ACTIVITIES AS I MENTIONED

2981
01:46:58,280 --> 01:47:00,280
INCLUDE THE WORKSHOP AND THE

2982
01:47:00,280 --> 01:47:01,920
LINKAGE SESSION.

2983
01:47:01,920 --> 01:47:03,240
OUTPUTS FOR WHICH ARE GOING TO

2984
01:47:03,240 --> 01:47:04,720
BE BEYOND THE TIMELINE SHOWN ON

2985
01:47:04,720 --> 01:47:10,080
SCREEN.

2986
01:47:10,080 --> 01:47:12,280
SO THIS SLIDE HIGHLIGHTS THE

2987
01:47:12,280 --> 01:47:14,120
GROWING COLLABORATIONS ACROSS

2988
01:47:14,120 --> 01:47:16,720
NIH AND OUTSIDE.

2989
01:47:16,720 --> 01:47:18,120
IT'S NOT AN ACKNOWLEDGMENT

2990
01:47:18,120 --> 01:47:19,360
SLIDE, IT WILL BE HARD TO FIT

2991
01:47:19,360 --> 01:47:21,200
THE NAMES ON ONE SLIDE.

2992
01:47:21,200 --> 01:47:23,560
THIS IS JUST A CURRENT LIST OF

2993
01:47:23,560 --> 01:47:29,040
MEMBERS ON THE NIH HIV AND AGINR

2994
01:47:29,040 --> 01:47:30,600
MEETING PLANNING GROUP.

2995
01:47:30,600 --> 01:47:32,360
THE NIH HIV AND AGING WORKING

2996
01:47:32,360 --> 01:47:35,560
GROUP BEING AN NIH INTERNAL

2997
01:47:35,560 --> 01:47:37,040
GROUP, SOME MEMBERS OVERLAP

2998
01:47:37,040 --> 01:47:38,600
BETWEEN THE TWO GROUPS.

2999
01:47:38,600 --> 01:47:40,440
AND YOU ALSO SEE THE

3000
01:47:40,440 --> 01:47:42,960
COLLABORATION WITH COMMUNITY AND

3001
01:47:42,960 --> 01:47:44,080
OTHER FEDERAL AGENCIES HERE IN

3002
01:47:44,080 --> 01:47:47,200
BLUE ON YOUR SCREEN.

3003
01:47:47,200 --> 01:47:51,240
AND AGAIN, THESE ARE CO-LED BY

3004
01:47:51,240 --> 01:47:52,960
NIA AND NIH O.A.R., AND JUST

3005
01:47:52,960 --> 01:47:55,160
WANT TO MAKE A POINT THAT THIS

3006
01:47:55,160 --> 01:47:57,640
IS A DYNAMIC TEAM, GROWING AS WE

3007
01:47:57,640 --> 01:47:58,800
MOVE FORWARD.

3008
01:47:58,800 --> 01:48:04,880
SO THIS IS NOT A STOP HERE.

3009
01:48:04,880 --> 01:48:10,440
THANK YOU.

3010
01:48:10,440 --> 01:48:16,800
>> THANK YOU, DR. BON SAL.

3011
01:48:16,800 --> 01:48:18,560
 BANSAL.

3012
01:48:18,560 --> 01:48:19,120
DR. ABEBE, PLEASE PROCEED.

3013
01:48:19,120 --> 01:48:21,480
>> THANK YOU, DR.
TURNBULL.

3014
01:48:21,480 --> 01:48:22,800
GOOD AFTERNOON, EVERYONE.

3015
01:48:22,800 --> 01:48:25,560
MY NAME IS RAHEL ABEBE, I'M A

3016
01:48:25,560 --> 01:48:27,360
PUBLIC HEALTH ANALYST AT NIH

3017
01:48:27,360 --> 01:48:27,800
O.A.R.

3018
01:48:27,800 --> 01:48:34,560
ON BEHALF OF DR. LIZ KA KELLER,I

3019
01:48:34,560 --> 01:48:36,440
WILL PRESENT AN UPDATE ON EARLY

3020
01:48:36,440 --> 01:48:40,120
CAREER INVESTIGATORS ON THE NIH

3021
01:48:40,120 --> 01:48:41,880
WORKSHOP THAT TOOK PLACE ON

3022
01:48:41,880 --> 01:48:42,520
APRIL 24TH.

3023
01:48:42,520 --> 01:48:44,320
DR. KELLER IS THE LEAD ORGANIZER

3024
01:48:44,320 --> 01:48:46,560
OF THE WORKSHOP ALONG WITH OOR

3025
01:48:46,560 --> 01:48:47,960
STAFF AND OTHER NIH WORKING

3026
01:48:47,960 --> 01:48:49,480
GROUP WHO HAVE BEEN VERY

3027
01:48:49,480 --> 01:48:50,800
INSTRUMENTAL TO MAKE THE

3028
01:48:50,800 --> 01:48:57,360
WORKSHOP POSSIBLE.

3029
01:48:57,360 --> 01:49:01,360
AS YOU HEARD EARLIER, O.A.R. HAS

3030
01:49:01,360 --> 01:49:02,880
FOUR SIGNATURE PROGRAMS:  EARLY

3031
01:49:02,880 --> 01:49:05,160
CAREER INVESTIGATOR OR ECI IS

3032
01:49:05,160 --> 01:49:06,200
ONE OF THEM.

3033
01:49:06,200 --> 01:49:08,800
I WILL BE FOCUSING ON ECI FOR

3034
01:49:08,800 --> 01:49:13,840
THE NEXT FEW MINUTES.

3035
01:49:13,840 --> 01:49:15,920
PLEASE NOTE THAT THE TERM EARLY

3036
01:49:15,920 --> 01:49:22,120
STAGE INVESTIGATORS OR ESI ARE

3037
01:49:22,120 --> 01:49:24,640
THOSE WITHIN 10 YEARS OF THEIR

3038
01:49:24,640 --> 01:49:27,360
TERMINAL DEGREE THAT DO NOT HAVE

3039
01:49:27,360 --> 01:49:31,720
R01 EQUIVALENT AWARD YET.

3040
01:49:31,720 --> 01:49:36,000
HERE IS THE ORDER ROVER VIEW OFY

3041
01:49:36,000 --> 01:49:36,360
PRESENTATION.

3042
01:49:36,360 --> 01:49:38,480
I WILL TALK ABOUT THE BACKGROUND

3043
01:49:38,480 --> 01:49:41,800
ON THE ECI SIGNATURE PROGRAM AND

3044
01:49:41,800 --> 01:49:44,440
OBJECTIVES, AND OUR MOST RECENT

3045
01:49:44,440 --> 01:49:48,160
ACTIVITIES AND FUTURE PLANS.

3046
01:49:48,160 --> 01:49:51,840
THE ECI SIGNATURE PROGRAM WAS

3047
01:49:51,840 --> 01:49:55,320
CREATED TO PROVIDE RESOURCES AND

3048
01:49:55,320 --> 01:49:58,840
NETWORKING OPPORTUNITIES FOR HIV

3049
01:49:58,840 --> 01:50:04,320
JUNIOR INVESTIGATORS.

3050
01:50:04,320 --> 01:50:07,040
ALIGNED WITH THE NEXT RESEARCH

3051
01:50:07,040 --> 01:50:08,560
OBJECTIVE TO PROVIDE

3052
01:50:08,560 --> 01:50:11,120
OPPORTUNITIES FOR EARLY RESEARCH

3053
01:50:11,120 --> 01:50:12,480
INDEPENDENCE WHILE ENHANCING

3054
01:50:12,480 --> 01:50:16,560
WORKFORCE DIVERSITY.

3055
01:50:16,560 --> 01:50:20,040
O.A.R. HAS FORMED PARTNERSHIP

3056
01:50:20,040 --> 01:50:22,080
WITH MULTIPLE INSTITUTES,

3057
01:50:22,080 --> 01:50:24,200
CENTERS AND OFFICES ACROSS NIH

3058
01:50:24,200 --> 01:50:26,600
TO FACILITATE A NETWORKING

3059
01:50:26,600 --> 01:50:30,080
ENVIRONMENT FOR ESIs AND

3060
01:50:30,080 --> 01:50:31,320
ECIs AND PROVIDE OPPORTUNITIES

3061
01:50:31,320 --> 01:50:33,280
FOR WORKFORCE DEVELOPMENT AND

3062
01:50:33,280 --> 01:50:43,000
DIVERSIFICATION.

3063
01:50:43,000 --> 01:50:44,760
I DON'T THINK YOU ARE ADVANCING

3064
01:50:44,760 --> 01:50:49,440
THE RIGHT SLIDE.

3065
01:50:49,440 --> 01:50:59,560
BACK.

3066
01:51:02,680 --> 01:51:04,440
I THINK I'M AT THE OVERVIEW.

3067
01:51:04,440 --> 01:51:11,120
OVERVIEW.

3068
01:51:11,120 --> 01:51:12,360
THANK YOU.

3069
01:51:12,360 --> 01:51:14,160
HERE IS THE OVERVIEW OF MY

3070
01:51:14,160 --> 01:51:18,880
PRESENTATION.

3071
01:51:18,880 --> 01:51:25,360
NEXT SLIDE, PLEASE.

3072
01:51:25,360 --> 01:51:28,840
THE ECI SIGNATURE PROGRAM WAS

3073
01:51:28,840 --> 01:51:31,120
CREATED TO PROVIDE RESOURCES AND

3074
01:51:31,120 --> 01:51:33,440
OPPORTUNITIES FOR HIV JUNIOR

3075
01:51:33,440 --> 01:51:35,720
INVESTIGATORS.

3076
01:51:35,720 --> 01:51:36,920
THE GOAL OF THE PROGRAM WAS

3077
01:51:36,920 --> 01:51:40,320
ALIGNED WITH THE NEXT GENERATION

3078
01:51:40,320 --> 01:51:42,800
RESEARCH INITIATIVE AND AIMED TO

3079
01:51:42,800 --> 01:51:44,720
PROVIDE OPPORTUNITIES FOR EARLY

3080
01:51:44,720 --> 01:51:46,000
RESEARCH INDEPENDENCE WHILE

3081
01:51:46,000 --> 01:51:47,840
ENHANCING WORKFORCE DIVERSITY.

3082
01:51:47,840 --> 01:51:51,760
O.A.R. HAS FORMED PARTNERSHIPS

3083
01:51:51,760 --> 01:51:54,080
WITH MULTIPLE INSTITUTES,

3084
01:51:54,080 --> 01:51:55,360
CENTERS AND OFFICES ACROSS THE

3085
01:51:55,360 --> 01:52:04,440
NIH.

3086
01:52:04,440 --> 01:52:14,720
SLIDE 6, PLEASE.

3087
01:52:17,800 --> 01:52:19,920
>> RAHEL, YOU CAN PROCEED
WITH

3088
01:52:19,920 --> 01:52:21,640
THE STRATEGIC PLAN.

3089
01:52:21,640 --> 01:52:24,840
>> OKAY.

3090
01:52:24,840 --> 01:52:29,200
THE HIV WORKFORCE IS A HIGH

3091
01:52:29,200 --> 01:52:30,200
PRIORITY AREA THAT IS

3092
01:52:30,200 --> 01:52:31,400
HIGHLIGHTED IN OUR STRATEGIC

3093
01:52:31,400 --> 01:52:32,040
PLAN.

3094
01:52:32,040 --> 01:52:34,040
THE NATIONAL HIV/AIDS STRATEGY

3095
01:52:34,040 --> 01:52:38,840
OR KNOWN AS NHANS -- THE

3096
01:52:38,840 --> 01:52:42,440
IMPLEMENTATION PLAN.

3097
01:52:42,440 --> 01:52:44,080
THE NIH STRATEGIC PLAN FOR HIV

3098
01:52:44,080 --> 01:52:45,680
AND HIV RELATED RESEARCH HAS

3099
01:52:45,680 --> 01:52:51,360
FOUR MAIN STRATEGY GOALS.

3100
01:52:51,360 --> 01:52:54,880
THE STRATEGY GOAL IS TO BUILD

3101
01:52:54,880 --> 01:52:57,040
HUMAN RESOURCES AND -- TO

3102
01:52:57,040 --> 01:52:59,840
ENHANCE SUSTAINABILITY OF

3103
01:52:59,840 --> 01:53:01,000
DISCOVERY AND IMPLEMENTATION OF

3104
01:53:01,000 --> 01:53:04,160
FINDINGS BY DIVERSE AND

3105
01:53:04,160 --> 01:53:08,640
MULTIDISCIPLINARY WORKFORCE.

3106
01:53:08,640 --> 01:53:12,480
IN THE NATIONAL NIH AIDS

3107
01:53:12,480 --> 01:53:14,120
STRATEGY -- CALLS FOR TRAINING

3108
01:53:14,120 --> 01:53:16,160
AND EXPANSION OF A DIVERSE HIV

3109
01:53:16,160 --> 01:53:17,280
WORKFORCE BY FURTHER DEVELOPING

3110
01:53:17,280 --> 01:53:20,360
AND PROMOTING OPPORTUNITIES TO

3111
01:53:20,360 --> 01:53:21,520
SUPPORT THE NEXT GENERATION OF

3112
01:53:21,520 --> 01:53:22,720
HIV PROVIDERS, INCLUDING

3113
01:53:22,720 --> 01:53:31,160
RESEARCHERS.

3114
01:53:31,160 --> 01:53:33,840
THE OBJECTIVE OF THE ECI

3115
01:53:33,840 --> 01:53:35,960
SIGNATURE PROGRAM ARE TO EXPAND

3116
01:53:35,960 --> 01:53:38,680
AND SUPPORT NEW HIV

3117
01:53:38,680 --> 01:53:40,640
INVESTIGATORS, COLLABORATE WITH

3118
01:53:40,640 --> 01:53:41,840
INSTITUTES, CENTERS AND OFFICES

3119
01:53:41,840 --> 01:53:44,760
ACROSS NIH, PROMOTE NETWORKING

3120
01:53:44,760 --> 01:53:46,840
AND MENTORSHIP ENVIRONMENTS, AND

3121
01:53:46,840 --> 01:53:49,320
DEVELOP AND DIVERSIFY THE HIV

3122
01:53:49,320 --> 01:53:53,720
RESEARCH WORKFORCE.

3123
01:53:53,720 --> 01:53:58,560
NOW I'LL TALK ABOUT THE OAR, THE

3124
01:53:58,560 --> 01:54:08,160
CURRENT ACTIVITIES.

3125
01:54:08,160 --> 01:54:12,960
IN 2022, WE HELD AN ECI WORKSHOP

3126
01:54:12,960 --> 01:54:13,760
IN 2023.

3127
01:54:13,760 --> 01:54:16,120
THE PURPOSE OF THE WORKSHOP WAS

3128
01:54:16,120 --> 01:54:17,440
TO STIMULATE SCIENTIFIC

3129
01:54:17,440 --> 01:54:19,680
EXCHANGE, NETWORKING AND

3130
01:54:19,680 --> 01:54:20,640
COLLABORATION AMONG THE NEXT

3131
01:54:20,640 --> 01:54:23,680
GENERATION OF HIV INVESTIGATORS.

3132
01:54:23,680 --> 01:54:25,640
FACILITATE INTERACTIONS BETWEEN

3133
01:54:25,640 --> 01:54:26,520
FELLOW INVESTIGATORS, MENTORS

3134
01:54:26,520 --> 01:54:30,520
AND NIH PROGRAM STAFF.

3135
01:54:30,520 --> 01:54:31,440
INCREASE FAMILIARITY ABOUT THE

3136
01:54:31,440 --> 01:54:36,280
NIH REVIEW AND FUNDING PROCESS,

3137
01:54:36,280 --> 01:54:38,240
AND HIV RELATED RESEARCH

3138
01:54:38,240 --> 01:54:39,240
PROGRAMS AVAILABLE ACROSS THE

3139
01:54:39,240 --> 01:54:40,400
NIH AS WELL AS PROVIDE A

3140
01:54:40,400 --> 01:54:41,720
PLATFORM TO DISSEMINATE

3141
01:54:41,720 --> 01:54:44,160
INFORMATION ABOUT HIV-RELATED

3142
01:54:44,160 --> 01:54:52,960
ACTIVITIES AND OPPORTUNITIES.

3143
01:54:52,960 --> 01:54:55,280
SLIDE 13, PLEASE.

3144
01:54:55,280 --> 01:54:56,040
THANK YOU.

3145
01:54:56,040 --> 01:54:57,960
ON THIS SLIDE, WHAT YOU SEE IS

3146
01:54:57,960 --> 01:55:00,720
THE OUTCOME OF THE 2023

3147
01:55:00,720 --> 01:55:01,360
WORKSHOP.

3148
01:55:01,360 --> 01:55:04,760
WE HAD A TOTAL OF 548

3149
01:55:04,760 --> 01:55:06,080
REGISTRANTS.

3150
01:55:06,080 --> 01:55:07,600
43% REPORTED THAT THEY APPLIED

3151
01:55:07,600 --> 01:55:12,320
FOR FUNDING, AND 26% REPORTED

3152
01:55:12,320 --> 01:55:14,280
THEY HAD OBTAINED FUNDING.

3153
01:55:14,280 --> 01:55:19,600
AS YOU CAN SEE ON THE PIE CHART,

3154
01:55:19,600 --> 01:55:21,240
PARTICIPANTS REPRESENTED

3155
01:55:21,240 --> 01:55:22,040
NUMEROUS DISCIPLINES OF HIV

3156
01:55:22,040 --> 01:55:32,120
RESEARCH.

3157
01:55:32,120 --> 01:55:33,520
THIS YEAR, WE HAVE INCORPORATED

3158
01:55:33,520 --> 01:55:35,040
LOTS OF FEEDBACK FROM LAST

3159
01:55:35,040 --> 01:55:37,720
YEAR'S WORKSHOP.

3160
01:55:37,720 --> 01:55:41,880
WHICH RESULTED IN SOME UPDATES

3161
01:55:41,880 --> 01:55:44,720
IN THE STRUCTURE OF THE FY 2023

3162
01:55:44,720 --> 01:55:45,160
EVENT.

3163
01:55:45,160 --> 01:55:47,640
BOTH THE 2022 AND 2023 WORKSHOP

3164
01:55:47,640 --> 01:55:49,960
WERE VIRTUAL.

3165
01:55:49,960 --> 01:55:52,040
HOWEVER, IN THE 2022 WORKSHOP,

3166
01:55:52,040 --> 01:55:53,880
WE INCLUDED INTERNATIONAL

3167
01:55:53,880 --> 01:55:54,760
ATTENDEES, INCREASE OUR

3168
01:55:54,760 --> 01:55:57,400
PROMOTION PLAN, HELD A WORKSHOP

3169
01:55:57,400 --> 01:55:59,200
IN WEBINAR FORMAT, MAINLY DUE TO

3170
01:55:59,200 --> 01:56:02,920
THE LARGE NUMBER OF ATTENDEES,

3171
01:56:02,920 --> 01:56:07,800
THEREFORE, WE COULDN'T ASK FOR

3172
01:56:07,800 --> 01:56:08,600
BREAKOUT SESSION BUT WE ARE IN

3173
01:56:08,600 --> 01:56:09,920
THE PROCESS OF EVALUATING

3174
01:56:09,920 --> 01:56:11,880
FEEDBACK FROM THIS YEAR.

3175
01:56:11,880 --> 01:56:12,960
ANOTHER DIFFERENCE WITH THAT,

3176
01:56:12,960 --> 01:56:14,960
THIS TIME WE FOCUSED ON

3177
01:56:14,960 --> 01:56:16,600
MENTORSHIP, AND DRS. JOHNSON AND

3178
01:56:16,600 --> 01:56:19,400
RODRIGUEZ FROM UCSF AND G.W.

3179
01:56:19,400 --> 01:56:20,760
GAVE THEIR PRESENTATION ON

3180
01:56:20,760 --> 01:56:22,160
MENTORSHIP AND SHARED THEIR

3181
01:56:22,160 --> 01:56:23,920
EXPERIENCE AS MENTORS AND

3182
01:56:23,920 --> 01:56:24,800
MENTEES.

3183
01:56:24,800 --> 01:56:27,840
WE ALSO EXPANDED OUR RESOURCES

3184
01:56:27,840 --> 01:56:30,240
MORE IN YEAR THAN LAST YEAR.

3185
01:56:30,240 --> 01:56:33,320
AS NOTED EARLIER, WE HAD OVER

3186
01:56:33,320 --> 01:56:36,280
500 REJ STRENTS AND ABOUT

3187
01:56:36,280 --> 01:56:42,400
260 ATTENDEES.

3188
01:56:42,400 --> 01:56:46,640
O.A.R. CONTINUES TO PRIORITIZE

3189
01:56:46,640 --> 01:56:48,320
WORKFORCE SUPPORT, TO INCREASE

3190
01:56:48,320 --> 01:56:49,960
HIV EARLY CAREER INVESTIGATORS,

3191
01:56:49,960 --> 01:56:51,480
O.A.R. HAS CREATED A PILOT

3192
01:56:51,480 --> 01:56:52,640
PROGRAM, THE OBJECTIVE OF THE

3193
01:56:52,640 --> 01:56:56,480
PROGRAM IS TO ACHIEVE 5% OF THE

3194
01:56:56,480 --> 01:56:58,600
HIV PORTFOLIO, WHICH IS SIMILAR

3195
01:56:58,600 --> 01:57:01,960
TO OVERALL NIH.

3196
01:57:01,960 --> 01:57:03,240
THROUGH A RECENT INTERNAL DATA

3197
01:57:03,240 --> 01:57:05,760
POLL, WE SUPPORTED SIX EARLY

3198
01:57:05,760 --> 01:57:08,520
CAREER INVESTIGATORS APPLICATION

3199
01:57:08,520 --> 01:57:11,800
FROM FIVE ICs.

3200
01:57:11,800 --> 01:57:14,120
THEY INCLUDE THREE INTRAMURAL

3201
01:57:14,120 --> 01:57:18,480
AWARDS, ONE K23 AWARD, ONE

3202
01:57:18,480 --> 01:57:21,080
R21 AND 1 R01, INCLUDING

3203
01:57:21,080 --> 01:57:22,960
POSTDOCS, NEW INTRAMURAL

3204
01:57:22,960 --> 01:57:25,680
INVESTIGATORS AND ONE OFFICIAL

3205
01:57:25,680 --> 01:57:31,120
ECI.

3206
01:57:31,120 --> 01:57:32,440
ONE OF THE MOST IMPORTANT ITEMS

3207
01:57:32,440 --> 01:57:34,400
THAT WE HEARD ABOUT THROUGH THE

3208
01:57:34,400 --> 01:57:36,480
VARIOUS LISTENING SESSION WE

3209
01:57:36,480 --> 01:57:38,880
HELD WITH THAT, THERE IS A NEED

3210
01:57:38,880 --> 01:57:43,600
OF HAVING A CONSOLIDATED PLACE

3211
01:57:43,600 --> 01:57:45,320
WHERE ONE CAN FIND AVAILABLE

3212
01:57:45,320 --> 01:57:47,640
RESOURCES ABOUT HIV PROGRAMS.

3213
01:57:47,640 --> 01:57:50,800
BASED ON THE FEEDBACK, O.A.R.

3214
01:57:50,800 --> 01:57:51,680
CREATED EARLY CAREER

3215
01:57:51,680 --> 01:57:53,560
INVESTIGATOR RESOURCES WEBPAGE

3216
01:57:53,560 --> 01:57:56,600
WHERE WE PUT AS MUCH INFORMATION

3217
01:57:56,600 --> 01:58:00,800
AS POSSIBLE ABOUT HIV TOOLS SUCH

3218
01:58:00,800 --> 01:58:05,600
AS GRANT INFORMATION, TRAINING

3219
01:58:05,600 --> 01:58:06,360
OPPORTUNITIES, CAREER

3220
01:58:06,360 --> 01:58:10,280
DEVELOPMENT, CONFERENCES, PEER

3221
01:58:10,280 --> 01:58:11,480
REVIEW AND SUBMISSION DATES AND

3222
01:58:11,480 --> 01:58:12,040
MORE.

3223
01:58:12,040 --> 01:58:19,040
FOR MORE INFORMATION ON T, PLEAE

3224
01:58:19,040 --> 01:58:20,800
CONNECT TO THE URL THAT YOU SEE

3225
01:58:20,800 --> 01:58:22,200
ON THIS WEBPAGE.

3226
01:58:22,200 --> 01:58:24,960
IN CONCLUSION, WE WILL CONTINUE

3227
01:58:24,960 --> 01:58:29,240
ENGAGEMENT WITH ESIs AND ECI.

3228
01:58:29,240 --> 01:58:30,680
WE PLAN TO INCLUDE SUMMER COFFEE

3229
01:58:30,680 --> 01:58:32,680
HOURS WITH THE NIH STAFF AND

3230
01:58:32,680 --> 01:58:35,440
INVITE HIV ESI TO TALK ABOUT

3231
01:58:35,440 --> 01:58:36,400
THEIR SCIENCE.

3232
01:58:36,400 --> 01:58:39,040
WE WILL START PLANNING THE 2024

3233
01:58:39,040 --> 01:58:43,080
WORKSHOP AND CONTINUE MENTORING

3234
01:58:43,080 --> 01:58:51,160
CONTINUE MONITORINGPROGRAM OF E.

3235
01:58:51,160 --> 01:58:52,600
FINALLY I WOULD LIKE TO

3236
01:58:52,600 --> 01:58:53,920
GRATEFULLY ACKNOWLEDGE ALL THE

3237
01:58:53,920 --> 01:58:55,560
WORKING GROUPS AND THE WORKSHOP

3238
01:58:55,560 --> 01:58:56,760
PLANNING GROUP THAT CONTRIBUTE

3239
01:58:56,760 --> 01:59:00,360
TO THE O.A.R. HIV ECI PROGRAM.

3240
01:59:00,360 --> 01:59:02,960
WITH THAT, I WILL END MY

3241
01:59:02,960 --> 01:59:04,160
PRESENTATION AND THANK YOU AND

3242
01:59:04,160 --> 01:59:06,400
OVER TO YOU, DR. TURNBULL.

3243
01:59:06,400 --> 01:59:10,360
THANK YOU.

3244
01:59:10,360 --> 01:59:15,240
>> THANK YOU, MS. ABEBE
AND

3245
01:59:15,240 --> 01:59:16,080
DR. BANSAL, FOR YOUR

3246
01:59:16,080 --> 01:59:16,440
PRESENTATIONS.

3247
01:59:16,440 --> 01:59:17,520
WE WILL NOW HAVE OPEN

3248
01:59:17,520 --> 01:59:18,240
DISCUSSION.

3249
01:59:18,240 --> 01:59:20,640
ONCE AGAIN AT THIS TIME, THIS IS

3250
01:59:20,640 --> 01:59:24,560
THE TIME TO ASK QUESTIONS ABOUT

3251
01:59:24,560 --> 01:59:28,080
HIV AND AGING AND EARLY CAREER

3252
01:59:28,080 --> 01:59:28,720
INVESTIGATOR PRESENTATION.

3253
01:59:28,720 --> 01:59:32,560
ONCE AGAIN, DR. GLENSHAW AND I

3254
01:59:32,560 --> 01:59:34,400
WILL MODERATE THE DISCUSSION.

3255
01:59:34,400 --> 01:59:37,160
LET'S START WITH COMMENTS IN THE

3256
01:59:37,160 --> 01:59:38,920
ROOM FIRST THIS TIME.

3257
01:59:38,920 --> 01:59:42,680
MARY, OVER TO YOU.

3258
01:59:42,680 --> 01:59:44,760
>> THANK YOU.

3259
01:59:44,760 --> 01:59:45,080
DR. MONTANER.

3260
01:59:45,080 --> 01:59:46,000
>> THANK YOU FOR THAT

3261
01:59:46,000 --> 01:59:46,640
PRESENTATION.

3262
01:59:46,640 --> 01:59:47,840
AND CONGRATULATIONS ON THE

3263
01:59:47,840 --> 01:59:48,120
WEBSITE.

3264
01:59:48,120 --> 01:59:50,840
I THINK IT'S REALLY NICE.

3265
01:59:50,840 --> 01:59:52,080
ONE SUGGESTION FOR THE WEBSITE

3266
01:59:52,080 --> 01:59:55,760
IS, YOU KNOW, THERE IS A LOT OF

3267
01:59:55,760 --> 01:59:57,640
CORES THAT ARE BEING SUPPORTED

3268
01:59:57,640 --> 01:59:59,800
THROUGH CENTER FOR AIDS

3269
01:59:59,800 --> 02:00:03,160
RESEARCH, AND A LOT OF THE INPUT

3270
02:00:03,160 --> 02:00:04,800
THAT I OFTEN HAVE TO REMIND

3271
02:00:04,800 --> 02:00:07,960
YOUNG INVESTIGATORS IS THAT

3272
02:00:07,960 --> 02:00:11,200
THESE COURSES ARE OPEN TRANS

3273
02:00:11,200 --> 02:00:12,040
INSTITUTIONALLY, MEANING THAT

3274
02:00:12,040 --> 02:00:13,200
JUST BECAUSE YOU'RE NOT PART OF

3275
02:00:13,200 --> 02:00:16,160
THE CFAR DOES NOT MEAN YOU CAN'T

3276
02:00:16,160 --> 02:00:18,760
EXCESS THE CORE.

3277
02:00:18,760 --> 02:00:19,120
ACCESS THE CORE.

3278
02:00:19,120 --> 02:00:20,200
THERE ARE MULTIPLE CORES THAT

3279
02:00:20,200 --> 02:00:22,680
HAVE BEEN CREATED THROUGH THIS

3280
02:00:22,680 --> 02:00:23,640
NETWORK NATIONALLY, AND IT WOULD

3281
02:00:23,640 --> 02:00:25,680
BE GOOD TO LIST THEM SOMEWHERE

3282
02:00:25,680 --> 02:00:27,600
AS A RESOURCE FOR YOUNG

3283
02:00:27,600 --> 02:00:29,320
INVESTIGATORS TO KNOW WHO TO

3284
02:00:29,320 --> 02:00:30,960
CONTACT AND WHAT TYPE OF

3285
02:00:30,960 --> 02:00:32,480
EXPERTISE IS OUT THERE FOR THEM

3286
02:00:32,480 --> 02:00:33,080
TO ACCESS.

3287
02:00:33,080 --> 02:00:35,560
AND AGAIN, I HAVE TO REMIND THEM

3288
02:00:35,560 --> 02:00:37,520
THAT JUST BECAUSE YOU'RE NOT IN

3289
02:00:37,520 --> 02:00:38,600
THE IN CROWD DOESN'T MEAN THAT

3290
02:00:38,600 --> 02:00:41,960
YOU CAN'T ASK FOR SUPPORT.

3291
02:00:41,960 --> 02:00:44,160
A LOT OF THEM ASSUME IF YOU'RE

3292
02:00:44,160 --> 02:00:45,600
NOT A MEMBER OF THE GROUP, THOSE

3293
02:00:45,600 --> 02:00:47,000
RESOURCES ARE NOT AS READILY

3294
02:00:47,000 --> 02:00:47,400
AVAILABLE.

3295
02:00:47,400 --> 02:00:49,960
SO MAYBE THIS WEBSITE CAN BE A

3296
02:00:49,960 --> 02:00:53,680
PLATFORM TO ENCOURAGE THAT.

3297
02:00:53,680 --> 02:00:55,640
>> THANK YOU, DR.
MONTANER.

3298
02:00:55,640 --> 02:00:56,480
THAT'S A GOOD SUGGESTION.

3299
02:00:56,480 --> 02:00:57,920
ANY OTHER COMMENTS FROM THE

3300
02:00:57,920 --> 02:01:00,760
ROOM?

3301
02:01:00,760 --> 02:01:01,000
DR. AKE?

3302
02:01:01,000 --> 02:01:01,840
>> THANKS SO MUCH.

3303
02:01:01,840 --> 02:01:04,560
I HAVE MAYBE A COMMENT AND A

3304
02:01:04,560 --> 02:01:11,480
QUESTION FOR GEETA, TO COMMENT

3305
02:01:11,480 --> 02:01:13,080
ON THE INCREASING IMPORTANCE OF

3306
02:01:13,080 --> 02:01:14,840
HIV AND AGING IN THE LMIC

3307
02:01:14,840 --> 02:01:17,360
SETTING AND TO LARGE BILATERAL

3308
02:01:17,360 --> 02:01:18,120
PROGRAMS LIKE PEPFAR.

3309
02:01:18,120 --> 02:01:20,960
I WAS JUST INTERESTED IN, YOU

3310
02:01:20,960 --> 02:01:24,120
KNOW, HOW THAT HIV AND AGING

3311
02:01:24,120 --> 02:01:27,160
AGENDA IS INCORPORATING, YOU

3312
02:01:27,160 --> 02:01:31,440
KNOW, GLOBAL HIV CONSIDERATIONS.

3313
02:01:31,440 --> 02:01:33,200
>> SO THANK YOU FOR THAT.

3314
02:01:33,200 --> 02:01:34,520
THAT'S A GREAT POINT.

3315
02:01:34,520 --> 02:01:35,880
SO WE HAVE BEEN DISCUSSING IN

3316
02:01:35,880 --> 02:01:37,880
OUR WORKING GROUP AND THE

3317
02:01:37,880 --> 02:01:39,640
PLANNING GROUP FOR THE SEPTEMBER

3318
02:01:39,640 --> 02:01:42,320
MEETING HOW WE CAN ADDRESS THAT

3319
02:01:42,320 --> 02:01:43,680
AND AT LEAST FOR THE SEPTEMBER

3320
02:01:43,680 --> 02:01:46,720
MEETING, WE ARE PLANNING TO HAVE

3321
02:01:46,720 --> 02:01:49,880
PROBABLY AT LEAST ONE

3322
02:01:49,880 --> 02:01:50,960
INTERNATIONAL SPEAKER

3323
02:01:50,960 --> 02:01:53,040
HIGHLIGHTING THAT AS WELL.

3324
02:01:53,040 --> 02:01:54,400
SO -- AND THEN MOVING FORWARD,

3325
02:01:54,400 --> 02:01:56,200
WE'LL BE DISCUSSING MORE OF THAT

3326
02:01:56,200 --> 02:02:06,640
IN OUR WORKING GROUP AS WELL.

3327
02:02:06,640 --> 02:02:09,000
>> I JUST WANT TO COMMENT
FROM

3328
02:02:09,000 --> 02:02:10,320
THE PEDIATRIC STANDPOINT, YOU

3329
02:02:10,320 --> 02:02:16,440
KNOW, IT'S HARD TO ADVISE JUNIOR

3330
02:02:16,440 --> 02:02:17,720
TRAINEES AND JUNIOR

3331
02:02:17,720 --> 02:02:18,840
INVESTIGATORS TO GO INTO

3332
02:02:18,840 --> 02:02:19,520
PEDIATRIC HIV.

3333
02:02:19,520 --> 02:02:21,360
WE'RE FURTHER ALONG THE

3334
02:02:21,360 --> 02:02:22,240
ELIMINATION TIMELINE.

3335
02:02:22,240 --> 02:02:24,200
AND YET THE RESOURCES ARE THERE,

3336
02:02:24,200 --> 02:02:26,400
AND SO WHAT WE HAVE AT NICHD

3337
02:02:26,400 --> 02:02:29,440
REALLY TRIED TO DO IS LOOK FOR

3338
02:02:29,440 --> 02:02:32,200
WAYS TO LEVERAGE BEING ABLE TO

3339
02:02:32,200 --> 02:02:34,360
UTILIZE AIDS FUNDING TO BUILD A

3340
02:02:34,360 --> 02:02:36,080
CAREER, AND I LOOK AT INFANT

3341
02:02:36,080 --> 02:02:37,760
IMMUNITY AS ONE REALLY, REALLY

3342
02:02:37,760 --> 02:02:38,720
IMPORTANT FACTOR, AND WE HEARD

3343
02:02:38,720 --> 02:02:41,480
IN THE LAST SESSION JUST, YOU

3344
02:02:41,480 --> 02:02:43,280
KNOW, SORT OF VERY QUICKLY THAT

3345
02:02:43,280 --> 02:02:45,080
INFANTS WHO ARE EXPOSED TO HIV

3346
02:02:45,080 --> 02:02:47,480
BUT ARE UNINFECTED HAVE A HIGHER

3347
02:02:47,480 --> 02:02:48,560
MORTALITY RATE THAN THOSE THAT

3348
02:02:48,560 --> 02:02:49,440
ARE UNEXPOSED.

3349
02:02:49,440 --> 02:02:51,720
AND REALLY, YOU KNOW, TRYING TO

3350
02:02:51,720 --> 02:02:53,680
CONCENTRATE ON THAT POPULATION

3351
02:02:53,680 --> 02:02:58,840
AS A WAY TO ACCESS THE FUNDING

3352
02:02:58,840 --> 02:03:00,360
BUT ALSO REALLY TO BE LOOKING AT

3353
02:03:00,360 --> 02:03:02,080
AREAS BROADER THAN JUST HIV, AND

3354
02:03:02,080 --> 02:03:03,280
SO I THINK THAT'S ONE THING THAT

3355
02:03:03,280 --> 02:03:06,040
I REALLY WANT TO COMMEND O.A.R.

3356
02:03:06,040 --> 02:03:09,560
FOR SUPPORTING THE AGENDA AROUND

3357
02:03:09,560 --> 02:03:11,520
THOSE WITH HIV WHO ARE EXPOSED

3358
02:03:11,520 --> 02:03:12,160
AND UNINFECTED.

3359
02:03:12,160 --> 02:03:13,800
AND THEN I JUST WANT TO QUICKLY

3360
02:03:13,800 --> 02:03:16,400
HIGHLIGHT, WE'VE HEARD NOW TWICE

3361
02:03:16,400 --> 02:03:18,280
ABOUT THE LIFE EXPECTANCY FOR

3362
02:03:18,280 --> 02:03:20,920
ADULTS WITH HIV, AND LET ME JUST

3363
02:03:20,920 --> 02:03:23,880
HIGHLIGHT THAT ANNE NEILAN ALONG

3364
02:03:23,880 --> 02:03:26,960
WITH -- PATEL AT HARVARD SCHOOL

3365
02:03:26,960 --> 02:03:27,480
OF PUBLIC HEALTH ARE NOW

3366
02:03:27,480 --> 02:03:29,560
STARTING TO LOOK AT THAT FOR

3367
02:03:29,560 --> 02:03:30,640
PERINATALLY ACQUIRED INFECTION.

3368
02:03:30,640 --> 02:03:32,080
HAVING TAKEN CARE OF THOSE

3369
02:03:32,080 --> 02:03:34,480
PATIENTS, HOW POWERFUL IT WILL

3370
02:03:34,480 --> 02:03:36,360
BE, ONCE ANNE'S DATA ARE FULLY

3371
02:03:36,360 --> 02:03:38,080
VETTED, I DON'T KNOW IF --

3372
02:03:38,080 --> 02:03:39,240
THEY'RE STILL UNDER REVIEW, I

3373
02:03:39,240 --> 02:03:43,880
THINK, BUT TO BE ABLE TO LOOK AT

3374
02:03:43,880 --> 02:03:48,360
AN ADOLESCENT WITH PERINATALLY

3375
02:03:48,360 --> 02:03:49,480
ACQUIRED HIVE IN THE EYE AND SAY

3376
02:03:49,480 --> 02:03:52,120
WE EXPECT TO YOU LIVE A NORMAL

3377
02:03:52,120 --> 02:03:54,680
LIFESPAN IS REALLY, REALLY

3378
02:03:54,680 --> 02:03:55,560
POWERFUL, SO JUST THANK THEM FOR

3379
02:03:55,560 --> 02:03:56,680
PUTTING THAT DATA TOGETHER,

3380
02:03:56,680 --> 02:03:57,520
DOING THAT ANALYSIS.

3381
02:03:57,520 --> 02:03:59,200
I KNOW IT'S TAKEN A WHILE.

3382
02:03:59,200 --> 02:04:01,480
>> SO THANK YOU, ROHAN.

3383
02:04:01,480 --> 02:04:02,040
GREAT POINTS.

3384
02:04:02,040 --> 02:04:04,680
I'D LIKE TO ALSO ADDRESS YOUR

3385
02:04:04,680 --> 02:04:06,840
POINT, JULIE, ABOUT -- OR YOUR

3386
02:04:06,840 --> 02:04:09,920
QUESTION ABOUT SORT OF THE

3387
02:04:09,920 --> 02:04:10,880
MULTILATERAL RELATIONSHIPS THAT

3388
02:04:10,880 --> 02:04:12,640
WE MIGHT HAVE WITH OTHER

3389
02:04:12,640 --> 02:04:15,720
AGENCIES, FOR EXAMPLE, SCAC, WE

3390
02:04:15,720 --> 02:04:17,560
HAVE HAD A LONG-STANDING

3391
02:04:17,560 --> 02:04:18,440
RELATIONSHIP WITH FOLKS THERE IN

3392
02:04:18,440 --> 02:04:20,080
THE PEPFAR PROGRAM AND NIH HAVE

3393
02:04:20,080 --> 02:04:21,720
BEEN WORKING TOGETHER, AND I

3394
02:04:21,720 --> 02:04:25,680
THINK WE'LL CONTINUE TO HAVE

3395
02:04:25,680 --> 02:04:28,960
ACTIVITY THAT WE ARE LOOKING AT

3396
02:04:28,960 --> 02:04:30,320
GOING FORWARD, LOOKING, IN

3397
02:04:30,320 --> 02:04:31,320
ADDITION TO THOSE THAT WE'VE

3398
02:04:31,320 --> 02:04:35,080
BEEN PART OF, AND I THINK IT'S

3399
02:04:35,080 --> 02:04:35,400
VERY VALUABLE.

3400
02:04:35,400 --> 02:04:38,280
I MEAN, AGING AND, YOU KNOW,

3401
02:04:38,280 --> 02:04:39,360
NON-COMMUNICABLE DISEASES, OTHER

3402
02:04:39,360 --> 02:04:41,000
AREAS ARE VERY RIPE FOR THE

3403
02:04:41,000 --> 02:04:42,200
PICKING, I THINK, AND WE DO NEED

3404
02:04:42,200 --> 02:04:51,200
TO ENGAGE MORE.

3405
02:04:51,200 --> 02:04:56,000
>> D

3406
02:04:56,000 --> 02:05:05,600
>> MORE REFLECTION THAT
THE

3407
02:05:05,600 --> 02:05:06,760
CRITICAL EVENT SUMMIT MENTAL

3408
02:05:06,760 --> 02:05:09,320
FUNDING FOR CAREER DEVELOPMENT

3409
02:05:09,320 --> 02:05:14,040
IS REALLY POWERFUL MECHANISM,

3410
02:05:14,040 --> 02:05:14,880
WHERE THERE ARE OPPORTUNITIES TO

3411
02:05:14,880 --> 02:05:16,280
FLAG THAT, I THINK THAT COULD BE

3412
02:05:16,280 --> 02:05:16,640
REALLY VALUABLE.

3413
02:05:16,640 --> 02:05:18,840
THANK YOU.

3414
02:05:18,840 --> 02:05:22,840
>> THANK YOU.

3415
02:05:22,840 --> 02:05:26,800
THESE ARE GREAT SUGGESTIONS.

3416
02:05:26,800 --> 02:05:27,000
ROHAN.

3417
02:05:27,000 --> 02:05:28,520
>> I THINK THE OTHER ONE
WE WANT

3418
02:05:28,520 --> 02:05:31,200
TO REALLY WANT TO TRY TO

3419
02:05:31,200 --> 02:05:32,680
HIGHLIGHT IS THE LOAN REPAYMENT

3420
02:05:32,680 --> 02:05:33,960
PROGRAM AND REALLY WANT TO MAKE

3421
02:05:33,960 --> 02:05:34,640
SURE THAT THE INFORMATION IS

3422
02:05:34,640 --> 02:05:36,960
THERE.

3423
02:05:36,960 --> 02:05:38,640
>> I SEE AN UPGRADE TO OUR

3424
02:05:38,640 --> 02:05:39,600
WEBSITE IN OUR FUTURE.

3425
02:05:39,600 --> 02:05:43,200
THANK YOU.

3426
02:05:43,200 --> 02:05:45,320
DR. TURNBULL, OVER TO YOU.

3427
02:05:45,320 --> 02:05:46,040
>> YES.

3428
02:05:46,040 --> 02:05:47,920
ARE THERE ANY PARTICIPANTS, ANY

3429
02:05:47,920 --> 02:05:50,000
MEMBERS WHO WANT TO MAKE A

3430
02:05:50,000 --> 02:05:51,320
COMMENT, PLEASE DON'T FORGET

3431
02:05:51,320 --> 02:05:54,160
RAISE YOUR HAND OR USE THE HAND

3432
02:05:54,160 --> 02:05:55,040
FUNCTION IN THE ZOOM.

3433
02:05:55,040 --> 02:06:05,480
SO YOU CAN BE RECOGNIZED.

3434
02:06:05,920 --> 02:06:06,080
DR. OTT.

3435
02:06:06,080 --> 02:06:11,160
>> I HAVE A QUESTION FOR
DR

3436
02:06:11,160 --> 02:06:11,440
DR. ABEBE.

3437
02:06:11,440 --> 02:06:13,520
I HAVE A QUESTION ABOUT THE

3438
02:06:13,520 --> 02:06:18,640
METRICS OF SUCCESS FOR THE EARLY

3439
02:06:18,640 --> 02:06:19,600
INVESTIGATOR, THE SIGNATURE

3440
02:06:19,600 --> 02:06:20,880
PROGRAM AND SEE HOW SUCCESSFUL

3441
02:06:20,880 --> 02:06:22,640
WE ARE TO REALLY RECRUIT YOUNG

3442
02:06:22,640 --> 02:06:23,560
INVESTIGATORS INTO THE PROGRAM

3443
02:06:23,560 --> 02:06:25,200
AND SORT OF HOW THE DYNAMICS ARE

3444
02:06:25,200 --> 02:06:26,320
OVER THE YEARS, AND WHETHER WE

3445
02:06:26,320 --> 02:06:30,040
SEE A DECREASE IN INTEREST AND

3446
02:06:30,040 --> 02:06:31,720
ALSO HOW SUCCESSFUL WE ARE IN

3447
02:06:31,720 --> 02:06:33,080
GIVING THEM ACTUALLY THE SUPPORT

3448
02:06:33,080 --> 02:06:36,320
THAT THEY NEED AND IN TERMS OF

3449
02:06:36,320 --> 02:06:42,160
SUCCESS IN R01 RECRUITMENT OR 

3450
02:06:42,160 --> 02:06:42,640
R01 ACHIEVEMENTS HERE.

3451
02:06:42,640 --> 02:06:46,080
SO I WOULD BE INTERESTED TO HEAR

3452
02:06:46,080 --> 02:06:51,360
MORE ABOUT THESE METRICS.

3453
02:06:51,360 --> 02:06:54,000
>> UNFORTUNATELY I DON'T
HAVE

3454
02:06:54,000 --> 02:06:55,400
THE METRICS AVAILABLE WITH ME,

3455
02:06:55,400 --> 02:06:58,800
BUT IN TERMS OF PROVIDING

3456
02:06:58,800 --> 02:07:02,160
SUPPORT LIKE I SAID EARLIER, WE

3457
02:07:02,160 --> 02:07:05,480
HAVE SPECIAL PROGRAM THROUGH OUR

3458
02:07:05,480 --> 02:07:10,640
INNOVATION PROGRAM, WE CONTINUE

3459
02:07:10,640 --> 02:07:17,640
TO PROVIDE SUPPORT FOR BOTH  ASI

3460
02:07:17,640 --> 02:07:21,160
AND ECI, LIKE I SAID WE TRY TO

3461
02:07:21,160 --> 02:07:22,360
ACHIEVE 5% OF THE HIV PORTFOLIO,

3462
02:07:22,360 --> 02:07:25,560
WHICH IS SIMILAR TO THE NIH

3463
02:07:25,560 --> 02:07:28,160
OVERALL GOAL, AND ALSO THROUGH

3464
02:07:28,160 --> 02:07:30,120
OUR DATA MOST RECENTLY, WE ARE

3465
02:07:30,120 --> 02:07:32,080
PLANNING OR IN FACT WE HAVE

3466
02:07:32,080 --> 02:07:33,840
PROVIDER SUPPORT FOR EARLY

3467
02:07:33,840 --> 02:07:36,680
INVESTIGATORS APPLICATION.

3468
02:07:36,680 --> 02:07:37,040
APPLICANTS.

3469
02:07:37,040 --> 02:07:38,440
LIKE I SAID, I DON'T HAVE THE

3470
02:07:38,440 --> 02:07:39,440
METRIC WITH ME, BUT IT'S

3471
02:07:39,440 --> 02:07:42,480
SOMETHING THAT I CAN FIND AND

3472
02:07:42,480 --> 02:07:43,880
CAN GET BACK TO YOU.

3473
02:07:43,880 --> 02:07:53,920
>> THANK YOU.

3474
02:07:53,920 --> 02:08:03,600
>> ANYONE ELSE ON THE
ZOOM?

3475
02:08:03,600 --> 02:08:05,040
I DON'T SEE ANY OTHER HANDS

3476
02:08:05,040 --> 02:08:05,800
RAISED ON THE ZOOM.

3477
02:08:05,800 --> 02:08:09,120
ANYBODY ELSE IN THE ROOM, MARY?

3478
02:08:09,120 --> 02:08:12,480
>> NO THE, NOT AT THIS
TIME, DR.

3479
02:08:12,480 --> 02:08:20,040
 TURNBULL, I THINK WE CANMOVE OT

3480
02:08:20,040 --> 02:08:20,480
PRESENTATION.

3481
02:08:20,480 --> 02:08:21,440
GLL OKAY, GREAT.

3482
02:08:21,440 --> 02:08:23,240
WE WILL NOW SHIFT GEARS TO A

3483
02:08:23,240 --> 02:08:25,400
DATA PRESENTATION AND DEMO BY

3484
02:08:25,400 --> 02:08:28,800
ROBERT CREGG.

3485
02:08:28,800 --> 02:08:32,320
MR. ROBERT CREGG IS THE LEAD OF

3486
02:08:32,320 --> 02:08:37,000
THE O.A.R. ANALYTICS AND

3487
02:08:37,000 --> 02:08:39,120
EVALUATIONS TEAM AND SENIOR

3488
02:08:39,120 --> 02:08:40,320
ANALYTICS ADVISOR.

3489
02:08:40,320 --> 02:08:44,040
HE JOINED O.A.R. IN 2016 AND

3490
02:08:44,040 --> 02:08:49,120
BRINGS OVER 20 YEARS OF NIH

3491
02:08:49,120 --> 02:08:52,840
EXPERIENCE SPECIALIZING IN

3492
02:08:52,840 --> 02:08:54,600
INFORMATION SYSTEMS, DESIGN AND

3493
02:08:54,600 --> 02:08:56,480
IMPLEMENTATION, FOCUSING ON TEXT

3494
02:08:56,480 --> 02:08:57,760
ANALYTICS, DATA SCIENCE AND

3495
02:08:57,760 --> 02:08:58,760
PORTFOLIO EVALUATION.

3496
02:08:58,760 --> 02:08:59,120
OVER TO YOU.

3497
02:08:59,120 --> 02:09:01,160
>> AGAIN, MY NAME IS ROB
CREGG,

3498
02:09:01,160 --> 02:09:02,360
SENIOR ANALYTICS ADVISOR AND

3499
02:09:02,360 --> 02:09:04,360
LEAD OF THE ANALYTICS AND

3500
02:09:04,360 --> 02:09:06,680
EVALUATION TEAM HERE AT THE

3501
02:09:06,680 --> 02:09:07,040
O.A.R.

3502
02:09:07,040 --> 02:09:08,440
THE O.A.R. AN LE TICS AND

3503
02:09:08,440 --> 02:09:09,560
EVALUATION TEAM IS RESPONSIBLE

3504
02:09:09,560 --> 02:09:12,440
FOR ANALYZING THE HIV RESEARCH

3505
02:09:12,440 --> 02:09:13,520
PORTFOLIO TO GAIN A BETTER

3506
02:09:13,520 --> 02:09:14,640
UNDERSTANDING OF THE TRAJECTORY

3507
02:09:14,640 --> 02:09:17,040
OF FUNDING FOR VARIOUS FACETS OF

3508
02:09:17,040 --> 02:09:20,440
HIV RESEARCH.

3509
02:09:20,440 --> 02:09:23,400
THE HIV PORTFOLIO IS MADE UP OF

3510
02:09:23,400 --> 02:09:25,240
ABOUT 3800 GRANTS, INTRAMURAL

3511
02:09:25,240 --> 02:09:28,240
PROJECTS AND CONTRACTS WITH AN

3512
02:09:28,240 --> 02:09:36,160
ANNUAL BUDGET OF ROUGHLY 3 MO 3-

3513
02:09:36,160 --> 02:09:39,520
THROUGH A SERIES OF INTERACTIVE

3514
02:09:39,520 --> 02:09:40,840
DASHBOARDS, WE CALL THE NIH

3515
02:09:40,840 --> 02:09:45,320
O.A.R. DATA HUB.

3516
02:09:45,320 --> 02:09:46,960
SO THE OFFICE OF AIDS RESEARCH

3517
02:09:46,960 --> 02:09:52,240
IS LEGISLATIVELY MANDATED TO DI

3518
02:09:52,240 --> 02:09:53,240
DISSEMINATE INFORMATION ABOUT

3519
02:09:53,240 --> 02:09:54,480
THE NIH HIV/AIDS RESEARCH

3520
02:09:54,480 --> 02:09:54,880
PORTFOLIO.

3521
02:09:54,880 --> 02:09:57,080
THE GOAL IS TO MAKE DATA ABOUT

3522
02:09:57,080 --> 02:09:58,240
THE RESEARCH PORTFOLIO AVAILABLE

3523
02:09:58,240 --> 02:10:00,040
TO THE PUBLIC IN A WAY THAT IS

3524
02:10:00,040 --> 02:10:01,360
CLEAR, COMPREHENSIVE AND

3525
02:10:01,360 --> 02:10:01,920
COMPREHENSIBLE.

3526
02:10:01,920 --> 02:10:03,320
THE PURPOSE OF THIS PROJECT IS

3527
02:10:03,320 --> 02:10:05,880
TO PROVIDE A WAY TO EXPLORE THE

3528
02:10:05,880 --> 02:10:09,080
NIH HIV FUNDED RESEARCH DATA TO

3529
02:10:09,080 --> 02:10:09,560
INVESTIGATORS, ADVOCACY

3530
02:10:09,560 --> 02:10:10,280
COMMUNITY, AND THE GENERAL

3531
02:10:10,280 --> 02:10:11,800
PUBLIC IN A WAY THAT IS EASY TO

3532
02:10:11,800 --> 02:10:18,720
USE AND INFORMATIVE.

3533
02:10:18,720 --> 02:10:21,720
SINCE THE O.A.R. WAS ESTABLISHED

3534
02:10:21,720 --> 02:10:22,640
IN 1988, THE MISSION CONTINUES

3535
02:10:22,640 --> 02:10:24,320
TO BE TO CATALYZE, COORDINATE,

3536
02:10:24,320 --> 02:10:26,000
COMMUNICATE AND COLLABORATE.

3537
02:10:26,000 --> 02:10:28,200
THIS PROJECT'S FOCUS IS ON

3538
02:10:28,200 --> 02:10:28,520
COMMUNICATION.

3539
02:10:28,520 --> 02:10:30,840
WE AIM TO DISSEMINATE

3540
02:10:30,840 --> 02:10:32,800
INFORMATION TO A PUBLIC AUDIENCE

3541
02:10:32,800 --> 02:10:35,160
THAT IS ACCESSIBLE AND

3542
02:10:35,160 --> 02:10:35,480
SEARCHABLE.

3543
02:10:35,480 --> 02:10:36,880
BY LEVERAGING AND DISPLAYING

3544
02:10:36,880 --> 02:10:38,720
PUBLICLY AVAILABLE DATA IN A

3545
02:10:38,720 --> 02:10:40,160
COMBINATION WITH THE HIV

3546
02:10:40,160 --> 02:10:41,680
RESEARCH OVERARCHING PRIORITIES

3547
02:10:41,680 --> 02:10:47,720
AND OBJECTIVES.

3548
02:10:47,720 --> 02:10:49,680
SO THIS PROJECT SUPPORTS THE

3549
02:10:49,680 --> 02:10:53,280
BROADER NIH EFFORT TO CAN

3550
02:10:53,280 --> 02:10:53,800
DISSEMINATE INFORMATION.

3551
02:10:53,800 --> 02:10:55,400
NIH'S EFFORT TO PROMOTE

3552
02:10:55,400 --> 02:10:56,480
SCIENTIFIC TRANSPARENCY AND

3553
02:10:56,480 --> 02:10:58,040
PUBLIC ACCOUNTABILITY, AND ALSO

3554
02:10:58,040 --> 02:11:00,040
NIH'S COMMITMENT TO SUPPORT AND

3555
02:11:00,040 --> 02:11:02,080
EXPAND THE HIV/AIDS RESEARCH

3556
02:11:02,080 --> 02:11:03,320
WORKFORCE, INCLUDING EARLY

3557
02:11:03,320 --> 02:11:04,720
CAREER INVESTIGATORS THAT YOU'VE

3558
02:11:04,720 --> 02:11:07,120
HEARD ABOUT EARLIER, OF DIVERSE

3559
02:11:07,120 --> 02:11:13,120
BACKGROUNDS.

3560
02:11:13,120 --> 02:11:15,360
SO HOW IS THIS PROJECT UNIQUE?

3561
02:11:15,360 --> 02:11:17,560
IT FOCUSES ON THE HIV RESEARCH

3562
02:11:17,560 --> 02:11:19,640
PORTFOLIO SPECIFICALLY.

3563
02:11:19,640 --> 02:11:22,040
INCLUDES DATA THAT IS ON THE NIH

3564
02:11:22,040 --> 02:11:24,480
HIV RESEARCH PRIORITIES AND

3565
02:11:24,480 --> 02:11:27,240
OBJECTIVES, ADDING MORE DETAIL

3566
02:11:27,240 --> 02:11:28,640
AND LINKS TO PUBLICLY AVAILABLE

3567
02:11:28,640 --> 02:11:29,200
PROJECT DATA.

3568
02:11:29,200 --> 02:11:30,720
IT INCLUDES THE ABILITY TO

3569
02:11:30,720 --> 02:11:32,480
VISUALIZE THE HIV PORTFOLIO IN

3570
02:11:32,480 --> 02:11:34,040
THE CONTEXT OF OTHER TOPICAL

3571
02:11:34,040 --> 02:11:37,480
AREAS OF SCIENCE, INCLUDING

3572
02:11:37,480 --> 02:11:40,360
EXAMPLES AGING, COMORBIDITIES,

3573
02:11:40,360 --> 02:11:41,280
COINFECTIONS.

3574
02:11:41,280 --> 02:11:42,920
THE DASHBOARD VISUALIZATIONS ARE

3575
02:11:42,920 --> 02:11:44,520
INTERACTIVE AND ALLOWS THE USE

3576
02:11:44,520 --> 02:11:45,120
INVENTORY DRILL DOWN TO

3577
02:11:45,120 --> 02:11:51,920
INFORMATION OF INTEREST.

3578
02:11:51,920 --> 02:11:53,760
SO IF WE COULD JUMP TO THE LIVE

3579
02:11:53,760 --> 02:11:54,760
DEMO, THAT WOULD BE GREAT.

3580
02:11:54,760 --> 02:11:55,840
SO BEFORE WE JUMP INTO THE

3581
02:11:55,840 --> 02:11:57,280
ACTUAL DEMO, I WOULD LIKE TO

3582
02:11:57,280 --> 02:11:58,600
START OFF BY GIVING A FEW

3583
02:11:58,600 --> 02:12:00,160
STATISTICS YOU MIGHT NOT BE

3584
02:12:00,160 --> 02:12:01,040
AWARE.

3585
02:12:01,040 --> 02:12:03,520
THE NIH INVESTS ABOUT

3586
02:12:03,520 --> 02:12:05,000
$49 BILLION ANNUALLY IN

3587
02:12:05,000 --> 02:12:06,400
BIOMEDICAL HEALTH RESEARCH, MORE

3588
02:12:06,400 --> 02:12:09,680
THAN 80% OF NIH'S FUNDING IS

3589
02:12:09,680 --> 02:12:12,440
AWARDED FOR EXTRAMURAL RESEARCH,

3590
02:12:12,440 --> 02:12:16,280
LARGELY THROUGH ABOUT 50,000

3591
02:12:16,280 --> 02:12:18,200
COMPETITIVE GRANTS TO MORE THAN

3592
02:12:18,200 --> 02:12:20,360
300,000 RESEARCHERS AT 2500

3593
02:12:20,360 --> 02:12:21,400
UNIVERSITIES, MEDICAL SCHOOLS

3594
02:12:21,400 --> 02:12:22,760
AND OTHER RESEARCH INSTITUTIONS

3595
02:12:22,760 --> 02:12:26,920
IN EVERY STATE.

3596
02:12:26,920 --> 02:12:28,600
ABOUT 10% OF THE NIH'S BUDGET

3597
02:12:28,600 --> 02:12:30,000
SUPPORTS INTRAMURAL RESEARCH

3598
02:12:30,000 --> 02:12:32,000
PROJECTS CONDUCTED BY NEARLY

3599
02:12:32,000 --> 02:12:34,320
6,000 SCIENTISTS IN ITS OWN

3600
02:12:34,320 --> 02:12:35,200
LABORATORIES, MOST OF WHICH ARE

3601
02:12:35,200 --> 02:12:36,720
ON THE NIH CAMPUS.

3602
02:12:36,720 --> 02:12:39,800
AS PART OF THE NIH INVESTMENT,

3603
02:12:39,800 --> 02:12:42,840
THE HIV/AIDS BUDGET IS AROUND

3604
02:12:42,840 --> 02:12:44,680
$3.2 BILLION AND SUPPORT CLOSE

3605
02:12:44,680 --> 02:12:46,320
TO 3800 ACTIVE PROJECTS

3606
02:12:46,320 --> 02:12:48,320
ANNUALLY, WHICH INCLUDE

3607
02:12:48,320 --> 02:12:52,040
EXTRAMURAL GRANTS, EXTRAMURAL

3608
02:12:52,040 --> 02:12:53,560
PROJECTS AS WELL AS CONTRACTS.

3609
02:12:53,560 --> 02:12:54,960
NOW I'D LIKE TO TALK A LITTLE

3610
02:12:54,960 --> 02:12:57,160
BIT ABOUT THE TYPES OF DATA

3611
02:12:57,160 --> 02:12:59,480
THAT'S AVAILABLE FOR HIV

3612
02:12:59,480 --> 02:13:02,120
RESEARESEARCH PROJECTS.

3613
02:13:02,120 --> 02:13:03,320
FIRST EVERY HIV PROJECT IS

3614
02:13:03,320 --> 02:13:05,680
MANUALLY CODED BY THE INSTITUTES

3615
02:13:05,680 --> 02:13:07,400
TO ONE OF MORE THAN 44 OBJECTIVE

3616
02:13:07,400 --> 02:13:08,800
CODES.

3617
02:13:08,800 --> 02:13:10,760
THESE OBJECTIVE CODES PROVIDE A

3618
02:13:10,760 --> 02:13:12,680
FAIRLY GRANULAR BREAKDOWN OF THE

3619
02:13:12,680 --> 02:13:13,880
TYPE OF RESEARCH BEING

3620
02:13:13,880 --> 02:13:14,200
CONDUCTED.

3621
02:13:14,200 --> 02:13:15,920
FOR EXAMPLE, ONE OF THE

3622
02:13:15,920 --> 02:13:18,480
OBJECTIVE CODES IS BASIC

3623
02:13:18,480 --> 02:13:20,880
MECHANISMS OF MUCOSAL

3624
02:13:20,880 --> 02:13:21,200
TRANSMISSION.

3625
02:13:21,200 --> 02:13:22,400
A PROJECT WILL BE CODED TO ONE

3626
02:13:22,400 --> 02:13:23,800
OR MORE OF THESE OBJECTIVE

3627
02:13:23,800 --> 02:13:25,560
CODES.

3628
02:13:25,560 --> 02:13:26,880
FINALLY, THROUGH THE OBJECTIVE

3629
02:13:26,880 --> 02:13:28,160
CODES, EACH GRANT IS MAPPED TO

3630
02:13:28,160 --> 02:13:31,160
ONE OF THE FIVE RESEARCH

3631
02:13:31,160 --> 02:13:34,600
PRIORITIES, INCLUDING COST

3632
02:13:34,600 --> 02:13:36,320
CUTTING RESEARCH, WHICH INCLUDES

3633
02:13:36,320 --> 02:13:37,080
TRAINING, INFRASTRUCTURE AND

3634
02:13:37,080 --> 02:13:38,520
CAPACITY BUILDING, BEHAVIORAL

3635
02:13:38,520 --> 02:13:40,440
SOCIAL SCIENCE RESEARCH, AND

3636
02:13:40,440 --> 02:13:42,240
CROSS-CUTTING BASIC RESEARCH.

3637
02:13:42,240 --> 02:13:45,960
IT ALSO INCLUDES HIV-ASSOCIATED

3638
02:13:45,960 --> 02:13:47,280
COMORBIDITIES, COINFECTIONS AND

3639
02:13:47,280 --> 02:13:48,280
COMPLICATIONS.

3640
02:13:48,280 --> 02:13:51,480
REDUCING THE INCIDENCE OF HIV,

3641
02:13:51,480 --> 02:13:53,320
WHICH INCLUDES VACCINE STUDIES

3642
02:13:53,320 --> 02:13:54,720
AND PREVENTION.

3643
02:13:54,720 --> 02:13:58,440
NEXT GENERATION THERAPIES, WHICH

3644
02:13:58,440 --> 02:13:59,120
INCLUDES ANTIRETROVIRAL THERAPY,

3645
02:13:59,120 --> 02:14:03,160
AND RESEARCH TOWARDS A CURE.

3646
02:14:03,160 --> 02:14:04,960
THIS HIERARCHICAL CODING SCHEME

3647
02:14:04,960 --> 02:14:06,240
ALLOWS US TO LOOK AT THE NIH

3648
02:14:06,240 --> 02:14:08,880
PORTFOLIO IN A VARIETY OF WAYS

3649
02:14:08,880 --> 02:14:13,160
DEPENDING ON THE NEED.

3650
02:14:13,160 --> 02:14:13,840
SWITCH GEARS.

3651
02:14:13,840 --> 02:14:17,840
SO ON OUR O.A.R. WEBSITE, ACTIVE

3652
02:14:17,840 --> 02:14:19,720
AS OF LAST NIGHT, YOU WILL SEE

3653
02:14:19,720 --> 02:14:21,480
THIS NEW -- IT ACTUALLY UNDER

3654
02:14:21,480 --> 02:14:23,240
THIS TAB RIGHT HERE AT THE VERY

3655
02:14:23,240 --> 02:14:25,320
BOTTOM.

3656
02:14:25,320 --> 02:14:28,520
THE O.A.R. DATA HUB SHOWCASING

3657
02:14:28,520 --> 02:14:30,480
THE NIH HIV/AIDS RESEARCH

3658
02:14:30,480 --> 02:14:30,720
PORTFOLIO.

3659
02:14:30,720 --> 02:14:33,000
SO ON THE LANDING PAGE, YOU WILL

3660
02:14:33,000 --> 02:14:33,920
HAVE ACCESS TO ALL OF THE

3661
02:14:33,920 --> 02:14:35,360
CURRENT DASHBOARDS THAT WE HAVE,

3662
02:14:35,360 --> 02:14:36,960
AND THERE'S ALSO A HELP PAGE TO

3663
02:14:36,960 --> 02:14:39,280
GET YOU STARTED, SO IF I CLICK

3664
02:14:39,280 --> 02:14:41,440
HERE, IT WILL TAKE YOU TO A

3665
02:14:41,440 --> 02:14:44,120
NUMBER OF VIDEO TUTORIALS THAT

3666
02:14:44,120 --> 02:14:45,560
WILL GUIDE YOU THROUGH EACH OF

3667
02:14:45,560 --> 02:14:54,200
THE DASHBOARDS.

3668
02:14:54,200 --> 02:14:57,800
AS WELL AS DATA NOTES AND

3669
02:14:57,800 --> 02:14:58,440
INFORMATION INTERPRETATION, SO

3670
02:14:58,440 --> 02:14:59,720
THIS WILL GIVE YOU ALL OF THE

3671
02:14:59,720 --> 02:15:01,320
GLOSSARY OF HOW TO INTERPRET THE

3672
02:15:01,320 --> 02:15:03,160
DATA THAT IS FOUND ON THE

3673
02:15:03,160 --> 02:15:03,880
DASHBOARD.

3674
02:15:03,880 --> 02:15:05,680
ALL OF THESE LINKS IN THE

3675
02:15:05,680 --> 02:15:07,680
GLOSSARY TAKE YOU BACK TO THE

3676
02:15:07,680 --> 02:15:18,200
NIH GLOSSARY ON THE NIH WEBSITE.

3677
02:15:19,840 --> 02:15:21,640
IF YOU WANT TO GET TO THE DATA

3678
02:15:21,640 --> 02:15:23,480
HUB, JUST CLICK DATA HUB.

3679
02:15:23,480 --> 02:15:27,240
NOW WE'LL JUMP TO THE ACTUAL

3680
02:15:27,240 --> 02:15:28,760
FIVE ACTIVE DASHBOARDS THAT WE

3681
02:15:28,760 --> 02:15:28,960
HAVE.

3682
02:15:28,960 --> 02:15:30,520
SO WE HAVE NIH AWARDS BY

3683
02:15:30,520 --> 02:15:34,720
RESEARCH TOPIC, HIV AWARDS BY

3684
02:15:34,720 --> 02:15:37,240
NOFO AND NOSI, WHICH ARE NOTICE

3685
02:15:37,240 --> 02:15:38,040
OF FUNDING OPPORTUNITY OR NOTICE

3686
02:15:38,040 --> 02:15:39,360
OF SPECIAL INTEREST.

3687
02:15:39,360 --> 02:15:41,400
YOU CAN LOOK AT THE HIV AWARDS

3688
02:15:41,400 --> 02:15:46,600
BY ORGANIZATION OR INVESTIGATOR.

3689
02:15:46,600 --> 02:15:49,080
YOU CAN LOOK AT THE HIV AWARDS

3690
02:15:49,080 --> 02:15:50,960
BY THE ADMIN INSTITUTE CENTER OR

3691
02:15:50,960 --> 02:15:52,840
OFFICE, ICO, THE FUNDING ICO,

3692
02:15:52,840 --> 02:15:55,480
THE ACTIVITY CODE OR MECHANISM,

3693
02:15:55,480 --> 02:15:57,040
AND THEN FINAL DASHBOARD IS ALL

3694
02:15:57,040 --> 02:15:59,760
OF THE DATA ELEMENTS TOGETHER.

3695
02:15:59,760 --> 02:16:00,880
SO THIS IS PHASE ONE OF THIS

3696
02:16:00,880 --> 02:16:01,520
PROJECT.

3697
02:16:01,520 --> 02:16:03,160
WE ANTICIPATE THAT THERE WILL BE

3698
02:16:03,160 --> 02:16:05,640
MANY ADDITIONAL DASHBOARDS IN

3699
02:16:05,640 --> 02:16:06,360
THE NEAR FUTURE.

3700
02:16:06,360 --> 02:16:08,240
SO ONE OF THE POWERFUL THINGS

3701
02:16:08,240 --> 02:16:10,200
ABOUT THIS PLATFORM IS THAT WE

3702
02:16:10,200 --> 02:16:12,480
CAN GENERATE THESE DASHBOARDS

3703
02:16:12,480 --> 02:16:15,280
WITHIN A NUMBER OF DAYS BASED ON

3704
02:16:15,280 --> 02:16:16,720
PUBLICLY AVAILABLE DATA AND

3705
02:16:16,720 --> 02:16:20,520
PUBLISH THEM TO OUR WEBSITE.

3706
02:16:20,520 --> 02:16:21,840
SO I'LL START HERE WITH THE

3707
02:16:21,840 --> 02:16:27,120
FIRST ONE.

3708
02:16:27,120 --> 02:16:28,640
SO WHEN YOU FIRST COME INTO IT,

3709
02:16:28,640 --> 02:16:30,080
YOU SEE THE OVERALL LANDSCAPE OF

3710
02:16:30,080 --> 02:16:33,520
WHAT THE HIV PORTFOLIO LOOKS

3711
02:16:33,520 --> 02:16:34,400
LIKE.

3712
02:16:34,400 --> 02:16:36,840
SO WE HAVE DATA GOING BACK TO

3713
02:16:36,840 --> 02:16:37,440
2018.

3714
02:16:37,440 --> 02:16:40,440
THIS ONE IS FOCUSED JUST ON

3715
02:16:40,440 --> 02:16:42,160
2022, SO YOU CAN SEE ALL OF THAT

3716
02:16:42,160 --> 02:16:46,680
HERE ON THE FIRST ROW.

3717
02:16:46,680 --> 02:16:50,520
THERE'S 3799 AWARDS FOR A TOTAL

3718
02:16:50,520 --> 02:16:54,440
OF $3.193 BILLION.

3719
02:16:54,440 --> 02:16:57,640
IT IS BROKEN DOWN BY THE HIV

3720
02:16:57,640 --> 02:16:58,760
RESEARCH PRIORITIES THAT I

3721
02:16:58,760 --> 02:16:59,480
MENTIONED BEFORE.

3722
02:16:59,480 --> 02:17:01,160
AS YOU CAN SEE THE NUMBER OF

3723
02:17:01,160 --> 02:17:03,720
AWARDS FOR CROSS-CUTTING

3724
02:17:03,720 --> 02:17:08,000
RESEARCH IS ROUGHLY 2500,

3725
02:17:08,000 --> 02:17:08,840
CO-OCCURRING CONDITIONS AND SO

3726
02:17:08,840 --> 02:17:11,480
ON DOWN THE LIST.

3727
02:17:11,480 --> 02:17:13,120
LIKE I SAID, EVERY PROJECT CAN

3728
02:17:13,120 --> 02:17:14,240
HAVE MORE THAN ONE OBJECTIVE

3729
02:17:14,240 --> 02:17:15,440
CODE, WHICH MEANS THAT IT CAN BE

3730
02:17:15,440 --> 02:17:18,320
MAPPED TO MORE THAN ONE RESEARCH

3731
02:17:18,320 --> 02:17:18,640
PRIORITY.

3732
02:17:18,640 --> 02:17:20,320
SO THAT'S WHY THE NUMBERS ADD UP

3733
02:17:20,320 --> 02:17:25,640
TO MORE THAN THAT, IF YOU WERE

3734
02:17:25,640 --> 02:17:26,600
LOOKING ACROSS ALL OF THESE.

3735
02:17:26,600 --> 02:17:28,120
I ALSO MENTIONED RESEARCH

3736
02:17:28,120 --> 02:17:31,400
OBJECTIVE, OF WHICH THERE ARE

3737
02:17:31,400 --> 02:17:34,240
44, THIS SHOWS THE NUMBER OF

3738
02:17:34,240 --> 02:17:36,040
PROJECTS BY EACH OF THOSE

3739
02:17:36,040 --> 02:17:39,440
44 DIFFERENT OBJECTIVE CODES.

3740
02:17:39,440 --> 02:17:42,920
IF WE WERE TO PICK ONE, SO SAY

3741
02:17:42,920 --> 02:17:50,160
DISEASE PROGRESSION, THE

3742
02:17:50,160 --> 02:17:51,520
DASHBOARD WILL UPDATE, THE

3743
02:17:51,520 --> 02:17:52,560
NUMBERS WILL UPDATE AND YOU WILL

3744
02:17:52,560 --> 02:17:54,080
BE ABLE TO SEE HOW MUCH FUNDING

3745
02:17:54,080 --> 02:17:58,360
GOES TOWARDS THAT PARTICULAR

3746
02:17:58,360 --> 02:18:00,120
RESEARCH OBJECTIVE, OF WHICH

3747
02:18:00,120 --> 02:18:02,560
THAT MAPS TO, AS YOU CAN TELL BY

3748
02:18:02,560 --> 02:18:03,840
THE COLOR CODING, TO THE

3749
02:18:03,840 --> 02:18:06,160
CO-OCCURRING CONDITIONS.

3750
02:18:06,160 --> 02:18:08,600
SO 136 MILLION OR 343 AWARDS

3751
02:18:08,600 --> 02:18:10,160
WERE IN THIS PARTICULAR RESEARCH

3752
02:18:10,160 --> 02:18:10,560
OBJECTIVE.

3753
02:18:10,560 --> 02:18:13,440
TO BACK OUT OF THIS TO GET BACK

3754
02:18:13,440 --> 02:18:15,160
TO THE MAIN LIST, YOU JUST CLICK

3755
02:18:15,160 --> 02:18:18,360
IT AGAIN.

3756
02:18:18,360 --> 02:18:19,800
IF YOU HOVER OVER ANY OF THESE,

3757
02:18:19,800 --> 02:18:21,120
IT WILL GIVE YOU A TOOL TIP,

3758
02:18:21,120 --> 02:18:22,640
WHICH TALKS ABOUT WHAT'S THE

3759
02:18:22,640 --> 02:18:24,640
FULL NAME AND WHAT'S THE TOTAL

3760
02:18:24,640 --> 02:18:26,960
FUNDING AND NUMBER OF AWARDS FOR

3761
02:18:26,960 --> 02:18:32,760
EACH OF THESE OBJECTIVES.

3762
02:18:32,760 --> 02:18:33,960
SO THIS PARTICULAR DASHBOARD IS

3763
02:18:33,960 --> 02:18:36,080
DEALING WITH THE NIH SPENDING

3764
02:18:36,080 --> 02:18:36,880
CATEGORIES.

3765
02:18:36,880 --> 02:18:38,880
OF WHICH THERE ARE ROUGHLY 300

3766
02:18:38,880 --> 02:18:40,640
CATEGORIES THAT ARE ON THE NIH

3767
02:18:40,640 --> 02:18:42,360
REPORTER WEBSITE.

3768
02:18:42,360 --> 02:18:43,680
SO IF WE WANT TO LOOK AT THE

3769
02:18:43,680 --> 02:18:44,360
INTERSECTION BETWEEN ANY OF

3770
02:18:44,360 --> 02:18:45,800
THESE SPENDING CATEGORIES AND

3771
02:18:45,800 --> 02:18:48,000
HIV, WE HAVE THAT HERE ON THIS

3772
02:18:48,000 --> 02:18:49,320
DASHBOARD.

3773
02:18:49,320 --> 02:18:51,080
SO IF WE'RE INTERESTED IN

3774
02:18:51,080 --> 02:18:52,320
LOOKING AT BEHAVIORAL AND SOCIAL

3775
02:18:52,320 --> 02:18:56,680
SCIENCE, WE CAN SEE THAT OF THE

3776
02:18:56,680 --> 02:18:59,160
37 OR 3800 PROJECTS, 1300 OF

3777
02:18:59,160 --> 02:19:02,640
THEM ARE IN BSSR.

3778
02:19:02,640 --> 02:19:04,160
IF WE CLICK ON THAT, IT WILL

3779
02:19:04,160 --> 02:19:07,480
FOCUS IN ON BSSR AND GIVE YOU AN

3780
02:19:07,480 --> 02:19:08,600
UPDATED LIST OF THE ICs THAT

3781
02:19:08,600 --> 02:19:11,480
ARE DOING RESEARCH IN THAT AREA.

3782
02:19:11,480 --> 02:19:13,240
AND THEN IF YOU SCROLL DOWN, IT

3783
02:19:13,240 --> 02:19:14,840
WILL ACTUALLY GIVE YOU A LIST OF

3784
02:19:14,840 --> 02:19:16,120
ALL OF THE PROJECTS WITH THE

3785
02:19:16,120 --> 02:19:19,840
FUNDING AMOUNT.

3786
02:19:19,840 --> 02:19:21,280
ONE OTHER THING YOU CAN DO IS

3787
02:19:21,280 --> 02:19:29,120
CLICK ON AN INDIVIDUAL PROJECT.

3788
02:19:29,120 --> 02:19:31,840
THEN YOU CAN ALSO CLICK ON THIS

3789
02:19:31,840 --> 02:19:32,720
LINK WHICH WILL TAKE YOU TO THE

3790
02:19:32,720 --> 02:19:33,840
REPORTER WEBSITE WHICH WILL GIVE

3791
02:19:33,840 --> 02:19:36,920
YOU THE ABSTRACT AND THE PUBLIC

3792
02:19:36,920 --> 02:19:38,160
HEALTH RELEVANCE, WHAT OTHER

3793
02:19:38,160 --> 02:19:39,800
SPENDING CATEGORIES IT'S IN,

3794
02:19:39,800 --> 02:19:42,000
SOME OF THE PROJECT TERMS, AS

3795
02:19:42,000 --> 02:19:45,360
WELL AS OTHER RELEVANT

3796
02:19:45,360 --> 02:19:47,240
INFORMATION, INCLUDING

3797
02:19:47,240 --> 02:19:51,520
ORGANIZATION, P.I., THE FOAs,

3798
02:19:51,520 --> 02:19:58,440
THINGS LIKE THAT.

3799
02:19:58,440 --> 02:19:59,920
IF YOU WANT TO COMPLETELY GO

3800
02:19:59,920 --> 02:20:03,080
BACK TO THE BEGINNING STATE, YOU

3801
02:20:03,080 --> 02:20:06,040
CAN CLICK THE BUTTON TO RESET.

3802
02:20:06,040 --> 02:20:07,920
AND IT WILL TAKE YOU BACK TO THE

3803
02:20:07,920 --> 02:20:15,680
OVERALL DASHBOARD.

3804
02:20:15,680 --> 02:20:16,880
LET'S JUMP TO THE NEXT ONE.

3805
02:20:16,880 --> 02:20:23,400
SO THIS ONE IS BY NOFO OR NOSI.

3806
02:20:23,400 --> 02:20:24,640
SO IF YOU'RE INTERESTED IN A

3807
02:20:24,640 --> 02:20:27,480
SPECIFIC NOFO, FOR EXAMPLE, IF

3808
02:20:27,480 --> 02:20:37,880
WE CLICK HERE, AND WE TYPE IN

3809
02:20:37,880 --> 02:20:39,320
AGING, IT WILL DO A SEARCH OF

3810
02:20:39,320 --> 02:20:41,400
ALL THE NOFO TITLES, IT WILL

3811
02:20:41,400 --> 02:20:43,360
BRING BACK A LIST OF THE FUNDING

3812
02:20:43,360 --> 02:20:45,720
OPPORTUNITIES AND THE NOTICE --

3813
02:20:45,720 --> 02:20:47,800
AND THE NOSIs THAT HAVE AGING

3814
02:20:47,800 --> 02:20:51,280
IN THE TITLE.

3815
02:20:51,280 --> 02:20:52,680
YOU CAN HOVER OVER, IT WILL GIVE

3816
02:20:52,680 --> 02:20:53,920
YOU THE FULL TITLE NAME AND ALL

3817
02:20:53,920 --> 02:20:55,400
OF THE PROJECTS THAT WERE FUNDED

3818
02:20:55,400 --> 02:20:57,440
UNDER A SPECIFIC NOFO.

3819
02:20:57,440 --> 02:20:59,840
AND AGAIN, IF YOU CLICK ON THE

3820
02:20:59,840 --> 02:21:02,240
PROJECT TITLE, IT WILL GIVE YOU

3821
02:21:02,240 --> 02:21:04,680
A LINK BACK TO THE REPORTER TO

3822
02:21:04,680 --> 02:21:14,960
DO MORE INVESTIGATING.

3823
02:21:14,960 --> 02:21:16,280
THE NEXT ONE IS BY ORGANIZATION

3824
02:21:16,280 --> 02:21:17,160
OR INVESTIGATOR.

3825
02:21:17,160 --> 02:21:20,720
SO AS THE NAME IMPLIES, YOU HAVE

3826
02:21:20,720 --> 02:21:25,080
THE SAME OVERALL -- THIS PART UP

3827
02:21:25,080 --> 02:21:27,240
HERE DOESN'T CHANGE, THE

3828
02:21:27,240 --> 02:21:28,720
FUNDING, THE CROSS-CUTTING, BUT

3829
02:21:28,720 --> 02:21:30,520
WHAT DOES CHANGE IS THE

3830
02:21:30,520 --> 02:21:31,440
ORGANIZATION AND THE INDIVIDUAL

3831
02:21:31,440 --> 02:21:31,960
INVESTIGATOR.

3832
02:21:31,960 --> 02:21:33,600
SO IF WE'RE INTERESTED IN

3833
02:21:33,600 --> 02:21:39,520
LOOKING AT UNC, CHAPEL HILL, YOU

3834
02:21:39,520 --> 02:21:41,520
CAN CLICK ON THAT, GET A LIST OF

3835
02:21:41,520 --> 02:21:43,360
INVESTIGATORS.

3836
02:21:43,360 --> 02:21:45,920
WITH THE NUMBER OF AWARDS.

3837
02:21:45,920 --> 02:21:49,320
AND THEN ALSO A LIST OF AWARDS

3838
02:21:49,320 --> 02:21:50,680
FOR THAT PARTICULAR INSTITUTE OR

3839
02:21:50,680 --> 02:21:52,280
IF YOU DRILL DOWN TO THE

3840
02:21:52,280 --> 02:21:53,440
INDIVIDUAL P.I., YOU CAN GET

3841
02:21:53,440 --> 02:22:01,640
THAT AS WELL.

3842
02:22:01,640 --> 02:22:04,360
SO THESE FILTERS HERE ARE

3843
02:22:04,360 --> 02:22:05,240
CLICKABLE BUT YOU ALSO HAVE

3844
02:22:05,240 --> 02:22:07,480
ANOTHER SET OF FILTERS HERE

3845
02:22:07,480 --> 02:22:08,480
WHICH CORRESPOND TO THE LIST SO

3846
02:22:08,480 --> 02:22:10,440
IF YOU WANT TO DO A

3847
02:22:10,440 --> 02:22:12,440
MULTI-SELECT, YOU CAN SELECT A

3848
02:22:12,440 --> 02:22:14,080
NUMBER OF DIFFERENT INSTITUTIONS

3849
02:22:14,080 --> 02:22:16,080
OR A NUMBER OF DIFFERENT PIs,

3850
02:22:16,080 --> 02:22:17,640
AND IT WILL DO BASICALLY THE

3851
02:22:17,640 --> 02:22:27,680
SAME THING.

3852
02:22:27,680 --> 02:22:30,440
SO FINALLY, WE HAVE BY I.C.

3853
02:22:30,440 --> 02:22:33,400
AND BY ACTIVITY CODE.

3854
02:22:33,400 --> 02:22:35,400
SO IT WAS MENTIONED EARLIER

3855
02:22:35,400 --> 02:22:37,040
ABOUT R21s, SO IF YOU'RE

3856
02:22:37,040 --> 02:22:38,160
REALLY INTERESTED IN THE NUMBER

3857
02:22:38,160 --> 02:22:40,480
OF R21s THAT WERE AWARDED IN

3858
02:22:40,480 --> 02:22:50,960
2022, YOU COULD CLICK HERE.

3859
02:22:55,880 --> 02:22:57,800
IT WILL UPDATE, IT WILL TELL YOU

3860
02:22:57,800 --> 02:22:58,280
WHICH INSTITUTES ARE

3861
02:22:58,280 --> 02:23:02,640
ADMINISTERING AND FUNDING THEM.

3862
02:23:02,640 --> 02:23:04,160
IT WILL TELL YOU THE BUDGET

3863
02:23:04,160 --> 02:23:06,200
MECHANISM, WHICH IS EITHER A

3864
02:23:06,200 --> 02:23:06,760
GRANTS OR INTRAMURAL OR

3865
02:23:06,760 --> 02:23:07,040
CONTRACT.

3866
02:23:07,040 --> 02:23:09,680
IT WILL ALSO GIVE YOU A LINK OR

3867
02:23:09,680 --> 02:23:11,120
A LIST OF ALL OF THOSE AWARDS,

3868
02:23:11,120 --> 02:23:12,680
AND AGAIN, A LINK BACK TO

3869
02:23:12,680 --> 02:23:17,400
REPORTER IF YOU'RE INTERESTED IN

3870
02:23:17,400 --> 02:23:24,800
FINDING OUT MORE INFORMATION.

3871
02:23:24,800 --> 02:23:26,000
AND FINALLY, I WON'T GO THROUGH

3872
02:23:26,000 --> 02:23:27,200
THE LAST ONE.

3873
02:23:27,200 --> 02:23:28,760
THE LAST ONE HAS GOT ALL OF THE

3874
02:23:28,760 --> 02:23:29,960
METRICS THAT WE WERE JUST

3875
02:23:29,960 --> 02:23:33,600
LOOKING AT ALL IN ONE SINGLE

3876
02:23:33,600 --> 02:23:33,960
DASHBOARD.

3877
02:23:33,960 --> 02:23:35,640
SO IT ALLOWS TO YOU LOOK ACROSS

3878
02:23:35,640 --> 02:23:37,080
EVERYTHING THAT WE'VE LOOKED AT

3879
02:23:37,080 --> 02:23:39,200
PRIOR TO THAT ALL IN ONE

3880
02:23:39,200 --> 02:23:39,680
DASHBOARD.

3881
02:23:39,680 --> 02:23:41,840
IT'S A LITTLE COMPLICATED, AND

3882
02:23:41,840 --> 02:23:43,760
BUSY, SO IF YOU WANT TO JUST

3883
02:23:43,760 --> 02:23:45,040
FOCUS IN, IT'S PROBABLY BETTER

3884
02:23:45,040 --> 02:23:48,360
TO USE ONE OF THESE OTHER ONES

3885
02:23:48,360 --> 02:23:52,920
FIRST.

3886
02:23:52,920 --> 02:23:54,520
WITH THAT, IF WE COULD JUMP BACK

3887
02:23:54,520 --> 02:23:59,680
TO THE SLIDES, PLEASE.

3888
02:23:59,680 --> 02:24:03,160
SO I WOULD LIKE TO THANK THE

3889
02:24:03,160 --> 02:24:04,640
ENTIRE TEAM AT O.A.R. THAT ARE

3890
02:24:04,640 --> 02:24:06,080
LISTED HERE THAT PLAYED A

3891
02:24:06,080 --> 02:24:07,280
SIGNIFICANT ROLE IN BUILDING

3892
02:24:07,280 --> 02:24:09,200
THIS EXCITING NEW TOOL.

3893
02:24:09,200 --> 02:24:09,960
I'D ALSO LIKE TO THANK TWO

3894
02:24:09,960 --> 02:24:11,920
MEMBERS OF OUR EXECUTIVE

3895
02:24:11,920 --> 02:24:14,560
COMMITTEE, ROB PALMER AND

3896
02:24:14,560 --> 02:24:15,920
KENDALL BRYANT WHO OFFERED

3897
02:24:15,920 --> 02:24:17,120
SUGGESTIONS AND FEEDBACK ON THE

3898
02:24:17,120 --> 02:24:17,880
DATA HUB.

3899
02:24:17,880 --> 02:24:20,440
I'D ESPECIALLY LIKE TO THANK

3900
02:24:20,440 --> 02:24:21,800
DANNY MURPHY FOR LEADING THE

3901
02:24:21,800 --> 02:24:22,760
DEVELOPMENT OF THIS ENDEAVOR.

3902
02:24:22,760 --> 02:24:24,080
HE'S REALLY BEEN A FORCE FOR

3903
02:24:24,080 --> 02:24:24,840
CHANGE IN THIS.

3904
02:24:24,840 --> 02:24:27,240
SO I APPRECIATE ALL OF HIS HARD

3905
02:24:27,240 --> 02:24:37,360
WORK.

3906
02:24:38,400 --> 02:24:39,800
THIS QR CODE WILL TAKE YOU

3907
02:24:39,800 --> 02:24:41,000
DIRECTLY TO THE DATA HUB, AND

3908
02:24:41,000 --> 02:24:42,320
WITH THAT, I WILL PASS IT BACK

3909
02:24:42,320 --> 02:24:47,920
TO YOU, DR. TURNBULL, AND TAKE

3910
02:24:47,920 --> 02:24:49,080
ANY QUESTIONS THAT YOU MIGHT

3911
02:24:49,080 --> 02:24:49,280
HAVE.

3912
02:24:49,280 --> 02:24:51,360
>> THANK YOU, MR. CREGG,
FOR A

3913
02:24:51,360 --> 02:24:54,760
VERY INFORMATIVE PRESENTATION ON

3914
02:24:54,760 --> 02:24:56,520
THIS NEW TOOL THAT HIGHLIGHTS

3915
02:24:56,520 --> 02:25:00,000
THE NIH HIV/AIDS RESEARCH

3916
02:25:00,000 --> 02:25:03,520
PORTFOLIO.

3917
02:25:03,520 --> 02:25:04,520
WE WILL NOW HAVE OPEN DISCUSSION

3918
02:25:04,520 --> 02:25:08,040
ABOUT THIS NEW O.A.R. DATA HUB.

3919
02:25:08,040 --> 02:25:10,560
AGAIN, DR. GLENSHAW AND I WILL

3920
02:25:10,560 --> 02:25:12,440
CO-FACILITATE THE DISCUSSION.

3921
02:25:12,440 --> 02:25:16,600
THIS TIME, LET'S START WITH ANY

3922
02:25:16,600 --> 02:25:17,600
COMMENTS FROM THE MEMBERS ON THE

3923
02:25:17,600 --> 02:25:22,440
ZOOM.

3924
02:25:22,440 --> 02:25:22,720
DR. NAGHAVI.

3925
02:25:22,720 --> 02:25:24,160
>> THANK YOU VERY MUCH.

3926
02:25:24,160 --> 02:25:31,280
THAT WAS A GREAT PRESENTATION.

3927
02:25:31,280 --> 02:25:33,080
I'M JUST WONDERING, WOULD IT BE

3928
02:25:33,080 --> 02:25:36,920
HELPFUL TO ADD A DA DASHBOARD TO

3929
02:25:36,920 --> 02:25:38,520
EARLY CAREER INVESTIGATORS SO

3930
02:25:38,520 --> 02:25:41,320
THAT JUNIORS CAN QUICKLY FIGURE

3931
02:25:41,320 --> 02:25:43,680
OUT HOW A SUCCESSFUL APPLICATION

3932
02:25:43,680 --> 02:25:45,240
LOOKS LIKE AMONGST THEIR PEERS?

3933
02:25:45,240 --> 02:25:46,400
>> ABSOLUTELY.

3934
02:25:46,400 --> 02:25:47,560
THAT WAS AT THE VERY TOP OF OUR

3935
02:25:47,560 --> 02:25:49,320
LIST FOR THE NEXT ROUND OF

3936
02:25:49,320 --> 02:25:52,000
DASHBOARDS TO BE CREATED.

3937
02:25:52,000 --> 02:25:54,400
>> I'M SORRY, I MISSED
THAT.

3938
02:25:54,400 --> 02:25:56,360
>> THAT'S ON THE TOP OF
OUR LIST

3939
02:25:56,360 --> 02:25:57,560
FOR -- I DIDN'T MENTION THAT.

3940
02:25:57,560 --> 02:25:59,040
THIS IS THE FIRST TIME I

3941
02:25:59,040 --> 02:25:59,880
MENTIONED IT, BUT IT WILL BE ON

3942
02:25:59,880 --> 02:26:01,280
THE TOP OF OUR LIST.

3943
02:26:01,280 --> 02:26:06,560
>> GOOD.

3944
02:26:06,560 --> 02:26:11,200
>> DR. GALARRAGA.

3945
02:26:11,200 --> 02:26:11,960
>> GREAT TOOL.

3946
02:26:11,960 --> 02:26:13,160
THANKS FOR THE PRESENTATION.

3947
02:26:13,160 --> 02:26:16,800
I WAS JUST WONDERING, HOW DOES

3948
02:26:16,800 --> 02:26:19,920
THE DASHBOARD AT O.A.R. INTERACT

3949
02:26:19,920 --> 02:26:25,600
WITH THE NIH REPORTER?

3950
02:26:25,600 --> 02:26:27,320
>> SO REPORTER IS ALL THE

3951
02:26:27,320 --> 02:26:28,640
PUBLICLY AVAILABLE DATA ACROSS

3952
02:26:28,640 --> 02:26:29,640
THE ENTIRE NIH.

3953
02:26:29,640 --> 02:26:33,040
THIS IS SPECIFICALLY FOCUSED ON

3954
02:26:33,040 --> 02:26:33,720
HIV.

3955
02:26:33,720 --> 02:26:35,040
THE ONE THING THAT REPORTER DOES

3956
02:26:35,040 --> 02:26:37,320
NOT HAVE THAT THE DATA HUB DOES

3957
02:26:37,320 --> 02:26:39,200
HAVE ARE THE INDIVIDUAL

3958
02:26:39,200 --> 02:26:41,440
OBJECTIVE CODES AND THE LINKS TO

3959
02:26:41,440 --> 02:26:44,680
THE OVERARCHING PRIORITIES.

3960
02:26:44,680 --> 02:26:46,000
SO AS I SHOWED, THERE ARE LINKS

3961
02:26:46,000 --> 02:26:47,280
THAT GO BACK AND FORTH

3962
02:26:47,280 --> 02:26:49,400
BETWEEN -- OR ACTUALLY JUST ONE

3963
02:26:49,400 --> 02:26:51,200
WAY TO REPORTER FROM THE DATA

3964
02:26:51,200 --> 02:26:52,400
HUB, WHICH WILL ALLOW YOU TO

3965
02:26:52,400 --> 02:26:57,120
LOOK AT SPECIFIC PROJECT DATA.

3966
02:26:57,120 --> 02:27:00,520
DOES THAT ANSWER YOUR QUESTION?

3967
02:27:00,520 --> 02:27:02,720
>> I WAS JUST CURIOUS IF
WE RUN,

3968
02:27:02,720 --> 02:27:06,760
SAY, A REPORT ON THE NUMBERS FOR

3969
02:27:06,760 --> 02:27:09,240
HIV PROJECT IN NIH REPORTER,

3970
02:27:09,240 --> 02:27:10,880
WILL WE GET THE SAME AS THE

3971
02:27:10,880 --> 02:27:15,480
NUMBERS FOR THE DASHBOARD IN

3972
02:27:15,480 --> 02:27:16,560
O.A.R., MEANING DO THEY COME

3973
02:27:16,560 --> 02:27:17,360
FROM THE SAME DATASET AND

3974
02:27:17,360 --> 02:27:18,680
THEY'RE PULLING THE SAME DATA,

3975
02:27:18,680 --> 02:27:21,160
OR ARE THERE GOING TO BE

3976
02:27:21,160 --> 02:27:21,760
DISCREPANCIES?  THAT IS JUST

3977
02:27:21,760 --> 02:27:22,640
WHAT I WAS WONDERING.

3978
02:27:22,640 --> 02:27:24,320
>> THAT'S WHERE IT GETS A
LITTLE

3979
02:27:24,320 --> 02:27:24,800
COMPLICATED.

3980
02:27:24,800 --> 02:27:25,760
THERE WILL BE DIFFERENCES

3981
02:27:25,760 --> 02:27:26,880
BECAUSE REPORTER IS BASED ON

3982
02:27:26,880 --> 02:27:28,080
WHAT'S CALLED CURRENT DATA, SO

3983
02:27:28,080 --> 02:27:29,640
ANYTHING THAT HAPPENS AFTER THE

3984
02:27:29,640 --> 02:27:32,160
END OF A FISCAL YEAR WOULD BE

3985
02:27:32,160 --> 02:27:33,360
REFLECTED IN REPORTER, BUT IT'S

3986
02:27:33,360 --> 02:27:34,840
NOT GOING TO BE REFLECTED IN OUR

3987
02:27:34,840 --> 02:27:37,040
DATA HUB BECAUSE THAT IS A

3988
02:27:37,040 --> 02:27:38,360
FROZEN DATASET FOR THAT

3989
02:27:38,360 --> 02:27:40,760
PARTICULAR FISCAL YEAR.

3990
02:27:40,760 --> 02:27:42,920
SO THAT'S WHAT'S REPORTED ON A

3991
02:27:42,920 --> 02:27:44,120
DIFFERENT WEBSITE WHICH ADDS UP

3992
02:27:44,120 --> 02:27:45,760
TO THE EXACT AMOUNT OF MONEY

3993
02:27:45,760 --> 02:27:48,120
THAT WAS ALLOCATED FOR HIV.

3994
02:27:48,120 --> 02:27:48,920
SO THAT'S A GOOD QUESTION,

3995
02:27:48,920 --> 02:27:49,320
THOUGH.

3996
02:27:49,320 --> 02:27:51,520
THEY'RE NOT GOING TO BE 100% THE

3997
02:27:51,520 --> 02:27:52,080
SAME.

3998
02:27:52,080 --> 02:27:55,400
THEY'LL BE 99% THE SAME, THOUGH.

3999
02:27:55,400 --> 02:27:57,760
>> MAYBE A FOOTNOTE, SMALL
PRINT

4000
02:27:57,760 --> 02:27:59,000
SOMEWHERE FOR THE RESEARCHERS.

4001
02:27:59,000 --> 02:28:00,160
I KNOW THAT THERE ARE COLLEAGUES

4002
02:28:00,160 --> 02:28:01,920
THAT, YOU KNOW, DO RESEARCH

4003
02:28:01,920 --> 02:28:04,000
BASED ON WHAT COMES OUT OF THE

4004
02:28:04,000 --> 02:28:06,680
REPORTER AND IF THE SAME IS NOT

4005
02:28:06,680 --> 02:28:07,520
FROM THE DASHBOARD, THEY'RE

4006
02:28:07,520 --> 02:28:10,920
GOING TO BE SURPRISED, SO MAYBE

4007
02:28:10,920 --> 02:28:12,800
A SMALL FOOTNOTE SOMEWHERE TO

4008
02:28:12,800 --> 02:28:14,280
THIS POINT MAY BE USEFUL FOR

4009
02:28:14,280 --> 02:28:14,720
SOME PEOPLE.

4010
02:28:14,720 --> 02:28:16,200
>> YES, THERE IS ONE
ACTUALLY,

4011
02:28:16,200 --> 02:28:16,880
BUT THANK YOU.

4012
02:28:16,880 --> 02:28:18,560
>> GREAT.

4013
02:28:18,560 --> 02:28:25,080
EXCELLENT.

4014
02:28:25,080 --> 02:28:26,560
>> MARY, ANY COMMENTS IN
THE

4015
02:28:26,560 --> 02:28:26,760
ROOM?

4016
02:28:26,760 --> 02:28:28,240
>> YES, DR. MONTANER.

4017
02:28:28,240 --> 02:28:29,920
>> SO CONGRATULATIONS,
THAT'S A

4018
02:28:29,920 --> 02:28:30,560
GREAT TOOL.

4019
02:28:30,560 --> 02:28:33,240
SO JUST TO CLARIFY, SO YOU'RE A

4020
02:28:33,240 --> 02:28:33,600
YEAR BEHIND?

4021
02:28:33,600 --> 02:28:36,600
ARE YOU SAYING THE FISCAL YEAR

4022
02:28:36,600 --> 02:28:38,680
STARTS TO PUT REPORTER ON

4023
02:28:38,680 --> 02:28:40,560
REALTIME, SO SAY AUGUST, YOU

4024
02:28:40,560 --> 02:28:41,560
DON'T UPLOAD UNTIL THE END OF

4025
02:28:41,560 --> 02:28:42,440
THE FISCAL YEAR?

4026
02:28:42,440 --> 02:28:45,200
>> SO REPORTER IS ALSO --

4027
02:28:45,200 --> 02:28:46,320
DOESN'T REPORT THE CURRENT

4028
02:28:46,320 --> 02:28:46,880
FISCAL YEAR.

4029
02:28:46,880 --> 02:28:49,920
IT'S NOT UNTIL THE FISCAL YEAR

4030
02:28:49,920 --> 02:28:50,480
CLOSES.

4031
02:28:50,480 --> 02:28:54,440
SO THERE WON'T BE '23 DATA UNTIL

4032
02:28:54,440 --> 02:28:55,200
'23 FISCAL YEAR CLOSES IN

4033
02:28:55,200 --> 02:28:55,760
OCTOBER.

4034
02:28:55,760 --> 02:28:57,320
THERE WILL BE CURRENT DATA BUT

4035
02:28:57,320 --> 02:28:59,680
IT WON'T BE, YOU KNOW, ASSIGNED

4036
02:28:59,680 --> 02:29:01,520
TO A SPECIFIC SPENDING CATEGORY.

4037
02:29:01,520 --> 02:29:03,040
SO YOU'LL SEE A GRANT IN

4038
02:29:03,040 --> 02:29:04,360
REPORTER BUT IT WON'T HAVE ANY

4039
02:29:04,360 --> 02:29:06,800
OF THOSE 300 SPENDING CATEGORIES

4040
02:29:06,800 --> 02:29:08,880
OR INCLUDING HIV.

4041
02:29:08,880 --> 02:29:10,760
>> SO MY ONLY SUGGESTION
MIGHT

4042
02:29:10,760 --> 02:29:12,040
BE, AS I SAY, YOU PROBABLY HAVE

4043
02:29:12,040 --> 02:29:16,240
A HUGE LIST OF WANTS.

4044
02:29:16,240 --> 02:29:18,040
BUT CRITERIA SUCH AS P.I.

4045
02:29:18,040 --> 02:29:20,680
SPECIFIC LIKE SEX, MINORITY,

4046
02:29:20,680 --> 02:29:24,280
YOUNG INVESTIGATOR OR PRIOR R01,

4047
02:29:24,280 --> 02:29:26,480
EARLY INVESTIGATOR VERSUS NOT,

4048
02:29:26,480 --> 02:29:27,120
AND ALSO INSTITUTIONAL

4049
02:29:27,120 --> 02:29:28,440
INFORMATION BECAUSE THE NUMBER,

4050
02:29:28,440 --> 02:29:30,440
YOU KNOW, WE KIND OF

4051
02:29:30,440 --> 02:29:31,440
CHARACTERIZE INSTITUTION AS

4052
02:29:31,440 --> 02:29:33,880
MINORITY RELATED OR PRIMARILY

4053
02:29:33,880 --> 02:29:36,600
UNDERGRADUATE WHEN IT COMES TO

4054
02:29:36,600 --> 02:29:38,360
SOME INSTRUMENTS LIKE R15 AND SO

4055
02:29:38,360 --> 02:29:39,280
FORTH, AND ALSO CLUSTERS OF

4056
02:29:39,280 --> 02:29:41,120
SPECIFIC AMOUNTS OF R01s

4057
02:29:41,120 --> 02:29:42,880
BECAUSE WE TEND TO TARGET SORT

4058
02:29:42,880 --> 02:29:44,800
OF INSTITUTIONS THAT HAVE LESS,

4059
02:29:44,800 --> 02:29:46,880
AND HAVING SOME CLARITY AS TO

4060
02:29:46,880 --> 02:29:48,440
WHAT IS THE LANDSCAPE WITH

4061
02:29:48,440 --> 02:29:50,280
RESPECT TO FUNDING WITH THESE

4062
02:29:50,280 --> 02:29:51,800
POCKETS WOULD BE USEFUL BECAUSE

4063
02:29:51,800 --> 02:29:54,480
THEN WE CAN ADVOCATE FOR OKAY,

4064
02:29:54,480 --> 02:29:56,560
LOOK AT THIS SUBSET THAT IS

4065
02:29:56,560 --> 02:29:57,080
UNDERREPRESENTED IN THE

4066
02:29:57,080 --> 02:29:58,920
PORTFOLIO OR SOME OTHER, YOU

4067
02:29:58,920 --> 02:30:01,360
KNOW, ACCOUNTABILITY MEASURE.

4068
02:30:01,360 --> 02:30:02,600
>> THAT'S A GREAT
SUGGESTION.

4069
02:30:02,600 --> 02:30:06,360
THANK YOU.

4070
02:30:06,360 --> 02:30:08,600
>> DR. SLEASMAN.

4071
02:30:08,600 --> 02:30:10,760
>> FANTASTIC TOOL.

4072
02:30:10,760 --> 02:30:12,000
I'M ASSUMING THAT YOU'LL BE ABLE

4073
02:30:12,000 --> 02:30:13,600
TO LOOK AT THIS AS A TOOL TO

4074
02:30:13,600 --> 02:30:17,200
LOOK AT THE PRIORITIES AND

4075
02:30:17,200 --> 02:30:20,600
ULTIMATELY EQUATE IT BACK TO THE

4076
02:30:20,600 --> 02:30:23,440
BUDGETARY P.J. AND C.J. BUDGETS

4077
02:30:23,440 --> 02:30:24,800
GOING FORWARD, SO PROVIDE, YOU

4078
02:30:24,800 --> 02:30:27,720
KNOW, BASICALLY DOCUMENTATION

4079
02:30:27,720 --> 02:30:30,280
THAT THE PRIORITY ARE BEING

4080
02:30:30,280 --> 02:30:30,520
FOLLOWED.

4081
02:30:30,520 --> 02:30:32,080
>> CORRECT, YES.

4082
02:30:32,080 --> 02:30:33,640
>> JOHN, THAT'S RIGHT ON
TARGET.

4083
02:30:33,640 --> 02:30:35,240
I MEAN, ONE OF THE INTENTS HERE

4084
02:30:35,240 --> 02:30:37,600
IS TO BE ABLE TO NOT HAVE SUCH

4085
02:30:37,600 --> 02:30:38,880
BLUNT INSTRUMENTS TO HAVE

4086
02:30:38,880 --> 02:30:41,320
SOMETHING THAT THEN CAN INFORM

4087
02:30:41,320 --> 02:30:42,400
MORE OBJECTIVELY WHAT WE'RE

4088
02:30:42,400 --> 02:30:44,320
DOING AND HOW WE'RE GOING

4089
02:30:44,320 --> 02:30:52,440
FORWARD.

4090
02:30:52,440 --> 02:30:54,520
>> I'D ALSO JUST LIKE TO
MAKE

4091
02:30:54,520 --> 02:30:56,360
THE POINT THAT I'M NOT CERTAIN

4092
02:30:56,360 --> 02:30:59,240
HOW CLEAR IT IS TO THE FOLKS

4093
02:30:59,240 --> 02:31:00,360
OUTSIDE OF OUR OFFICE THAT, YOU

4094
02:31:00,360 --> 02:31:02,280
KNOW, WE DO HAVE THESE FIVE

4095
02:31:02,280 --> 02:31:03,400
OVERARCHING RESEARCH PRIORITIES,

4096
02:31:03,400 --> 02:31:07,200
BUT WE HAVE THE 44 OBJECTIVES

4097
02:31:07,200 --> 02:31:09,360
THAT ARE MUCH MORE GRANULAR IN

4098
02:31:09,360 --> 02:31:11,440
NATURE, AND SO SORT OF A

4099
02:31:11,440 --> 02:31:13,480
DIFFERENT WAY OF CATEGORIZING

4100
02:31:13,480 --> 02:31:15,000
THE DATA THAT IS NOW AVAILABLE

4101
02:31:15,000 --> 02:31:16,640
TO ANYONE.

4102
02:31:16,640 --> 02:31:19,760
IT'S A VERY, VERY USEFUL LEVEL

4103
02:31:19,760 --> 02:31:21,440
OF ANALYSIS INSTEAD OF JUST THE

4104
02:31:21,440 --> 02:31:24,000
FIVE BI BIG BUCKETS.

4105
02:31:24,000 --> 02:31:29,720
ANY MORE COMMENTS FROM THE ROOM?

4106
02:31:29,720 --> 02:31:33,600
>>  -- 44 WERE DEFINED?

4107
02:31:33,600 --> 02:31:36,560
HOW DID YOU DEFINE WHO THOSE

4108
02:31:36,560 --> 02:31:36,800
44 ARE?

4109
02:31:36,800 --> 02:31:38,560
>> THAT GOES WAY BACK.

4110
02:31:38,560 --> 02:31:44,040
IT'S BEEN CODED THAT WAY FOR AT

4111
02:31:44,040 --> 02:31:44,440
2008.

4112
02:31:44,440 --> 02:31:45,520
SO I DON'T KNOW WHO ACTUALLY

4113
02:31:45,520 --> 02:31:47,360
CAME UP WITH THEM, BUT THEY HAVE

4114
02:31:47,360 --> 02:31:48,720
BEEN AROUND FOR QUITE A WHILE.

4115
02:31:48,720 --> 02:31:52,160
AND THEY DO MAP WHAT USED TO BE

4116
02:31:52,160 --> 02:31:53,640
CALLED THE AREAS OF EMPHASIS,

4117
02:31:53,640 --> 02:31:54,640
THERE WERE NINE OF THOSE.

4118
02:31:54,640 --> 02:31:56,960
WE'VE GOTTEN RID OF THE AREAS OF

4119
02:31:56,960 --> 02:31:58,680
EMPHASIS AND WE'VE GONE DIRECTLY

4120
02:31:58,680 --> 02:31:59,560
FROM THE OBJECTIVE CODE STRAIGHT

4121
02:31:59,560 --> 02:32:00,360
TO THE PRIORITY.

4122
02:32:00,360 --> 02:32:03,000
BUT I CAN'T GIVE YOU A MORE

4123
02:32:03,000 --> 02:32:04,360
DEFINITIVE HISTORY ON THE

4124
02:32:04,360 --> 02:32:04,840
OBJECTIVE CODES.

4125
02:32:04,840 --> 02:32:06,440
>> THE ONLY THING I CAN
ADD TO

4126
02:32:06,440 --> 02:32:09,960
THAT IS SORT OF HISTORICAL PR

4127
02:32:09,960 --> 02:32:10,880
PERIPHERAL KNOWLEDGE, THERE WERE

4128
02:32:10,880 --> 02:32:11,720
WORKING GROUPS THAT MET EVERY

4129
02:32:11,720 --> 02:32:14,360
YEAR THAT INCLUDED ACADEMIC,

4130
02:32:14,360 --> 02:32:16,000
INCLUDED EXTRAMURAL CLINICIANS

4131
02:32:16,000 --> 02:32:17,200
AND NIH FOLKS AND THEN THEY CAME

4132
02:32:17,200 --> 02:32:18,280
UP WITH A LOT OF THESE

4133
02:32:18,280 --> 02:32:22,840
CATEGORIES THAT WE REFINED

4134
02:32:22,840 --> 02:32:25,200
ANNUALLY, SO I THINK MORE THAN

4135
02:32:25,200 --> 02:32:26,160
THAT, WE'LL HAVE TO GO INTO THE

4136
02:32:26,160 --> 02:32:26,360
BOOKS.

4137
02:32:26,360 --> 02:32:27,800
>> THEY'RE POSTED ON THE

4138
02:32:27,800 --> 02:32:28,760
WEBSITE, THE 44?

4139
02:32:28,760 --> 02:32:29,200
>> YES.

4140
02:32:29,200 --> 02:32:29,720
>> GREAT.

4141
02:32:29,720 --> 02:32:34,680
THANK YOU.

4142
02:32:34,680 --> 02:32:36,640
>> I THINK THAT'S IT FROM
THE

4143
02:32:36,640 --> 02:32:37,480
ROOM, DR. TURNBULL.

4144
02:32:37,480 --> 02:32:38,080
>> THANK YOU.

4145
02:32:38,080 --> 02:32:40,520
AND I DON'T SEE ANY MORE

4146
02:32:40,520 --> 02:32:41,600
MEMBERS' HANDS RAISED IN THE

4147
02:32:41,600 --> 02:32:43,240
ZOOM.

4148
02:32:43,240 --> 02:32:44,920
SO THANK YOU ALL ONCE AGAIN,

4149
02:32:44,920 --> 02:32:47,320
COLLEAGUES, FOR SUCH A RICH

4150
02:32:47,320 --> 02:32:47,680
DISCUSSION.

4151
02:32:47,680 --> 02:32:50,160
WE WILL NOW HAVE OUR LAST

4152
02:32:50,160 --> 02:32:51,920
15-MINUTE BREAK.

4153
02:32:51,920 --> 02:32:55,560
PLEASE RETURN PROMPTLY AT

4154
02:32:55,560 --> 02:32:57,640
3:35 P.M. EASTERN TIME.

4155
02:32:57,640 --> 02:33:00,080
AS A REMINDER, DO NOT TURN OFF

4156
02:33:00,080 --> 02:33:03,520
YOUR ZOOM, BUT FEEL FREE TO TURN

4157
02:33:03,520 --> 02:33:06,920
OFF YOUR CAMERA AND YOU CAN MUTE

4158
02:33:06,920 --> 02:33:07,680
YOUR SOUND.

4159
02:33:07,680 --> 02:33:10,560
>> ACTUALLY, SORRY,

4160
02:33:10,560 --> 02:33:11,240
DR. TURNBULL, WE'RE A LITTLE BIT

4161
02:33:11,240 --> 02:33:14,960
AHEAD OF SCHEDULE, SO IF

4162
02:33:14,960 --> 02:33:16,080
COLLEAGUES AGREE, WE COULD

4163
02:33:16,080 --> 02:33:19,480
RETURN AT ABOUT 3:20?

4164
02:33:19,480 --> 02:33:20,360
AND WE CAN MAKE UP A LITTLE BIT

4165
02:33:20,360 --> 02:33:23,120
OF TIME.

4166
02:33:23,120 --> 02:33:23,840
>> OKAY.

4167
02:33:23,840 --> 02:33:25,960
>> THAT WILL GIVE US ABOUT
A

4168
02:33:25,960 --> 02:33:26,360
15-MINUTE BREAK.

4169
02:33:26,360 --> 02:33:29,240
>> OKAY.

4170
02:33:29,240 --> 02:33:32,960
SO 3:20, YOU SAID?

4171
02:33:32,960 --> 02:33:34,080
>> THANKS, EVERYONE.

4172
02:33:34,080 --> 02:33:35,040
SEE YOU IN 15 MINUTES.

4173
02:33:35,040 --> 02:33:35,360
>> OKAY.

4174
02:33:35,360 --> 02:33:38,000
THANK YOU.

4175
02:33:38,000 --> 02:33:39,040
>>WELCOME BACK, EVERYONE.

4176
02:33:39,040 --> 02:33:41,120
WE WILL NOW HEAR BRIEF UPDATES

4177
02:33:41,120 --> 02:33:44,280
FROM OTHER NIH ADVISORY COUNCIL,

4178
02:33:44,280 --> 02:33:45,760
AND THE NATIONAL AIDS EXECUTIVE

4179
02:33:45,760 --> 02:33:46,880
COMMITTEE.

4180
02:33:46,880 --> 02:33:50,560
I WOULD LIKE TO INVITE DR. CARL

4181
02:33:50,560 --> 02:33:52,520
DIEFFENBACH, MS. CORETTA BYRD,

4182
02:33:52,520 --> 02:33:56,600
AND DR. DIANNE RAUSCH TO PROVIDE

4183
02:33:56,600 --> 02:33:57,840
SHORT SUMMARIES OF RECENT

4184
02:33:57,840 --> 02:34:01,040
MEETINGS.

4185
02:34:01,040 --> 02:34:02,240
DR. DIEFFENBACH SERVES AS

4186
02:34:02,240 --> 02:34:05,240
DIRECTOR OF THE DIVISION OF AIDS

4187
02:34:05,240 --> 02:34:09,080
AT NIAID.

4188
02:34:09,080 --> 02:34:11,480
DR. DIEFFENBACH OVERSEES THE

4189
02:34:11,480 --> 02:34:12,800
GLOBAL HIV/AIDS RESEARCH

4190
02:34:12,800 --> 02:34:15,440
PORTFOLIO OF MORE THAN

4191
02:34:15,440 --> 02:34:17,520
$1 BILLION, AND A STAFF OF MORE

4192
02:34:17,520 --> 02:34:21,960
THAN 150 FEDERAL EMPLOYEES.

4193
02:34:21,960 --> 02:34:23,240
DR. DIEFFENBACH PLAYED A KEY

4194
02:34:23,240 --> 02:34:26,520
ROLE IN RESTRUCTURING THE

4195
02:34:26,520 --> 02:34:28,480
DIVISION OF AIDS SUPPORTED

4196
02:34:28,480 --> 02:34:29,560
CLINICAL TRIALS RESEARCH

4197
02:34:29,560 --> 02:34:31,440
NETWORKS, AND HAS ACTIVELY

4198
02:34:31,440 --> 02:34:33,320
FOSTERED COLLABORATION AND

4199
02:34:33,320 --> 02:34:36,600
PARTNERSHIP WITH OTHER FEDERAL

4200
02:34:36,600 --> 02:34:39,280
AGENCIES, INTERNATIONAL RESEARCH

4201
02:34:39,280 --> 02:34:40,840
ORGANIZATIONS, PROFESSIONAL

4202
02:34:40,840 --> 02:34:42,680
SOCIETIES, FOUNDATIONS,

4203
02:34:42,680 --> 02:34:44,360
COMMUNITY ADVOCACY GROUPS, AND

4204
02:34:44,360 --> 02:34:48,200
INDUSTRY.

4205
02:34:48,200 --> 02:34:52,400
MS. CORETTA BYRD JOINED THE NIH

4206
02:34:52,400 --> 02:34:54,360
O.A.R. IN MARCH 2021 AS A HEALTH

4207
02:34:54,360 --> 02:34:59,280
SCIENCE POLICY ANALYST,

4208
02:34:59,280 --> 02:35:01,200
COORDINATING O.A.R. HIV INFO AND

4209
02:35:01,200 --> 02:35:03,640
CLINICAL GUIDELINE ACTIVITIES.

4210
02:35:03,640 --> 02:35:07,480
AND DR. DIANNE RAUSCH IS THE

4211
02:35:07,480 --> 02:35:10,440
DIRECTOR OF THE OFFICE OF AIDS

4212
02:35:10,440 --> 02:35:12,480
AT THE NATIONAL INSTITUTE OF

4213
02:35:12,480 --> 02:35:14,880
MENTAL HEALTH.

4214
02:35:14,880 --> 02:35:15,680
DR. DIEFFENBACH, WE WILL BEGIN

4215
02:35:15,680 --> 02:35:19,520
WITH YOU.

4216
02:35:19,520 --> 02:35:23,280
>> THANK YOU FOR THAT
LOVELY

4217
02:35:23,280 --> 02:35:23,880
INTRODUCTION.

4218
02:35:23,880 --> 02:35:25,760
GO AHEAD AND START A TIMER SO I

4219
02:35:25,760 --> 02:35:27,800
STAY ON TIME.

4220
02:35:27,800 --> 02:35:30,720
SO I'M HERE TO REPORT ON THE

4221
02:35:30,720 --> 02:35:33,440
MOST RECENT ARAC MEETING THAT

4222
02:35:33,440 --> 02:35:34,440
WAS HELD JUST A COUPLE WEEKS

4223
02:35:34,440 --> 02:35:37,000
AGO.

4224
02:35:37,000 --> 02:35:39,840
SO THE STRUCTURE OF THE ARAC

4225
02:35:39,840 --> 02:35:43,400
MEETING THAT I'M GOING TO TALK

4226
02:35:43,400 --> 02:35:45,840
ABOUT IS -- I'LL GIVE YOU A

4227
02:35:45,840 --> 02:35:47,680
SUMMARY OF MY DIRECTOR'S REPORT

4228
02:35:47,680 --> 02:35:50,040
THAT WAS PART OF THE MEETING AND

4229
02:35:50,040 --> 02:35:51,600
THEN I'LL GIVE YOU A PREVIEW OR

4230
02:35:51,600 --> 02:35:53,640
A QUICK SNAPSHOT OF THE NEW AND

4231
02:35:53,640 --> 02:35:55,640
RENEWING FISCAL YEAR

4232
02:35:55,640 --> 02:35:56,000
'25 INITIATIVES.

4233
02:35:56,000 --> 02:35:57,000
THESE ARE RESEARCH PROGRAMS THAT

4234
02:35:57,000 --> 02:35:59,080
WE ARE EITHER SEEKING TO

4235
02:35:59,080 --> 02:36:02,600
CONTINUE OR START ANEW WITH

4236
02:36:02,600 --> 02:36:05,040
FISCAL YEAR 25 DOLLARS.

4237
02:36:05,040 --> 02:36:07,240
WITHIN NIAID, WE'RE USUALLY

4238
02:36:07,240 --> 02:36:08,360
PLANNING WITHIN THREE FISCAL

4239
02:36:08,360 --> 02:36:10,920
YEARS, CLOSING UP ONE AND IN A

4240
02:36:10,920 --> 02:36:12,800
STAGE OF EXECUTION, SO IN

4241
02:36:12,800 --> 02:36:14,560
GENERAL, WE'RE WORKING IN FOUR

4242
02:36:14,560 --> 02:36:15,440
FISCAL YEARS.

4243
02:36:15,440 --> 02:36:16,440
PARENTHETICALLY, WE'RE STARTING

4244
02:36:16,440 --> 02:36:18,240
OUR PLANNING FOR FISCAL YEAR

4245
02:36:18,240 --> 02:36:19,480
'26.

4246
02:36:19,480 --> 02:36:20,760
'25 IS PRETTY MUCH IN THE BOOKS.

4247
02:36:20,760 --> 02:36:23,800
SO TO START, WE'VE HAD A NUMBER

4248
02:36:23,800 --> 02:36:26,680
OF IMPORTANT CHANGES WITHIN

4249
02:36:26,680 --> 02:36:29,200
NIAID THAT WERE SPECIFICALLY

4250
02:36:29,200 --> 02:36:31,360
RELEVANT TO THE AIDS RESEARCH

4251
02:36:31,360 --> 02:36:32,200
ADVISORY COMMITTEE.

4252
02:36:32,200 --> 02:36:35,520
WE HAVE A NEW DIRECTOR AT THE

4253
02:36:35,520 --> 02:36:42,400
VRC, TED PIERSON JOINED AS VRC

4254
02:36:42,400 --> 02:36:42,680
DREKD TORE.

4255
02:36:42,680 --> 02:36:45,320
DIRECTOR.

4256
02:36:45,320 --> 02:36:46,920
IT'S GREAT TO HAVE HIM ON BOARD.

4257
02:36:46,920 --> 02:36:48,760
WE HAVE A NEW CHAIR FOR ARAC.

4258
02:36:48,760 --> 02:36:50,400
ELAINE ABRAMS HAS AGREED TO BE

4259
02:36:50,400 --> 02:36:51,840
THE CHAIR.

4260
02:36:51,840 --> 02:36:53,200
ELAINE IS A PROFESSOR OF

4261
02:36:53,200 --> 02:36:54,480
EPIDEMIOLOGY AND PEDIATRICS AT

4262
02:36:54,480 --> 02:36:54,880
COLUMBIA.

4263
02:36:54,880 --> 02:36:57,120
THIS WAS HER FIRST FULL MEETING,

4264
02:36:57,120 --> 02:37:00,520
AND IT WAS GREAT TO HAVE HER

4265
02:37:00,520 --> 02:37:01,480
SITTING THERE AND PARTICIPATING

4266
02:37:01,480 --> 02:37:04,440
AS THE CHAIR.

4267
02:37:04,440 --> 02:37:09,760
AND WE HAD A NEW O.A.R. ADVISORY

4268
02:37:09,760 --> 02:37:13,680
COMMITTEE LIAISON, ANNE NEILAN.

4269
02:37:13,680 --> 02:37:15,000
I GET TO SEE HER IN PERSON FOR

4270
02:37:15,000 --> 02:37:16,880
THIS MEETING.

4271
02:37:16,880 --> 02:37:22,440
SO NO PRESENTATION AT NIAID FROM

4272
02:37:22,440 --> 02:37:23,400
THE INSTITUTE IS COMPLETE

4273
02:37:23,400 --> 02:37:24,200
WITHOUT A BUDGET SLIDE.

4274
02:37:24,200 --> 02:37:27,280
SO THIS IS WHERE WE ARE FOR THE

4275
02:37:27,280 --> 02:37:30,840
FISCAL YEAR '23 ENACTED BUDGET.

4276
02:37:30,840 --> 02:37:33,560
YOU CAN SEE THAT NIAID IS

4277
02:37:33,560 --> 02:37:34,920
FLAT-FUNDED, ACCORDING TO THE

4278
02:37:34,920 --> 02:37:35,440
PRESIDENT'S BUDGET.

4279
02:37:35,440 --> 02:37:39,360
ALL OF THIS REMAINS TO BE WORKED

4280
02:37:39,360 --> 02:37:42,360
OUT IN LIGHT OF THE RECENT BILL

4281
02:37:42,360 --> 02:37:48,520
THAT WAS PASSED ON, CREATING THE

4282
02:37:48,520 --> 02:37:52,080
SPACE FOR KEEPING THE GOVERNMENT

4283
02:37:52,080 --> 02:37:53,320
OPEN.

4284
02:37:53,320 --> 02:37:56,200
WE HEAR LOTS OF NOISE COMING OUT

4285
02:37:56,200 --> 02:37:57,480
OF THE MAJORITY PARTY IN THE

4286
02:37:57,480 --> 02:37:58,960
HOUSE NOW ABOUT ADDITIONAL CUTS

4287
02:37:58,960 --> 02:38:02,160
THAT MAY BE COMING.

4288
02:38:02,160 --> 02:38:04,240
SO WE'LL SEE HOW THIS GETS

4289
02:38:04,240 --> 02:38:08,560
ENACTED INTO LAW WHEN THEY GET

4290
02:38:08,560 --> 02:38:11,440
AROUND TO PASSING THE FUNDING

4291
02:38:11,440 --> 02:38:14,600
FOR NEXT FISCAL YEAR.

4292
02:38:14,600 --> 02:38:15,280
SOMETHING THAT'S VERY IMPORTANT

4293
02:38:15,280 --> 02:38:17,600
TO THE INSTITUTE AND THE

4294
02:38:17,600 --> 02:38:20,040
DIVISION OF AIDS IN PARTICULAR

4295
02:38:20,040 --> 02:38:20,960
IS DIVERSITY, EQUITY AND

4296
02:38:20,960 --> 02:38:21,800
INCLUSION AND ABILITY.

4297
02:38:21,800 --> 02:38:24,600
I MADE IT A PRAY OR THE FOR

4298
02:38:24,600 --> 02:38:25,760
EVERY SINGLE MEETING TO HAVE A

4299
02:38:25,760 --> 02:38:26,840
SLIDE ON WHAT WE HAVE

4300
02:38:26,840 --> 02:38:30,880
ACCOMPLISHED IN THAT SHORT

4301
02:38:30,880 --> 02:38:32,440
PERIOD OF A COUPLE OF MONTHS

4302
02:38:32,440 --> 02:38:34,320
RELATIVE TO DIVERSITY, EQUITY

4303
02:38:34,320 --> 02:38:35,480
AND INCLUSION AND ACCESSIBILITY,

4304
02:38:35,480 --> 02:38:38,200
AND WHAT IS LISTED ON HERE ARE A

4305
02:38:38,200 --> 02:38:40,480
NUMBER OF FUNDING ANNOUNCEMENTS,

4306
02:38:40,480 --> 02:38:42,520
NOFOs, AND OTHER ACTIVITIES

4307
02:38:42,520 --> 02:38:46,160
THAT ARE RELEVANT TO DIVERSITY,

4308
02:38:46,160 --> 02:38:49,360
EQUITY AND INCLUSION AND

4309
02:38:49,360 --> 02:38:51,320
ACCESSIBILITY, ALSO HIGHLIGHTING

4310
02:38:51,320 --> 02:38:54,280
A VERY IMPORTANT CFAR PROGRAM

4311
02:38:54,280 --> 02:38:56,800
CALLED CDIPI, WHICH FOSTERS THE

4312
02:38:56,800 --> 02:38:59,400
ADVANCEMENT OF HIGH SCHOOL AND

4313
02:38:59,400 --> 02:39:03,800
COLLEGE STUDENTS ENGAGED IN --

4314
02:39:03,800 --> 02:39:05,880
GETTING THEM ENGAGED IN RESEARCH

4315
02:39:05,880 --> 02:39:08,240
AT ACADEMIC INSTITUTIONS SO THEY

4316
02:39:08,240 --> 02:39:09,240
LEARN ABOUT THE IMPORTANCE OF

4317
02:39:09,240 --> 02:39:13,720
HIV, LEARN HOW TO GET ENGAGED IN

4318
02:39:13,720 --> 02:39:16,920
HIV RESEARCH AND THEN CREATE A

4319
02:39:16,920 --> 02:39:18,880
PIPELINE OF DIVERSE

4320
02:39:18,880 --> 02:39:20,400
POPULATION GOING INTO GRADUATE

4321
02:39:20,400 --> 02:39:24,480
SCHOOL AND MEDICAL SCHOOL.

4322
02:39:24,480 --> 02:39:27,400
WE ALSO HAVE HAD NOTICE OF

4323
02:39:27,400 --> 02:39:29,640
SPECIAL INTEREST ADMINISTRATIVE

4324
02:39:29,640 --> 02:39:32,040
SUPPLEMENTS FOR AIDS RESEARCH

4325
02:39:32,040 --> 02:39:36,080
DONE IN COLLABORATION WITH NIMHD

4326
02:39:36,080 --> 02:39:39,160
THAT WAS PUBLISHED IN THE PAST

4327
02:39:39,160 --> 02:39:41,280
THREE MONTHS.

4328
02:39:41,280 --> 02:39:42,320
I ALWAYS HAVE A COUPLE OF

4329
02:39:42,320 --> 02:39:43,640
RESEARCH HIGHLIGHTS AS WELL, AND

4330
02:39:43,640 --> 02:39:47,240
I HAVE THREE THAT I'LL SHARE.

4331
02:39:47,240 --> 02:39:48,920
THIS IS A RESULT THAT CAME OUT

4332
02:39:48,920 --> 02:39:49,560
IN APRIL.

4333
02:39:49,560 --> 02:39:52,640
THIS WAS A CLINICAL TRIAL THAT

4334
02:39:52,640 --> 02:39:55,560
WE STARTED PLANNING FOR IN 2013.

4335
02:39:55,560 --> 02:39:57,760
IT STARTED ENROLLING IN 2015.

4336
02:39:57,760 --> 02:40:01,720
AND THE QUESTION IS, WHAT

4337
02:40:01,720 --> 02:40:03,200
HAPPENS -- IS THERE A CLINICAL

4338
02:40:03,200 --> 02:40:06,000
BENEFIT TO ADDING A STATIN TO A

4339
02:40:06,000 --> 02:40:11,160
PERSON'S HIV DRUG REGIMEN IF

4340
02:40:11,160 --> 02:40:12,800
THEY DON'T ACTUALLY QUALIFY FOR

4341
02:40:12,800 --> 02:40:14,040
A STATIN OTHER THAN THE FACT

4342
02:40:14,040 --> 02:40:16,360
THAT THEY ARE LIVING WITH HIV?

4343
02:40:16,360 --> 02:40:18,240
IT'S IMPORTANT TO THINK ABOUT

4344
02:40:18,240 --> 02:40:20,640
THIS, THAT WE ENROLLED A

4345
02:40:20,640 --> 02:40:23,280
RELATIVELY YOUNG POPULATION

4346
02:40:23,280 --> 02:40:26,000
STARTING AT AGE 40, AND YOU CAN

4347
02:40:26,000 --> 02:40:28,560
SEE WE ALSO DID A VERY GOOD JOB

4348
02:40:28,560 --> 02:40:29,440
ENROLLING WOMEN, 30% OF THE

4349
02:40:29,440 --> 02:40:31,640
ENROLLMENT WAS IN WOMEN.

4350
02:40:31,640 --> 02:40:34,040
WHAT WE SAW TOTALLY SURPRISED

4351
02:40:34,040 --> 02:40:35,240
US.

4352
02:40:35,240 --> 02:40:38,040
WE WERE EXPECTING AN EFFECT SIZE

4353
02:40:38,040 --> 02:40:39,600
OF BETWEEN 25 AN 30%.

4354
02:40:39,600 --> 02:40:42,320
WHAT WE SAW WAS A SIGNIFICANTLY

4355
02:40:42,320 --> 02:40:47,080
LARGER EFFECT SIZE OF 35%

4356
02:40:47,080 --> 02:40:48,280
REDUCTION IN CARDIOVASCULAR

4357
02:40:48,280 --> 02:40:48,520
DISEASE.

4358
02:40:48,520 --> 02:40:51,480
ALL WE HAVE RIGHT NOW IS THE TOP

4359
02:40:51,480 --> 02:40:53,520
LINE INFORMATION THAT THE DSMB

4360
02:40:53,520 --> 02:40:54,840
USED TO STOP THE STUDY.

4361
02:40:54,840 --> 02:41:01,520
THE PAPER IS MOVING THROUGH THE

4362
02:41:01,520 --> 02:41:03,200
PROCESS OF GETTING PUBLISHED IN

4363
02:41:03,200 --> 02:41:03,960
THE NEW ENGLAND JOURNAL OF MED

4364
02:41:03,960 --> 02:41:08,080
SAIND SHOULD MEDICINE AND SHOULN

4365
02:41:08,080 --> 02:41:08,360
MID JULY.

4366
02:41:08,360 --> 02:41:09,800
SO WE'RE VERY EXCITED ABOUT THE

4367
02:41:09,800 --> 02:41:12,200
QUALITY AND DEPTH OF THIS DATA.

4368
02:41:12,200 --> 02:41:14,240
YOU CAN SEE WE HAD A VERY LARGE

4369
02:41:14,240 --> 02:41:15,440
ENROLLMENT IN THE STUDY, AND A

4370
02:41:15,440 --> 02:41:17,560
LOT OF DATA WILL COME OUT ON

4371
02:41:17,560 --> 02:41:18,640
THIS STUDY OVER THE NEXT SEVERAL

4372
02:41:18,640 --> 02:41:22,440
YEARS.

4373
02:41:22,440 --> 02:41:23,760
IN TERMS OF CLINICAL TRIALS TO

4374
02:41:23,760 --> 02:41:25,880
WATCH, WE STILL ARE FINISHING UP

4375
02:41:25,880 --> 02:41:27,400
ONE OF THE RANDOMIZED CLINICAL

4376
02:41:27,400 --> 02:41:29,600
TRIALS OF A CORONAVIRUS VACCINE

4377
02:41:29,600 --> 02:41:32,000
IN SUB-SAHARAN AFRICA, LOOKING

4378
02:41:32,000 --> 02:41:35,080
SPECIFICALLY AT HOW THIS VACCINE

4379
02:41:35,080 --> 02:41:38,560
FUNCTIONS IN PEOPLE LIVING WITH

4380
02:41:38,560 --> 02:41:39,000
HIV.

4381
02:41:39,000 --> 02:41:42,200
THERE'S A LOT OF HYBRID IMMUNITY

4382
02:41:42,200 --> 02:41:43,760
IN SOUTH AFRICA, SO IT WILL BE

4383
02:41:43,760 --> 02:41:47,600
VERY INTERESTING TO PARSE OUT

4384
02:41:47,600 --> 02:41:48,800
PEOPLE WHO ARE LIVEING WITH HIV,

4385
02:41:48,800 --> 02:41:51,840
THE EFFECT OF THE VACCINE AND

4386
02:41:51,840 --> 02:41:53,680
THE EFFECT OF PRIOR INFECTION.

4387
02:41:53,680 --> 02:41:56,720
NOW THE DSMB FOR THIS IS COMING

4388
02:41:56,720 --> 02:41:57,080
UP FAIRLY SOON.

4389
02:41:57,080 --> 02:41:58,400
AND LAST BUT NOT LEAST, THERE'S

4390
02:41:58,400 --> 02:42:02,240
A STUDY THAT WE'RE HOPING MAYBE

4391
02:42:02,240 --> 02:42:03,840
IT WILL ENROLL BUT THAT MEANS

4392
02:42:03,840 --> 02:42:06,800
WE'RE HAVING ANOTHER MPOX

4393
02:42:06,800 --> 02:42:07,120
OUTBREAK.

4394
02:42:07,120 --> 02:42:09,160
SO THIS IS A STUDY WE LAUNCHED

4395
02:42:09,160 --> 02:42:11,920
AT THE VERY TAIL END OF THE

4396
02:42:11,920 --> 02:42:13,680
SUMMER LAST YEAR.

4397
02:42:13,680 --> 02:42:17,480
OUR ENROLLMENT HIT THE WALL

4398
02:42:17,480 --> 02:42:19,160
LITERALLY BECAUSE MPOX PRETTY

4399
02:42:19,160 --> 02:42:20,120
MUCH DRIED UP.

4400
02:42:20,120 --> 02:42:24,480
WE'RE STARTING TO SEE THREE

4401
02:42:24,480 --> 02:42:25,600
CASES IN DENVER, SEVEN CASES IN

4402
02:42:25,600 --> 02:42:26,120
CHICAGO.

4403
02:42:26,120 --> 02:42:27,480
WE'VE ALSO OPENED

4404
02:42:27,480 --> 02:42:29,760
INTERNATIONALLY AND WE ALSO HAVE

4405
02:42:29,760 --> 02:42:32,720
MOVED TO REMOTE ENROLLMENT.

4406
02:42:32,720 --> 02:42:35,040
SO THERE'S A PHONE NUMBER YOU

4407
02:42:35,040 --> 02:42:36,600
CAN CALL, IF YOU HAVE A PATIENT

4408
02:42:36,600 --> 02:42:43,160
AND YOU CAN GET REFERRED AND GET

4409
02:42:43,160 --> 02:42:44,680
DRUG DROP-SHIPPED IF THE PERSON

4410
02:42:44,680 --> 02:42:45,840
AGREES TO PARTICIPATE IN THE

4411
02:42:45,840 --> 02:42:46,280
STUDY.

4412
02:42:46,280 --> 02:42:49,640
WE'RE HOPING WE CAN GET TO FULL

4413
02:42:49,640 --> 02:42:51,200
ENROLLMENT WITHIN THE NEXT YEAR

4414
02:42:51,200 --> 02:42:52,200
OR SO.

4415
02:42:52,200 --> 02:42:53,640
SO WE DIDN'T CLOSE THE STUDY, WE

4416
02:42:53,640 --> 02:42:55,400
JUST KEPT IT GOING, AND EXPANDED

4417
02:42:55,400 --> 02:42:56,880
THE NUMBER OF SITES AND MOVED

4418
02:42:56,880 --> 02:42:59,880
INTERNATIONALLY.

4419
02:42:59,880 --> 02:43:02,120
THAT SAID, I'M NOW GOING TO MOVE

4420
02:43:02,120 --> 02:43:03,480
ON AND GROUP THE INITIATIVES

4421
02:43:03,480 --> 02:43:06,840
THAT WE PRESENTED TO THE COUNCIL

4422
02:43:06,840 --> 02:43:09,720
AND BUNDLE THEM SO THAT THERE IS

4423
02:43:09,720 --> 02:43:11,440
SOME DEGREE OF COHERENCE IN WHAT

4424
02:43:11,440 --> 02:43:13,080
WAS PRESENTED AND WHAT YOU'LL

4425
02:43:13,080 --> 02:43:15,160
HEAR ABOUT.

4426
02:43:15,160 --> 02:43:17,480
SO FIRST UP ARE THE HIV VACCINE

4427
02:43:17,480 --> 02:43:20,400
RESEARCH CONCEPTS THAT ARE

4428
02:43:20,400 --> 02:43:23,160
GRANTS THAT WERE PRESENTED AT

4429
02:43:23,160 --> 02:43:24,280
THE COUNCIL.

4430
02:43:24,280 --> 02:43:30,760
FIRST UP WAS A TOPIC OF -- THEY

4431
02:43:30,760 --> 02:43:34,480
WANT TO FUND RESEARCH AND

4432
02:43:34,480 --> 02:43:39,840
MECHANISMS FOR ESTABLISHING AND

4433
02:43:39,840 --> 02:43:41,680
MAIN TAKING IMMUNITY TO HIV IN

4434
02:43:41,680 --> 02:43:43,640
EARLY LIFE.

4435
02:43:43,640 --> 02:43:45,080
THE IMMUNITY AN INFANT OR

4436
02:43:45,080 --> 02:43:46,520
TODDLER DEVELOPS WHEN EXPOSED TO

4437
02:43:46,520 --> 02:43:49,560
A VACCINE, PARTICULARLY HIV, MAY

4438
02:43:49,560 --> 02:43:51,560
BE BETTER AND MORE DURABLE THAN

4439
02:43:51,560 --> 02:43:53,400
WHAT HAPPENS WITH ADULTS.

4440
02:43:53,400 --> 02:43:55,160
THERE'S DATA FROM NON-HUMAN

4441
02:43:55,160 --> 02:43:56,680
PRIMATES AND OTHERS, AND THERE

4442
02:43:56,680 --> 02:43:58,560
WERE ACTUALLY SOME VACCINE

4443
02:43:58,560 --> 02:44:00,440
STUDIES DONE YEARS AGO THAT

4444
02:44:00,440 --> 02:44:01,200
SUPPORT THIS.

4445
02:44:01,200 --> 02:44:03,680
WE ALSO HAVE RECENTLY STARTED

4446
02:44:03,680 --> 02:44:06,960
STUDIES WITH SOME OF THE NEW

4447
02:44:06,960 --> 02:44:09,680
MODERN IMMUNOGENS, RECENTLY

4448
02:44:09,680 --> 02:44:10,920
DEVELOPED IMMUNOGENS, TO SEE HOW

4449
02:44:10,920 --> 02:44:12,440
THIS ACTUALLY WORKS.

4450
02:44:12,440 --> 02:44:13,640
SO THIS IS AN AREA OF IMPORTANCE

4451
02:44:13,640 --> 02:44:17,560
TO US, TO SEE IF WE CAN TAKE

4452
02:44:17,560 --> 02:44:19,640
ADVANTAGE OF THE IMMUNITY IN

4453
02:44:19,640 --> 02:44:24,920
EARLY LIFE TO BOOST HIV IMMUN 

4454
02:44:24,920 --> 02:44:25,560
IMMUNITY.

4455
02:44:25,560 --> 02:44:29,280
ONE OF OUR PROGRAMS WE'VE HAD

4456
02:44:29,280 --> 02:44:31,680
SEEMINGLY FOR A VERY LONG TIME

4457
02:44:31,680 --> 02:44:36,880
IS THE HIVRAD, A

4458
02:44:36,880 --> 02:44:37,800
MULTIDISCIPLINARY PROGRAM WHERE

4459
02:44:37,800 --> 02:44:40,480
PEOPLE APPLY FOR PROJECT TBRANTS

4460
02:44:40,480 --> 02:44:44,360
TO TRY TO EXPLAIN FUNDAMENTAL

4461
02:44:44,360 --> 02:44:45,480
MECHANISMS IN HIV VACCINE

4462
02:44:45,480 --> 02:44:48,520
RESEARCH, WERE IT'S IMMUNOGEN

4463
02:44:48,520 --> 02:44:51,280
DESIGN, T-CELL BEHAVIOR, BETTER

4464
02:44:51,280 --> 02:44:52,360
ADJUVANTS, YOU NAME IT.

4465
02:44:52,360 --> 02:44:54,120
SO ONE OF THE THINGS, AN EXAMPLE

4466
02:44:54,120 --> 02:44:56,720
OF A RESEARCH TOPIC WAS HOW DO

4467
02:44:56,720 --> 02:45:00,000
YOU BUILD A STABILIZED ENVELOPE

4468
02:45:00,000 --> 02:45:00,680
TRIMER.

4469
02:45:00,680 --> 02:45:04,400
JOHN MOORE BUILT THE FIRST SOCIP

4470
02:45:04,400 --> 02:45:07,560
THROUGH THIS PROGRAM.

4471
02:45:07,560 --> 02:45:10,840
LEO HAS BUILT SOME REALLY

4472
02:45:10,840 --> 02:45:12,040
EXCITING IMMUNOGENS THROUGH THIS

4473
02:45:12,040 --> 02:45:13,480
PROGRAM, AND THIS HAS LED TO A

4474
02:45:13,480 --> 02:45:16,320
NUMBER OF VACCINE CONCEPTS BEING

4475
02:45:16,320 --> 02:45:19,200
ADVANCED, INCLUDING DAN BARUK'S

4476
02:45:19,200 --> 02:45:22,720
WORD ON ED26.

4477
02:45:22,720 --> 02:45:24,040
ON THE CONTRACT SIDE, WE HAVE A

4478
02:45:24,040 --> 02:45:27,200
VERY LARGE PROGRAM CALLED THE

4479
02:45:27,200 --> 02:45:29,160
SIMIAN VACCINE EVALUATION UNITS

4480
02:45:29,160 --> 02:45:31,960
OR SVEUs, AND LINKED TO THOSE

4481
02:45:31,960 --> 02:45:33,920
EVALUATION UNITS ARE A SERIES OF

4482
02:45:33,920 --> 02:45:34,560
STANDARDIZED LABORATORIES.

4483
02:45:34,560 --> 02:45:36,800
SO THAT THE DATA THAT COMES OUT

4484
02:45:36,800 --> 02:45:39,840
OF THE LABS IS STANDARDIZED AND

4485
02:45:39,840 --> 02:45:44,640
YOU CAN THEN COMPARE APPLES TO

4486
02:45:44,640 --> 02:45:46,600
APPLES THAT ARE RESPONSIVE,

4487
02:45:46,600 --> 02:45:48,040
VACCINE A TO VACCINE B, BECAUSE

4488
02:45:48,040 --> 02:45:49,360
IT'S BEING DONE IN THE SAME

4489
02:45:49,360 --> 02:45:49,800
LABORATORIES.

4490
02:45:49,800 --> 02:45:53,120
SO WHAT WE HAD WERE

4491
02:45:53,120 --> 02:45:54,120
PRESENTATIONS ON FOUR OF THESE

4492
02:45:54,120 --> 02:45:57,360
ACTIVITIES, THE VIROLOGY LAB,

4493
02:45:57,360 --> 02:45:59,880
HUMORAL IMMUNOLOGY LAB,

4494
02:45:59,880 --> 02:46:02,280
FUNCTIONAL OMICS LAB, AND THEN A

4495
02:46:02,280 --> 02:46:03,360
RESOURCE SUPPORT PROGRAM THAT

4496
02:46:03,360 --> 02:46:04,360
MAKES REAGENTS AVAILABLE THAT

4497
02:46:04,360 --> 02:46:06,080
ARE TAILORED TO VACCINE RESEARCH

4498
02:46:06,080 --> 02:46:08,880
THAT ARE NOT READILY AVAILABLE

4499
02:46:08,880 --> 02:46:09,200
COMMERCIALLY.

4500
02:46:09,200 --> 02:46:11,200
THIS IS IN MANY WAYS --

4501
02:46:11,200 --> 02:46:12,960
DOVETAILS VERY NICELY WITH THE

4502
02:46:12,960 --> 02:46:16,560
HIV REAGENT PROGRAM THAT NIAID

4503
02:46:16,560 --> 02:46:19,320
HAS RUN FOR ABOUT 30 YEARS.

4504
02:46:19,320 --> 02:46:20,880
THESE TEND TO BE

4505
02:46:20,880 --> 02:46:21,560
VACCINE-SPECIFIC.

4506
02:46:21,560 --> 02:46:26,000
SO MOVING ON TO THERAPEUTICS, WE

4507
02:46:26,000 --> 02:46:27,080
HAVE REALLY THOUGHT ABOUT WHAT

4508
02:46:27,080 --> 02:46:29,080
WE COULD DO TO FACILITATE THE

4509
02:46:29,080 --> 02:46:30,360
ADVANCEMENT OF THERAPEUTICS

4510
02:46:30,360 --> 02:46:32,440
RESEARCH AND THERE'S THIS AREA,

4511
02:46:32,440 --> 02:46:33,760
THE VALLEY OF DEATH, THAT NEEDS

4512
02:46:33,760 --> 02:46:34,760
TO BE ADDRESSED.

4513
02:46:34,760 --> 02:46:38,040
SO CAN WE PROVIDE SUPPORT TO

4514
02:46:38,040 --> 02:46:39,360
INVESTIGATORS OR SMALL COMPANIES

4515
02:46:39,360 --> 02:46:43,200
THAT NEED TO ADVANCE A SPECIFIC

4516
02:46:43,200 --> 02:46:44,520
PRODUCT THROUGH THIS AREA.

4517
02:46:44,520 --> 02:46:46,360
SO THERE'S A PLANNING GRANT

4518
02:46:46,360 --> 02:46:48,240
PROCESS THAT WILL BE FUNDABLE

4519
02:46:48,240 --> 02:46:51,040
THROUGH AN R24 THAT WILL ALLOW

4520
02:46:51,040 --> 02:46:53,600
SOMEBODY WITH A GOOD IDEA TO

4521
02:46:53,600 --> 02:46:55,280
BUILD OUT THEIR PROCESS TO PUT

4522
02:46:55,280 --> 02:46:59,080
TOGETHER AN IND AND HELP GET

4523
02:46:59,080 --> 02:47:03,400
THROUGH THIS AREA OF TREMENDOUS

4524
02:47:03,400 --> 02:47:04,320
DIFFICULTY THAT PEOPLE HAVE A

4525
02:47:04,320 --> 02:47:10,560
HARD TIME-AND-A- TIME NAVIGATIN.

4526
02:47:10,560 --> 02:47:11,680
ADDITIONALLY, THERE'S SO MUCH

4527
02:47:11,680 --> 02:47:13,320
EXCITEMENT ABOUT CURE FOR HIV,

4528
02:47:13,320 --> 02:47:15,400
THERE'S ALSO A LARGE AMOUNT OF

4529
02:47:15,400 --> 02:47:17,400
EXCITEMENT FOR CURE IN HBV.

4530
02:47:17,400 --> 02:47:20,360
BECAUSE WE HAVE TO DEAL WITH HBV

4531
02:47:20,360 --> 02:47:24,040
AS A MAJOR COINFECTION AND IN

4532
02:47:24,040 --> 02:47:25,360
PEOPLE LIVING WITH HIV, WE THINK

4533
02:47:25,360 --> 02:47:27,000
IT'S IMPORTANT THAT WE START A

4534
02:47:27,000 --> 02:47:28,640
MULTIDISCIPLINARY RESEARCH

4535
02:47:28,640 --> 02:47:30,280
PROGRAM TO ACCELERATE THE

4536
02:47:30,280 --> 02:47:32,560
EVALUATION OF HBV CURE

4537
02:47:32,560 --> 02:47:33,920
ACTIVITIES IN PEOPLE LIVING WITH

4538
02:47:33,920 --> 02:47:34,640
HIV.

4539
02:47:34,640 --> 02:47:36,920
SO THIS IS AN AREA OF GROWTH FOR

4540
02:47:36,920 --> 02:47:41,320
US STARTING IN 2025.

4541
02:47:41,320 --> 02:47:45,000
IN THE AREA OF ADVANCING NOVEL

4542
02:47:45,000 --> 02:47:46,320
CURE CONCEPTS, WE HAVE THREE

4543
02:47:46,320 --> 02:47:49,840
THAT WE'RE PUSHING FORWARD.

4544
02:47:49,840 --> 02:47:51,680
ONE IS WHAT ARE THE BIOLOGICAL

4545
02:47:51,680 --> 02:47:52,640
PRODUCTS THAT COULD BE

4546
02:47:52,640 --> 02:47:53,880
DEVELOPED, WHETHER IT'S AN

4547
02:47:53,880 --> 02:47:55,720
ANTIBODY WITH A MODIFIED FC, IS

4548
02:47:55,720 --> 02:47:58,600
THERE A WAY OF USING CYTOKINES

4549
02:47:58,600 --> 02:48:03,280
TO TRIGGER APOPTOSIS THAT COULD

4550
02:48:03,280 --> 02:48:05,280
ELIMINATE THE HIV INFECTED

4551
02:48:05,280 --> 02:48:06,240
CELLS.

4552
02:48:06,240 --> 02:48:07,880
THAT'S A CONCEPT OF HOW YOU CAN

4553
02:48:07,880 --> 02:48:08,520
KILL.

4554
02:48:08,520 --> 02:48:10,160
WE TALK ABOUT AND HEAR A LOT

4555
02:48:10,160 --> 02:48:11,920
ABOUT KICK AND KILL.

4556
02:48:11,920 --> 02:48:14,120
WE'VE TENDED TO NEGLECT THE KILL

4557
02:48:14,120 --> 02:48:14,560
PART.

4558
02:48:14,560 --> 02:48:16,120
IT'S REALLY TIME TO SPEND SOME

4559
02:48:16,120 --> 02:48:17,400
TIME ON THAT.

4560
02:48:17,400 --> 02:48:19,120
WE ARE INTERESTED IN CONTINUING

4561
02:48:19,120 --> 02:48:20,560
TO GROW THE PIPELINE FOR CELL

4562
02:48:20,560 --> 02:48:22,080
AND GENE THERAPIES FOR HIV CURE,

4563
02:48:22,080 --> 02:48:23,240
AND A CONCEPT, IF YOU THINK

4564
02:48:23,240 --> 02:48:24,480
ABOUT IT, THAT WOULD BE REALLY

4565
02:48:24,480 --> 02:48:26,040
INTERESTING IS, COULD YOU TAKE

4566
02:48:26,040 --> 02:48:28,440
AN INDIVIDUAL THAT'S VERY WELL

4567
02:48:28,440 --> 02:48:32,480
CHARACTERIZED AND TAILOR A

4568
02:48:32,480 --> 02:48:33,360
CURATIVE STRATEGY BASED ON WHAT

4569
02:48:33,360 --> 02:48:35,240
YOU KNOW ABOUT THEIR VIRUS,

4570
02:48:35,240 --> 02:48:37,480
THEIR GENETIC MAKEUP, THEIR

4571
02:48:37,480 --> 02:48:39,160
IMMUNE RESPONSE, SO THERE'S THE

4572
02:48:39,160 --> 02:48:41,000
ABILITY HERE TO REALLY EXPLORE

4573
02:48:41,000 --> 02:48:43,200
THIS NOTION OF TAILORING A CURE.

4574
02:48:43,200 --> 02:48:44,600
I'M NOT SAYING THIS WILL EVER BE

4575
02:48:44,600 --> 02:48:47,480
AN EFFECTIVE STRATEGY THAT WOULD

4576
02:48:47,480 --> 02:48:50,320
GO FOR PUBLIC HEALTH, BUT THE

4577
02:48:50,320 --> 02:48:52,400
IDEA OF SEEING HOW YOU COULD

4578
02:48:52,400 --> 02:48:55,120
EXPLORE, SAY, ANTIGEN-BASED

4579
02:48:55,120 --> 02:48:57,000
ACTIVATION OF CD4 CELLS FOR THE

4580
02:48:57,000 --> 02:49:03,240
PURPOSE OF ELIMINATING A

4581
02:49:03,240 --> 02:49:05,080
RESERVOIR IS AN EXAMPLE OF THE

4582
02:49:05,080 --> 02:49:06,240
KINDS OF THINGS THAT COULD BE

4583
02:49:06,240 --> 02:49:06,440
DONE.

4584
02:49:06,440 --> 02:49:07,600
SO WITH THAT I'LL CLOAL CLOSE

4585
02:49:07,600 --> 02:49:08,800
AND LEAVE YOU WITH IF YOU WANT

4586
02:49:08,800 --> 02:49:10,760
TO SEE -- WE RECORD EVERY ONE OF

4587
02:49:10,760 --> 02:49:12,000
OUR ADVISORY COMMITTEE MEETINGS,

4588
02:49:12,000 --> 02:49:17,880
THEY'RE AVAILABLE ON THE WEBCAST

4589
02:49:17,880 --> 02:49:18,160
ARCHIVE.

4590
02:49:18,160 --> 02:49:19,920
I'M ALSO HAPPY TO ANSWER ANY

4591
02:49:19,920 --> 02:49:20,160
QUESTIONS.

4592
02:49:20,160 --> 02:49:23,920
THANK YOU.

4593
02:49:23,920 --> 02:49:27,680
>> THANK YOU, DR.
DIEFFENBACH.

4594
02:49:27,680 --> 02:49:31,520
AND NOW WE'LL HEAR FROM MS. BYRD

4595
02:49:31,520 --> 02:49:41,760
AND DR. ROUSH.

4596
02:49:44,560 --> 02:49:45,560
>> CAN YOU HEAR ME?

4597
02:49:45,560 --> 02:49:45,960
HELLO?

4598
02:49:45,960 --> 02:49:46,520
GOOD AFTERNOON.

4599
02:49:46,520 --> 02:49:49,480
MY NAME IS CORETTA BYRD, AND I

4600
02:49:49,480 --> 02:49:51,120
AM A MEMBER OF THE O.A.R.

4601
02:49:51,120 --> 02:49:54,080
SCIENCE TEAM, AND I WILL BE

4602
02:49:54,080 --> 02:49:56,840
PRESENTING THE NEW AND REISSUED

4603
02:49:56,840 --> 02:49:58,360
CLEARED CONCEPTS BY INSTITUTES,

4604
02:49:58,360 --> 02:50:06,880
CENTERS AND OFFICES WITHIN NIH.

4605
02:50:06,880 --> 02:50:08,640
TO START OFF, THIS IS A SUMMARY

4606
02:50:08,640 --> 02:50:09,840
OF THE NEW AND REISSUED

4607
02:50:09,840 --> 02:50:10,280
CONCEPTS.

4608
02:50:10,280 --> 02:50:11,320
AS YOU CAN SEE HERE, THERE ARE

4609
02:50:11,320 --> 02:50:13,640
14 NEW AND 12 REISSUED CONCEPTS.

4610
02:50:13,640 --> 02:50:15,360
WHICH IS, OF COURSE, 26 IN

4611
02:50:15,360 --> 02:50:20,320
TOTAL.

4612
02:50:20,320 --> 02:50:23,400
SO TO START OFF, THE NATIONAL

4613
02:50:23,400 --> 02:50:24,680
CANCER INSTITUTE HAS ONE NEW

4614
02:50:24,680 --> 02:50:27,240
CONCEPT, TRANSLATIONAL RESEARCH

4615
02:50:27,240 --> 02:50:31,880
TOWARD DEVELOPMENT OF A KAPOSI

4616
02:50:31,880 --> 02:50:34,480
SARCOMA HERPES VIRUS VACCINE.

4617
02:50:34,480 --> 02:50:37,000
THE NATIONAL INSTITUTE OF

4618
02:50:37,000 --> 02:50:38,320
DIABETES AND DIGESTIVE AND

4619
02:50:38,320 --> 02:50:40,440
KIDNEY DISEASES HAS THREE NEW

4620
02:50:40,440 --> 02:50:41,440
CONCEPTS LISTED HERE.

4621
02:50:41,440 --> 02:50:42,840
THE FIRST IMPACT OF

4622
02:50:42,840 --> 02:50:44,400
COMORBIDITIES AND COINFECTIONS

4623
02:50:44,400 --> 02:50:48,640
ON HIV RESERVOIRS, SEEKS TO

4624
02:50:48,640 --> 02:50:49,880
BRING TOGETHER MULTIDISCIPLINARY

4625
02:50:49,880 --> 02:50:52,440
TEAMS TO ADDRESS HOW

4626
02:50:52,440 --> 02:50:55,640
COMORBIDITIES AND COINFECTIONS

4627
02:50:55,640 --> 02:50:57,040
PREVALENT IN PEOPLE WITH HIV

4628
02:50:57,040 --> 02:50:59,680
INTERACT WITH VIRAL RESERVOIRS

4629
02:50:59,680 --> 02:51:03,080
IN WAYS THAT CONFOUND CURE

4630
02:51:03,080 --> 02:51:03,600
STRATEGIES.

4631
02:51:03,600 --> 02:51:05,680
THE SECOND, EX VIVO STUDIES OF

4632
02:51:05,680 --> 02:51:07,000
HIV INFECTION AND PATHOGENESIS

4633
02:51:07,000 --> 02:51:15,200
WITHIN THE MISS -- PATHOGENESISD

4634
02:51:15,200 --> 02:51:17,200
THIRD, SYNDEMICS IMPACTING THE

4635
02:51:17,200 --> 02:51:19,840
HEALTH OF PEOPLE WITH HIV AND

4636
02:51:19,840 --> 02:51:21,560
NIDDK COMORBIDITIES ADDRESSES

4637
02:51:21,560 --> 02:51:26,600
THE IMPACT OF SYNDEMIC RACISM,

4638
02:51:26,600 --> 02:51:27,480
HOMOPHOBIA, TRANSPHOBIA,

4639
02:51:27,480 --> 02:51:29,240
DISCRIMINATION, AND STIGMA, AND

4640
02:51:29,240 --> 02:51:31,240
THEIR INTERRELATIONSHIPS WITH

4641
02:51:31,240 --> 02:51:34,680
SOCIAL RISK ON DEVELOPMENT.

4642
02:51:34,680 --> 02:51:35,760
EXACERBATION AND EFFECTIVE

4643
02:51:35,760 --> 02:51:38,400
MANAGEMENT OF HIV COMORBIDITIES

4644
02:51:38,400 --> 02:51:41,800
AND COINFECTIONS.

4645
02:51:41,800 --> 02:51:44,200
SO DR. DIEFFENBACH JUST

4646
02:51:44,200 --> 02:51:46,720
DISCUSSED THE SEVEN NEW CONCEPTS

4647
02:51:46,720 --> 02:51:49,800
LISTED HERE, SO I WILL NOT GO

4648
02:51:49,800 --> 02:51:53,840
INTO ANY DETAIL.

4649
02:51:53,840 --> 02:51:55,080
WITH THAT, I WILL TURN IT OVER

4650
02:51:55,080 --> 02:51:59,760
TO DR. DIANNE RAUSCH TO TALK

4651
02:51:59,760 --> 02:52:02,240
ABOUT THE NIMH CONCEPTS.

4652
02:52:02,240 --> 02:52:04,040
>> THANK YOU, AND I'M
PLEASED TO

4653
02:52:04,040 --> 02:52:05,920
BE ABLE TO PRESENT THREE

4654
02:52:05,920 --> 02:52:09,320
CONCEPTS BASED ON SOME OF OUR

4655
02:52:09,320 --> 02:52:11,240
INITIATIVE PLANNING PROCESS THAT

4656
02:52:11,240 --> 02:52:13,720
I'M REPRESENTING DR. MARGUERITA

4657
02:52:13,720 --> 02:52:17,080
LIGHTFOOT, WHO IS OUR NIMH

4658
02:52:17,080 --> 02:52:19,720
REPRESENTATIVE TO THE OARAC BUT

4659
02:52:19,720 --> 02:52:20,680
COULDN'T BE HERE TODAY.

4660
02:52:20,680 --> 02:52:23,800
JUST AS A REMINDER WHAT NIMH

4661
02:52:23,800 --> 02:52:25,360
DOES, OUR RESEARCH SPANS A BROAD

4662
02:52:25,360 --> 02:52:28,640
RANGE OF ISSUES FROM -- AROUND

4663
02:52:28,640 --> 02:52:30,360
MENTAL HEALTH, LOOKING AT

4664
02:52:30,360 --> 02:52:31,560
BEHAVIORAL AND SOCIAL SCIENCE

4665
02:52:31,560 --> 02:52:34,640
ISSUES THAT IMPACT HEALTH

4666
02:52:34,640 --> 02:52:38,400
OUTCOMES AND ALSO NEUROSCIENCE

4667
02:52:38,400 --> 02:52:40,560
THAT LOOKS AT THE EFFECT OF HIV

4668
02:52:40,560 --> 02:52:42,360
ON THE CNS AND THE PATHOGENESIS

4669
02:52:42,360 --> 02:52:44,000
THAT RESULTS.

4670
02:52:44,000 --> 02:52:45,800
SO OUR THREE CONCEPTS, THE FIRST

4671
02:52:45,800 --> 02:52:50,400
ONE IS STREAMING MENTAL HEALTH

4672
02:52:50,400 --> 02:52:51,240
INTERVENTIONS FOR YOUTH LIVING

4673
02:52:51,240 --> 02:52:53,440
IN HIV AND LOW INCOME COUNTRIES.

4674
02:52:53,440 --> 02:52:54,760
THE OVERALL GOAL OF THIS IS TO

4675
02:52:54,760 --> 02:52:56,200
ADAPT SCALABLE MENTAL HEALTH

4676
02:52:56,200 --> 02:52:57,200
INTERVENTIONS FOR YOUTH LIVING

4677
02:52:57,200 --> 02:52:59,160
WITH HIV IN LOW AND MIDDLE

4678
02:52:59,160 --> 02:53:00,160
INCOME COUNTRIES THAT WILL LEAD

4679
02:53:00,160 --> 02:53:01,560
TO IMPROVEMENTS IN BOTH MENTAL

4680
02:53:01,560 --> 02:53:03,680
HEALTH AND HIV OUTCOMES.

4681
02:53:03,680 --> 02:53:06,320
AND THE COMPONENTS OF THIS

4682
02:53:06,320 --> 02:53:07,600
INCLUDE DEVELOPING INTERVENTIONS

4683
02:53:07,600 --> 02:53:10,120
THAT ARE TAILORED TO THE UNIQUE

4684
02:53:10,120 --> 02:53:11,880
NEEDS OF ADOLESCENTS LIVING WITH

4685
02:53:11,880 --> 02:53:14,600
HIV, AND ENSURE THAT THESE ARE

4686
02:53:14,600 --> 02:53:17,360
STREAMLINED SO THAT THEY CAN BE

4687
02:53:17,360 --> 02:53:19,200
IMPLEMENTED IN RESEARCH LIMITED

4688
02:53:19,200 --> 02:53:20,640
SETTINGS BROADLY.

4689
02:53:20,640 --> 02:53:21,960
THE SECOND ONE IS IN OUR

4690
02:53:21,960 --> 02:53:24,960
NEUROSCIENCE AREA, AND THAT IS

4691
02:53:24,960 --> 02:53:26,800
MECHANISMS OF RECIPROCAL

4692
02:53:26,800 --> 02:53:28,080
INTERACTIONS BETWEEN HIV

4693
02:53:28,080 --> 02:53:29,680
ASSOCIATED NEUROINFLAMMATION AND

4694
02:53:29,680 --> 02:53:31,440
CNS PERSISTENCE, AND TO LACK AT

4695
02:53:31,440 --> 02:53:34,640
IMPLICATIONS FOR THIS IN HIV

4696
02:53:34,640 --> 02:53:35,440
NEUROPATHOGENESIS AND CURE.

4697
02:53:35,440 --> 02:53:37,040
THIS IS TO ENCOURAGE RESEARCH

4698
02:53:37,040 --> 02:53:41,520
USING NOVEL CNS CELL SYSTEMS,

4699
02:53:41,520 --> 02:53:43,000
ORGANOID NO DELLS AND

4700
02:53:43,000 --> 02:53:45,520
TECHNOLOGIES, TO EXAMINE --

4701
02:53:45,520 --> 02:53:47,160
BETWEEN HIV ASSOCIATED NEURAL

4702
02:53:47,160 --> 02:53:49,960
INFLAMMATION AND HIV

4703
02:53:49,960 --> 02:53:51,800
PERSISTENCE, DESPITE EFFECTIVE

4704
02:53:51,800 --> 02:53:54,600
ART WITH THE ULTIMATE GOAL OF

4705
02:53:54,600 --> 02:53:56,680
ERADICATING CNS RESERVOIRS AND

4706
02:53:56,680 --> 02:53:57,720
UNDERSTANDING MECHANISMS OF

4707
02:53:57,720 --> 02:54:01,320
ASSOCIATED COMORBIDITIES.

4708
02:54:01,320 --> 02:54:03,720
THE THIRD ONE IS TARGETING

4709
02:54:03,720 --> 02:54:08,960
ADVANCINGSADVANCINGS TESTING, PN

4710
02:54:08,960 --> 02:54:11,040
AND CARE THROUGH PHARMACISTS AND

4711
02:54:11,040 --> 02:54:12,760
PHARMACIES, AND THE GOAL OF THIS

4712
02:54:12,760 --> 02:54:13,920
IS TO SUPPORT RESEARCH TO

4713
02:54:13,920 --> 02:54:15,760
FURTHER CAPACITY AND SCALE

4714
02:54:15,760 --> 02:54:18,720
ROUTINE DELIVERY OF HIV TESTING

4715
02:54:18,720 --> 02:54:20,360
PREVENTION AND CARE TO

4716
02:54:20,360 --> 02:54:21,880
PHARMACIST AND PHARMACY

4717
02:54:21,880 --> 02:54:23,760
SETTINGS, AND ANOTHER GOAL IS TO

4718
02:54:23,760 --> 02:54:25,600
ADVANCE TRAINING, CURRICULA AND

4719
02:54:25,600 --> 02:54:26,600
PROGRAMS TO ENABLE PHARMACY

4720
02:54:26,600 --> 02:54:27,720
STUDENTS, PHARMACISTS AND

4721
02:54:27,720 --> 02:54:29,560
PHARMACIES TO EFFECTIVELY

4722
02:54:29,560 --> 02:54:30,880
DELIVER HIV SERVICES WITHESE AND

4723
02:54:30,880 --> 02:54:31,280
EQUITY.

4724
02:54:31,280 --> 02:54:32,520
THE RATIONALE BEHIND THIS IS

4725
02:54:32,520 --> 02:54:34,440
THAT PHARMACISTS' KNOWLEDGE AND

4726
02:54:34,440 --> 02:54:36,840
ACCESSIBILITY IN NEARLY EVERY

4727
02:54:36,840 --> 02:54:38,160
URBAN AND RURAL COMMUNITY CAN BE

4728
02:54:38,160 --> 02:54:40,920
LEVERAGED AS PART OF A

4729
02:54:40,920 --> 02:54:41,880
COMPREHENSIVE HIV PREVENTION AND

4730
02:54:41,880 --> 02:54:43,680
CARE STRATEGY TO EXPAND ACCESS

4731
02:54:43,680 --> 02:54:46,080
TO CARE AND IMPROVE POPULATION

4732
02:54:46,080 --> 02:54:48,280
HELP.

4733
02:54:48,280 --> 02:54:48,600
WEALTH.

4734
02:54:48,600 --> 02:54:50,720
WE ARE CO-SPONSORING A MEETING

4735
02:54:50,720 --> 02:54:52,640
NEXT WEEK WITH O.A.R. ON WORK IN

4736
02:54:52,640 --> 02:54:53,320
PHARMACIES, AND THAT MEETING

4737
02:54:53,320 --> 02:54:55,480
WILL BE NEXT WEDNESDAY AND

4738
02:54:55,480 --> 02:54:56,400
THURSDAY AND WE CAN SEND AROUND

4739
02:54:56,400 --> 02:54:58,720
THE LINK TO EVERYONE IF THEY'RE

4740
02:54:58,720 --> 02:54:59,800
INTERESTING IN ATTENDING.

4741
02:54:59,800 --> 02:55:02,240
SO THANK YOU, AND ANSWER TO

4742
02:55:02,240 --> 02:55:07,080
ANSWER ANY QUESTIONS.

4743
02:55:07,080 --> 02:55:07,680
>> THANK YOU.

4744
02:55:07,680 --> 02:55:09,240
SO IN TERMS OF REISSUED

4745
02:55:09,240 --> 02:55:12,560
CONCEPTS, I WILL NOW DISCUSS

4746
02:55:12,560 --> 02:55:15,080
FOGARTY INTERNATIONAL CENTER HAS

4747
02:55:15,080 --> 02:55:16,680
TWO CONCEPTS.

4748
02:55:16,680 --> 02:55:18,760
INTERVENTIONS FOR STIGMA

4749
02:55:18,760 --> 02:55:20,760
REDUCTION TO IMPROVE HIV/AIDS

4750
02:55:20,760 --> 02:55:22,200
PREVENTION, TREATMENT AND CARE

4751
02:55:22,200 --> 02:55:27,240
IN LOW, MIDDLE INCOME COUNTRIES.

4752
02:55:27,240 --> 02:55:28,560
SEEKS TO SUPPORT RESEARCH TO

4753
02:55:28,560 --> 02:55:30,160
DEVELOP AND PILOT-TEST

4754
02:55:30,160 --> 02:55:31,720
INTERVENTIONS TO REDUCE THE

4755
02:55:31,720 --> 02:55:36,160
IMPACT OF HIV ASSOCIATED STIGMA

4756
02:55:36,160 --> 02:55:41,400
ON THE REVENGS AND TR THE PREVET

4757
02:55:41,400 --> 02:55:42,920
OF HIV AND ON THE QUALITY OF

4758
02:55:42,920 --> 02:55:44,240
LIFE OF PEOPLE WITH HIV.

4759
02:55:44,240 --> 02:55:46,520
THE SECOND CONCEPT, HIV

4760
02:55:46,520 --> 02:55:47,240
ASSOCIATED NON-COMMUNICABLE

4761
02:55:47,240 --> 02:55:51,600
DISEASES RESEARCH AT LMIC

4762
02:55:51,600 --> 02:55:53,920
INSTITUTIONS, SEEKS TO SUPPORT

4763
02:55:53,920 --> 02:55:57,080
LOCALLY RELEVANT RESEARCH IN

4764
02:55:57,080 --> 02:55:59,920
CRITICAL AREAS OF HIV-ASSOCIATED

4765
02:55:59,920 --> 02:56:02,560
NON-COMMUNICABLE DISEASES AT

4766
02:56:02,560 --> 02:56:04,600
LMIC INSTITUTIONS TO ENHANCE

4767
02:56:04,600 --> 02:56:10,800
RESEARCH CAPACITY.

4768
02:56:10,800 --> 02:56:13,960
THE NATIONAL CANCER INSTITUTE

4769
02:56:13,960 --> 02:56:14,960
HAS TWO REISSUE CONCEPTS.

4770
02:56:14,960 --> 02:56:17,600
THE RESEARCH ON HIV-ASSOCIATED

4771
02:56:17,600 --> 02:56:19,760
MALIGNANCIES, NOSI, WILL

4772
02:56:19,760 --> 02:56:21,520
CONTINUE ADVANCING THE

4773
02:56:21,520 --> 02:56:24,800
UNDERSTANDING OF THE RISKS,

4774
02:56:24,800 --> 02:56:25,800
DEVELOPMENT, PROGRESSION,

4775
02:56:25,800 --> 02:56:28,520
DIAGNOSES, AND TREATMENT OF

4776
02:56:28,520 --> 02:56:29,960
MALIGNANCIES OBSERVED IN

4777
02:56:29,960 --> 02:56:31,840
INDIVIDUALS WITH AN UNDERLYING

4778
02:56:31,840 --> 02:56:35,560
HIV INFECTION.

4779
02:56:35,560 --> 02:56:36,240
THE SECOND IMPLEMENTATION

4780
02:56:36,240 --> 02:56:37,640
SCIENCE FOR CANCER CONTROL IN

4781
02:56:37,640 --> 02:56:42,240
PEOPLE LIVING WITH HIV AND

4782
02:56:42,240 --> 02:56:44,320
LMICs, WILL CONTINUE TO

4783
02:56:44,320 --> 02:56:45,400
SUPPORT IMPLEMENTATION SCIENCE

4784
02:56:45,400 --> 02:56:47,480
RESEARCH TO ACCELERATE THE

4785
02:56:47,480 --> 02:56:51,080
INTEGRATION OF EVIDENCE-BASED

4786
02:56:51,080 --> 02:56:54,520
CANCER CONTROL INTERVENTIONS FOR

4787
02:56:54,520 --> 02:56:56,480
PEOPLE WITH HIV BY LEVERAGING

4788
02:56:56,480 --> 02:56:58,480
EXISTING HIV TREATMENT AND

4789
02:56:58,480 --> 02:57:02,920
PREVENTION INFRASTRUCTURE.

4790
02:57:02,920 --> 02:57:04,120
THE NATIONAL INSTITUTE ON

4791
02:57:04,120 --> 02:57:07,240
ALCOHOL ABUSE AND ALCOHOLISM HAS

4792
02:57:07,240 --> 02:57:10,080
REISSUED HIV PREVENTION AND

4793
02:57:10,080 --> 02:57:14,800
ALCOHOL FOR BOTH THE R34 AND R0.

4794
02:57:14,800 --> 02:57:17,800
THESE NOFOs SEEK TO EXPAND THE

4795
02:57:17,800 --> 02:57:20,520
HIV PREVENTION TOOLKIT AMONG

4796
02:57:20,520 --> 02:57:23,120
ALCOHOL IMPACTED POPULATIONS

4797
02:57:23,120 --> 02:57:24,600
WITH A RANGE OF PATTERNS OF

4798
02:57:24,600 --> 02:57:27,720
EPISODIC AND LONG-TERM USE AND

4799
02:57:27,720 --> 02:57:29,600
ASSOCIATED BEHAVIORAL AND

4800
02:57:29,600 --> 02:57:32,080
BIOLOGICAL CONTRIBUTORS FOR

4801
02:57:32,080 --> 02:57:35,280
VULNERABILITY TO HIV ACQUISI 

4802
02:57:35,280 --> 02:57:37,960
ACQUISITION.

4803
02:57:37,960 --> 02:57:40,960
AS DR. DIEFFENBACH HAS DISCUSSED

4804
02:57:40,960 --> 02:57:43,360
THE REISSUED CONCEPTS FOR NIAID,

4805
02:57:43,360 --> 02:57:46,120
I WILL GO TO THE NEXT SLIDE,

4806
02:57:46,120 --> 02:57:47,560
PLEASE.

4807
02:57:47,560 --> 02:57:50,400
AND LASTLY, THE OFFICE OF

4808
02:57:50,400 --> 02:57:52,040
RESEARCH INFRASTRUCTURE PROGRAMS

4809
02:57:52,040 --> 02:57:57,160
HAS REISSUED ONE CONCEPT, ANIMAL

4810
02:57:57,160 --> 02:58:00,880
MODELS AND ANIMAL AND BIOLOGICAL

4811
02:58:00,880 --> 02:58:02,000
MATERIALS CENTER AND RESOURCE

4812
02:58:02,000 --> 02:58:03,640
PROGRAMS, WHICH SUPPORTS SPECIAL

4813
02:58:03,640 --> 02:58:06,360
COLONIES OF LABORATORY ANIMALS,

4814
02:58:06,360 --> 02:58:07,840
ANIMAL-RELATED MODELS, AND OTHER

4815
02:58:07,840 --> 02:58:10,120
RESOURCES THAT SERVE THE

4816
02:58:10,120 --> 02:58:11,120
BIOMEDICAL COMMUNITY IN A

4817
02:58:11,120 --> 02:58:13,160
VARIETY OF RESEARCH AREAS ON A

4818
02:58:13,160 --> 02:58:16,520
NATIONAL BASIS.

4819
02:58:16,520 --> 02:58:17,720
WITH THAT, I WANT TO THANK YOU

4820
02:58:17,720 --> 02:58:20,320
AND I WILL TURN IT BACK OVER TO

4821
02:58:20,320 --> 02:58:28,680
DR. TU TURNBULL.

4822
02:58:28,680 --> 02:58:30,000
>> THANK YOU, COLLEAGUES,
FOR

4823
02:58:30,000 --> 02:58:30,520
YOUR UPDATES.

4824
02:58:30,520 --> 02:58:34,680
WE ARE NOW OPEN FOR DISCUSSION.

4825
02:58:34,680 --> 02:58:36,440
DR. GLENSHAW, ARE THERE ANY

4826
02:58:36,440 --> 02:58:39,160
COMMENTS OR QUESTIONS IN THE

4827
02:58:39,160 --> 02:58:43,760
ROOM?

4828
02:58:43,760 --> 02:58:46,720
>> YES, DR. TURNBULL.

4829
02:58:46,720 --> 02:58:47,040
DR. MONTANER.

4830
02:58:47,040 --> 02:58:47,480
>> YES, THANK YOU.

4831
02:58:47,480 --> 02:58:53,400
I JUST WANT TO COMMEND THE NIH

4832
02:58:53,400 --> 02:58:54,680
DATES PROGRAM FOR THE LEADERSHIP

4833
02:58:54,680 --> 02:58:56,360
ON THE CURE AGENDA, WHICH I'M

4834
02:58:56,360 --> 02:59:00,200
VERY PARTIAL TOO, BU TO, BUT I S

4835
02:59:00,200 --> 02:59:00,920
WHAT I WANTED TO PERHAPS RAISE

4836
02:59:00,920 --> 02:59:02,200
FOR CONSIDERATION AND MAYBE --

4837
02:59:02,200 --> 02:59:03,120
OR I'M NOT SURE WHETHER THAT

4838
02:59:03,120 --> 02:59:05,720
WOULD BE ANOTHER POTENTIAL IS

4839
02:59:05,720 --> 02:59:07,840
THAT THERE'S BEEN A LOT OF -- I

4840
02:59:07,840 --> 02:59:08,800
THINK A LOT OF DISCUSSION ABOUT

4841
02:59:08,800 --> 02:59:12,000
THE NEED TO EXTEND CURE RESEARCH

4842
02:59:12,000 --> 02:59:15,280
INTO AN INTERNATIONAL KIND OF

4843
02:59:15,280 --> 02:59:17,120
SETTING.

4844
02:59:17,120 --> 02:59:18,200
ONE OF THE BLESSINGS AND CURSE

4845
02:59:18,200 --> 02:59:20,720
OF OUR ADVANCEMENT IN THE LAST

4846
02:59:20,720 --> 02:59:22,760
FIVE YEARS IS THAT WE HAVE BEEN

4847
02:59:22,760 --> 02:59:28,200
ABLE NOW TO CHARACTERIZE VERY

4848
02:59:28,200 --> 02:59:29,600
ACUTELY THE HIV RESERVOIR

4849
02:59:29,600 --> 02:59:30,600
THROUGH MULTIPLE ASSAYS THAT

4850
02:59:30,600 --> 02:59:33,000
GIVE US A LOT OF RESOLUTION, AND

4851
02:59:33,000 --> 02:59:34,520
THE ENTIRE FIELD HAS EMBRACED

4852
02:59:34,520 --> 02:59:38,680
THIS NEW TECHNOLOGY WITH RESPECT

4853
02:59:38,680 --> 02:59:40,240
TO THE DIFFERENT WAYS THAT WE

4854
02:59:40,240 --> 02:59:42,960
CAN MEASURE THE PERSISTENCE OF

4855
02:59:42,960 --> 02:59:46,080
HIV ON SOMEONE THAT IS ON

4856
02:59:46,080 --> 02:59:47,680
ANTIRETROVIRAL THERAPY.

4857
02:59:47,680 --> 02:59:49,240
HOWEVER, THE LIMITATION COMES IN

4858
02:59:49,240 --> 02:59:50,880
THAT A LOT OF THESE ASSAYS THAT

4859
02:59:50,880 --> 02:59:57,640
ARE THE MOST PROMINENT ARE BASED

4860
02:59:57,640 --> 02:59:59,600
ON -- DETERMINATIONS.

4861
02:59:59,600 --> 03:00:00,720
SO TO ACTUALLY PROPOSE WHAT

4862
03:00:00,720 --> 03:00:03,880
WOULD BE A CREDIBLE PATH TO

4863
03:00:03,880 --> 03:00:05,000
EXTEND IN AN INTERNATIONAL

4864
03:00:05,000 --> 03:00:06,080
SETTING, YOU WOULD HAVE TO HAVE

4865
03:00:06,080 --> 03:00:09,640
THE SAME ASSAY ON OTHER PLATES,

4866
03:00:09,640 --> 03:00:11,640
AND THAT IS NOT READILY

4867
03:00:11,640 --> 03:00:12,240
ACCESSIBLE.

4868
03:00:12,240 --> 03:00:14,520
THE METHODS HAVE NOT BEEN YET

4869
03:00:14,520 --> 03:00:15,400
DEVELOPED AND THE COMMERCIAL

4870
03:00:15,400 --> 03:00:17,600
ENTITIES THAT ARE OTHERWISE

4871
03:00:17,600 --> 03:00:19,280
ENGAGED WITH THIS ARE VERY MUCH

4872
03:00:19,280 --> 03:00:20,320
INTERESTED TO DEVELOP THESE

4873
03:00:20,320 --> 03:00:21,320
ASSAYS BECAUSE WE'VE BEEN IN

4874
03:00:21,320 --> 03:00:28,560
TOUCH WITH THEM, PARTICULARLY

4875
03:00:28,560 --> 03:00:30,600
ACELOVIR, SO THEY'RE RECOGNIZED

4876
03:00:30,600 --> 03:00:32,800
AND THEY'RE WORKING WITH IT, BUT

4877
03:00:32,800 --> 03:00:34,120
WHEN YOU TRY TO MATCH

4878
03:00:34,120 --> 03:00:34,800
INDIVIDUALS WITH THE MAJORITY OF

4879
03:00:34,800 --> 03:00:36,880
THE SAMPLES WITH COMMERCIAL

4880
03:00:36,880 --> 03:00:39,560
ENTITIES, THERE'S SOME NATURAL

4881
03:00:39,560 --> 03:00:40,640
NEGOTIATION THAT NEEDS TO OCCUR

4882
03:00:40,640 --> 03:00:41,640
ABOUT ACCESS OF METHODS

4883
03:00:41,640 --> 03:00:42,440
AFTERWARDS AND THAT'S WHERE IT

4884
03:00:42,440 --> 03:00:44,480
KIND OF STOPS.

4885
03:00:44,480 --> 03:00:49,320
SO I WOULD MAYBE ENCOURAGE

4886
03:00:49,320 --> 03:00:50,760
MORE -- I'M NOT SURE WHETHER AN

4887
03:00:50,760 --> 03:00:52,520
RFA OR ANY OTHER INSTRUMENT THAT

4888
03:00:52,520 --> 03:00:53,840
TRIES TO INCENTIVIZE THE

4889
03:00:53,840 --> 03:00:55,800
DEVELOPMENT OF THESE ASSAYS FOR

4890
03:00:55,800 --> 03:00:56,960
MULTIPLE CLADES, BECAUSE THAT IS

4891
03:00:56,960 --> 03:01:00,960
A LIMITING FACTOR FOR ANY STUDY

4892
03:01:00,960 --> 03:01:03,560
PLAN TRIAL IN ORDER TO PROPOSE

4893
03:01:03,560 --> 03:01:08,200
IT IN AREAS WHERE CLADE B IS NOT

4894
03:01:08,200 --> 03:01:09,280
THE PREVALENT CLADE.

4895
03:01:09,280 --> 03:01:10,680
SO I'M SURE THIS IS NOT ANYTHING

4896
03:01:10,680 --> 03:01:11,240
NEW.

4897
03:01:11,240 --> 03:01:13,240
WE'VE ALL KNOWN THIS, BUT I

4898
03:01:13,240 --> 03:01:16,040
DON'T KNOW WHAT PROGRAMS ARE

4899
03:01:16,040 --> 03:01:19,000
UNDERWAY TO MAKE THESE

4900
03:01:19,000 --> 03:01:20,080
DEVELOPMENTAL INVESTMENTS

4901
03:01:20,080 --> 03:01:21,200
BECAUSE I UNDERSTAND THERE'S A

4902
03:01:21,200 --> 03:01:22,520
LOT OF SEQUENCING THAT NEEDS TO

4903
03:01:22,520 --> 03:01:25,480
BE AVAILABLE, A LOT OF ITERATIVE

4904
03:01:25,480 --> 03:01:28,320
PROCESS OF DETERMINING THE BEST

4905
03:01:28,320 --> 03:01:29,760
PRIMERS, ET CETERA, WHICH IS NOT

4906
03:01:29,760 --> 03:01:31,160
SOMETHING ANY ONE LAB CAN DO ON

4907
03:01:31,160 --> 03:01:33,600
THE SIDE.

4908
03:01:33,600 --> 03:01:35,760
SO IT WOULD BE GOOD TO CONSIDER

4909
03:01:35,760 --> 03:01:46,320
WHAT COULD WE DO IN THAT DOMAIN.

4910
03:01:48,360 --> 03:01:52,560
>> DR. AKE?

4911
03:01:52,560 --> 03:01:58,280
>> MHRP DOES A LOT OF
TRIALS IN

4912
03:01:58,280 --> 03:02:02,240
LOW MIDDLE INCOME SETTINGS WITH

4913
03:02:02,240 --> 03:02:03,240
NON-CLADE B AND WE RAN INTO

4914
03:02:03,240 --> 03:02:04,320
THOSE SAME ISSUES.

4915
03:02:04,320 --> 03:02:05,880
AND I THINK -- I'M SURE OUR

4916
03:02:05,880 --> 03:02:07,520
COLLEAGUES CAN DESCRIBE SOME OF

4917
03:02:07,520 --> 03:02:08,560
THE EFFORTS THAT ARE BEING MADE

4918
03:02:08,560 --> 03:02:14,720
TO FURTHER SUPPORT EXCELIVIER

4919
03:02:14,720 --> 03:02:15,600
AND SOME OTHER -- YOU KNOW,

4920
03:02:15,600 --> 03:02:17,360
EFFORTS IN, YOU KNOW, IN OTHER

4921
03:02:17,360 --> 03:02:19,120
LABS TO SUPPORT.

4922
03:02:19,120 --> 03:02:20,840
I AGREE IT'S A GAP.

4923
03:02:20,840 --> 03:02:21,560
THE ONE OTHER THING I WOULD ADD

4924
03:02:21,560 --> 03:02:24,360
TO IT, THOUGH, IS THAT I THINK

4925
03:02:24,360 --> 03:02:25,800
THOSE ASSAYS ARE IN DEVELOPMENT

4926
03:02:25,800 --> 03:02:27,200
AND THE TRIALS TAKE SO LONG TO

4927
03:02:27,200 --> 03:02:33,240
DESIGN AND GET STARTED THAT

4928
03:02:33,240 --> 03:02:34,240
RESTRICTIONS ON THE TRIALS,

4929
03:02:34,240 --> 03:02:35,520
BECAUSE THERE'S NO ASSAY FOR THE

4930
03:02:35,520 --> 03:02:37,120
RESERVOIR THAT'S ALREADY BEEN

4931
03:02:37,120 --> 03:02:37,960
VALIDATED, IS PROBABLY NOT THE

4932
03:02:37,960 --> 03:02:38,640
WAY TO GO.

4933
03:02:38,640 --> 03:02:41,280
I THINK YOU CAN START WITH THE

4934
03:02:41,280 --> 03:02:42,560
TRIAL, BY THE TIME YOU ACTUALLY

4935
03:02:42,560 --> 03:02:44,360
HAVE THE SPECIMENS, THE ASSAYS

4936
03:02:44,360 --> 03:02:44,680
CAN BE THERE.

4937
03:02:44,680 --> 03:02:45,760
I DON'T THINK YOU CAN WAIT UNTIL

4938
03:02:45,760 --> 03:02:47,280
YOU HAVE A VALIDATED ASSAY

4939
03:02:47,280 --> 03:02:48,600
BEFORE WE START DOING THE TRIALS

4940
03:02:48,600 --> 03:02:53,320
IN THOSE SETTINGS.

4941
03:02:53,320 --> 03:02:54,840
BUT I THINK MORE IMPETUS WHEN

4942
03:02:54,840 --> 03:02:57,040
YOU'VE GOT THE STUDIES ALREADY

4943
03:02:57,040 --> 03:02:59,800
GOING IN MY VIEW.

4944
03:02:59,800 --> 03:03:02,400
THE ONE COMMENT I WANTED TO MAKE

4945
03:03:02,400 --> 03:03:04,480
ABOUT THE PRESENTATIONS THAT I'M

4946
03:03:04,480 --> 03:03:05,800
ABSOLUTELY IN AGREEMENT THAT'S

4947
03:03:05,800 --> 03:03:12,920
JUST A FINAL POINT, WAS JUST TO

4948
03:03:12,920 --> 03:03:14,000
NOTE A COMMENDATION FOR THE

4949
03:03:14,000 --> 03:03:16,200
IMMUNITY IN EARLY LIFE CONCEPT.

4950
03:03:16,200 --> 03:03:17,600
SO THE DOD OBVIOUSLY, YOU KNOW,

4951
03:03:17,600 --> 03:03:19,160
IN THE ABSENCE OF CHILD

4952
03:03:19,160 --> 03:03:20,800
SOLDIERS, WE DO NOT MAKE

4953
03:03:20,800 --> 03:03:23,240
VACCINES FOR CHILDREN, BUT THE

4954
03:03:23,240 --> 03:03:23,680
CONCEPT, RIGHT?

4955
03:03:23,680 --> 03:03:25,440
I MEAN, WE ALL KNOW VERY WELL,

4956
03:03:25,440 --> 03:03:27,840
YOU KNOW, THE IMPROVEMENT IN

4957
03:03:27,840 --> 03:03:30,880
IMMUNITY, I MEAN, NOT EVEN JUST

4958
03:03:30,880 --> 03:03:32,440
IN YOUNG VERSUS OLDER

4959
03:03:32,440 --> 03:03:34,080
INDIVIDUALS, BUT WHEN THERE'S A

4960
03:03:34,080 --> 03:03:38,880
LONG GAP TWEE BETWEEN PRIMES AND

4961
03:03:38,880 --> 03:03:40,320
BOOSTS, SO ONE CAN, IN A PUBLIC

4962
03:03:40,320 --> 03:03:41,120
HEALTH CONCEPT, EASILY IMAGINE

4963
03:03:41,120 --> 03:03:42,600
IN VERY HIGH RISK SETTINGS, YOU

4964
03:03:42,600 --> 03:03:44,080
KNOW, WHERE YOU MIGHT HAVE

4965
03:03:44,080 --> 03:03:46,800
CHILDHOOD VACCINATIONS AND

4966
03:03:46,800 --> 03:03:49,080
SUBSEQUENT BOOSTS, PRE-SEXUAL

4967
03:03:49,080 --> 03:03:50,520
DEBUT, THAT COULD FIT IN WELL

4968
03:03:50,520 --> 03:03:53,840
WITH ESTABLISHED, YOU KNOW,

4969
03:03:53,840 --> 03:03:56,320
PUBLIC HEALTH VACCINATION

4970
03:03:56,320 --> 03:03:57,200
STRATEGIES IN SOME OF THE AREAS

4971
03:03:57,200 --> 03:03:59,440
OF THE WORLD WHERE HIV HAS SORT

4972
03:03:59,440 --> 03:04:01,240
OF HIT THE HARDEST.

4973
03:04:01,240 --> 03:04:06,400
SO SCIENTIFICALLY, I THINK IT'S

4974
03:04:06,400 --> 03:04:09,480
VERY COMELL COMPELLING AND EVENO

4975
03:04:09,480 --> 03:04:11,680
BECAUSE OF ITS POTENTIAL PUBLIC

4976
03:04:11,680 --> 03:04:14,960
HEALTH TRANSLATABILITY, AND JUST

4977
03:04:14,960 --> 03:04:17,480
WANTED TO COMMEND DATES ON THE

4978
03:04:17,480 --> 03:04:19,040
ISSUANCE OF THAT NEW CONCEPT.

4979
03:04:19,040 --> 03:04:22,400
>> IF YOU DON'T MIND,
MARY, I'LL

4980
03:04:22,400 --> 03:04:23,520
MAKE A COUPLE OF COMMENTS.

4981
03:04:23,520 --> 03:04:26,160
JULIE, I THINK YOU'RE ABSOLUTELY

4982
03:04:26,160 --> 03:04:27,440
RIGHT ON THE ASSAYS THAT WE ARE

4983
03:04:27,440 --> 03:04:29,400
IN THIS PROCESS OF VALIDATION

4984
03:04:29,400 --> 03:04:31,520
AND RE-VALIDATION, AND THE

4985
03:04:31,520 --> 03:04:34,800
HURDLE TO GET OVER A CLIA

4986
03:04:34,800 --> 03:04:36,120
CERTIFIED ASSAY SO YOU COULD USE

4987
03:04:36,120 --> 03:04:40,800
IT IN A CLINICAL TRIAL, THE

4988
03:04:40,800 --> 03:04:42,800
RETURN OF DATA IS A MAJOR HURDLE

4989
03:04:42,800 --> 03:04:43,880
THAT HAS TO BE CONQUERED.

4990
03:04:43,880 --> 03:04:45,520
THAT'S WHERE WE'RE AT.

4991
03:04:45,520 --> 03:04:47,200
THROWING MONEY AT THE PROBLEM BY

4992
03:04:47,200 --> 03:04:48,520
GIVING LABS SOME ADDITIONAL TIME

4993
03:04:48,520 --> 03:04:50,720
TO GO MAKE ADDITIONAL PRIMERS, I

4994
03:04:50,720 --> 03:04:53,160
DON'T THINK IS GOING TO HELP.

4995
03:04:53,160 --> 03:04:55,560
WE'VE PUT OUT -- THERE WAS SOME

4996
03:04:55,560 --> 03:04:59,240
SBIR ACTIVITIES ON SOME OF THIS,

4997
03:04:59,240 --> 03:05:00,800
BUT IT'S ALL IN PROCESS.

4998
03:05:00,800 --> 03:05:03,520
YOU HAVE ABSOLUTELY DESCRIBED

4999
03:05:03,520 --> 03:05:07,440
EXACTLY THE THOUGHT BEHIND THE

5000
03:05:07,440 --> 03:05:09,080
EARLY IMMUNITY THAT'S EXACTLY

5001
03:05:09,080 --> 03:05:10,440
WHAT WE'RE THINKING ABOUT, IS

5002
03:05:10,440 --> 03:05:13,360
THIS IDEA THAT VACCINATIONS IN

5003
03:05:13,360 --> 03:05:17,080
YOUTH OR PREADOLESCENT, THAT

5004
03:05:17,080 --> 03:05:18,560
THEY NEED TO BE ADOLESCENT OR

5005
03:05:18,560 --> 03:05:19,640
OLDER, THIS IDEA OF REST AND

5006
03:05:19,640 --> 03:05:21,520
BOOST WILL BE REALLY, REALLY

5007
03:05:21,520 --> 03:05:23,720
IMPORTANT.

5008
03:05:23,720 --> 03:05:26,240
SO MAYBE YOU SHOULD TALK TO PHIL

5009
03:05:26,240 --> 03:05:27,440
ABOUT SEEING IF WE COULD WORK

5010
03:05:27,440 --> 03:05:35,320
TOGETHER ON THIS ONE TOO.

5011
03:05:35,320 --> 03:05:36,960
>> YES, DR. SLEASMAN.

5012
03:05:36,960 --> 03:05:37,200
THANKS.

5013
03:05:37,200 --> 03:05:39,360
>> I JUST WANTED TO ASK A
QUICK

5014
03:05:39,360 --> 03:05:41,680
QUESTION, SORT OF ACROSS THE

5015
03:05:41,680 --> 03:05:42,800
INITIATIVES, AND HOW ARE WE

5016
03:05:42,800 --> 03:05:47,480
LOOKING AT NOVEL ANALYTICS?

5017
03:05:47,480 --> 03:05:49,280
THE DATA ANALYSIS PARTICULARLY

5018
03:05:49,280 --> 03:05:50,880
OF BIG DATA, ARTIFICIAL

5019
03:05:50,880 --> 03:05:52,320
INTELLIGENCE AND THE USE OF

5020
03:05:52,320 --> 03:05:57,600
THESE TYPES OF TOOLS PROBABLY IS

5021
03:05:57,600 --> 03:06:01,920
SOMETHING THAT IS -- SHOULD BE

5022
03:06:01,920 --> 03:06:03,080
WOVEN INTO ALL OF THESE

5023
03:06:03,080 --> 03:06:03,560
APPLICATIONS.

5024
03:06:03,560 --> 03:06:07,800
FOR ME, THE RATE LIMITING STEP

5025
03:06:07,800 --> 03:06:09,200
FOR MANY OF THESE THINGS WE DO

5026
03:06:09,200 --> 03:06:10,840
HAS BECOME THE ANALYTICAL STEP,

5027
03:06:10,840 --> 03:06:12,160
BECAUSE IT BECOMES SO

5028
03:06:12,160 --> 03:06:13,320
COMPLICATED AND SO SPECIALIZED

5029
03:06:13,320 --> 03:06:14,880
AND THE WORKFLOW HAS REALLY

5030
03:06:14,880 --> 03:06:17,800
SLOWED DOWN AT THAT LEVEL, AND

5031
03:06:17,800 --> 03:06:19,280
IS THERE A WAY TO SPEED THAT UP

5032
03:06:19,280 --> 03:06:26,960
ACROSS THE BOARD.

5033
03:06:26,960 --> 03:06:27,480
>> ALL GOOD COMMENTS.

5034
03:06:27,480 --> 03:06:28,720
THANK YOU.

5035
03:06:28,720 --> 03:06:29,600
DR. TURNBULL, I THINK THAT'S IT

5036
03:06:29,600 --> 03:06:30,240
FOR THE ROOM.

5037
03:06:30,240 --> 03:06:32,360
>> OKAY, THANK YOU,

5038
03:06:32,360 --> 03:06:33,000
DR. GLENSHAW.

5039
03:06:33,000 --> 03:06:34,560
ANY OTHER MEMBERS ON ZOOM WOULD

5040
03:06:34,560 --> 03:06:36,960
LIKE TO MAKE A COMMENT OR HAVE A

5041
03:06:36,960 --> 03:06:39,160
QUESTION?

5042
03:06:39,160 --> 03:06:45,720
PLEASE RAISE YOUR HAND.

5043
03:06:45,720 --> 03:06:46,000
DR. NAGHAVI?

5044
03:06:46,000 --> 03:06:49,440
>> OH, I THINK IT'S GREAT
THAT

5045
03:06:49,440 --> 03:06:51,640
THE ASSAYS THAT WE ARE -- I

5046
03:06:51,640 --> 03:06:55,680
MEAN, BEING DEVELOPED TO

5047
03:06:55,680 --> 03:06:57,120
ELIMINATE THE RESERVOIRS, BUT

5048
03:06:57,120 --> 03:06:58,680
I'M JUST WONDERING HOW MUCH

5049
03:06:58,680 --> 03:07:00,960
EFFORT ARE THEY PUTTING IN IN

5050
03:07:00,960 --> 03:07:02,920
IDENTIFYING THE RESERVOIRS?

5051
03:07:02,920 --> 03:07:06,000
BECAUSE WE STILL DON'T

5052
03:07:06,000 --> 03:07:07,320
UNDERSTAND WHAT ALL THESE

5053
03:07:07,320 --> 03:07:08,240
RESERVOIRS ARE.

5054
03:07:08,240 --> 03:07:10,520
LIKE FOR EXAMPLE, IN THE CNS,

5055
03:07:10,520 --> 03:07:11,160
RIGHT?

5056
03:07:11,160 --> 03:07:13,680
SO WITHOUT UNDERSTANDING THE

5057
03:07:13,680 --> 03:07:16,640
RESERVOIRS, FOCUSING JUST ON

5058
03:07:16,640 --> 03:07:20,160
ELIMINATING THEM, IT KIND OF A

5059
03:07:20,160 --> 03:07:21,560
BIG -- I MEAN, LACKING KNOWLEDGE

5060
03:07:21,560 --> 03:07:23,240
FOR ME, GAP FOR ME, SO I WAS

5061
03:07:23,240 --> 03:07:26,040
JUST WONDERING IF ANYONE HAS ANY

5062
03:07:26,040 --> 03:07:28,840
COMMENTS ON THAT.

5063
03:07:28,840 --> 03:07:36,120
DO WE HAVE A SPECIFIC -- FOR

5064
03:07:36,120 --> 03:07:36,640
IDENTIFYING RESERVOIRS?

5065
03:07:36,640 --> 03:07:41,520
>> YES, WE'VE HAD MAJOR
PROGRAMS

5066
03:07:41,520 --> 03:07:43,360
ON RESERVOIR IDENTIFICATION

5067
03:07:43,360 --> 03:07:45,920
TRACKING, USE OF NON-HUMAN

5068
03:07:45,920 --> 03:07:49,200
PRIMATES, SPECIFICALLY WITH THE

5069
03:07:49,200 --> 03:07:51,000
BARCODED VIRUSES TO REALLY

5070
03:07:51,000 --> 03:07:52,480
UNDERSTAND WHERE THE RESERVOIR

5071
03:07:52,480 --> 03:07:55,560
IS, AND WHERE IT'S GOING.

5072
03:07:55,560 --> 03:07:56,840
ADDITIONALLY, THERE'S A VERY

5073
03:07:56,840 --> 03:07:58,160
SPECIFIC INSTITUTE THAT WE

5074
03:07:58,160 --> 03:08:03,280
COLLABORATE WITH THAT IS

5075
03:08:03,280 --> 03:08:10,520
DEDICATED TO -- AND MY COLLEAGUE

5076
03:08:10,520 --> 03:08:13,960
HERE FROM NIMH AND -- ARE JOINED

5077
03:08:13,960 --> 03:08:15,040
AT THE HIP ADDRESSING THESE

5078
03:08:15,040 --> 03:08:20,560
ISSUES OF NEUROAIDS AND THE --

5079
03:08:20,560 --> 03:08:21,680
SO VERY ACTIVE PROGRAMS.

5080
03:08:21,680 --> 03:08:27,800
>> GREAT.

5081
03:08:27,800 --> 03:08:29,400
>> ANY OTHER COMMENTS FROM
THE

5082
03:08:29,400 --> 03:08:36,400
MEMBERS ON ZOOM?

5083
03:08:36,400 --> 03:08:37,400
DR. GLENSHAW, ANY ADDITIONAL

5084
03:08:37,400 --> 03:08:37,920
COMMENTS IN THE ROOM?

5085
03:08:37,920 --> 03:08:39,400
>> I DON'T THINK SO,
MA'AM.

5086
03:08:39,400 --> 03:08:47,080
>> OKAY.

5087
03:08:47,080 --> 03:08:48,040
>> OKAY.

5088
03:08:48,040 --> 03:08:49,800
OUR FINAL UPDATE FOR TODAY WILL

5089
03:08:49,800 --> 03:08:51,800
COME FROM THE HIV CLINICAL

5090
03:08:51,800 --> 03:08:55,400
GUIDELINES WORKING GROUPS OF

5091
03:08:55,400 --> 03:08:56,120
OARAC.

5092
03:08:56,120 --> 03:08:57,120
THESE INCLUDE BOTH GUIDELINES

5093
03:08:57,120 --> 03:08:59,560
AND PANEL UPDATES.

5094
03:08:59,560 --> 03:09:03,040
WE HAVE FOUR PRESENTERS TODAY.

5095
03:09:03,040 --> 03:09:09,080
DRS. HENRY MASUR, ALICE PAU,

5096
03:09:09,080 --> 03:09:13,120
ROHAN HAZRA, AND BILL

5097
03:09:13,120 --> 03:09:17,280
KAPOGIANNIS.

5098
03:09:17,280 --> 03:09:19,120
DR. MASUR IS THE CHIEF OF THE

5099
03:09:19,120 --> 03:09:20,680
CLINICAL CARE MEDICINE

5100
03:09:20,680 --> 03:09:22,640
DEPARTMENT AT THE CLINICAL

5101
03:09:22,640 --> 03:09:25,880
CENTER AT NIH.

5102
03:09:25,880 --> 03:09:29,920
HE'S THE FOUNDING EDITOR OF THE

5103
03:09:29,920 --> 03:09:32,520
NIH CDC IDSA GUIDELINES FOR

5104
03:09:32,520 --> 03:09:34,760
MANAGEMENT OF OPPORTUNISTIC

5105
03:09:34,760 --> 03:09:38,360
INFECTIONS IN ADOLESCENTS, AND

5106
03:09:38,360 --> 03:09:39,360
ADULTS WITH HIV.

5107
03:09:39,360 --> 03:09:41,680
HE'S THE CO-AUTHOR OF THE

5108
03:09:41,680 --> 03:09:43,880
TEXTBOOK "AIDS THERAPY" AND IS

5109
03:09:43,880 --> 03:09:49,760
THE PAST PRESIDENT OF IDSA.

5110
03:09:49,760 --> 03:09:51,640
DR. PAU IS THE PRINCIPAL

5111
03:09:51,640 --> 03:09:53,760
INVESTIGATOR FOR RESEARCH

5112
03:09:53,760 --> 03:09:56,440
INTERESTS IN HIV TREATMENT

5113
03:09:56,440 --> 03:09:59,080
FAILURE AND DRUG RESISTANCE.

5114
03:09:59,080 --> 03:10:01,000
SHE HAS BEEN A CRITICAL MEMBER

5115
03:10:01,000 --> 03:10:04,400
OF THE U.S. DEPARTMENT OF HEALTH

5116
03:10:04,400 --> 03:10:06,880
AND HUMAN SERVICES ADULT AND

5117
03:10:06,880 --> 03:10:08,720
ADOLESCENT ANTIRETROVIRAL

5118
03:10:08,720 --> 03:10:10,400
GUIDELINES PANEL SINCE 1998 AND

5119
03:10:10,400 --> 03:10:12,520
BECAME THE EXECUTIVE SECRETARY

5120
03:10:12,520 --> 03:10:18,880
OF THE PANEL IN 2004.

5121
03:10:18,880 --> 03:10:28,960
SHE IS A COED TORE OF T OF THE

5122
03:10:28,960 --> 03:10:33,120
DEPARTMENDEPARTMENT OF HEALTH AN

5123
03:10:33,120 --> 03:10:35,000
SERVICES PANEL ON TREATMENT AND

5124
03:10:35,000 --> 03:10:36,280
PREVENTION OF OPPORTUNISTIC

5125
03:10:36,280 --> 03:10:37,040
INFECTION.

5126
03:10:37,040 --> 03:10:38,240
DR. HAZRA WAS APPOINTED AS THE

5127
03:10:38,240 --> 03:10:42,640
DREDIRECTOR OF NICHD, DIVISION F

5128
03:10:42,640 --> 03:10:44,440
EXTRAMURAL RESEARCH IN MARCH OF

5129
03:10:44,440 --> 03:10:44,640
2022.

5130
03:10:44,640 --> 03:10:46,200
HE PROVIDES SCIENTIFIC

5131
03:10:46,200 --> 03:10:47,520
LEADERSHIP FOR DOMESTIC AND

5132
03:10:47,520 --> 03:10:49,080
INTERNATIONAL RESEARCH, RESEARCH

5133
03:10:49,080 --> 03:10:51,480
TRAINING, AND CAREER DEVELOPMENT

5134
03:10:51,480 --> 03:10:54,120
PROGRAMS RELATED TO THE

5135
03:10:54,120 --> 03:10:56,440
EPIDEMIOLOGY, DIAGNOSIS,

5136
03:10:56,440 --> 03:10:59,280
TRANSMISSION, TREATMENT AND

5137
03:10:59,280 --> 03:11:02,760
PREVENTION OF HIV AND ITS

5138
03:11:02,760 --> 03:11:04,000
COMPLICATIONS, AS WELL AS OTHER

5139
03:11:04,000 --> 03:11:06,400
SELECTED PATHOGENS IN INFANTS,

5140
03:11:06,400 --> 03:11:07,600
CHILDREN, ADOLESCENTS AND

5141
03:11:07,600 --> 03:11:12,560
PREGNANT PEOPLE.

5142
03:11:12,560 --> 03:11:14,440
AND DR. KAPOGIANNIS WAS

5143
03:11:14,440 --> 03:11:15,440
INTRODUCED EARLIER IN THE

5144
03:11:15,440 --> 03:11:17,480
AGENDA.

5145
03:11:17,480 --> 03:11:18,800
DR. MASUR, WE WILL START WITH

5146
03:11:18,800 --> 03:11:21,240
YOU.

5147
03:11:21,240 --> 03:11:24,440
>> THANKS VERY MUCH,

5148
03:11:24,440 --> 03:11:25,640
DR. TURNBULL, AND I'M SURE

5149
03:11:25,640 --> 03:11:31,560
YOU'LL BE SHOWING MY POWERPO 

5150
03:11:31,560 --> 03:11:32,400
POWERPOINTS.

5151
03:11:32,400 --> 03:11:33,280
SO THE FIRST GUIDELINE WE'RE

5152
03:11:33,280 --> 03:11:35,280
GOING TO TALK ABOUT AS

5153
03:11:35,280 --> 03:11:36,520
DR. TURNBULL MENTIONED IS THE

5154
03:11:36,520 --> 03:11:38,240
GUIDELINE FOR THE PREVENTION AND

5155
03:11:38,240 --> 03:11:39,040
TREATMENT OF OPPORTUNISTIC

5156
03:11:39,040 --> 03:11:39,600
INFECTIONS.

5157
03:11:39,600 --> 03:11:40,920
I THINK ALL THE GUIDELINES HERE

5158
03:11:40,920 --> 03:11:41,800
ARE PARTICULARLY PLEASED TO BE

5159
03:11:41,800 --> 03:11:45,600
ABLE TO PRESENT THESE UPDATES

5160
03:11:45,600 --> 03:11:48,040
BECAUSE OF THE MANY THINGS THAT

5161
03:11:48,040 --> 03:11:51,040
O.A.R. SUPPORTS, THIS IS ONE OF

5162
03:11:51,040 --> 03:11:53,680
THEIR MANY CONTRIBUTIONS OF HIGH

5163
03:11:53,680 --> 03:11:55,200
IMPACT, BOTH IN THE UNITED

5164
03:11:55,200 --> 03:11:56,680
STATES AND GLOBALLY.

5165
03:11:56,680 --> 03:11:58,080
WE'RE ALSO PLEASED THAT WE THINK

5166
03:11:58,080 --> 03:12:00,920
THAT THESE ARE CONSIDERED AS

5167
03:12:00,920 --> 03:12:02,160
DEFINITIVE BECAUSE I THINK

5168
03:12:02,160 --> 03:12:06,560
THEY'RE WELL RESEARCHED AND

5169
03:12:06,560 --> 03:12:09,600
THEY'RE WELL DOCUMENTED IN TERMS

5170
03:12:09,600 --> 03:12:11,680
OF THE STRENGTH OF THE EVIDENCE.

5171
03:12:11,680 --> 03:12:12,480
THIS NEXT SLIDE IS THE SAME

5172
03:12:12,480 --> 03:12:14,200
SLIDE THAT YOU'VE SEEN BEFORE.

5173
03:12:14,200 --> 03:12:17,280
WE JUST WANT TO EMPHASIZE THAT

5174
03:12:17,280 --> 03:12:18,800
ALL THE GUIDELINES ARE WIDELY

5175
03:12:18,800 --> 03:12:23,920
USED WHICH I SUGGESTS THAT THEYE

5176
03:12:23,920 --> 03:12:25,880
STILL NEEDED EVEN 30 YEARS AFTER

5177
03:12:25,880 --> 03:12:27,280
THE EPIDEMIC AND SPECIFICALLY

5178
03:12:27,280 --> 03:12:30,880
FOR THE ADULT OPPORTUNISTIC --

5179
03:12:30,880 --> 03:12:33,920
YOU CAN SEE WE HAVE ALMOST 500

5180
03:12:33,920 --> 03:12:35,840
PAGE VIEWS FROM BOTH THE UNITED

5181
03:12:35,840 --> 03:12:37,480
STATES AND GLOBALLY SO WE THINK

5182
03:12:37,480 --> 03:12:39,240
THESE STILL HAVE A MAJOR PLACE

5183
03:12:39,240 --> 03:12:41,440
AS A SOURCE OF INFORMATION FOR

5184
03:12:41,440 --> 03:12:44,880
CLINICIANS.

5185
03:12:44,880 --> 03:12:47,520
WE HAVE 30 GROUPS THAT MEET ON

5186
03:12:47,520 --> 03:12:51,040
SPECIFIC CONTENT AREAS.

5187
03:12:51,040 --> 03:12:52,440
THEY MEET THROUGHOUT THE YEAR,

5188
03:12:52,440 --> 03:12:54,960
REVIEW THE LITERATURE, AND WE

5189
03:12:54,960 --> 03:12:58,240
HAVE ROLLING UPDATES SO THAT

5190
03:12:58,240 --> 03:12:59,440
WHEN SOMETHING IS RELEVANT AND

5191
03:12:59,440 --> 03:13:02,080
NEEDS TO BE UPDATED FOR A

5192
03:13:02,080 --> 03:13:03,000
SPECIFIC CHAPTER, WE WILL UPDATE

5193
03:13:03,000 --> 03:13:07,280
ONE OR MORE CHAPTERS AS NEEDED.

5194
03:13:07,280 --> 03:13:10,640
SINCE YOU LAST MET, THE MAJOR

5195
03:13:10,640 --> 03:13:15,000
UPDATE HAS BEEN TO CHAGAS

5196
03:13:15,000 --> 03:13:17,120
DISEASE, IF CLINICIANS IN THE

5197
03:13:17,120 --> 03:13:27,400
U.S. SEE A CASE OF CHAGAS RYES -

5198
03:13:27,400 --> 03:13:29,040
THEY GET SOME IDEA AS TO WHAT

5199
03:13:29,040 --> 03:13:29,920
THE CURRENT MANAGEMENT IS.

5200
03:13:29,920 --> 03:13:32,240
SO THE PARTICULAR UPDATE FOCUS

5201
03:13:32,240 --> 03:13:33,080
ON THE EPIDEMIOLOGY AND SOME

5202
03:13:33,080 --> 03:13:36,960
CHANGES IN THE FDA LABELING AND

5203
03:13:36,960 --> 03:13:39,400
AVAILABILITY OF NITROFIRIMOX.

5204
03:13:39,400 --> 03:13:42,040
WE HAVE MANY OTHER SECTIONS

5205
03:13:42,040 --> 03:13:45,520
WHICH ARE EITHER JUST PUBLISHED

5206
03:13:45,520 --> 03:13:50,160
OR ABOUT TO BECOME.

5207
03:13:50,160 --> 03:13:52,360
WE'VE REVISED THE WAY OUR TABLES

5208
03:13:52,360 --> 03:13:54,680
ARE PRESENTED AND YOU CAN SEE

5209
03:13:54,680 --> 03:13:56,400
WHAT'S RECENTLY PUBLISHED IN

5210
03:13:56,400 --> 03:13:57,600
THOSE SECTIONS ON THE LEFT.

5211
03:13:57,600 --> 03:14:00,200
IN THE VERY NEAR FUTURE, YOU'RE

5212
03:14:00,200 --> 03:14:03,520
GOING TO SEE UPDATES ON MPOX, ON

5213
03:14:03,520 --> 03:14:07,040
SYPHILIS, ON HPV, ON

5214
03:14:07,040 --> 03:14:08,680
IMMUNIZATION, WHICH IS REALLY A

5215
03:14:08,680 --> 03:14:10,080
COMPILATION OF RECOMMENDATIONS

5216
03:14:10,080 --> 03:14:15,000
FROM INDIVIDUAL CHAPTERS, AND

5217
03:14:15,000 --> 03:14:18,080
THERE WILL BE NEW INFORMATION ON

5218
03:14:18,080 --> 03:14:19,320
MPOX.

5219
03:14:19,320 --> 03:14:20,880
ONE THING WE'VE WRECK HE NIEZED

5220
03:14:20,880 --> 03:14:22,880
OVER THE PAST YEAR IS PROGRESS

5221
03:14:22,880 --> 03:14:23,720
HAS BEEN SLOWER THAN WHAT WE

5222
03:14:23,720 --> 03:14:24,040
WANT.

5223
03:14:24,040 --> 03:14:27,480
WE WANT OUR DEADLINE TO BE

5224
03:14:27,480 --> 03:14:28,400
CURRENT -- WE'VE TRIED TO STREAM

5225
03:14:28,400 --> 03:14:28,840
LIKE THIS.

5226
03:14:28,840 --> 03:14:30,400
ONE OF THE PROBLEMS IS THAT

5227
03:14:30,400 --> 03:14:35,680
SINCE WE'RE CO-SPONSORED BY CDC,

5228
03:14:35,680 --> 03:14:39,840
BY HIBMAN IDSA, THERE ARE THREE

5229
03:14:39,840 --> 03:14:40,640
DIFFERENT GROUPS THAT NEED TO

5230
03:14:40,640 --> 03:14:43,800
LOOK AT THESE RECOMMENDATIONS.

5231
03:14:43,800 --> 03:14:45,480
SO THAT WE'VE TAKEN A CLOSE LOOK

5232
03:14:45,480 --> 03:14:48,000
AT WHAT OUR PROCESS IS, WE'VE

5233
03:14:48,000 --> 03:14:51,160
TRIED TO STREAMLINE THIS AND

5234
03:14:51,160 --> 03:14:52,640
EVEN WITH THIS, FROM THE TIME

5235
03:14:52,640 --> 03:14:55,320
THAT A NEW CHAPTER IS SUBMITTED,

5236
03:14:55,320 --> 03:14:57,240
BY THE TIME IT'S REVIEWED BY

5237
03:14:57,240 --> 03:14:57,960
THESE PROFESSIONAL GROUPS AS

5238
03:14:57,960 --> 03:15:02,560
WELL AS SOME OF OUR CONTENT AR 

5239
03:15:02,560 --> 03:15:04,840
AREAS IN PHARMACOLOGY AND

5240
03:15:04,840 --> 03:15:06,480
PREGNANCY, 16 WEEKS IS ABOUT THE

5241
03:15:06,480 --> 03:15:07,760
FASTEST WE CAN GO.

5242
03:15:07,760 --> 03:15:10,160
WE'RE ALWAYS LOOKING FOR WAYS TO

5243
03:15:10,160 --> 03:15:13,240
MAKE THIS FASTER BECAUSE, AGAIN,

5244
03:15:13,240 --> 03:15:15,160
WE REALIZE THAT CURRENCY IS ONE

5245
03:15:15,160 --> 03:15:16,240
OF THE IMPORTANT FEATURES OF

5246
03:15:16,240 --> 03:15:17,480
THESE GUIDELINES.

5247
03:15:17,480 --> 03:15:20,640
15 AGAIN, THIS IS JUST FOR YOUR

5248
03:15:20,640 --> 03:15:21,680
INFORMATION NOW THAT WE ARE

5249
03:15:21,680 --> 03:15:22,640
FOCUSED ON HOW TO MAKE THESE

5250
03:15:22,640 --> 03:15:22,960
MORE CURRENT.

5251
03:15:22,960 --> 03:15:24,560
SO WITH THAT, I'LL TURN IT OVER

5252
03:15:24,560 --> 03:15:29,200
TO ALICE PAW, BUT AG PAU, BUT AE

5253
03:15:29,200 --> 03:15:30,880
VERY APPRECIATIVE OF THE SUPPORT

5254
03:15:30,880 --> 03:15:35,680
WHICH GIVES US -- TO MAKE THIS

5255
03:15:35,680 --> 03:15:37,880
POSSIBLE AND ADVICE TO MAKE

5256
03:15:37,880 --> 03:15:42,080
THESE POSSIBLE AND ADVICE THEY

5257
03:15:42,080 --> 03:15:42,320
GIVE --

5258
03:15:42,320 --> 03:15:43,840
>> WE'VE HAD A SLIGHT
AGENDA

5259
03:15:43,840 --> 03:15:44,040
CHANGE.

5260
03:15:44,040 --> 03:15:45,200
>> OKAY.

5261
03:15:45,200 --> 03:15:47,640
>> SO AFTER YOUR
PRESENTATION,

5262
03:15:47,640 --> 03:15:51,240
WE'RE GOING TO GO TO DR. HAZRA

5263
03:15:51,240 --> 03:15:51,400
NOW.

5264
03:15:51,400 --> 03:15:52,320
>> ALL RIGHT, GOOD.

5265
03:15:52,320 --> 03:15:54,800
>> SO DR. HAZRA, OVER TO
YOU.

5266
03:15:54,800 --> 03:15:55,440
>> ALL RIGHT.

5267
03:15:55,440 --> 03:15:56,320
THANK YOU VERY MUCH.

5268
03:15:56,320 --> 03:15:58,400
I'M JUST GOING TO GIVE AN

5269
03:15:58,400 --> 03:16:00,280
OVERVIEW OF THE PEDIATRIC

5270
03:16:00,280 --> 03:16:01,160
GUIDELINES.

5271
03:16:01,160 --> 03:16:04,480
WE DO USUALLY AN ANNUAL UPDATE

5272
03:16:04,480 --> 03:16:11,240
SO THIS WAS OUR REPORT ON THAT.

5273
03:16:11,240 --> 03:16:13,600
WE USUALLY TRY TO AIM TO UPDATE

5274
03:16:13,600 --> 03:16:14,560
SOMETIME IN THE SPRING, TWO

5275
03:16:14,560 --> 03:16:15,920
MONTHS OR SO AFTER KROI, WE WANT

5276
03:16:15,920 --> 03:16:19,160
TO LOOK TO CROIX AS ANY

5277
03:16:19,160 --> 03:16:20,680
LATEBREAKING DATA THAT WE CAN

5278
03:16:20,680 --> 03:16:23,200
INCLUDE AND THEN DO OUR

5279
03:16:23,200 --> 03:16:24,400
PUBLICATIONS WE PUBLISHED JUST A

5280
03:16:24,400 --> 03:16:26,080
COUPLE MONTHS AGO, APRIL 11TH OF

5281
03:16:26,080 --> 03:16:27,680
2023.

5282
03:16:27,680 --> 03:16:30,320
JUST TO REMIND YOU FROM THE LAST

5283
03:16:30,320 --> 03:16:31,720
OARAC MEETING, WE ALSO HAVE

5284
03:16:31,720 --> 03:16:34,320
SEVERAL SECTIONS THAT WE DEVELOP

5285
03:16:34,320 --> 03:16:36,160
AND REVIEW AND PUBLISH JOINTLY

5286
03:16:36,160 --> 03:16:39,120
WITH THE PERINATAL GUIDELINES.

5287
03:16:39,120 --> 03:16:40,200
THAT SPECIFICALLY WAS AROUND THE

5288
03:16:40,200 --> 03:16:41,520
INFANT FEEDINGS, REMEMBER WE HAD

5289
03:16:41,520 --> 03:16:42,840
THE SESSION ON THAT LAST SPRING.

5290
03:16:42,840 --> 03:16:46,080
SO THOSE FOUR SECTIONS WERE

5291
03:16:46,080 --> 03:16:48,920
PUBLISHED AS PART OF THE FULL

5292
03:16:48,920 --> 03:16:50,240
PERINATAL GUIDELINES UPDATE ON

5293
03:16:50,240 --> 03:16:52,120
JANUARY 31ST, BUT WE ALSO THEN

5294
03:16:52,120 --> 03:16:55,520
UPDATED THOSE FOUR SECTIONS IN

5295
03:16:55,520 --> 03:16:58,160
OUR GUIDELINES AS WELL.

5296
03:16:58,160 --> 03:16:59,880
SOME OF THE OTHER UPDATES WE

5297
03:16:59,880 --> 03:17:02,280
MADE, NSK IN FACT, I THINK IN

5298
03:17:02,280 --> 03:17:04,200
COLLABORATION WITH THE PEDIATRIC

5299
03:17:04,200 --> 03:17:05,320
GUIDELINES WAS REALLY TO CLARIFY

5300
03:17:05,320 --> 03:17:08,240
THAT RAPID INITIATION OF ART

5301
03:17:08,240 --> 03:17:10,880
SHOULD BE RECONSIDERED IF A

5302
03:17:10,880 --> 03:17:16,280
CHILD HAS A PARTICULAR -- IN

5303
03:17:16,280 --> 03:17:20,440
THIS CASE -- IN THE CLINICAL AND

5304
03:17:20,440 --> 03:17:22,440
LABORATORY MONITORING OF THE

5305
03:17:22,440 --> 03:17:23,760
PEDIATRIC HIV SECTION, WE

5306
03:17:23,760 --> 03:17:26,760
ACTUALLY HAD A TABLE FOR MANY

5307
03:17:26,760 --> 03:17:28,640
YEARS ON CD4 CELL COUNTS AND

5308
03:17:28,640 --> 03:17:30,200
PERCENTAGES IN HEALTHY CHILDREN

5309
03:17:30,200 --> 03:17:31,120
AND DISTRIBUTION BY AGE.

5310
03:17:31,120 --> 03:17:33,000
THAT HAD BEEN TAKEN OUT SEVERAL

5311
03:17:33,000 --> 03:17:35,160
CYCLES AGO, AND I THINK FOUND --

5312
03:17:35,160 --> 03:17:36,880
WE GOT FEEDBACK THAT PEOPLE WERE

5313
03:17:36,880 --> 03:17:37,760
MISSING THAT, SO WE'VE ADDED

5314
03:17:37,760 --> 03:17:40,160
THAT TABLE BACK IN.

5315
03:17:40,160 --> 03:17:43,520
THEN WE'VE ALSO ADDED GUIDANCE

5316
03:17:43,520 --> 03:17:45,720
ABOUT VIRAL LOAD MONITORING FOR

5317
03:17:45,720 --> 03:17:48,960
ADOLESCENTS INITIATING

5318
03:17:48,960 --> 03:17:53,440
LONG-ACTING -- OF COURSE WE

5319
03:17:53,440 --> 03:17:54,160
DEVELOPED GUIDELINES FOR

5320
03:17:54,160 --> 03:17:55,960
CHILDREN AND ADOLESCENTS PRIOR

5321
03:17:55,960 --> 03:17:58,680
TO PUBERTY, AND THEN THE

5322
03:17:58,680 --> 03:18:00,160
ADOLESCENT ADULT GUIDELINES DEAL

5323
03:18:00,160 --> 03:18:00,880
WITH PUBERTY.

5324
03:18:00,880 --> 03:18:03,280
AND SO THERE'S SOMETIMES

5325
03:18:03,280 --> 03:18:04,760
INFORMATION THAT WE SHARE ACROSS

5326
03:18:04,760 --> 03:18:06,640
WITH THE ADULT GUIDELINES AS

5327
03:18:06,640 --> 03:18:07,920
WELL, AND ONE OF THE THINGS I

5328
03:18:07,920 --> 03:18:10,760
THINK THAT WE NOTE IS THAT WHILE

5329
03:18:10,760 --> 03:18:13,720
THE CABOTEGRAVIR AND -- STUDIES

5330
03:18:13,720 --> 03:18:16,840
WERE DONE IN THIS IDEAL

5331
03:18:16,840 --> 03:18:17,600
POPULATION THAT ALREADY WAS

5332
03:18:17,600 --> 03:18:19,760
SUPPRESSED, THAT FRANKLY THE ONE

5333
03:18:19,760 --> 03:18:22,440
USE FOR INJECTABLES MAY WELL BE

5334
03:18:22,440 --> 03:18:25,160
IN ADOLESCENTS THAT ACTUALLY

5335
03:18:25,160 --> 03:18:26,600
NEED A NEW REGIMEN, SOMETHING

5336
03:18:26,600 --> 03:18:28,800
LIKE AN INJECTABLE TO ACTUALLY

5337
03:18:28,800 --> 03:18:30,240
ACHIEVE GOOD ADHERENCE.

5338
03:18:30,240 --> 03:18:31,040
SO WE TALKED ABOUT THAT, AND

5339
03:18:31,040 --> 03:18:32,240
AGAIN, THIS IS ONE OF THOSE

5340
03:18:32,240 --> 03:18:33,880
AREAS WHERE THERE'S NOT

5341
03:18:33,880 --> 03:18:34,920
NECESSARILY DATA THAT'S

5342
03:18:34,920 --> 03:18:35,880
INFORMING IT, BUT IT'S REALLY

5343
03:18:35,880 --> 03:18:38,080
THE EXPERT OPINION OF MANY OF

5344
03:18:38,080 --> 03:18:42,080
THE MEMBERS ALLOWED US TO PUT

5345
03:18:42,080 --> 03:18:42,320
THAT IN.

5346
03:18:42,320 --> 03:18:43,680
THEN, OF COURSE, UNFORTUNATELY,

5347
03:18:43,680 --> 03:18:45,280
YOU KNOW, CHILDREN AND YOUTH

5348
03:18:45,280 --> 03:18:47,400
WITH HIV ARE NOT IMMUNE TO WHAT

5349
03:18:47,400 --> 03:18:48,960
WE'RE SEEING THROUGHOUT THE

5350
03:18:48,960 --> 03:18:50,480
COUNTRY, WHICH IS A SUBSTANTIAL

5351
03:18:50,480 --> 03:18:53,640
INCREASE IN MENTAL HEALTH

5352
03:18:53,640 --> 03:18:55,200
CHALLENGES THAT ACTUALLY

5353
03:18:55,200 --> 03:18:56,200
PREDATED THE PANDEMIC AND NOW

5354
03:18:56,200 --> 03:18:58,200
JUST CONTINUE, SO WE'VE ADDED

5355
03:18:58,200 --> 03:18:59,400
ISSUES AROUND AGE-APPROPRIATE

5356
03:18:59,400 --> 03:19:02,120
SCREENING FOR SUICIDALITY IN THE

5357
03:19:02,120 --> 03:19:03,840
CARE OF CHILDREN AND ADOLESCENTS

5358
03:19:03,840 --> 03:19:07,800
WITH HIV.

5359
03:19:07,800 --> 03:19:10,640
AS PART OF INCLUDING

5360
03:19:10,640 --> 03:19:12,800
CABOTEGRAVIR HERE, WE UPDATED

5361
03:19:12,800 --> 03:19:15,720
THE CENTRAL NERVOUS SYSTEM

5362
03:19:15,720 --> 03:19:16,640
TOXICITY SECTION, AND OF COURSE

5363
03:19:16,640 --> 03:19:17,960
WITH ALL THE DIFFERENT CHANGES

5364
03:19:17,960 --> 03:19:19,880
IN APPROVALS AND GATHERING OF

5365
03:19:19,880 --> 03:19:20,640
EVIDENCE, THERE ARE ALWAYS

5366
03:19:20,640 --> 03:19:21,920
CHANGES THAT NEED TO BE MADE IN

5367
03:19:21,920 --> 03:19:23,560
THE MANAGEMENT OF CHILDREN

5368
03:19:23,560 --> 03:19:25,760
RECEIVING ART SECTION TO

5369
03:19:25,760 --> 03:19:27,080
INCORPORATE THE MOST RECENT

5370
03:19:27,080 --> 03:19:29,240
SWITCH OPTIONS IN LINE WITH

5371
03:19:29,240 --> 03:19:33,040
AVAILABLE DATA AND APPROVALS.

5372
03:19:33,040 --> 03:19:34,760
THEN FINALLY, WE HAVE, OF

5373
03:19:34,760 --> 03:19:35,880
COURSE, AN EXTENSIVE DRUG

5374
03:19:35,880 --> 03:19:37,480
SECTION WHERE WE REALLY GO INTO

5375
03:19:37,480 --> 03:19:40,120
A LOT OF DETAIL AROUND DOSING OF

5376
03:19:40,120 --> 03:19:41,880
THESE AGENTS IN PEDIATRICS,

5377
03:19:41,880 --> 03:19:43,080
ESPECIALLY WHEN THERE'S ACTUALLY

5378
03:19:43,080 --> 03:19:45,120
NOT GOOD DATA.

5379
03:19:45,120 --> 03:19:46,200
THAT WE'RE SOMETIMES OFTENTIMES

5380
03:19:46,200 --> 03:19:49,360
LIMITED TO JUST SOMEWHAT LIMITED

5381
03:19:49,360 --> 03:19:50,720
PHARMACOKINETIC DATA WITHOUT

5382
03:19:50,720 --> 03:19:53,080
LARGE TRIALS, SO WE'VE UPDATED

5383
03:19:53,080 --> 03:19:55,360
THROUGHOUT THERE, AND THEN

5384
03:19:55,360 --> 03:19:56,680
IMPORTANTLY, ABOUT HOW DO YOU

5385
03:19:56,680 --> 03:19:58,160
ADMINISTER CERTAIN OF THESE

5386
03:19:58,160 --> 03:20:06,480
AGENTS, AND SO HERE WITH

5387
03:20:06,480 --> 03:20:07,800
BIKTARVY, WE'RE ABLE TO PROVIDE

5388
03:20:07,800 --> 03:20:09,160
INFORMATION ABOUT SPLITTING OR

5389
03:20:09,160 --> 03:20:10,160
DISSOLVING THE TABLET BUT THAT

5390
03:20:10,160 --> 03:20:11,440
CLEARLY SAYING BASED ON THE DATA

5391
03:20:11,440 --> 03:20:14,120
IN ADULTS THAT CRUSHING TABLETS

5392
03:20:14,120 --> 03:20:15,480
IS NOT RECOMMENDED.

5393
03:20:15,480 --> 03:20:21,280
THE RALTEGRAVIR SECTION NOW --

5394
03:20:21,280 --> 03:20:25,960
WE'VE UPDATED THAT AS WELL.

5395
03:20:25,960 --> 03:20:27,920
WE HAD THREE NEW PANEL MEMBERS

5396
03:20:27,920 --> 03:20:29,440
THAT WE WELCOMED IN THIS CYCLE,

5397
03:20:29,440 --> 03:20:31,440
SO MARY TANNER IS OUR NEW

5398
03:20:31,440 --> 03:20:33,000
REPRESENTATIVE FROM CDC WHO

5399
03:20:33,000 --> 03:20:36,840
REPLACED A LEGEND IN PEDIATRIC

5400
03:20:36,840 --> 03:20:39,760
HIV, STEVE NESHEIM, WHO RETIRED

5401
03:20:39,760 --> 03:20:42,080
JUST OVER A YEAR AGO, SO MARY IS

5402
03:20:42,080 --> 03:20:43,400
OUR NEW CDC REPRESENTATIVE.

5403
03:20:43,400 --> 03:20:47,160
WE ALSO HAD IN THE PRIOR CYCLE A

5404
03:20:47,160 --> 03:20:48,080
VIROLOGIST WHO ALSO HAD BEEN ON

5405
03:20:48,080 --> 03:20:50,480
THE PANEL FOR QUITE SOME TIME,

5406
03:20:50,480 --> 03:20:53,160
PAUL POLEMBO, RETIRE, SO REALLY

5407
03:20:53,160 --> 03:20:54,920
SPECIFICALLY LOOKED FOR AND

5408
03:20:54,920 --> 03:20:57,080
SOLICITED FOR SOMEONE WITH

5409
03:20:57,080 --> 03:20:59,120
EXPERTISE IN VIROLOGY,

5410
03:20:59,120 --> 03:21:00,760
IMMUNOLOGY AND DIAGNOSTICS.

5411
03:21:00,760 --> 03:21:02,640
SO REALLY, REALLY PLEASED THAT

5412
03:21:02,640 --> 03:21:04,440
NICOLE TOBIN CAN BE THERE.

5413
03:21:04,440 --> 03:21:06,720
I THINK SHE'S AT UCLA, SO

5414
03:21:06,720 --> 03:21:07,400
UNIVERSITY OF CALIFORNIA

5415
03:21:07,400 --> 03:21:07,840
LOS ANGELES THERE.

5416
03:21:07,840 --> 03:21:09,920
AND THEN FINALLY, SOMEONE FROM

5417
03:21:09,920 --> 03:21:12,200
OUR INSTITUTE, WHO'S A NEW

5418
03:21:12,200 --> 03:21:14,400
MEDICAL OFFICER IN THE OLD

5419
03:21:14,400 --> 03:21:16,120
BRANCH OF BILL AND MINE,

5420
03:21:16,120 --> 03:21:17,320
FRANKLIN YATES IS ALSO ON THE

5421
03:21:17,320 --> 03:21:18,840
PANEL AS WELL.

5422
03:21:18,840 --> 03:21:21,480
AND THEN THIS SLIDE IS REALLY

5423
03:21:21,480 --> 03:21:21,720
SOMETHING.

5424
03:21:21,720 --> 03:21:23,120
I THINK FOR THOSE OF YOU WHO

5425
03:21:23,120 --> 03:21:24,200
HAVE BEEN IN THE FIELD OF

5426
03:21:24,200 --> 03:21:26,040
PEDIATRIC HIV, YOU'RE LOOKING AT

5427
03:21:26,040 --> 03:21:29,120
PROBABLY OVER A HUNDRED YEARS OF

5428
03:21:29,120 --> 03:21:30,520
SERVICE COLLECTIVELY OF FOLKS

5429
03:21:30,520 --> 03:21:32,120
THAT HAVE STEPPED DOWN, AND

5430
03:21:32,120 --> 03:21:34,760
REALLY JUST SOME REALLY GIANTS

5431
03:21:34,760 --> 03:21:37,480
IN OUR FIELD.

5432
03:21:37,480 --> 03:21:39,360
SO PAT FLYNN HAD BEEN ON THE

5433
03:21:39,360 --> 03:21:41,800
PANEL FOR ALMOST 20 YEARS, AND

5434
03:21:41,800 --> 03:21:44,000
SHE HAS NOW STEPPED DOWN, THOUGH

5435
03:21:44,000 --> 03:21:46,400
SHE FORTUNATELY IS STAYING ON

5436
03:21:46,400 --> 03:21:48,440
THE PERINATAL PANEL.

5437
03:21:48,440 --> 03:21:56,920
LINDA LEWIS, CURRENTLY AT CHAI,

5438
03:21:56,920 --> 03:21:58,800
SHE WAS INVOLVED IN SOME OF THE

5439
03:21:58,800 --> 03:22:00,920
EARLY STUDIES THAT WERE DONE IN

5440
03:22:00,920 --> 03:22:05,120
THE NCI INTRAMURAL PROGRAM,

5441
03:22:05,120 --> 03:22:06,120
RITONAVIR -- SHE HAS BEEN ON THE

5442
03:22:06,120 --> 03:22:07,640
PANEL AGAIN FOR A GENERATION AS

5443
03:22:07,640 --> 03:22:08,080
WELL.

5444
03:22:08,080 --> 03:22:11,640
SO SHE HAS STEPPED DOWN.

5445
03:22:11,640 --> 03:22:15,360
MARK MIROCHNICK HAS BEEN ON AND

5446
03:22:15,360 --> 03:22:18,120
HAS PROVIDED TREMENDOUS SERVICE

5447
03:22:18,120 --> 03:22:20,040
WITH RESPECT TO PHARMACOLOGY IN

5448
03:22:20,040 --> 03:22:21,680
PREMATURE INFANTS, NEONATES AND

5449
03:22:21,680 --> 03:22:23,320
INFANTS AS WELL, SO REALLY A

5450
03:22:23,320 --> 03:22:28,000
VERY DIFFICULT ROLE TO REPLACE.

5451
03:22:28,000 --> 03:22:29,200
DIFFICULT EXPERTISE TO REPLACE,

5452
03:22:29,200 --> 03:22:32,800
BUT ALSO REALLY CRITICAL

5453
03:22:32,800 --> 03:22:34,080
EXPERTISE BECAUSE WHEN WE TALK

5454
03:22:34,080 --> 03:22:35,840
ABOUT LIMITED DATA FOR

5455
03:22:35,840 --> 03:22:37,120
PHARMACOKINETICS IN CHILDREN,

5456
03:22:37,120 --> 03:22:39,040
IT'S EVEN MORE LIMITED IN

5457
03:22:39,040 --> 03:22:41,040
NEONATES AND ESPECIALLY IN

5458
03:22:41,040 --> 03:22:44,640
PREMANPREMATURE INFANTS AS WELL.

5459
03:22:44,640 --> 03:22:45,760
LUCKILY HIS WIFE IS STAYING ON

5460
03:22:45,760 --> 03:22:47,680
THE PANEL SO WE KNOW HOW TO

5461
03:22:47,680 --> 03:22:49,000
REACH HIM ABOUT PARTICULAR

5462
03:22:49,000 --> 03:22:50,360
QUESTIONS, BUT A REAL LOSS FOR

5463
03:22:50,360 --> 03:22:51,360
THE PANEL.

5464
03:22:51,360 --> 03:22:56,720
PATRICK JEAN-PHILLIPE HAS BEEN

5465
03:22:56,720 --> 03:22:58,080
ON THE PANEL FOR I THINK 15

5466
03:22:58,080 --> 03:22:59,040
YEARS, HE IS STEPPING DOWN.

5467
03:22:59,040 --> 03:23:06,520
THEN THE QUEEN HERSELF, LYNNE

5468
03:23:06,520 --> 03:23:11,040
MOFENSON, SHE BASICALLY FOUNDED

5469
03:23:11,040 --> 03:23:13,120
THESE GUIDELINES.

5470
03:23:13,120 --> 03:23:14,760
SHE WAS ACTUALLY INVOLVED IN

5471
03:23:14,760 --> 03:23:15,920
GUIDELINES PRIOR TO THAT AS

5472
03:23:15,920 --> 03:23:18,560
WELL.

5473
03:23:18,560 --> 03:23:20,840
AS 0706 SHOWED THAT AZT WAS ABLE

5474
03:23:20,840 --> 03:23:23,080
TO REDUCE TRANSMISSION BY ABOUT

5475
03:23:23,080 --> 03:23:23,760
70%, RIGHT AWAY THERE WAS NEED

5476
03:23:23,760 --> 03:23:26,160
FOR A GUIDELINE ABOUT HOW DO YOU

5477
03:23:26,160 --> 03:23:29,040
ROLL THAT OUT, AND LYNNE WAS

5478
03:23:29,040 --> 03:23:29,960
INVOLVED IN THAT AS WELL.

5479
03:23:29,960 --> 03:23:32,440
FOR THOSE OF US WHO KNOW HER,

5480
03:23:32,440 --> 03:23:33,880
IT'S QUITE SOMETHING FOR HER TO

5481
03:23:33,880 --> 03:23:35,720
SAY I THINK I'M READY TO STEP

5482
03:23:35,720 --> 03:23:37,120
AWAY, SO SHE'S STEPPED AWAY FROM

5483
03:23:37,120 --> 03:23:38,480
THE GUIDELINE BUT SHE ALSO WILL

5484
03:23:38,480 --> 03:23:40,200
BE STAYING ON THE PERINATAL

5485
03:23:40,200 --> 03:23:40,920
GUIDELINE.

5486
03:23:40,920 --> 03:23:42,880
BUT AGAIN I'M IN AWE OF THIS

5487
03:23:42,880 --> 03:23:43,600
SLIDE BECAUSE THIS IS REALLY --

5488
03:23:43,600 --> 03:23:45,080
AS I SAID, IF YOU WANT TO ADD IT

5489
03:23:45,080 --> 03:23:47,120
UP, OVER 100 YEARS OF SERVICE TO

5490
03:23:47,120 --> 03:23:48,360
THE GUIDELINES, AND WE CAN JUST

5491
03:23:48,360 --> 03:23:50,760
SEE THE IMPACT THAT THAT ALL HAS

5492
03:23:50,760 --> 03:23:52,240
HAD, RIGHT, WITH RESPECT TO THE

5493
03:23:52,240 --> 03:23:54,320
FACT THAT WE'RE NOW BASICALLY

5494
03:23:54,320 --> 03:23:56,280
CAN SAY WE'VE ELIMINATED

5495
03:23:56,280 --> 03:23:57,520
PEDIATRIC HIV IN THIS COUNTRY,

5496
03:23:57,520 --> 03:23:59,880
AND THAT WE WERE TALKING ABOUT

5497
03:23:59,880 --> 03:24:01,520
INFANTS AND CHILDREN BORN WITH

5498
03:24:01,520 --> 03:24:03,080
HIV BEING ABLE TO LIVE

5499
03:24:03,080 --> 03:24:05,240
POTENTIALLY A NORMAL LIFESPAN,

5500
03:24:05,240 --> 03:24:08,200
AND IT REALLY IS A TRIBUTE TO

5501
03:24:08,200 --> 03:24:09,400
PEOPLE LIKE THEM AND THEN THOSE

5502
03:24:09,400 --> 03:24:12,120
THAT THEY'VE INSPIRED AS WELL.

5503
03:24:12,120 --> 03:24:13,840
I THINK WITH THAT, THAT'S MY

5504
03:24:13,840 --> 03:24:15,600
LAST SLIDE AND I'LL TURN TO

5505
03:24:15,600 --> 03:24:23,280
BILL.

5506
03:24:23,280 --> 03:24:25,640
>> THANK YOU, DR. HAZRA.

5507
03:24:25,640 --> 03:24:27,400
NEXT WE'LL TURN TO

5508
03:24:27,400 --> 03:24:27,880
DR. KAPOGIANNIS.

5509
03:24:27,880 --> 03:24:29,120
>> THANK YOU, IVY.

5510
03:24:29,120 --> 03:24:30,000
AND THANK YOU, ROHAN.

5511
03:24:30,000 --> 03:24:32,080
WHAT A TERRIFIC WAY TO END YOUR

5512
03:24:32,080 --> 03:24:32,720
PRESENTATION.

5513
03:24:32,720 --> 03:24:34,360
I REALLY WANT TO ECHO THE

5514
03:24:34,360 --> 03:24:34,920
SENTIMENTS YOU SHARED.

5515
03:24:34,920 --> 03:24:39,240
I MEAN, FOR THE LUMINARIES ON

5516
03:24:39,240 --> 03:24:40,920
THAT SLIDE IN PEDIATRIC HIV,

5517
03:24:40,920 --> 03:24:44,960
WHAT A TREMENDOUS EFFORT AND

5518
03:24:44,960 --> 03:24:45,400
ACCOMPLISHMENT.

5519
03:24:45,400 --> 03:24:50,200
SO MY THANKS TO THEM AS WELL.

5520
03:24:50,200 --> 03:24:51,440
I HAVE PROBABLY A SHORTER

5521
03:24:51,440 --> 03:24:52,160
PRESENTATION BECAUSE I DIDN'T

5522
03:24:52,160 --> 03:24:54,120
WANT TO GO TOO MUCH INTO THE

5523
03:24:54,120 --> 03:24:56,840
DETAILS, BUT REALLY WANTED TO

5524
03:24:56,840 --> 03:24:58,840
SAY FIRST AS THIS SLIDE HAS TIME

5525
03:24:58,840 --> 03:25:05,400
TO SETTLE, WE PUBLISH OUR

5526
03:25:05,400 --> 03:25:07,800
PEDIATRIC GUIDELINES KIND OF

5527
03:25:07,800 --> 03:25:09,320
SIMILAR TO DR. MASUR'S APPROACH

5528
03:25:09,320 --> 03:25:12,480
IN THAT THEY'RE ROLLING UPDATE,

5529
03:25:12,480 --> 03:25:17,080
AND SO WE HAVE -- WE PUBLISHED

5530
03:25:17,080 --> 03:25:18,360
THOSE AND I'M ABOUT TO SHOW A

5531
03:25:18,360 --> 03:25:19,960
COUPLE OF THE SECTIONS THAT ARE

5532
03:25:19,960 --> 03:25:22,440
COMING UP AT THE END OF THIS

5533
03:25:22,440 --> 03:25:23,720
MONTH.

5534
03:25:23,720 --> 03:25:24,840
WE ALSO COLLABORATIVELY WORK

5535
03:25:24,840 --> 03:25:26,120
WITH THE OTHER PANELS, INCLUDING

5536
03:25:26,120 --> 03:25:28,480
THE PEDIATRIC ANTIRETROVIRAL

5537
03:25:28,480 --> 03:25:30,600
GROUP AND THE PERINATAL GROUP,

5538
03:25:30,600 --> 03:25:32,680
AND AS ROHAN ARTICULATED TO MAKE

5539
03:25:32,680 --> 03:25:37,360
SURE THAT WE HAVE HARMONY ACROSS

5540
03:25:37,360 --> 03:25:38,560
SECTIONS THAT OVERLAP OR HAVE

5541
03:25:38,560 --> 03:25:39,760
OVERLAPPING POTENTIAL FOR OUR

5542
03:25:39,760 --> 03:25:40,560
RECOMMENDATIONS.

5543
03:25:40,560 --> 03:25:45,440
SO TO THE END OF -- GOING BACK

5544
03:25:45,440 --> 03:25:46,920
TO THE POINT I WAS TRYING TO

5545
03:25:46,920 --> 03:25:49,560
MAKE WITH THIS SLIDE IS THAT WE

5546
03:25:49,560 --> 03:25:51,280
UNDERTOOK -- SINCE THE LAST

5547
03:25:51,280 --> 03:25:54,480
UPDATE I PROVIDED AROUND THIS

5548
03:25:54,480 --> 03:25:56,000
TIME LAST YEAR, YOU MAY RECALL I

5549
03:25:56,000 --> 03:25:58,080
MENTIONED THAT WE UNDERTOOK A

5550
03:25:58,080 --> 03:26:00,440
RESCOPE OF THE GUIDELINE LOOKING

5551
03:26:00,440 --> 03:26:05,440
AT ALL THE 25 OPPORTUNISTIC

5552
03:26:05,440 --> 03:26:10,280
INFECTION SECTIONS AND THOSE

5553
03:26:10,280 --> 03:26:11,760
THAT INCLUDED

5554
03:26:11,760 --> 03:26:12,840
VACCINE-PREVENTABLE DISEASES AND

5555
03:26:12,840 --> 03:26:13,480
RECOMMENDATIONS, ET CETERA, AND

5556
03:26:13,480 --> 03:26:15,440
INCLUDED A BROAD CONSULTATION

5557
03:26:15,440 --> 03:26:19,400
WITH THE PEDIATRIC HIV AND

5558
03:26:19,400 --> 03:26:19,960
INFECTIOUS DISEASE COMMUNITY

5559
03:26:19,960 --> 03:26:21,800
THAT LED TO IMPLEMENTATION OF A

5560
03:26:21,800 --> 03:26:24,080
PLAN THAT HAD BEEN BROUGHT TO

5561
03:26:24,080 --> 03:26:26,240
O.A.R. AT THAT TIME AND APPROVED

5562
03:26:26,240 --> 03:26:30,120
BY YOU ALL TO RESCOPE THE

5563
03:26:30,120 --> 03:26:34,120
GUIDELINE TO MORE ALIGN WITH

5564
03:26:34,120 --> 03:26:37,320
CURRENT EPIDEMIOLOGY AND IN

5565
03:26:37,320 --> 03:26:38,800
PEDIATRICS AND HIV AND THE

5566
03:26:38,800 --> 03:26:41,800
PROVIDERS CARING FOR THOSE

5567
03:26:41,800 --> 03:26:43,320
CHILDREN, AND SO WE ARE UNDERWAY

5568
03:26:43,320 --> 03:26:45,760
IN IMPLEMENTING THAT AND ONE OF

5569
03:26:45,760 --> 03:26:46,400
THOSE RECOMMENDATIONS WAS THAT

5570
03:26:46,400 --> 03:26:48,960
WE NEEDED MORE EDITORIAL HANDS

5571
03:26:48,960 --> 03:26:50,920
AND THERE YOU HAVE IT ON THIS

5572
03:26:50,920 --> 03:26:56,840
SLIDE, BY A LOT OF -- WE HAVE

5573
03:26:56,840 --> 03:26:58,480
UNDERGONE A TWOFOLD INCREASE IN

5574
03:26:58,480 --> 03:27:01,680
SIZE OF THE LEADERSHIP GROUP.

5575
03:27:01,680 --> 03:27:02,760
TO INTRODUCE SOME OF THE NEWEST

5576
03:27:02,760 --> 03:27:04,720
PANEL MEMBERS, BECAUSE I THINK

5577
03:27:04,720 --> 03:27:05,600
SOME OF THE INDIVIDUALS ON THAT

5578
03:27:05,600 --> 03:27:07,240
PRIOR SLIDE, WE DID INTRODUCE

5579
03:27:07,240 --> 03:27:07,480
BEFORE.

5580
03:27:07,480 --> 03:27:10,120
SO THESE MEMBERS, YOU HAVE NOT

5581
03:27:10,120 --> 03:27:12,840
HEARD FROM ME LAST YEAR.

5582
03:27:12,840 --> 03:27:17,560
THIS IS TO REPLACE EXPERTISE

5583
03:27:17,560 --> 03:27:20,920
THAT -- DR. DIANNE CLARKE

5584
03:27:20,920 --> 03:27:24,240
RETIRED FROM OUR PHARM-D

5585
03:27:24,240 --> 03:27:26,160
PERSPECTIVE AND PARTICULARLY THE

5586
03:27:26,160 --> 03:27:30,080
TABLES ADDRESSING TOXICITIES OF

5587
03:27:30,080 --> 03:27:32,880
ANT RETROVIRALS AND INTERACTIONS

5588
03:27:32,880 --> 03:27:36,520
WITH OTHER ANTIINFECTIVES AND

5589
03:27:36,520 --> 03:27:37,400
PARTICULARLY THERE'S ANOTHER

5590
03:27:37,400 --> 03:27:38,920
ADDITION THAT WILL TABLE ON

5591
03:27:38,920 --> 03:27:41,200
DRUG-DRUG INTERACTIONS

5592
03:27:41,200 --> 03:27:42,200
THEMSELVES, AND SO WE HAVE

5593
03:27:42,200 --> 03:27:46,920
BROUGHT ABOARD TWO VERY HIGHLY

5594
03:27:46,920 --> 03:27:49,480
QUALIFIED INDIVIDUALS, DR. SUSAN

5595
03:27:49,480 --> 03:27:52,080
CARR AND DR. JULIE RICHARDSON

5596
03:27:52,080 --> 03:27:53,800
WHO ARE BOTH FROM ST. JUDE'S

5597
03:27:53,800 --> 03:27:55,000
CHILDREN'S RESEARCH HOSPITAL,

5598
03:27:55,000 --> 03:27:58,200
AND REALLY ARE GOING TO BE THE

5599
03:27:58,200 --> 03:28:00,920
LEAD -- CO-LEADS OF THESE

5600
03:28:00,920 --> 03:28:02,880
SECTIONS.

5601
03:28:02,880 --> 03:28:09,120
AND THEN WE HAVE DR. KEVIN

5602
03:28:09,120 --> 03:28:11,520
O'CALLAGHAN FROM THE CENTERS FOR

5603
03:28:11,520 --> 03:28:12,400
DISEASE CONTROL AND PREVENTION,

5604
03:28:12,400 --> 03:28:15,360
HE WILL BE TAKING ON THE LEAD

5605
03:28:15,360 --> 03:28:16,840
AUTHORSHIP OF THE SYPHILIS

5606
03:28:16,840 --> 03:28:17,800
SECTION.

5607
03:28:17,800 --> 03:28:21,520
ADDITIONALLY WANT TO MENTION DRR

5608
03:28:21,520 --> 03:28:29,280
OF THE PEDIATRIC HIV SOCIETY AND

5609
03:28:29,280 --> 03:28:33,440
PART OF THE PEDIATRIC AND

5610
03:28:33,440 --> 03:28:35,360
RETROVIRAL GUIDELINES.

5611
03:28:35,360 --> 03:28:37,120
HE IS THE LIAISON BETWEEN OUR

5612
03:28:37,120 --> 03:28:39,520
GROUPS AND IN HELPING ACHIEVE

5613
03:28:39,520 --> 03:28:43,280
SOME OF THE -- SPECIFICALLY I DO

5614
03:28:43,280 --> 03:28:45,440
WANT TO CALL OUT SOME ACTIVITY

5615
03:28:45,440 --> 03:28:50,360
ON THE SARS-COV SECTIONS THAT WE

5616
03:28:50,360 --> 03:28:55,480
ARE GOING TO BE ADDING, THERE IS

5617
03:28:55,480 --> 03:28:56,920
A SECTION FOR CHILDREN AND WE

5618
03:28:56,920 --> 03:29:01,000
HAVE A BROADER BOARD EXPERTISE.

5619
03:29:01,000 --> 03:29:04,440
LASTLY DR. FRANKLIN YATES, A

5620
03:29:04,440 --> 03:29:07,720
CLEEJ FROM NICHD, WHO IS A

5621
03:29:07,720 --> 03:29:08,680
LEADERSHIP GROUP MEMBER WITH ME

5622
03:29:08,680 --> 03:29:09,680
ON THIS PANEL.

5623
03:29:09,680 --> 03:29:11,520
SO GETTING TO THE MEAT OF THE

5624
03:29:11,520 --> 03:29:13,040
SECTION UPDATES THAT I

5625
03:29:13,040 --> 03:29:17,680
MENTIONED, AP ANTICIPATE TO HAVE

5626
03:29:17,680 --> 03:29:18,880
PUBLICATION BY THE END OF JUNE,

5627
03:29:18,880 --> 03:29:22,920
THE SITE LOW MELLOW VIRUS,

5628
03:29:22,920 --> 03:29:25,360
PUBLICATIONS IN 2013, SO THE

5629
03:29:25,360 --> 03:29:27,960
UPDATE HERE ARE THEIR

5630
03:29:27,960 --> 03:29:29,400
RECOMMENDATIONS TO TEST INFANTS

5631
03:29:29,400 --> 03:29:32,840
EXPOSED TO HIV FOR CONGENITAL

5632
03:29:32,840 --> 03:29:33,560
CMV INFECTION BECAUSE OF THE

5633
03:29:33,560 --> 03:29:35,280
HIGH RISK OF TRANSMISSION IN

5634
03:29:35,280 --> 03:29:36,920
MOTHERS WITH HIV.

5635
03:29:36,920 --> 03:29:40,960
AND THEN ALSO HARMONIZING THE

5636
03:29:40,960 --> 03:29:43,480
CONGENITAL CMV TREATMENT

5637
03:29:43,480 --> 03:29:47,520
RECOMMENDATIONS FOR THOSE WITH

5638
03:29:47,520 --> 03:29:49,280
CMV INFECTION, HOPEFULLY

5639
03:29:49,280 --> 03:29:50,920
PRESENTING WITHIN THE FIRST

5640
03:29:50,920 --> 03:30:01,640
MONTH TO START IV ENPSY -- THE

5641
03:30:02,360 --> 03:30:02,720
PEDIATRICS RED BOOK

5642
03:30:02,720 --> 03:30:03,080
RECOMMENDATIONS.

5643
03:30:03,080 --> 03:30:07,000
SO THE OTHER SECTION IS THE LONG

5644
03:30:07,000 --> 03:30:10,840
AWAITED MTB SECTION, AGAIN

5645
03:30:10,840 --> 03:30:11,720
REFERENCING -- SO THE MAIN

5646
03:30:11,720 --> 03:30:14,600
UPDATES HERE ARE REALLY THREE

5647
03:30:14,600 --> 03:30:15,520
AREAS.

5648
03:30:15,520 --> 03:30:17,600
AROUND DIAGNOSTICS AND

5649
03:30:17,600 --> 03:30:19,680
CONGRUENCY WITH THE AAP GUIDANCE

5650
03:30:19,680 --> 03:30:21,320
RECOMMENDING THE INTERFATHER ON

5651
03:30:21,320 --> 03:30:24,480
GAMMA RELEASE ASSAYS TO DIAGNOSE

5652
03:30:24,480 --> 03:30:26,480
LTBI AND TODDLERS OVER 2.

5653
03:30:26,480 --> 03:30:28,760
AND THEN THERE ARE

5654
03:30:28,760 --> 03:30:33,000
RECOMMENDATIONS ON CHILDREN OVER

5655
03:30:33,000 --> 03:30:35,400
2 WITH HIV WHO HAVE LTBI ARE

5656
03:30:35,400 --> 03:30:39,880
THEN ABLE TO RECEIVE THE 12-DOSE

5657
03:30:39,880 --> 03:30:41,240
LTBI TREATMENT WITH -- AND -- AS

5658
03:30:41,240 --> 03:30:43,520
LONG AS THERE AREN'T SIGNIFICANT

5659
03:30:43,520 --> 03:30:45,280
DRUG-DRUG INTERACTIONS WITH THE

5660
03:30:45,280 --> 03:30:46,440
ANTIRETROVIRALS.

5661
03:30:46,440 --> 03:30:48,760
FINALLY RECOMMENDATIONS FOR

5662
03:30:48,760 --> 03:30:50,720
DOLUTEGRAVIR AND -- BASED

5663
03:30:50,720 --> 03:30:51,280
ANTIVIRAL REGIMENS IN THE

5664
03:30:51,280 --> 03:30:54,960
CONTEXT OF TB DISEASE FOR

5665
03:30:54,960 --> 03:30:57,600
CHILDREN WITH HIV OVER 20KGs

5666
03:30:57,600 --> 03:31:00,120
AND THOSE UNDER 20 RESPECTIVELY.

5667
03:31:00,120 --> 03:31:03,160
THEN FINALLY AND IMPORTANTLY, WE

5668
03:31:03,160 --> 03:31:04,400
REALLY NEED TO DO AN OVERALL OF

5669
03:31:04,400 --> 03:31:06,320
THE TWO SECTIONS THAT ARE

5670
03:31:06,320 --> 03:31:07,960
INTRODUCING THE GUIDELINE, THAT

5671
03:31:07,960 --> 03:31:10,000
THE SUMMARY AND THEN THE BLACK

5672
03:31:10,000 --> 03:31:11,000
GROUND AND RECOMMENDATIONS

5673
03:31:11,000 --> 03:31:13,960
RATING SCHEME SECTIONS THAT A

5674
03:31:13,960 --> 03:31:16,440
LOT OF HISTORICAL CONTEXT AND

5675
03:31:16,440 --> 03:31:19,320
INFORMATION THAT I THINK HAS

5676
03:31:19,320 --> 03:31:20,680
REALLY NEEDED TO BE UPDATED AND

5677
03:31:20,680 --> 03:31:22,280
HAS BEEN ARCHIVED AND

5678
03:31:22,280 --> 03:31:23,080
CONSOLIDATED INTO A SINGLE

5679
03:31:23,080 --> 03:31:26,480
SECTION THAT IS AN INTRODUCTION

5680
03:31:26,480 --> 03:31:28,520
TO MAKE IT MORE CONGRUENT WITH

5681
03:31:28,520 --> 03:31:29,720
HOW THE OTHER GUIDELINES ARE

5682
03:31:29,720 --> 03:31:31,320
FLOWING AND MAKE IT EASIER TO

5683
03:31:31,320 --> 03:31:34,080
FIND INFORMATION LIKE SEXUAL

5684
03:31:34,080 --> 03:31:36,080
MATURITY RATING SCHEMES AND

5685
03:31:36,080 --> 03:31:39,480
T-CELL COUNTS AND SEVERITY OF

5686
03:31:39,480 --> 03:31:40,200
IMMUNOSUPPRESSION.

5687
03:31:40,200 --> 03:31:45,880
SO THE TABLE FOR THAT IS EASY TO

5688
03:31:45,880 --> 03:31:46,920
ACCESS FROM ONE PLACE, SO THIS

5689
03:31:46,920 --> 03:31:48,080
INTRODUCTION IS ALSO COMING OUT

5690
03:31:48,080 --> 03:31:49,080
THE END OF THIS MONTH.

5691
03:31:49,080 --> 03:31:50,680
AND THEN FINALLY, THE TABLES

5692
03:31:50,680 --> 03:31:53,040
THAT GO ALONG WITH THE

5693
03:31:53,040 --> 03:31:53,640
APPROPRIATE SECTIONS THAT ARE

5694
03:31:53,640 --> 03:31:56,280
BEING UPDATED FOR PRIMARY AND

5695
03:31:56,280 --> 03:31:57,800
SECONDARY PROPHYLAX EASE AND

5696
03:31:57,800 --> 03:32:01,760
TPROPHYLAXIS ANDTREAT

5697
03:32:01,760 --> 03:32:02,920
TREATMENT ARE BEING UPDATED.

5698
03:32:02,920 --> 03:32:04,280
SO THAT IS IT.

5699
03:32:04,280 --> 03:32:05,680
>> THANK YOU, BILL.

5700
03:32:05,680 --> 03:32:08,560
AND FINALLY, DR. PAU?

5701
03:32:08,560 --> 03:32:12,560
>> THANK YOU.

5702
03:32:12,560 --> 03:32:15,800
THANK YOU FOR PLET LEATHE LETTIA

5703
03:32:15,800 --> 03:32:17,040
LITTLE BIT LATER TODAY.

5704
03:32:17,040 --> 03:32:18,560
I'M GOING TO GIVE A QUICK REPORT

5705
03:32:18,560 --> 03:32:19,480
OF WHAT HAPPENED SINCE THE LAST

5706
03:32:19,480 --> 03:32:24,080
REPORT WE DID IN OCTOBER, ON THE

5707
03:32:24,080 --> 03:32:28,080
ADULTS AND ADOLESCENTS ART

5708
03:32:28,080 --> 03:32:28,400
GUIDELINES.

5709
03:32:28,400 --> 03:32:30,320
THE LAST UPDATE WE HAD WAS MARCH

5710
03:32:30,320 --> 03:32:33,160
OF THIS YEAR, JUST A FEW MONTHS

5711
03:32:33,160 --> 03:32:40,040
AGO, WITH A FOCUS -- PRIMARILY

5712
03:32:40,040 --> 03:32:46,160
FOCUS ON LENACAPAVIR THAT WAS

5713
03:32:46,160 --> 03:32:47,360
APPROVED IN DECEMBER 2022,

5714
03:32:47,360 --> 03:32:48,800
PRIMARILY FOR PATIENTS WITH

5715
03:32:48,800 --> 03:32:50,640
MULTIPLE DRUG RESISTANCE HIV AND

5716
03:32:50,640 --> 03:32:52,920
WITH VIROLOGIC FAILURE.

5717
03:32:52,920 --> 03:32:55,560
THIS DOSE IS SUBCUTANEOUSLY

5718
03:32:55,560 --> 03:32:57,200
GIVEN EVERY SIX MONTHS, SO IT IS

5719
03:32:57,200 --> 03:33:00,760
THE LONGEST ACTING AGENT THAT IS

5720
03:33:00,760 --> 03:33:02,040
CURRENTLY FDA-APPROACHED.

5721
03:33:02,040 --> 03:33:03,440
BECAUSE OF THIS APPROVAL, A

5722
03:33:03,440 --> 03:33:09,000
NUMBER OF SECTIONS WERE UPDATED

5723
03:33:09,000 --> 03:33:09,680
WITH INFORMATION WITH REGARDS TO

5724
03:33:09,680 --> 03:33:12,720
THE USE OF IT, WITH REGARDS TO

5725
03:33:12,720 --> 03:33:13,360
POTENTIAL DRUG-DRUG INTERACTIONS

5726
03:33:13,360 --> 03:33:14,920
AND OTHER INFORMATION.

5727
03:33:14,920 --> 03:33:16,360
SO THE SECTIONS RELATING TO

5728
03:33:16,360 --> 03:33:17,760
VIROLOGIC FAILURE, DRUG

5729
03:33:17,760 --> 03:33:19,400
RESISTANCE TESTING, BASICALLY

5730
03:33:19,400 --> 03:33:20,360
INDICATING THAT THERE IS

5731
03:33:20,360 --> 03:33:22,600
CURRENTLY NO COMMERCIALLY

5732
03:33:22,600 --> 03:33:24,680
AVAILABLE TEST AVAILABLE TO

5733
03:33:24,680 --> 03:33:27,200
IDENTIFY WHETHER THERE'S ANY

5734
03:33:27,200 --> 03:33:33,320
GIGENOTYPIC RESISTANCE TO LEN

5735
03:33:33,320 --> 03:33:33,760
LENACAPAVIR.

5736
03:33:33,760 --> 03:33:36,600
WE ADDED THE INFORMATION IN THE

5737
03:33:36,600 --> 03:33:37,880
ADVERSE REACTIONS AS WELL AS THE

5738
03:33:37,880 --> 03:33:38,680
COST CONSIDERATION SECTION.

5739
03:33:38,680 --> 03:33:41,200
BY ADDING THE COST CONSIDERATION

5740
03:33:41,200 --> 03:33:43,120
SECTION WHICH COSTS ABOUT

5741
03:33:43,120 --> 03:33:43,920
$18,000 PER DOSE EVERY SIX

5742
03:33:43,920 --> 03:33:45,320
MONTHS, WE ALSO UPDATED THE

5743
03:33:45,320 --> 03:33:49,800
COSTS FOR ALL THE OTHER

5744
03:33:49,800 --> 03:33:51,960
ANTIRETROVIRAL DRUGS CURRENTLY

5745
03:33:51,960 --> 03:33:52,400
FDA-APPROVED AS WELL.

5746
03:33:52,400 --> 03:33:54,320
BECAUSE THERE'S THE POTENTIAL OF

5747
03:33:54,320 --> 03:33:55,400
DRUG-DRUG INTERACTIONS WITH THIS

5748
03:33:55,400 --> 03:33:59,240
AGENT, WE UPDATED WITH

5749
03:33:59,240 --> 03:34:00,800
INFORMATION ABOUT WHAT ARE THE

5750
03:34:00,800 --> 03:34:04,200
POTENTIAL PROBLEMS WITH

5751
03:34:04,200 --> 03:34:05,200
INTERACTIONS WITH THIS

5752
03:34:05,200 --> 03:34:09,080
LONG-ACTING LENACAPAVIR, AND THE

5753
03:34:09,080 --> 03:34:10,720
DRUG CHARACTERISTICS TABLE WAS

5754
03:34:10,720 --> 03:34:12,800
ALSO UPDATED AS WELL.

5755
03:34:12,800 --> 03:34:14,280
JUST LIKE ALL THE OTHER GROUPS,

5756
03:34:14,280 --> 03:34:15,960
FOR THE FIRST TIME IN THREE

5757
03:34:15,960 --> 03:34:18,360
YEARS, ACTUALLY, WE WERE ABLE TO

5758
03:34:18,360 --> 03:34:20,080
RECRUIT NEW MEMBERS DURING THE

5759
03:34:20,080 --> 03:34:21,000
PAN AT THE MIBG.

5760
03:34:21,000 --> 03:34:23,080
MESS OF US HAD BEEN VERY BUSY

5761
03:34:23,080 --> 03:34:25,480
WITH COVID-19, AND IT WAS

5762
03:34:25,480 --> 03:34:27,280
DIFFICULT FOR US TO BE ABLE TO

5763
03:34:27,280 --> 03:34:30,000
IDENTIFY NEW MEMBERS DURING THAT

5764
03:34:30,000 --> 03:34:31,200
PERIOD OF TIME, BUT THIS IS THE

5765
03:34:31,200 --> 03:34:33,680
YEAR WHERE WE WANT TO

5766
03:34:33,680 --> 03:34:36,360
REINVIGORATE THE GUIDELINES AS

5767
03:34:36,360 --> 03:34:38,400
WELL AS INCLUDING NEW MEMBERS

5768
03:34:38,400 --> 03:34:41,680
AND SENDING OFF SOME OF THE

5769
03:34:41,680 --> 03:34:42,680
MEMBERS THAT HAD GRACIOUSLY

5770
03:34:42,680 --> 03:34:45,920
AGREED TO STAY ON A LITTLE BIT

5771
03:34:45,920 --> 03:34:46,600
LONGER TERMS.

5772
03:34:46,600 --> 03:34:49,680
SO THE GROUPS THAT I LISTED HERE

5773
03:34:49,680 --> 03:34:53,280
INCLUDED MEMBERS THAT ARE --

5774
03:34:53,280 --> 03:34:56,360
WITH EXPERTISE IN ANTIRETROVIRAL

5775
03:34:56,360 --> 03:34:58,200
THERAPY, EXPERTISE IN WOMEN AND

5776
03:34:58,200 --> 03:34:59,760
HIV ADHERENCE, AS WELL AS

5777
03:34:59,760 --> 03:35:01,240
IMMUNOLOGY, WITH THE GOAL TO

5778
03:35:01,240 --> 03:35:08,280
REPLACE SEVERAL OF THE MEMBERS.

5779
03:35:08,280 --> 03:35:11,880
WHICH ARE INCLUDED IN HERE.

5780
03:35:11,880 --> 03:35:15,280
DR. RAJESH GANDHI FROM MASS

5781
03:35:15,280 --> 03:35:17,280
GENERAL AND HARVARD HAS BEEN ON

5782
03:35:17,280 --> 03:35:18,680
THE PANEL 10 YEARS NOW INSTEAD

5783
03:35:18,680 --> 03:35:20,000
OF EIGHT.

5784
03:35:20,000 --> 03:35:22,200
DR. TOM GIORDANO, WHOSE TERM IS

5785
03:35:22,200 --> 03:35:25,120
UP BY THE END OF THIS YEAR, OUR

5786
03:35:25,120 --> 03:35:26,440
ADHERENCE GROUP.

5787
03:35:26,440 --> 03:35:29,960
DR. PETER HUNT FROM UCSF, HIS

5788
03:35:29,960 --> 03:35:31,720
MAIN AREA OF EXPERTISE IS

5789
03:35:31,720 --> 03:35:33,040
IMMUNOLOGY.

5790
03:35:33,040 --> 03:35:34,360
DR. KELLER, HER EXPERTISE HAD

5791
03:35:34,360 --> 03:35:36,840
BEEN IN ART AS WELL AS WOMEN.

5792
03:35:36,840 --> 03:35:40,680
AS WELL AS DR. JEFF LENNOX AND

5793
03:35:40,680 --> 03:35:43,000
DR. PABLO TEBAS, BOTH OF WHICH

5794
03:35:43,000 --> 03:35:46,160
ARE EXPERTS IN ADULT

5795
03:35:46,160 --> 03:35:47,440
ANTIRETROVIRAL THERAPY.

5796
03:35:47,440 --> 03:35:49,080
WE HOPE TO BE ABLE TO SEND THEM

5797
03:35:49,080 --> 03:35:50,960
OFF IN SEPTEMBER OF 2023, WHEN

5798
03:35:50,960 --> 03:35:54,080
WE HAVE OUR FIRST IN THREE YEARS

5799
03:35:54,080 --> 03:35:59,560
FACE-TO-FACE MEETING.

5800
03:35:59,560 --> 03:36:01,560
SO THE UPCOMING EVENTS, WE HAVE

5801
03:36:01,560 --> 03:36:03,080
NOT HAD FACE-TO-FACE MEETING

5802
03:36:03,080 --> 03:36:04,400
SINCE MAY OF 2019.

5803
03:36:04,400 --> 03:36:07,160
WE WERE SUPPOSED TO HAVE ONE IN

5804
03:36:07,160 --> 03:36:09,440
MAY 2020, BUT THAT WAS CAN KAHN

5805
03:36:09,440 --> 03:36:10,680
SELLED BECAUSE OF THE PANDEMIC,

5806
03:36:10,680 --> 03:36:12,160
SO FOR THE FIRST TIME, WE WERE

5807
03:36:12,160 --> 03:36:13,480
ABLE TO MEET TOGETHER SO THAT

5808
03:36:13,480 --> 03:36:14,360
WOULD BE THE TIME WHEN WE WOULD

5809
03:36:14,360 --> 03:36:17,280
BE ABLE TO SEND OFF THE OLD

5810
03:36:17,280 --> 03:36:18,640
MEMBERS AS WELL AS WELCOMING THE

5811
03:36:18,640 --> 03:36:18,960
NEW MEMBERS.

5812
03:36:18,960 --> 03:36:21,120
EVEN THOUGH THE NEW MEMBERS HAD

5813
03:36:21,120 --> 03:36:23,880
ALREADY BEEN STARTING TO WORK

5814
03:36:23,880 --> 03:36:24,560
SINCE MAY.

5815
03:36:24,560 --> 03:36:27,200
IN FACT, BEFORE THIS CALL, I WAS

5816
03:36:27,200 --> 03:36:29,400
ON ANOTHER CALL WHERE WE'RE

5817
03:36:29,400 --> 03:36:31,320
TRYING TO WRITE A SECTION ON HIV

5818
03:36:31,320 --> 03:36:32,240
AND TRANSPLANT.

5819
03:36:32,240 --> 03:36:33,440
THE WORK IS UNDERWAY.

5820
03:36:33,440 --> 03:36:35,080
WE HOPE TO BE ABLE TO PRESENT TO

5821
03:36:35,080 --> 03:36:38,360
THE PANEL ABOUT THIS SECTION IN

5822
03:36:38,360 --> 03:36:39,320
SEPTEMBER.

5823
03:36:39,320 --> 03:36:39,960
NSKS, THIS SECTION WAS SUPPOSED

5824
03:36:39,960 --> 03:36:42,600
TO BE WRITTEN UP IN TWEB 20, AND

5825
03:36:42,600 --> 03:36:43,600
EVERYTHING WAS PUT ON HOLD

5826
03:36:43,600 --> 03:36:47,360
BECAUSE OF THE PANDEMIC, BUT WE

5827
03:36:47,360 --> 03:36:48,640
ARE NOW DIGGING OUT AND TRYING

5828
03:36:48,640 --> 03:36:52,800
TO BE ABLE TO PUT THIS TOGETHER.

5829
03:36:52,800 --> 03:36:54,040
ALONG WITH THAT, THERE'S A

5830
03:36:54,040 --> 03:36:55,080
NUMBER OF SECTIONS THAT ARE

5831
03:36:55,080 --> 03:36:56,400
BEING UPDATED AT DIFFERENT

5832
03:36:56,400 --> 03:36:58,480
STAGES AT THIS POINT, INCLUDING

5833
03:36:58,480 --> 03:37:00,680
EARLY, ACUTE AND RECENT, SHOULD

5834
03:37:00,680 --> 03:37:04,600
I BE IN OLDER PEOPLE, WOMEN,

5835
03:37:04,600 --> 03:37:06,600
ADOLESCENTS, HIV 2 INFECTION,

5836
03:37:06,600 --> 03:37:09,240
SUBSTANCE USE AND HIV, AS WELL

5837
03:37:09,240 --> 03:37:11,280
AS DRUG-DRUG INTERACTION.

5838
03:37:11,280 --> 03:37:12,960
ONE THING I DIDN'T MENTION HERE

5839
03:37:12,960 --> 03:37:14,560
IS THAT WE ALONG WITH THE FULL

5840
03:37:14,560 --> 03:37:16,440
OTHER GUIDELINES GROUP IN 2020,

5841
03:37:16,440 --> 03:37:19,720
WE PUT TOGETHER A SECTION ON

5842
03:37:19,720 --> 03:37:21,840
COVID-19 AND HIV, SPECIFICALLY

5843
03:37:21,840 --> 03:37:24,680
FOCUSED ON SOME OF THE AREAS

5844
03:37:24,680 --> 03:37:26,440
THAT WE -- AT THAT TIME IN 2020,

5845
03:37:26,440 --> 03:37:29,280
THOUGHT TO BE IMPORTANT,

5846
03:37:29,280 --> 03:37:30,400
INCLUDING NEEDING TO TRIAGE

5847
03:37:30,400 --> 03:37:32,000
PATIENTS WITH HIV AND THEY

5848
03:37:32,000 --> 03:37:35,200
SHOULD NOT BE DENIED THERAPY IF

5849
03:37:35,200 --> 03:37:36,480
NECESSARY, WHAT TO DO IN

5850
03:37:36,480 --> 03:37:38,920
PATIENTS WHO CANNOT BE IN

5851
03:37:38,920 --> 03:37:41,640
PERSON, HAVE TO DO TELEHEALTH

5852
03:37:41,640 --> 03:37:44,960
AND FILLING PRESCRIPTION, ZO SON

5853
03:37:44,960 --> 03:37:46,040
AND SO FORTH, AND BECAUSE OF THE

5854
03:37:46,040 --> 03:37:49,320
FACT THAT THE PANDEMIC EMERGENCY

5855
03:37:49,320 --> 03:37:50,400
IS OVER AND THERE IS THE

5856
03:37:50,400 --> 03:37:52,240
COVID-19 TREATMENT GUIDELINES IN

5857
03:37:52,240 --> 03:37:54,360
WHICH MANY OF THE GUIDELINES

5858
03:37:54,360 --> 03:37:56,760
PANEL MEMBERS ARE ALSO PART OF,

5859
03:37:56,760 --> 03:37:59,240
AND ALSO WRITE UP THE SECTION ON

5860
03:37:59,240 --> 03:38:00,280
COVID-19 AND IMMUNOFLORESCENT,

5861
03:38:00,280 --> 03:38:02,800
WE DECIDED WITH THE CONCURRENCE

5862
03:38:02,800 --> 03:38:04,480
OF THIS GROUP AS WELL AS THE

5863
03:38:04,480 --> 03:38:07,000
OTHER GUIDELINES PANELS, TO

5864
03:38:07,000 --> 03:38:09,720
RETIRE THE SECTION THAT IS

5865
03:38:09,720 --> 03:38:12,240
CURRENTLY ONLINE IN THE HIV INFO

5866
03:38:12,240 --> 03:38:14,960
WEBSITE, AND REFER CLINICIANS TO

5867
03:38:14,960 --> 03:38:16,760
THE SECTIONS IN THE NIH COVID-19

5868
03:38:16,760 --> 03:38:20,720
TREATMENT GUIDELINES, COVID-19

5869
03:38:20,720 --> 03:38:21,320
AND HIV.

5870
03:38:21,320 --> 03:38:28,440
AND I THINK THAT'S ALL I HAVE.

5871
03:38:28,440 --> 03:38:29,360
>> THANK YOU, DR. PAU.

5872
03:38:29,360 --> 03:38:30,640
AND THANK YOU TO ALL THE OTHER

5873
03:38:30,640 --> 03:38:33,040
PRESENTERS.

5874
03:38:33,040 --> 03:38:37,040
WE ARE NOW OPEN FOR DISCUSSION.

5875
03:38:37,040 --> 03:38:40,720
LET'S START WITH THE ZOOM

5876
03:38:40,720 --> 03:38:41,680
MEETING ATTENDEES.

5877
03:38:41,680 --> 03:38:43,280
IF YOU HAVE A QUESTION OR A

5878
03:38:43,280 --> 03:38:46,080
COMMENT, PLEASE USE THE ZOOM

5879
03:38:46,080 --> 03:38:56,480
RAISE YOUR HAND FEATURE.

5880
03:39:14,920 --> 03:39:17,200
I DON'T SEE ANY HANDS IN THE --

5881
03:39:17,200 --> 03:39:19,480
FROM THE ZOOM ATTENDEES.

5882
03:39:19,480 --> 03:39:21,120
DR. GLENSHAW, ARE THERE ANY

5883
03:39:21,120 --> 03:39:22,200
QUESTIONS OR COMMENTS IN THE

5884
03:39:22,200 --> 03:39:23,000
ROOM?

5885
03:39:23,000 --> 03:39:25,600
>> YES.

5886
03:39:25,600 --> 03:39:27,120
THANKS, DR. TURNBULL.

5887
03:39:27,120 --> 03:39:27,440
DR. SLEASMAN?

5888
03:39:27,440 --> 03:39:29,200
>> YES, I JUST WANTED TO
FOLLOW

5889
03:39:29,200 --> 03:39:30,600
UP, IF YOU REMEMBER LAST MEETING

5890
03:39:30,600 --> 03:39:32,800
IN MARCH, WE HAD A LOT OF

5891
03:39:32,800 --> 03:39:34,440
DISCUSSION ON THE CHANGING

5892
03:39:34,440 --> 03:39:36,000
GUIDELINES IN BREASTFEEDING FOR

5893
03:39:36,000 --> 03:39:37,520
HIV INFECTED WOMEN.

5894
03:39:37,520 --> 03:39:39,880
HAVIS THERE ANY FOLLOW-UP ON TH?

5895
03:39:39,880 --> 03:39:41,240
HOW MUCH ARE THE GUIDELINES

5896
03:39:41,240 --> 03:39:41,800
BEING UTILIZED?

5897
03:39:41,800 --> 03:39:47,280
IS THERE ANY WAY TO TRACK THAT,

5898
03:39:47,280 --> 03:39:51,560
ANY CHANGE IN POLICY AND HOW HAS

5899
03:39:51,560 --> 03:39:54,880
THAT AFFECTED -- I KNOW A LOT OF

5900
03:39:54,880 --> 03:39:56,320
MY COLLEAGUES ARE GOING AROUND

5901
03:39:56,320 --> 03:39:58,720
GIVING TALKS, SO -- SOME GOOD

5902
03:39:58,720 --> 03:39:59,360
HAS COME OUT OF IT.

5903
03:39:59,360 --> 03:40:01,520
>> I KNOW INTERNALLY,
RIGHT, WE

5904
03:40:01,520 --> 03:40:04,160
WORKED CLOSELY WITH HRSA AND --

5905
03:40:04,160 --> 03:40:06,800
RIGHT, AND THEY WERE CREATING

5906
03:40:06,800 --> 03:40:08,840
THE DIFFERENT MATERIALS,

5907
03:40:08,840 --> 03:40:09,280
TRAINING PEERLS.

5908
03:40:09,280 --> 03:40:11,120
I KNOW CDC WAS ALSO GOING TO BE

5909
03:40:11,120 --> 03:40:12,040
UPDATING THEIR WEBSITE.

5910
03:40:12,040 --> 03:40:13,760
I DON'T KNOW IF WE'VE GOTTEN AN

5911
03:40:13,760 --> 03:40:15,520
UPDATE, BUT THEY WERE GOING TO

5912
03:40:15,520 --> 03:40:17,800
GO THROUGH, BECAUSE THIS WAS

5913
03:40:17,800 --> 03:40:20,920
THROUGHOUT THEIR WEBSITE THAT

5914
03:40:20,920 --> 03:40:21,360
IT'S WRITTEN THERE.

5915
03:40:21,360 --> 03:40:24,760
I KNOW ON THE PERINATAL OUTLINE

5916
03:40:24,760 --> 03:40:27,080
THAT TED AND OTHERS HELPED

5917
03:40:27,080 --> 03:40:28,720
OVERSEE, THEY UPDATED THEIR

5918
03:40:28,720 --> 03:40:32,360
SCRIPTS AND THINGS LIKE THAT

5919
03:40:32,360 --> 03:40:32,760
TOO.

5920
03:40:32,760 --> 03:40:34,760
BUT GOOD QUESTION, I THINK, YOU

5921
03:40:34,760 --> 03:40:36,080
KNOW, FOR US TO SORT OF FIGURE

5922
03:40:36,080 --> 03:40:37,000
OUT WHAT ELSE IS HAPPENING.

5923
03:40:37,000 --> 03:40:38,800
THE OTHER THING I HAVE HEARD

5924
03:40:38,800 --> 03:40:41,160
TOO, IN FACT, YOU KNOW, RESEARCH

5925
03:40:41,160 --> 03:40:43,080
PROPOSALS ALSO ON NOW MONITORING

5926
03:40:43,080 --> 03:40:43,880
WHAT'S HAPPENING AS WELL.

5927
03:40:43,880 --> 03:40:46,640
SO I THINK THERE WILL BE SOME

5928
03:40:46,640 --> 03:40:54,280
PROJECTS FROM THAT STAIN -- SEEE

5929
03:40:54,280 --> 03:41:00,800
CAN SYSTEM A ADVE SYSTEMATIZE TN

5930
03:41:00,800 --> 03:41:02,440
AND THEN BEING ABLE TO MONITOR.

5931
03:41:02,440 --> 03:41:03,280
SO GOOD POINT, JOHN.

5932
03:41:03,280 --> 03:41:04,720
>> THOSE ARE GREAT POINTS,

5933
03:41:04,720 --> 03:41:05,160
ROHAN.

5934
03:41:05,160 --> 03:41:06,520
THE ONLY THING I WOULD SAY FROM

5935
03:41:06,520 --> 03:41:07,960
OUR STANDPOINT IS WE'D BE ABLE

5936
03:41:07,960 --> 03:41:11,240
TO CAPTURE THE DATA FROM THE

5937
03:41:11,240 --> 03:41:16,480
BACK END FR THAT WE'RE ABLE TO

5938
03:41:16,480 --> 03:41:19,600
PROVIDE FROM OUR FOLKS AT --

5939
03:41:19,600 --> 03:41:21,560
WHICH PAGES ARE COMING UP MOST

5940
03:41:21,560 --> 03:41:25,480
OR IF THIS PARTICULAR --

5941
03:41:25,480 --> 03:41:26,600
>> ONE ADDITIONAL COMMENT
ON

5942
03:41:26,600 --> 03:41:28,120
THAT, WE DID HEAR IT WOULD BE

5943
03:41:28,120 --> 03:41:29,760
VERY USEFUL FOR PROVIDERS TO

5944
03:41:29,760 --> 03:41:32,600
HAVE JOB AIDS AND SORT OF QUICK

5945
03:41:32,600 --> 03:41:34,560
REFERENCES AROUND THE SPECIFIC

5946
03:41:34,560 --> 03:41:36,760
TOPIC AROUND FEEDING RATHER THAN

5947
03:41:36,760 --> 03:41:39,000
ONLY PATIENT FACING MATERIALS,

5948
03:41:39,000 --> 03:41:41,000
WHICH IS WHAT WE INTEND TO

5949
03:41:41,000 --> 03:41:42,000
CREATE, SO THAT'S SOMETHING WE

5950
03:41:42,000 --> 03:41:51,840
NEED TO WORK ON.

5951
03:41:51,840 --> 03:41:53,120
DR. TURNBULL, I THINK THAT'S THE

5952
03:41:53,120 --> 03:41:55,000
END OF THE COMMENTS FROM THE

5953
03:41:55,000 --> 03:41:55,200
ROOM.

5954
03:41:55,200 --> 03:41:57,920
I WOULD JUST LIKE TO SAY A NOTE

5955
03:41:57,920 --> 03:41:59,800
OF THANKS TO THE VOTING MEMBERS

5956
03:41:59,800 --> 03:42:01,760
FOR PROVIDING THE NOTATIONAL

5957
03:42:01,760 --> 03:42:05,160
VOTE TO ARCHIVE THE COVID AND

5958
03:42:05,160 --> 03:42:07,120
HIV GUIDELINES AS DR. PAU

5959
03:42:07,120 --> 03:42:07,920
MENTIONED.

5960
03:42:07,920 --> 03:42:10,960
THEY ARE ARCHIVED AND STILL

5961
03:42:10,960 --> 03:42:13,280
ACCESSIBLE, BUT THE CURRENT PAGE

5962
03:42:13,280 --> 03:42:16,120
REFERS THE USER OVER TO THE

5963
03:42:16,120 --> 03:42:17,200
BROADER COVID GUIDELINES WITH

5964
03:42:17,200 --> 03:42:18,840
THE HIV SECTION.

5965
03:42:18,840 --> 03:42:23,800
SO THANK YOU ALL FOR GOING THAT

5966
03:42:23,800 --> 03:42:28,600
DIRECTION.

5967
03:42:28,600 --> 03:42:29,600
 FOR VOTING THAT

5968
03:42:29,600 --> 03:42:30,680
DIRECTION.

5969
03:42:30,680 --> 03:42:31,000
DR. TURNBULL?

5970
03:42:31,000 --> 03:42:32,400
>> YES, DR. GLENSHAW.

5971
03:42:32,400 --> 03:42:34,240
I DON'T SEE ANY ADDITIONAL

5972
03:42:34,240 --> 03:42:35,560
COMMENTS IN THE ZOOM.

5973
03:42:35,560 --> 03:42:38,640
SO I GUESS WE'RE GOING TO MOVE

5974
03:42:38,640 --> 03:42:39,720
FORWARD WITH THE PUBLIC

5975
03:42:39,720 --> 03:42:41,720
COMMENTS, CLOSING REMARKS AND

5976
03:42:41,720 --> 03:42:46,880
MEETING ADJOURNMENT.

5977
03:42:46,880 --> 03:42:48,360
>> YES, MA'AM.

5978
03:42:48,360 --> 03:42:50,000
WE DO HAVE A COUPLE OF PUBLIC

5979
03:42:50,000 --> 03:42:51,200
COMMENTS.

5980
03:42:51,200 --> 03:42:53,040
>> OKAY.

5981
03:42:53,040 --> 03:42:55,240
SO JUST LET ME SAY, YOU KNOW,

5982
03:42:55,240 --> 03:42:56,240
THANK EVERYONE AGAIN.

5983
03:42:56,240 --> 03:42:59,240
AS WE BEGIN TO CLOSE, THIS IS

5984
03:42:59,240 --> 03:43:00,680
REALLY THE TIME THAT HAS BEEN

5985
03:43:00,680 --> 03:43:03,880
ALLOTTED FOR PUBLIC COMMENT.

5986
03:43:03,880 --> 03:43:06,160
SO MY QUESTION TO DR. GLENSHAW

5987
03:43:06,160 --> 03:43:08,320
IS, DR. GLENSHAW, HAVE YOU

5988
03:43:08,320 --> 03:43:09,520
RECEIVED ANY COMMENTS FOR

5989
03:43:09,520 --> 03:43:12,080
TODAY'S MEETING?

5990
03:43:12,080 --> 03:43:14,760
>> AS A MATTER OF FACT,
YES.

5991
03:43:14,760 --> 03:43:16,160
WE HAVE.

5992
03:43:16,160 --> 03:43:17,280
WE HAVE TWO PUBLIC COMMENTS THAT

5993
03:43:17,280 --> 03:43:17,840
HAVE COME IN.

5994
03:43:17,840 --> 03:43:19,040
I'LL BE HAPPY TO SHARE THEM IN

5995
03:43:19,040 --> 03:43:20,920
JUST A MOMENT.

5996
03:43:20,920 --> 03:43:23,160
BEFORE I DO THAT, JUST A COUPLE

5997
03:43:23,160 --> 03:43:24,600
OF NOTES FOR THE FOLKS IN THE

5998
03:43:24,600 --> 03:43:26,880
ROOM AND ON THE ZOOM.

5999
03:43:26,880 --> 03:43:29,640
IN THE ROOM, YOU'LL FIND A

6000
03:43:29,640 --> 03:43:30,400
CONFLICTS OF INTEREST FORM IN

6001
03:43:30,400 --> 03:43:31,160
YOUR FOLDER.

6002
03:43:31,160 --> 03:43:36,520
IF YOU COULD KINDLY JUST SIGN TO

6003
03:43:36,520 --> 03:43:38,040
CONFIRM NO CONFLICTS WERE

6004
03:43:38,040 --> 03:43:39,000
PRESENTED FOR YOU TODAY, AND

6005
03:43:39,000 --> 03:43:40,440
PLEASE RETURN THAT TO EITHER

6006
03:43:40,440 --> 03:43:48,880
CORETTE OR MYSELF.

6007
03:43:48,880 --> 03:43:50,560
AND IF THERE ARE ANY TRAVEL

6008
03:43:50,560 --> 03:43:53,760
NEEDS AS YOU DEPART, PLEASE SEE

6009
03:43:53,760 --> 03:43:57,520
JANAYA WHO IS IN THE LOBBY.

6010
03:43:57,520 --> 03:44:01,760
SO DR. TURN B TURNBULL, I'LL GOD

6011
03:44:01,760 --> 03:44:02,960
AND START THE PUBLIC COMMENTS

6012
03:44:02,960 --> 03:44:03,120
NOW.

6013
03:44:03,120 --> 03:44:06,600
>> YES.

6014
03:44:06,600 --> 03:44:07,440
>> OKAY.

6015
03:44:07,440 --> 03:44:09,480
THE FIRST IS FROM A PERSON NAMED

6016
03:44:09,480 --> 03:44:11,280
DAVID KIWANA.

6017
03:44:11,280 --> 03:44:16,720
WHO IS FROM THE ASHOWAD

6018
03:44:16,720 --> 03:44:17,720
CHRISTIAN CHARITABLE

6019
03:44:17,720 --> 03:44:18,800
ORGANIZATION FOR VENERABLE

6020
03:44:18,800 --> 03:44:20,640
GROUPS OF CHILDREN, YOUTH AND

6021
03:44:20,640 --> 03:44:21,520
WIDOWS, DISABLED PERSONS AND

6022
03:44:21,520 --> 03:44:25,000
PEOPLE LIVING WITH HIV IN

6023
03:44:25,000 --> 03:44:30,040
UGANDA, CASANDA DISTRICT, IN THE

6024
03:44:30,040 --> 03:44:34,760
K IGA LAMA PARISH.

6025
03:44:34,760 --> 03:44:36,840
THIS PERSON SAYS ACCESS TO

6026
03:44:36,840 --> 03:44:38,040
HEALTH SERVICES AND FACILITIES

6027
03:44:38,040 --> 03:44:40,240
FOR THOSE PEOPLE AND THOSE ON

6028
03:44:40,240 --> 03:44:42,400
ARV ARE A REALLY BIG PROBLEM IN

6029
03:44:42,400 --> 03:44:43,400
OUR COMMUNITY.

6030
03:44:43,400 --> 03:44:44,360
THROUGH YOUR SUPPORT AND

6031
03:44:44,360 --> 03:44:46,240
PARTNERSHIP, WE HOPE TO CREATE

6032
03:44:46,240 --> 03:44:47,000
AN IMPACT.

6033
03:44:47,000 --> 03:44:48,720
AND FURTHER STATES THAT,

6034
03:44:48,720 --> 03:44:50,280
CREATING AWARENESS PROGRAMS FOR

6035
03:44:50,280 --> 03:44:53,880
YOUNG GIRLS AND YOUNG ADULT IN

6036
03:44:53,880 --> 03:44:55,960
UGANDA IN THE CASANDA DISTRICT

6037
03:44:55,960 --> 03:44:57,200
WHERE THEY ARE MOST VULNERABLE

6038
03:44:57,200 --> 03:45:00,840
IS NEEDED.

6039
03:45:00,840 --> 03:45:02,280
THE SECOND PUBLIC COMMENT IS

6040
03:45:02,280 --> 03:45:09,840
FROM JEWE JULESLEVIN.

6041
03:45:09,840 --> 03:45:11,240
HE STATES I'M WATCHING VET

6042
03:45:11,240 --> 03:45:11,800
INTERESTING AND IMPORTANT

6043
03:45:11,800 --> 03:45:12,200
DISCUSSIONS TODAY.

6044
03:45:12,200 --> 03:45:14,920
I WOULD LIKE TO THANK THE

6045
03:45:14,920 --> 03:45:22,120
O.A.R., BILL KAPOGIANNIS AND --

6046
03:45:22,120 --> 03:45:25,720
AND THANK THE NIH WOMEN'S

6047
03:45:25,720 --> 03:45:25,960
PROGRAM.

6048
03:45:25,960 --> 03:45:27,480
THANK YOU ALSO TO DR. KASSAYE

6049
03:45:27,480 --> 03:45:28,720
FOR HER COMMITMENT TO THE WIHS

6050
03:45:28,720 --> 03:45:29,640
COHORT.

6051
03:45:29,640 --> 03:45:30,760
HE STATES, INDEED MANY OF US

6052
03:45:30,760 --> 03:45:32,520
OLDER AND PARTICULARLY ELDERLY

6053
03:45:32,520 --> 03:45:34,920
PERSONS LIVING WITH HIV ARE

6054
03:45:34,920 --> 03:45:36,920
SUFFERING SEVERE EFFECTS OF

6055
03:45:36,920 --> 03:45:39,000
AGING WITH HIV, INCLUDING

6056
03:45:39,000 --> 03:45:40,400
PHYSICAL AND MENTAL IMPAIRMENT

6057
03:45:40,400 --> 03:45:41,200
AND DISABILITY.

6058
03:45:41,200 --> 03:45:44,000
IT'S PAINFULLY OBVIOUS TO MANY

6059
03:45:44,000 --> 03:45:45,960
OF US ELDERLY AND OLDER PERSONS

6060
03:45:45,960 --> 03:45:47,600
WITH HIV THAT WE ARE NOT GETTING

6061
03:45:47,600 --> 03:45:49,800
OUR CARE NEEDS MET.

6062
03:45:49,800 --> 03:45:51,080
YOUR RECOGNITION OF THIS PROBLEM

6063
03:45:51,080 --> 03:45:52,720
IS IMPORTANT.

6064
03:45:52,720 --> 03:45:58,240
WOMEN WHO DO -- WOMEN DO

6065
03:45:58,240 --> 03:46:00,840
EXPERIENCE WORSE RACE OF

6066
03:46:00,840 --> 03:46:01,960
COMORBIDITIES AND DECLINE AS

6067
03:46:01,960 --> 03:46:02,280
THEY AGE.

6068
03:46:02,280 --> 03:46:03,680
I HAVE SUGGESTED BEFORE THAT WE

6069
03:46:03,680 --> 03:46:05,400
NEED IMPLEMENTATION RESEARCH TO

6070
03:46:05,400 --> 03:46:06,520
HELP PROVIDE BETTER CARE, AND I

6071
03:46:06,520 --> 03:46:07,840
THINK DR. KASSAYE DISCUSSED THIS

6072
03:46:07,840 --> 03:46:08,680
TOO.

6073
03:46:08,680 --> 03:46:10,640
WE COULD, FOR EXAMPLE, PROVIDE A

6074
03:46:10,640 --> 03:46:11,600
SUPPORT PROJECT FOR WOMEN AND

6075
03:46:11,600 --> 03:46:14,600
MEN TO BETTER EVALUATE AND

6076
03:46:14,600 --> 03:46:15,840
MONITOR CARE FOR HEART DISEASE

6077
03:46:15,840 --> 03:46:20,080
AND BONE DISEASE AS ONE EXAMPLE.

6078
03:46:20,080 --> 03:46:21,520
IMPLEMENTATION STUDIES OF

6079
03:46:21,520 --> 03:46:24,360
GERIATRIC SCREENINGS AND SUPPORT

6080
03:46:24,360 --> 03:46:25,960
HIV CLINICS WOULD ALSO BE

6081
03:46:25,960 --> 03:46:26,200
USEFUL.

6082
03:46:26,200 --> 03:46:27,320
HE CLOSES BY SAYING THOUSANDS OF

6083
03:46:27,320 --> 03:46:30,520
PERSONS WITH HIV ARE OVER 65 NOW

6084
03:46:30,520 --> 03:46:32,680
AND NEED IMMEDIATE INTERVENTIONS

6085
03:46:32,680 --> 03:46:35,880
AS THEY ARE NOT RECEIVING THEM.

6086
03:46:35,880 --> 03:46:37,160
IMPLEMENTATION RESEARCH IS A

6087
03:46:37,160 --> 03:46:40,680
GREAT WAY TO INSERT GERIATRIC

6088
03:46:40,680 --> 03:46:46,960
CARE AND SCREENINGS INTO HIV

6089
03:46:46,960 --> 03:46:47,200
CLINICS.

6090
03:46:47,200 --> 03:46:48,880
AND THAT CONCLUDES OUR PUBLIC

6091
03:46:48,880 --> 03:46:49,120
COMMENT.

6092
03:46:49,120 --> 03:46:56,160
>> THANK YOU, DR.
GLENSHAW.

6093
03:46:56,160 --> 03:46:57,120
DR. KAPOGIANNIS, I TURN IT OVER

6094
03:46:57,120 --> 03:47:00,560
TO YOU FOR CLOSING REMARKS.

6095
03:47:00,560 --> 03:47:03,720
>> THANK YOU, DR.
TURNBULL.

6096
03:47:03,720 --> 03:47:05,440
WELL, WHAT A FANTASTIC AND

6097
03:47:05,440 --> 03:47:06,440
INFORMATIVE MEATING.

6098
03:47:06,440 --> 03:47:11,040
INFORMATIVE MEETING.

6099
03:47:11,040 --> 03:47:13,120
REALLY APPRECIATE EVERYBODY,

6100
03:47:13,120 --> 03:47:16,520
YOUR CONTINUED AND VALUABLE

6101
03:47:16,520 --> 03:47:20,560
FEEDBACK AND THE DI VE DIVERSITF

6102
03:47:20,560 --> 03:47:21,560
PERSPECTIVES IN YOUR ENGAGEMENT

6103
03:47:21,560 --> 03:47:24,680
IS REALLY CRITICAL TO MOVING THE

6104
03:47:24,680 --> 03:47:26,120
NIH HIV RESEARCH AGENDA FORWARD

6105
03:47:26,120 --> 03:47:27,120
AND REALLY THANK YOU SO MUCH FOR

6106
03:47:27,120 --> 03:47:28,200
ALL OF THIS.

6107
03:47:28,200 --> 03:47:29,480
I ALSO WANT TO THANK OUR

6108
03:47:29,480 --> 03:47:31,480
COLLEAGUES AT O.A.R. AND THE

6109
03:47:31,480 --> 03:47:33,240
STAFF WHO HELPED BRING THIS

6110
03:47:33,240 --> 03:47:35,080
MEETING TOGETHER, PARTICULARLY

6111
03:47:35,080 --> 03:47:36,600
TO DR. GLENSHAW, HERE, FOR

6112
03:47:36,600 --> 03:47:38,720
REALLY HELPING ORGANIZE AND

6113
03:47:38,720 --> 03:47:40,240
STRUCTURE EVERYTHING SO NICELY.

6114
03:47:40,240 --> 03:47:43,960
AND LASTLY, THANK YOU,

6115
03:47:43,960 --> 03:47:46,800
DR. TURNBULL, FOR A TERRIFIC JOB

6116
03:47:46,800 --> 03:47:49,400
AND YOUR SERVICE AS CHAIR OF

6117
03:47:49,400 --> 03:47:50,200
OARAC.

6118
03:47:50,200 --> 03:47:53,600
REALLY, WELL-RUN MEETING AND

6119
03:47:53,600 --> 03:47:54,240
MUCH APPRECIATE ALL OF YOUR

6120
03:47:54,240 --> 03:47:54,760
EFFORT.

6121
03:47:54,760 --> 03:47:56,640
THANK YOU, AND NOW BACK TO YOU.

6122
03:47:56,640 --> 03:47:58,920
>> THANK YOU SO VERY MUCH,

6123
03:47:58,920 --> 03:48:00,040
DR. KAPOGIANNIS.

6124
03:48:00,040 --> 03:48:01,600
AND EVERYONE IN ATTENDANCE AT

6125
03:48:01,600 --> 03:48:05,920
THE MEETING TODAY.

6126
03:48:05,920 --> 03:48:07,560
AS MY FINAL WORDS FOR THIS

6127
03:48:07,560 --> 03:48:12,040
CLOSING OUT OF TODAY'S MEETING,

6128
03:48:12,040 --> 03:48:13,280
TODAY'S MEET SOMETHING NOW

6129
03:48:13,280 --> 03:48:13,720
OFFICIALLY ADJOURNED.

6130
03:48:13,720 --> 03:48:15,760
THANK YOU ALL FOR ATTENDING, AND

6131
03:48:15,760 --> 03:48:17,320
HAVE A GOOD REST OF YOUR DAY.

6132
03:48:17,320 --> 03:48:18,760
THANK YOU.

6133
03:48:18,760 --> 00:00:00,000
>> THANK YOU.